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ABSTRACT
The obesity pandemic has become perhaps the most prevalent health
issue of our time, with more than 10% of the world’s population now being
obese. Obesity can be defined as abnormal or excess fat accumulation
that may impair health and results from an imbalance between energy
intake and energy expenditure. A decrease in physical activity due to an
increase in sedentary forms of work, changing modes of transport and
increasing urbanization is likely a major contributory factor. Diet is
another major factor with the increased availability and intake of calorie
dense, high fat foods being of global concern. Notably, with respect to
this thesis, over the last decade advances in the field of next generation
sequencing (NGS) have facilitated investigations to determine the
relationship between the gut microbiota and obesity.
Initially, we established that a high fat diet alters microbial
composition but that changes in the microbiota were dissociated from
markers of energy harvest. These results highlighted that the relationship
between the gut microbiota and energy harvesting capacity is more
complicated than previously considered and that future studies should
consider the possibility of microbial adaptation to diet and time. The
objectives of this thesis were to investigate the impact of a variety of
factors on the obesity-associated gut microbiota and, in turn, how these
factors could affect weight gain. In order to achieve this, NGS
technologies were employed to assess the impact of different
interventions on the composition of the gut microbiota and, in turn, weight
gain.
First, the impact of two antimicrobial strategies on metabolic
abnormalities in murine diet-induced obesity was explored. Our approach
involved the administration of vancomycin and a bacteriocin-producing
probiotic (Lactobacillus salivarius UCC118 Bac+) to diet induced obese
mice and assessing the impact on microbial composition and metabolic
abnormalities associated with obesity. This study suggested that altering
the gut microbiota in a specific manner can have a positive influence on
iii
health, as vancomycin treatment resulted in a reduction in weight gain
and an improved metabolic profile, but that alterations made by the
bacteriocin producing probiotic provided only transient benefits. The
investigation of these effects with time also highlighted the resilience of
the gut microbiota and suggested that interventions may need to be
monitored and continually adjusted to ensure the sustained modification
of the gut microbiota.
The impact of the production of specific bile salt hydrolases on the
gut microbiota and in turn weight gain was also assessed. A significant
reduction is weight gain was observed in mice in receipt of an Escherichia
coli strain producing a bile salt hydrolase (BSH) from L. salivarius
JCM1046 (BSH1), which were fed either high or low fat diets, relative to
mice fed an E. coli strain producing a BSH from L. salivarius UCC118
(BSH2). These results were accompanied by changes in microbial
composition and, ultimately, highlighted the effect of diet, antibiotics and,
in particular, the impact of the production of different BSHs on gut
microbial communities.
Further investigations focussed on assessing the effect of diet and
the microbiota on the progression of colitis and colitis-associated
colorectal cancer (CAC) progression. Mice were fed a high fat or low fat
diet, followed by one azoxymethane (AOM) injection and 3x dextran
sodium sulphate (DSS) cycles (CAC model) or 3xDSS cycles alone
(colitis model). High fat feeding protected mice from developing colitis
and CAC on the basis of weight and cytokine profile, tumour incidence
and number as well as colon length. NGS based analysis of the murine
gut microbiota showed a reduction in gut microbial diversity in LF-colitis
and LF-CAC mice relative to their HF-fed counterparts. These results
provide an initial insight into the relationship between diet, inducers of
colitis and colon cancer and the gut microbiota.
Finally, the degree to which exercise and diet affects the gut
microbial population was examined. Since extremes of exercise often
accompany extremes of diet, we addressed the issue by studying
professional athletes from an international rugby union squad. Gut
iv
microbial analysis revealed athletes had a greater microbial diversity than
controls, which in turn correlated with protein consumption. These results
provide evidence for a beneficial impact of exercise on the gut microbiota
but also indicate that the relationship is related to accompanying dietary
changes.
Overall the results presented in this thesis highlight that microbial
diversity is influenced by diet, exercise, antibiotics and disease state,
however it is only through further understanding of the structure and
function that we can identify targets that can impact on health.
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1Chapter 1
The gut microbiota and its relationship to diet and obesity:
new insights
Gut Microbes (2012) 3: 186-202
21.1 ABSTRACT
Obesity develops from a prolonged imbalance of energy intake and energy
expenditure. However, the relatively recent discovery that the composition
and function of the gut microbiota impacts on obesity has lead to an
explosion of interest in what is now a distinct research field. Here, research
relating to the links between the gut microbiota, diet and obesity will be
reviewed under five major headings: (i) the gut microbiota of lean and obese
animals, (ii) the composition of the gut microbiota of lean and obese humans,
(iii) the impact of diet on the gut microbiota, (iv) manipulating the gut
microbiota and (v) the mechanisms by which the gut microbiota can impact
on weight gain.
31.2 INTRODUCTION
Obesity has become one of the most prevalent health issues of our time. In
2008, the World Health Organisation (WHO) estimated that there were over
1.5 billion overweight adults in the world and, of these, approximately 500
million are clinically obese. Indeed, more deaths are caused worldwide by
excessive weight than those which caused by being underweight (WHO,
2013). Obesity is a multifactorial condition but it can be most simply
described as being the result of a long-term imbalance between energy
intake and energy expenditure. While modern eating habits and ever
increasingly sedentary lifestyles are major contributory factors, researchers
are gaining an ever greater appreciation of other important risk factors. One
such issue that has emerged in recent years is the link between obesity and
the composition and functionality of the microorganisms in the gut. Here we
review the literature related to this topic under five major headings i.e. (i) the
gut microbiota of lean and obese animals, (ii) the composition of the gut
microbiota of lean and obese humans, (iii) the impact of diet on the gut
microbiota, (iv) manipulating the gut microbiota and (v) the mechanisms by
which the gut microbiota can impact on weight gain (Fig 1).
41.3 GUT MICROBIOTA OF LEAN AND OBESE ANIMALS
Mouse models are frequently employed by researchers investigating obesity
and the role of the gut microbiota in obesity. The following sub-sections will
focus on the various mouse models that have been employed and the
outcome from studies carried out to date.
1.3.1 Microbiota of genetically obese mice
Many studies have examined the difference in the composition of the gut
microbiota of lean and obese mice using a wide range of molecular methods
(listed in Table 1). The possible existence of a link between obesity and the
gut microbiota only became apparent upon the application of DNA
sequencing on a large scale to facilitate an unbiased analysis of the entire
gut microbiota (i.e. including culturable and unculturable microbes). This
DNA sequencing approach initially focussed on the 16S rRNA gene which,
because of the presence of highly conserved and variable regions, can be
employed to classify bacteria (Fig 2). In 2005, (Ley et al.) first employed this
approach in an obesity context to analyse 5,088 bacterial 16S rRNA
sequences corresponding to the caecal microbiota of ob/ob, ob/+ and +/+
mice. ob/ob mice are leptin deficient, eat excessively and are obese as a
consequence of this genotype. Traditional ‘Sanger’ sequencing was
employed in this instance (Sanger et al., 1977). The investigation revealed
that the two most abundant bacterial divisions in mice were the phylum
Firmicutes (60-80% of sequences) and the Phylum Bacteroidetes (20-40% of
sequences) and it was established that the proportions of Bacteroidetes and
Firmicutes were reduced and increased, respectively, in the obese animals
relative to their lean counterparts. These shifts were division wide (i.e. no
particular subgroup of Firmicutes and/or Bacteroidetes were lost or gained)
(Ley et al., 2005). (Turnbaugh et al.) added to our knowledge in this area in
2006 in a study which differed by virtue of being carried out on a larger scale
and the use of an alternative approach, i.e. random or shotgun metagenomic
sequencing of the murine (ob/ob, ob/+ and +/+) caecal microbial DNA (Fig 2).
In this case both traditional Sanger and high throughput 454 pyrosequencing
technologies were employed (Margulies et al., 2005). This study again
5highlighted an increased ratio of Firmicutes to Bacteroidetes in obese mice
relative to their lean counterparts. It was also noted that the gut microbiota of
ob/ob mice contained a higher proportion of Archaea than were present in
the cecum of their lean counterparts (Turnbaugh et al., 2006). Though these
results are interesting, the possibility that the animal’s genotype could also
influence the gut microbial composition can not be excluded. Notably, since
this study, high throughput DNA sequencing approaches have essentially
replaced Sanger sequencing and other strategies when the objective is to
assess alternations in the gut microbiota composition. The methods used to
analyse the gut microbiota in the studies referred to in this review are
summarised in Table 2.
1.3.2 Microbiota of diet-induced obese mice
Another murine model has been developed which focuses on obesity that
arises due to consumption of a high-fat, ‘western’ diet (i.e. diet induced
obesity or DIO), rather than genetics. In 2008, (Turnbaugh et al.) showed
that the western diet associated caecal microbial community had a
significantly lower proportion of Bacteroidetes and a specific increase in the
Mollicutes subpopulation of the Firmicutes. In 2009, (Hildebrandt et al.)
investigated the microbial communities from both wild type and resistin-like
molecule (RELM) β knock-out (KO) mice fed a standard chow diet and a high
fat diet. The RELMβ gene is expressed by colonic goblet cells and its
expression has been shown to be dependant on the gut microbiome (He et
al., 2003) and can be induced by a high fat diet (Shojima et al., 2005).
Wildtype and RELMβ KO mice were compared in order to further investigate
the relationships between diet, obesity and microbiota composition. A
sequence based analysis of murine faecal samples revealed that the gut
microbiota communities of 13 week old wild type and RELMβ KO mice fed a
standard chow diet were very similar, with Bacteroidetes, followed by
Firmicutes, being the dominant groups. The phyla Proteobacteria,
Tenericutes and TM7 were also detected. After three months consumption of
a high fat diet, the gut microbiota of both groups of animals differed from
those fed the standard chow diet. More specifically, the Phylum Firmicutes
class Clostridiales, Actinobacteria and Deltaproteobacteria increased their
6respective proportions in the gut of both groups of animals fed a high fat diet
which was accompanied by a reduction in the abundance of class
Bacteroidales. An increase in the Mollicutes population was also noted in
these animals, although this bloom was not as dramatic as had been
observed by (Turnbaugh et al., 2008). Despite these similarities with respect
to gut microbial composition, the RELMβ KO mice consuming a high fat diet
remained lean, whereas the corresponding wild type mice became obese.
From this study, the authors concluded that, because the general changes in
the composition of the gut microbiota were similar in the wild type and KO
mice, the effect of diet was dominant i.e. the high fat diet, and not the obese
state, accounted for the alteration in the gut microbial communities. We will
return to the implications of this study later. A recent 16S rRNA-based study
by (Murphy et al., 2010) has provided further insight. Here the faecal
microbiota of lean (+/+), ob/ob as well as +/+ mice fed a high fat (HF) diet,
was investigated at 7 weeks (the time points at which the low and high fat
groups were separated), 11 weeks and 15 weeks of age. It was established
that, in addition to the Firmicutes and Bacteroidetes, a high proportion of
Actinobacteria was present in the gut. While no significant changes in the
proportions of the different microbial populations was observed in lean mice
over the 8 week period, there was a progressive increase in the proportions
of Firmicutes in the faecal microbiota of HF-fed and ob/ob mice.
Bacteroidetes levels decreased overtime in all groups but this reduction
reached statistical significance in ob/ob mice only. The levels of
Actinobacteria fluctuated in all three groups with significant increases in their
proportions being apparent in the ob/ob and HF-fed mice when samples from
weeks 7 and 11 and from weeks 7 and 15 were compared. It was also noted
that Proteobacteria decreased in HF-fed mice from distal weeks 11 to 15
while in ob/ob mice Deferribacteria and Lactococcus decreased overtime
(Murphy et al., 2010).
1.3.3 Humanized mice
Studies have revealed that although the gut of both mice and humans
contains microbes from the same dominant range of bacterial phyla (i.e.
Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria and, to a lesser
7extent, Verrucomicrobia, Cyanobacteria, TM7, Fusobacteria, and
Spirochaeates), many of the bacterial genera and species present in mice
are not detected in humans and vice versa (Ley et al., 2005). With a view to
addressing this, and to thus improve the murine model, (Turnbaugh et al.,
2009 )used an animal model of the human gut ecosystem by transplanting
human faecal microbial communities into germ-free mice. Then this
demonstrated how these humanized animals can be utilized to conduct
controlled proof-of-principle “clinical” metagenomic studies of host-
microbiome interrelations. It was established that all bacterial phyla, 11 of 12
bacterial classes, and 88% (58 of 66) of genus-level taxa detected in the
sample from the human donor were present in the recipient mice.
Furthermore, the genera that were absent from the humanized mice were
those present at low abundance (0.008% on average) in the donor sample. It
was also established that the human gut microbiota could be successfully
transferred from the humanised mice to germ-free recipient mice without a
significant drop in diversity. Use of these model animals, and examination of
the gut microbial community thereof, revealed that the gut microbiota in
those consuming a ‘western’ diet contained a higher proportion of the
Firmicutes classes Erysipelotrichi and a lower proportion of Bacteroidetes
and Bacillus than did the microbiota of those in receipt of a to low fat/plant
polysaccharide diet.
81.4 THE COMPOSITION OF THE GUT MICROBIOTA OF LEAN AND
OBESE HUMANS
Mice are useful models in that they can be housed in controlled
environments and fed specific diets. For obvious reasons, human studies
lack these levels of control, and thus shifts in the associated microbiota can
be considerably more variable. However, any shifts in populations deemed to
be of importance with respect to weight gain ultimately need to be validated
through human studies.
1.4.1 Gut microbiota of lean and obese adult humans
The gut microbiota of lean and obese individuals was compared in 2006 by
(Ley et al.) through 16S rRNA sequencing of DNA extracted from faecal
samples. It was revealed that the Bacteroidetes and Firmicutes divisions
again dominated the microbiota (92.6%) but with obese individuals
possessing a lower proportion of Bacteroidetes and higher levels of
Firmicutes than their lean counterparts, thus resembling the patterns
established in previous murine studies (Ley et al., 2005). In 2009,
(Turnbaugh et al.) characterized the gut microbiota of 154 individuals,
consisting of monozygotic or dizygotic twins and their mothers. The study
revealed that the composition of the gut microbiota is more similar between
family members than unrelated individuals. However, it was also evident that
each individual’s gut microbiota was distinct and that a similar degree of co-
variation existed between adult monozygotic and dizygotic twin pairs.
Notably with respect to the topic of this review, it was also apparent that
there was a lower proportion of Bacteroidetes in the gut of obese individuals
compared to their lean counterparts, that the proportions of Actinobacteria
was elevated in obese individuals and that the microbial population was in
general less diverse. Notably, unlike the previous study, no significant
difference in proportions of Firmicutes was apparent when the gut microbiota
of lean and obese individuals was compared.
Indeed, considerable debate continues regarding the significance of
the Firmicutes and Bacteroidetes proportions with respect to obesity in
humans. In 2009 (Schwiertz et al.) studied lean and obese volunteers of both
9sexes and assessed the associated faecal microbiota. Firmicutes belonging
to the Clostridium leptum and the Clostridium coccoides groups as well as
Bacteroides spp. (phylum Bacteroidetes) were the most abundant bacterial
groups in general. In contrast to the studies cited above, it was noted that
proportions of the genus Bacteroides were greater in overweight volunteers
than lean and obese volunteers (p=0.002 and p=0.145, respectively)
whereas the Ruminococcus flavefaciens subgroup, C. leptum group,
Methanobrevibacter and the genus Bifidobacterium was less abundant in
overweight and obese subjects. The significance of the proportion of
Bacteroidetes and Firmicutes present was also questioned by (Duncan et al.,
2007) when they found that weight loss did not change the relative
proportions of the Bacteroides spp., or the percentage of Firmicutes present,
in the human gut. The composition of the gut microbiota of both African
Americans and Caucasian Americans was also investigated by (Mai et al.,
2009). Of greatest relevance to this review is the observation by Mai et al.,
that while a number of diet related trends were observed i.e. individuals that
consumed high levels of fat had fewer Clostridia, lactic acid bacteria levels
were higher in subjects that consumed fibre, and levels of Clostridium cluster
XIVa were elevated in subjects with a higher intake of heterocyclic amines
(HCAs), none of these changes were statistically significant. Similarly, no
association between the body mass index (BMI) and the proportions of
Bacteroidetes and Clostridium cluster XIVa was detected. Finally, in 2009
(Armougom et al.) assessed the gut microbiota of obese, lean and patients
suffering from anorexia nervosa. The study revealed that the proportion of
Firmicutes present in the gut of all three groups was similar, the proportion of
Bacteroidetes was reduced in obese individuals and that Methanobrevibacter
smithii was present in higher proportions in the gut of the anorexic group. A
recent development in the area of human gut microbial composition is the
potential discovery of distinct clusters or enterotypes in the human
microbiome using sequencing data from thirty three gut microbiomes across
different nationalities (French, Spanish, Italian, Danish, Japanese and
American) (Arumugam et al., 2011). The three enterotypes can be identified
on the basis of variations in the relative levels of Bacteroides, Prevotella and
Ruminococcus. Enterotype 1 is enriched in Bacteroides and the co-occurring
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Parabacteroides. These both derive energy mainly from carbohydrates and
proteins by fermentation (Martens et al., 2009). Enterotype 2 is enriched in
Prevotella which co-occurs with Desulfovibrio. These are known to operate in
synergy to break down mucin glycoproteins (Wright et al., 2000). Enterotype
3 is the most common enterotype and is distinguished on the basis of an
enrichment in the levels of Ruminococcus and the co-occurring
Akkermansia, both of which contain species capable of degrading mucins
(Derrien et al., 2004). The relationship between diet and enterotype is
addressed below.
1.4.2 Impact of bariatric surgery on the gut microbiota
Bariatric surgery is increasingly employed as an anti-obesity treatment, and
for a morbidly obese patient it is the only option available that can deliver
substantial and sustained weight loss (Buchwald et al., 2004). The surgery
can be performed in a number of different ways in that, in some cases, it
involves a reduction in the size of the stomach using a gastric band, in others
a portion of the stomach is removed, while another option involves the
creation a small stomach pouch and resecting/re-routing it to the small
intestine. The impact of such surgery on the composition of the gut
microbiota of patients has been investigated through a comparison of the gut
microbiota of 3 obese, 3 lean and 3 post gastric bypass individuals (Zhang et
al., 2009b). The investigation established that the gut microbiota of
individuals who had undergone gastric bypass differed from that of both the
obese and lean individuals by virtue of an increase in proportions of
Gammaproteobacteria (including the Enterobacteriaceae) and
Fusobacteriaceae and a proportional decrease in Clostridia. In addition, the
gut microbiota of lean individuals contained elevated proportions of
sequences corresponding to the Lachnospira (order Clostridiales) compared
to that of obese and gastric bypass individuals. It was also noted that the gut
microbiota of obese individuals contained a lower proportion Verrucomicrobia
and a higher proportion of Archaea relative to the other two groups. Finally,
Methanobacteriales was found in all obese individuals but in only one gastric
bypass patient (Zhang et al., 2009b).
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Another recent paper also focused on this topic but incorporated a
larger number of individuals, i.e. 30 obese individuals who had undergone
bariatric surgery and 13 lean volunteers, and instead relied on a qPCR-
based analysis (Furet et al., 2010). The investigation established that after
surgery the levels of Bacteroides/Prevotella were higher than they had been
prior to surgery. This increase brought the Bacteroides/Prevotella more
closely in line what that observed in the lean controls. An increase in
Escherichia coli and Faecalibacterium prausnitzii was also noted when post-
surgical samples from individuals were compared with their pre-surgery
equivalents. The relatively low levels of F. prausnitzii in pre-surgical samples
was more apparent in the obese diabetic cohort than in their obese non
diabetic counterparts. In contrast, decreases in levels of the combined
Lactobacillus/Leuconostoc/Pediococcus group and in Bifidobacterium sp.
were apparent in post-, relative to pre-, surgical samples. Body weight, BMI,
body fat mass and leptin concentration all negatively correlated with
Bacteroides/Prevotella and E. coli but positively correlated with
Bifidobacterium populations. The F. prausnitzzi population strongly
negatively correlated with changes in inflammatory markers and
orosomucoid serum levels. While these results are interesting and suggest
that this area requires further attention, the possibility exists that the roux-en-
Y gastric bypass procedure may contribute to changes in gut microbial
composition as a consequence of the associated change in pH and the
downstream delivery of bile acids (Furet et al., 2010).
Finally, in one case the impact of bariatric surgery on the microbial
composition of wistar rats was assessed. Although differing from the
previous studies by virtue of its reliance on an animal model, an increase in
Gammaproteobacteria was again apparent. However, in this instance a
reduction in Firmicutes and Bacteroidetes was observed, (Li et al., 2011) the
significance or cause of which is not known.
1.4.3 Gut microbiota of normal and overweight pregnant women
The gut microbiota of normal weight and overweight pregnant women was
investigated by (Collado et al., 2008). In addition to being of interest with
respect to the health and weight of the mother, such investigations are also
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of importance given that, in cases of natural delivery, the child is first
colonized by microbiota from the mother (Langhendries, 2005). While an
overall increase in the number of bacteria was observed between the first
and third trimester in both groups, significant differences between the gut
microbiota composition of pregnant women of different weight were noted.
More specifically, higher numbers of representatives of the Bacteroides
group and Staphylococcus aureus were recorded in overweight individuals.
Indeed a one kilogram gain in weight correlated with a corresponding
increase in Bacteroides numbers by 0.006 log units. The levels of the
Clostridium group increased in overweight women from the first trimester to
the third (p=0.054). Bifidobacterium proportions were higher in women who
exhibited a relatively lower weight gain during pregnancy. Finally, it was also
noted that overweight women tended to give birth to heavier infants. More
recently, (Santacruz et al., 2010) investigated the faecal microbiota of 50
pregnant women who were assigned into one of two groups, i.e. overweight
or normal weight, based on their BMI. As with the Collado study, higher
numbers of Staphylococcus and lower numbers of Bifidobacterium were
noted in overweight women. However, in contrast with the previous study,
Bacteroides numbers were found to be lower in overweight women.
Increased numbers of Enterobacteriaceae in general and of E. coli in
particular, were also associated with overweight women. The gut microbiota
of women who gained excessive weight during pregnancy underwent similar
increases and decreases in microbial numbers as were associated with
overweight women. (Santacruz et al., 2010) also investigated the relationship
between gut microbiota composition and metabolomic parameters. It was
found that increased Staphylococcus numbers corresponded with increased
serum levels of cholesterol, a rise in numbers of Enterobacteriaceae and E.
coli was linked with increased levels of serum ferritin, saturation transferrin
index and decreased levels of transferrin, while greater numbers of
Bifidobacterium correlated with reduced levels of ferritin, saturation
transferring index and increased levels of transferrin and folic acid. Finally,
increased Bacteroides numbers were associated with increased levels of
high density lipoprotein (HDL) -cholesterol, folic acid and lower levels of
triacylglycerol (TAG).
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1.4.4 Gut microbiota of lean and obese children
The WHO estimated that in 2010 there were over 42 million overweight
children under the age of five worldwide (WHO, 2010). The alarming
increase in obesity rates in children has lead to a particular interest in
investigating the gut microbiota of lean and obese children. A seven year
study to investigate the composition of the faecal microbiota of children,
published by (Kalliomaki et al., 2008) found that normal weight development
was linked to a lower number of faecal S. aureus number and a higher
number of bifidobacteria relative to those present in the feces of overweight
children. The S. aureus finding is doubly interesting in the context of the
increase in number of Staphylococcus in the gut of overweight pregnant
women referred to above. (Balamurugan et al., 2009) noted that obese and
non obese Indian children had similar dietary intakes of energy and, thus, it
was apparent that other factors were at play. Thus the nature of the
dominant faecal microbiota within each group was investigated. Although this
revealed that there were no significant differences with respect to the levels
of the Bacteroides-Prevotella, Bifidobacterium, Eubacterium rectale or
Lactobacillus acidophilus groups in the gut, it did reveal that, unlike the
aforementioned study by (Furet et al., 2010) the obese subjects had
significantly higher levels of F. prausnitzii, a representative of the Firmicutes
which can ferment unabsorbed carbohydrate. It was thus postulated that the
presence of this bacterium in greater numbers in obese children could lead
to increased energy extraction from carbohydrate that would not otherwise
contribute to dietary energy intake. (Luoto et al., 2011) analysed the faecal
microbiota of a group of children over 10 years. At 3 months of age there
was no statistically significant difference in the faecal bacterial counts of the
children. However children who were overweight by the time they reached
age 10 years tended to have lower bifidobacterial numbers in their faeces
when it were assessed at 3 months of age. Interestingly 10 year old normal
weight children had significantly higher mean concentrations of serum-
soluble innate microbial receptor (sCD14) than overweight children. sCD14 is
involved in innate immunity and its expression is increased by the presence
of LPS and fatty acids that resemble the lipid portion of LPS (Manco et al.,
14
2010). It was also noted that mothers of children who were normal weight at
age 10 years had statistically significantly higher mean concentrations of
adiponectin in maternal colostrum than mothers of overweight children.
Adiponectin is a protein hormone secreted from adipose tissue (Gavrila et
al., 2003) and the placenta (Chen et al., 2006) into the blood stream. It has
an important role in glucose regulation and fatty acid metabolism (Okamoto
et al., 2006, Tsatsanis et al., 2006) and provides protection against metabolic
syndrome (Li et al., 2009) as well as having antiatherogenic and anti-
inflammatory properties (Fantuzzi, 2005). Diabetics and obese individuals
have low levels of adiponectin (Gavrila et al., 2003).
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1.5 IMPACT OF DIET ON THE GUT MICROBIOTA
Until recently, the relationship between diet, microbes and, in turn, optimal
health has remained obscure. However, a number of recent studies have
investigated the primacy of diet amongst lifestyle factors that influence the
composition of the gut microbiota. That which is known with respect to the
impact of diet on the gut microbiota is summarised in Table 3.
1.5.1 Low carbohydrate/calorie diets
The effects of a fat restricted or carbohydrate restricted low calorie diet
randomly assigned to 12 obese people has been investigated by (Ley et al.,
2006). While it was established that over time the relative abundance of
Bacteroidetes increased and the abundance of Firmicutes decreased, these
changes appeared to be irrespective of the low calorie diet consumed.
(Duncan et al., 2007) also studied the effect of an altered carbohydrate
intake on the gut microbiota. They recruited 19 obese, but otherwise healthy
individuals and allocated them to 3 different diets i.e. a maintenance diet, a
high protein/medium carbohydrate diet (HPMC) and a high protein/low
carbohydrate diet (HPLC). The investigation established that bacterial
numbers were greatest in individuals on the maintenance diet and that the
Gram negative Bacteroides and the Gram positive C. coccoides were the
most abundant bacterial groups (approximately 29% and 22% of total
bacteria respectively) in all cases. It was apparent that the bifidobacteria,
Roseburia spp. and E. rectale from the Clostridium group were all negatively
impacted upon by decreased carbohydrate intake. The consumption of the
HPMC and HPLC diets also resulted in the lowering of the Short Chain Fatty
Acid (SCFA) concentrations, with butyrate concentrations being most
dramatically reduced.
The influence of an obesity treatment program on the gut microbiota
and body weight of overweight adolescents has been examined by
(Santacruz et al., 2009). The participants in this study were subjected to a
calorie restricted diet and increased physical activity programme over 10
weeks. After the treatment, a group of subjects, experiencing a >4kg weight
loss and showing significant BMI reductions, was identified. The remaining
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individuals lost <2.0kg in weight despite the fact that there were no
significant differences in the dietary intake of the two groups. In general, the
treatment led to an increase in Bacteroides fragilis and Lactobacillus groups
and a decrease in the C. coccoides, Bifidobacterium longum and
Bifidobacterium adolescentis numbers. The post intervention microbiota
shifts were most significant in individuals that responded more successfully
to treatment. It was also noted that Bifidobacterium bifidum, the C. coccoides
group, the Lactobacillus group, Bifidobacterium and Bifidobacterium breve
were significantly lower in the high weight loss group compared with the low
weight loss group before and after the treatment. Conversely total bacteria,
the B. fragilis, the C. leptum, and the Bifidobacterium catenulatum groups
were significantly higher in the more abundant weight loss group before and
after treatment (Santacruz et al., 2009). In another such study by (Nadal et
al., 2009) the adolescent obesity treatment programmes incorporated
nutritional and individual diet counselling, calorie restriction and increased
physical activity over a ten week period. The maximum energy intake
permitted was 1,800 kcal/d for females and 2,200 kcal/d for males. Most of
the participants experienced significant weight loss ranging from 4.1 to
16.6kg after the 10 week period. Overall, the intervention programme led to
reductions in the proportions of Clostridium histolyticum and, in line with
previous investigations, E. rectale-C. coccoides. A correlation between C.
histolyticum and E. rectale-C. coccoides proportions and BMI was also
evident. Bacteroides proportions increased as a consequence of the
intervention and almost achieved significant levels of correlation with weight
loss. Although the Lactobacillus-Enterococcus populations also increased as
weight and BMI correlations decreased, these correlations were not
significant. In the group which did not experience a significant loss in weight
(<2.5kg), the bacterial groups analyzed did not differ significantly as a
consequence of the intervention programme. No correlations were detected
between bacterial proportions and either body weight or BMI reductions in
this low weight loss group. Unsurprisingly, a number of animal studies have
also taken place. The caecal microbial composition of high fat fed and control
mice was quantified by (Cani et al., 2007). They found that, in the high fat
diet mice, Bacteroides-like microbes were significantly reduced compared
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with controls. Furthermore, although the E. rectale-C. coccoides group were
found to be the dominant microbiota, a reduction in this group, and of
Bifidobacterium, relative to controls was also noted.
In a study discussed briefly above (Turnbaugh et al., 2008) took an
alternative approach to investigate the relationship between diet and the gut
microbiota. More specifically, conventionally raised (CONV-R; i.e. mice which
have been allowed to acquire their microbiota naturally from birth) mice were
weaned onto a ‘western’ or a low-fat chow diet rich in structurally complex
plant polysaccharides (CHO diet) for 8-9 weeks. Mice on the ‘western’ diet
unsurprisingly gained more weight and had a significantly larger adiposity.
The researchers then carried out investigations to determine if the gut
microbiota of these DIO animals possessed attributes that can more
successfully increase host adiposity than the microbiota of CHO fed animals.
This involved the transplantation of the caecal microbiota of the lean and
obese animals to GF, CHO-fed recipients. Recipients of the DIO associated
microbiota brought about a significantly greater proportional increase in body
fat compared to the recipients of the CHO-associated microbiota was
capable of. (Turnbaugh et al., 2008) also tested the impact of defined shifts
in diet on the body weight, adiposity and distal gut microbial ecology of
obese mice. CONV-R mice were fed either a ‘western’ diet, a ‘western’ diet
with reduced carbohydrates (CARB-R) or a ‘western’ diet with reduced fat
(FAT-R). Mice on CARB-R or FAT-R diets had reduced Mollicutes levels and
an increased abundance of Bacteroidetes. It would thus seem that both FAT-
R and CARB-R diets repress the multiple effects associated with ‘western’
diet induced obesity.
The impact of fasting on the gut microbiota of hibernating animals has
also been the subject of investigation. (Sonoyama et al., 2009) compared the
gut microbiota of male Syrian hamsters which were separated into a (i) fed,
active, non-hibernating group, (ii) a fasted, active, non hibernating group and
a (iii) hibernating group, with the latter being housed in constant darkness at
4ºC in order to bring on hibernation. It was established that the total bacterial
populations were significantly reduced in fasted active hamsters when
compared with fed active and hibernating hamsters, whereas there was no
significant difference between the latter two groups. HPLC analysis of the
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caecal contents also showed that fasted active hamsters had significantly
lower concentrations of total SCFA and acetic acid than fed active or
hibernating hamsters. A 16S rRNA-based investigation of caecal bacteria
showed that the class Clostridia was the most abundant taxonomic group in
all treatment groups but that the proportion of the Clostridia in fasted active
hamsters tended to be lower than that in fed active and hibernating
hamsters. Verrucomicrobia and Proteobacteria were the second and third
most abundant groups. Notably, all Verrucomicrobia-associated sequences
in fasted active hamsters were classified to the genus Akkermansia. The
family Desulfovibrionaceae was the most common family in the phylum
Proteobacteria and the proportion of this family was higher in fasted active
hamsters than in the other two groups. It has been suggested that fasting
stimulates the growth of sulfate-reducing bacteria such as Desulfovibrio spp.
through increased degradation of mucins by A. muciniphila in the cecum of
fasted active hamsters. Overall the results suggest that gut microbiota
respond differently to fasting and hibernation in Syrian hamsters.
An examination of humanized mice fed a ‘western’ diet revealed an
increased representation of the Erysipelotrichi class of bacteria or, more
specifcially, Clostridium innocuum, Eubacterium dolichum, and
Catenibacterium mitsuokai, in the faecal samples of these animals compared
to those of mice fed a low fat/plant polysaccharide (LF/PP) diet (Turnbaugh
et al., 2009 ). A significant increase in the relative abundance of another
class of Firmicutes, the Bacilli (corresponding primarily to Enterococcus sp.),
was also associated with the ‘western’ diet. These increases were apparent
along the entire length of the gut. A significant decrease in the representation
of members of the Bacteroidetes in ‘western’ diet fed mice was also
apparent. A parallel assessment of the gene composition of the gut
microbiome revealed an obvious shift within 1 day of the switch to the
‘western’ diet in the form of the enrichment of ATP-binding cassette
transporters and phosphotransferase systems. The microbiome associated
with the LF/PP diet was enriched for pathways including N-glycan
degradation, sphingolipid metabolism, and glycosaminoglycan degradation,
all of which are pathways which are also enriched in Bacteroidetes.
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The effects of a LF/PP and ‘western’ diet on two dominant phyla has
been investigated by (Mahowald et al., 2009). In this study the authors
specifically selected E. rectale and Bacteroides thetaiotaomicron as
representatives of the two dominant bacterial phyla, Firmicutes and
Bacteroidetes, and investigated how these microbes were affected by
changes in the host diet. Co-colonised mice were fed one of 3 diets, i.e. a
standard LF/PP, a high fat, high sugar ‘western-type’ diet (HF/HS) or a low
fat, high sugar, control diet (LF/HS). B. thetaiotaomicron was not affected by
diet but colonisation by E. rectale was significantly reduced in mice fed either
the LF/HS or HF/HS diets. The authors propose a number of explanations for
this occurrence, i.e. (i) E. rectale does not possess the glycoside hydrolase
and polysaccharide lyases that can process host glycans, (ii) it cannot use
the sugars that are derived from mucosal polysaccharides and/or (iii) the
glycobiome of the host includes enzymes that can directly process the simple
sugars in these two diets. Transcriptional profiling of B. thetaiotaomicron
revealed that it significantly up-regulated polysaccharide utilization loci
(PULs) involved in breakdown of host polysaccharides and down-regulated
PULs involved in breakdown of plant polysaccharides when mice were
subjected to a HF/HS or LF/HS diet. E. rectale responded to the HF/HS and
LF/HS diets by down-regulating several glycoside hydrolases and sugar
transporters (Mahowald et al., 2009).
The impact of a high fat diet on the gut microbiota was again
examined by (Zhang et al.) 2009. In contrast to animals fed a normal chow
diet (NC), it was noted that apolipoprotein A1 (Apoa-I) knockout and wild type
mice fed a high fat diet (HFD) lacked Bifidobacteriaceae in their faeces.
Apoa-I knockout mice were included in the study as they have been shown
to have impaired glucose tolerance (IGT) and increased body fat (Han et al.,
2007). After 25 weeks on a HFD the WT mice also exhibited IGT. The family
Desulfovibrionaceae was more prevalent in Apoa-I-/- on NC or HFD and WT
fed a HFD than WT NC control mice. An examination of the microbiota of the
mice failed to identify phylum-wide changes associated with IGT/obesity. It
was apparent, however, that diet and host health can have different effects
on lineages within the family more specifically, levels of Erysipelotrichaceae
from the Class Mollicutes. The family Erysipelotrichaceae of the class
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Mollicutes can be subdivided into four phylogenetic clusters i.e. M1, M2, M3
and M4. The M1 cluster were reduced in Apoa-I-/- and HFD mice. Levels of
the M2 cluster increased in HFD mice, the M3 cluster was severely
diminished in the HFD mice and the M4 cluster was only present in the HFD
mice. WT mice fed a HFD were the most obese group after the 25 week trial.
Finally, it is notable that the impact of diet on a combination of ten
human gut bacteria has been the subject of a recent investigation (Faith et
al., 2011). Strains of Blautia hydrogenotrophica, Bacteroides ovatus,
Bacteroides caccae, B. thetaiotaomicron, Clostridium symbiosum, Collinsella
aerofaciens, Desulfovibrio piger, E. rectale, E. coli and Marvinbryantia
formatexigens were introduced into the gut of germ free mice which were
then provided with refined diets which changed every two weeks. Each diet
systematically varied the concentrations of four ingredients, i.e. casein, corn
oil, cornstarch and sucrose. It was revealed that changes in diet impacted on
the relative abundance of the various species. In particular, it was noted that
the abundance of all ten species was significantly associated with casein, i.e.
seven species showed positive correlation to increasing casein while the
abundance of the others (E. rectale, D. piger and M. formatexigens)
decreased with increased casein levels. A parallel increase in the expression
of pathways associated with amino acid metabolism was apparent in the
seven species with which a positive correlation with casein existed (Faith et
al., 2011).
1.5.2 Other dietary-related influences
In addition to digestible carbohydrate, the impact of other dietary
components on the gut microbiota has also been investigated. In one case
the impact of controlled changes in the main type of non-digestible
carbohydrate components upon the microbial community of fourteen
overweight humans was examined (Walker et al., 2011). A significant
increase in the percent of Ruminococcus bromii-like bacteria was apparent in
individuals consuming a resistant starch (RS) diet relative to those in receipt
of a non-starch polysaccharide (NSP) diet. A significant increase in
Oscillibacter valericigenes-like bacteria was also noted in individuals on RS
and a reduced carbohydrate/high protein (WL) diet compared to those fed a
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maintenance or NSP diets (Walker et al., 2011). Finally, Roseburia and E.
rectale were also significantly increased among individuals consuming RS
diets but were decreased in individuals consuming a WL diet (Walker et al.,
2011).
New evidence has also demonstrated a link between dietary fat and
the metabolism of the intestinal microbiota with atherosclerosis (Wang et al.,
2011). It has been reported that the atherosclerosis-associated upregulation
of two macrophage scavenger receptors, CD36 and SR-A1, occurs in mice
that have choline, trimethylamine N-oxide (TMAO) or betaine (three
metabolites of the lipid phosphatidylcholine [PC]) added to their diet
(Kuchibhotla et al., 2008) and that supplementation with choline and TMAO
promotes the formation of atherosclerosis in mice (Wang et al., 2011). The
link between these phenomena and the gut microbiota was made by
comparing the microbiota of mice in receipt of choline or PC with or without
antibiotics. Mice fed a diet supplemented with 1% choline displayed
augmented atherosclerosis but this impact was lessened in mice on the
same diet but which were treated with broad spectrum antibiotics. Similarly
the presence of the gut microbiota is required for the formation of TMAO.
More specifically, the formation of TMAO is observed in mice in receipt of PC
or choline but is suppressed in their antibiotic-treated mice equivalents
(Wang et al., 2011).
Using a three stage colonic model the impact of a high dietary fibre
intake was examined with relation to the effect on microbial composition
(Shen et al., 2011). An increase in dietary fibre resulted in a significant
increase in the numbers of Bifidobacterium, Ruminococcus and
Lactobacillus-Enterococcus group in an in vitro three stage colonic model.
High fibre intake in the vessel representing the proximal colon significantly
increased the numbers of F. prausnitzii and E. rectale – C. coccoides groups.
The impact of diet on the microbiota is also very much evident when
the microbiota of omnivores, herbivores and carnivores (thirty three
mammals and eighteen humans) is compared (Muegge et al., 2011).
Principal coordinate analysis (PCoA) plots of both bacterial 16S rRNA and
whole community gene data sets separated carnivores and omnivores from
herbivores. Twelve amino acids biosynthetic enzymes were enriched in
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herbivores whereas as no such enrichment was apparent among carnivores.
In contrast, the enrichment of nine amino acid degradation pathways was
observed in carnivores. PCoA plots of diet and the human microbiome
revealed total protein intake was significantly associated with KEGG
orthology (KO) data whereas, insoluble dietary fibre was significantly
associated with bacterial operational taxonomic units (OTU) content
(Muegge et al., 2011).
Finally, in a recent study of 98 individuals, the effects of diet on the gut
microbial enterotypes was examined (Wu et al., 2011). It was noted that only
long term diet correlated with enterotypes. Short term controlled identical
feeding was shown not to affect intersubject variation. A food frequency
questionnaire found that the Bacteroides enterotype was highly associated
with animal protein. In contrast Prevotella enterotype was linked to high
carbohydrate and simple sugars. Vegans (n=1) and vegetarians (n=11) were
enriched in the Prevotella enterotype.
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1.6 MANIPULATION OF THE GUT MICROBIOTA
In addition to the aforementioned studies, which have highlighted the impact
of the overall levels of carbohydrate and/or fat on the composition of the gut
microbiota, the impact of other specific components of diet, i.e. food
additives, probiotics and prebiotics, have also been investigated.
Grain sorghum is an abundant source of phytochemicals that are of
possible benefit to health (Carr et al., 2005). (Martinez et al., 2009) used the
hamster model of hypercholesterolemia to investigate if changes in the gut
microbiota are linked with the positive effects of grain sorghum lipid extract
(GSL) on cholesterol metabolism. The hamsters’ diet was supplemented with
0%, 1% or 5% GSL. Although high animal-to-animal variability at both the
family and genus level was apparent, it was established that one family, the
Coriobacteriaceae, and two genera, both of which were unclassified
members of the family Erysipelotrichaceae, were significantly reduced in
abundance as a consequence of the addition of GSL to the hamsters’ diet.
Furthermore, 5% GSL was shown to reduce the overall diversity of the gut
microbiota. In contrast, levels of the genus Pseudoramibacter and
Allobaculum increased with increased GSL levels. A significant increase in
Bifidobacterium in hamsters fed GSL was also observed and this increase
was positively linked with high-density lipoprotein (HDL) plasma cholesterol
levels (r = 0.75, p=0.001). GLS feeding caused a decrease in the proportion
of Coriobacteriaceae. This decrease in Coriobacteriaceae showed a strong
correlation with non-HDL plasma cholesterol (r = 36 0.84, p=0.0002). These
findings suggest that GLS feeding influences the HDL/non-HDL equilibrium
via a mechanism that appears to be through the alteration of the intestinal
microbiota. Overall this analysis would imply that bifidobacteria are beneficial
and Coriobacteriaceae are detrimental with respect to plasma cholesterol
levels in hamsters.
The impact of probiotics on the composition of the gut microbiota has
been the focus of particularly great attention in recent years. Probiotics are
defined by the food and agriculture organisation of the United Nations and
the WHO as “live microorganisms which when administered in adequate
amounts confer a health benefit on the host” (WHO/FAO, 2001). Notably,
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(Schiffrin et al., 2009) carried out an investigation to determine if
administration of a probiotic containing yoghurt can ameliorate or treat small
intestinal bacterial overgrowth (SIBO) by improving gut barrier function or as
a consequence of their antibacterial, immunomodulatory and/or anti
inflammatory effects. SIBO most frequently occurs in older people and can
lead to chronic diarrhoea, anorexia and nausea as well as malabsorption and
malnutrition (Donald et al., 1992, Riordan et al., 1997). In the study, 23
elderly subjects with a positive glucose/H2 breath test (SPH) and 13 subjects
with a negative test (SNH) were administered the probiotic yoghurt
Lactobacillus johnsonii La1 for 4 weeks. The glucose/H2 breath test
measures the excretion of hydrogen in the breath which is reflective of
glucose metabolism by microbes in the intestine. Patients with a positive
result are suspected of having SIBO (Parlesak et al., 2003, Romagnuolo et
al., 2002). After 4 weeks of yoghurt consumption, the authors noticed a trend
towards a reduction of endotoxin concentration in the SPH group and a
significant decrease in plasma endotoxin was also noted in the SNH after
probiotic consumption. In conclusion, Schiffrin and colleagues suggest that
an altered intestinal ecology underlies the low grade inflammatory status that
favours catabolism and loss of lean body mass in the elderly and, thus,
redressing such ecological imbalances could provide health benefits.
In 2009, (Hamad et al.) investigated the ability of milk fermented by
Lactobacillus gasseri SBT2055 (LGSP) to impact on adipocyte size by
inhibition of dietary fat absorption in Zucker rats. Obese Zucker rats have a
spontaneous mutation in the leptin receptor gene causing early onset severe
obesity due to over-eating (Chua et al., 1996, Zucker and Zucker, 1961).
Rats fed a LGSP diet had reduced total, mesenteric and subcutaneous
adipose tissue masses compared with those fed a control skimmed milk diet
(SM). No significant effect was observed on other white adipose tissue. The
mesenteric fat mass in lean rats was reduced even more dramatically than
that of obese rats fed the LGSP diet (p<0.05). The LGSP diet also had a
significant effect on serum leptin concentrations which were decreased by
36% in lean rats but were not significantly altered in obese rats. However,
the LGSP diet had no effect on the serum levels of both glucose and
adiponectin in lean or obese rats. The LGSP diet caused a significant
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reduction in the levels of total and HDL-cholesterol in serum and a significant
increase in faecal cholesterol in both groups. Overall, the results of this study
revealed that the milk fermented by L. gasseri reduced visceral adipose
tissue mass and adipocyte hypertrophy in lean Zucker rat through a
decrease in fatty acid absorption (Hamad et al., 2009).
The benefits of consuming prebiotics have also been the focus of ever
greater attention in recent years. Prebiotics are defined as “non-digestible
food ingredients that beneficially affect the host by selectively stimulating the
growth and/or activity of one or a limited number of bacterial species already
resident in the colon, and thus attempt to improve host health” (Gibson and
Roberfroid, 1995). Cani and colleagues hypothesised that the control of gut
permeability through the selective modulation of gut microbiota by prebiotics
helps to protect ob/ob mice from metabolic diseases and carried out
investigations which revealed that mice fed the prebiotic (oligofructose) had
lower levels of the cytokines TNF-α, IL-1b, IL1-α, IL-6 and INFγ, all of which 
are known to promote tight-junction disruption (Cani et al., 2009). This study
also showed that altering the gut microbiota through the increase in
abundance of Bifidobacterium spp. through the use of prebiotics is linked
with a notable reduction of gut permeability. The improved gut barrier of
ob/ob prebiotic (Ob-Pre) fed mice also correlated with lower plasma LPS
levels and inflammatory tone. A decrease in markers of oxidative and
inflammatory stress in liver tissue significantly correlated with the lowering of
systemic inflammation by prebiotics. Overall these data suggest that
prebiotics could act favourably on the gut barrier, hence improving metabolic
disorders (Cani et al., 2009). The authors also noted that when the gut
microbiota is changed using prebiotics, an increase in endogenous
production of the glucagon-like peptide-2 (GLP-2) occurs which may explain
the associated improvement in intestinal barrier function. Evidence for this
was provided when it was established that a GLP-2 antagonist completely
blocked the positive effects of prebiotic treatment on both intestinal tight-
junction proteins and proglucagon mRNA (Cani et al., 2009). The effect of
inulin-type fructans (ITFs) with prebiotic properties on the gut microbiota of
animals fed a high fat diet was investigated by (Dewulf et al., 2010). While it
was established that caecal content was significantly reduced in mice fed a
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high fat (HF) diet relative to that of mice fed a control (CT) diet, this effect
was reversed in mice co-administered ITFs with the HF diet. Total bacterial
numbers were reduced in HF fed mice relative to CT fed animals while qPCR
revealed a 100 fold increase in bifidobacteria numbers and a reduction in
Roseburia spp. and Clostridium cluster XIVa in ITF-HF mice compared to CT
and HF fed mice. Notably, weight gain and subcutaneous adipose tissue
accumulation was reduced in ITF treated HF mice even though they ingested
fat to a level similar to that for non-ITF treated HF mice (Dewulf et al., 2010).
The consequences of consuming different concentrations of prebiotic
fibre (inulin and oligofructose), over a ten week period, on the gut microbiota
of lean and obese rats was the subject of another recent investigation
(Parnell and Reimer, 2011). Obese and lean rats were broken into three diet
groups: controls (C), 10% prebiotic fibre (LF) and 20% prebiotic fibre (HF). In
control rats the levels of Bacteroides/Prevotella, C. leptum and
Enterobacteriaceae as well as the overall bacterial population were greater in
lean than obese rats. Obese rats on the HF diet had significantly increased
levels of total bacteria, Bacteroides/Prevotella, C. leptum, Lactobacillus,
Bifidobacterium and Enterobacteriaceae when compared with obese
controls. Meanwhile lean rats fed a HF diet had significantly increased
Bacteroides/Prevotella and Bifidobacterium populations while a significant
decrease in the C. leptum and C. coccoides populations was apparent. No
statistically significant difference was seen between LF diet rats and controls.
Percentage body fat, body weight, fasting insulin, insulin, incremental area
under the curve (iAUC) and energy intake negatively correlated with
Bacteroides and total bacteria. Total energy intake, glucose iAUC, body
weight and fat positively correlate with Lactobacillus spp. The population of
Enterobacteriaceae increases with increases in glucose iAUC and GLP-1
total area under the curve (tAUC). A positive correlation was noted between
Bacteroides and total bacteria and ghrelin tAUC.
Despite these promising results, there has been some debate
recently, prompted by a proposal by Prof Didier Raoult that a link may exist
between probiotics and obesity (Raoult, 2009). Prof Raoult has suggested
that there are dangers associated with promoting the consumption of
products containing bacteria that have been associated with weight gain in
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the animal food industry. Raoult’s opinion is based on four points: 1. (Ley et
al., 2006) found that the gut of obese individuals contained more Firmicutes
than that of lean individuals, 2. The farming industry uses probiotics which
can contain Firmicutes, including Lactobacillus spp., Bifidobacterium spp.
and Enterococcus spp. as growth promoters. 3. L. acidophilus, at levels
equivalent to those found in functional foods, causes weight gain in piglets
and, finally, 4. Lactobacillus species have shown to cause weight gain in
children (Chouraqui and Leclaire, 2008). This view has been rejected in
responses by other scientists (Delzenne and Reid, 2009, Ehrlich, 2009) and,
indeed the arguments made by Dr Raoult do not accurately reflect the data
present in the papers he has cited, or consider the data presented by other
papers, some of which have already been discussed in this review. Most
notably, lactobacilli represent just a small fraction of Firmicutes in the gut.
Furthermore, Raoult’s editorial refers to Bifidobacterium as a Firmicute, when
in fact it belongs to the phylum Actinobacteria. In addition, in the studies cited
by Raoult, (Chouraqui and Leclaire, 2008, Guandalini et al., 2000) probiotics
did not significantly impact on weight gain in children. Finally, in a recent
review (Simon, 2005) it was revealed that only 3 out of 22 studies showed a
significant weight gain in piglets.
Many antibiotics used to treat humans have a broad spectrum of
activity which facilitates the treatment of infections of unknown aetiology. As
these antibiotics are not selective in their killing, there are associated impacts
on the natural biota of the human gut. In this instance the importance of the
gut microbiota with respect to obesity and metabolism was investigated
through disruption of the gut microbiota by treatment with ampicillin or
neomycin (Cani et al., 2008). WT mice were fed a control, control with
antibiotics, high fat or high fat with antibiotics (carbohydrate free) diet for 4
weeks. ob/ob mice were also fed a control diet or a control diet with
antibiotics. The 4 week antibiotic therapy had considerable impacts. The
endotoxin content per gram of caecal content was considerably decreased
after antibiotic treatment in both the control and high fat diet groups.
Adiposity was also reduced in high fat, antibiotic-treated mice compared with
high fat, untreated controls and, furthermore, antibiotic treatment significantly
lowered plasma LPS levels, gut permeability. The occurrence of visceral
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(mesentric) adipose tissue inflammation, oxidative stress, macrophage
infiltration and metabolic disorders was also lowered. Microbiological
analysis revealed that the high fat diet mice reduced Lactobacillus spp. and
Bifidobacterium spp. numbers, but increased Bacteroides-Prevotella spp.
numbers, compared to control mice. High-fat fed, antibiotic-treated mice had
reduced numbers of all 3 of these groups compared with the high fat diet
mice. Indeed the microbiota of the high-fat fed, antibiotic-treated mice had
numbers of all 3 groups which were very similar to those present in control
antibiotic mice. ob/ob mice had higher Lactobacillus spp. and Bifidobacterium
spp. but lower Bacteroides-Prevotella numbers, than ob/ob mice.
Unsurprisingly, antibiotic treatment dramatically changed the ob/ob mice gut
microbiota, reducing Lactobacillus spp., Bifidobacterium spp. and
Bacteroides-Prevotella spp. (Cani et al., 2008).
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1.7 MECHANISMS BY WHICH THE GUT MICROBIOTA MAY IMPACT
ON OBESITY
Thus far this review has focussed on studies in which differences in the
microbiota of lean and obese animals and humans and the impact of diet on
these microbial populations were investigated. However, a key question is
how these microbial populations are impacting on weight gain. In this section
mechanisms via which these gut microbes can impact on obesity is
discussed (see also Fig 3).
1.7.1 Energy extraction, leptin, Fiaf and AMPK
As noted briefly above, the gut microbiota is capable of the breakdown of
otherwise indigestible components of the mammalian diet, thus affecting the
energy balance. In 2004 (Backhed et al.) analysed germ free (GF), CONV-R
and conventionalized (CONV-D) mice to examine the hypothesis that the
microbiota acts through host signalling pathways to regulate energy storage
in the host. GF mice are raised in the absence of any microbiota, while
CONV-D mice are initially germ free but are then colonized with the
microbiota from CONV-R donors. The study found that CONV-R animals had
42% more total body fat and 47% more epididymal fat pad weight than GF
mice and that their epididymal fat pad weights were significantly greater. This
was despite the fact that their consumption of chow was 29% less than their
GF counterparts. CONV-D mice had 57% greater total body fat content and
61% greater epididymal fat pad weight than GF mice. Like CONV-R mice,
CONV-D animals also consumed less food, in this case 27% less than GF
mice. Increased energy expenditure by GF mice was excluded as an
explanation for the decreased body fat content of GF mice as these animals
were shown to have a metabolic rate that was 27% lower than either CONV-
R or CONV-D mice. Further investigation revealed that microbial colonization
caused an increase in leptin levels which was proportional to the increase in
body fat. Leptin is mainly an adipocyte-derived hormone which reduces food
intake and increases energy expenditure in mice and thus the impact of the
microbiota on leptin levels may be of importance (Maffei et al., 1995,
Pelleymounter et al., 1995). An increased in lipoprotein lipase (LPL) has also
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been observed in the epididymal fat pads of CONV-D mice compared with
GF mice. This is significant as LPL is a vital regulator in the release of fatty
acids from lipoproteins in muscle, heart and fat (Preiss-Landl et al., 2002).
Notably, the Bäckhed study also showed that the presence of a microbial
population in the gut promotes increased monosaccharide uptake (Backhed
et al., 2004). Analysis of the gut microbiome by (Turnbaugh et al., 2006) also
revealed that the gut microbiome of ob/ob mice had an increased capacity to
ferment polysaccharides compared to the lean-associated equivalent. It was
thus postulated that this could lead to more energy being extracted from
complex carbohydrates, leading to increased energy in the host. Bomb
calorimetry supported this theory, in that it was found that stool samples from
obese mice contained less energy than their lean counterparts. To test this
idea further, GF mice were colonised with the gut microbiota from ob/ob or
+/+ donors. Noticeably the mice colonized with the ob/ob microbiota had a
significantly greater percentage increase in body fat over 2 weeks than mice
colonized with a +/+ microbiota. This prompted further investigation and in
2007 Bäckhed and colleagues again studied GF and CONV-R mice to
establish if GF mice are resistant to DIO (Backhed et al., 2007). After being
fed a ‘western’ diet for 8 weeks it was again found that CONV-R mice had
gained significantly more weight than their germ free counterparts and, as
had been found previously (Backhed et al., 2004), the epididymal fat pad
weights were also significantly greater in conventionalised mice than GF
mice. GF mice fed a ‘western’ diet for 8 weeks showed no significant weight
gain when compared to GF mice on a low fat diet. However, unlike the
previous cited investigation, it was found that the amounts of chow
consumed by CONV-R and GF mice were similar. Notably, it was
established that GF mice had higher levels of Fiaf (fasting induced adipose
factor) expression in the intestine than CONV-R mice. Fiaf is a circulating
lipoprotein lipase inhibitor whose expression is normally selectively
suppressed in the gut epithelium by the microbiota (Backhed et al.,
2004).The relevance of Fiaf expression was highlighted when it was
established that when GF wild type and Fiaf--/-- mice were fed a ‘western
diet’, Fiaf deficient animals gained significantly more weight and had
significantly greater epididymal fat pads than their wild type littermates
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(Backhed et al., 2007). Higher levels of LPL activity (67%) in the epididymal
fat pads of Fiaf--/-- mice compared to GF wild type mice was also noted
(Backhed et al., 2004). GF mice were also found to have increased skeletal
muscle and liver levels of phosphorylated AMP activated protein kinase
(AMPK). AMPK is a heterotrimeric enzyme that functions as a “fuel gauge”
that monitors cellular energy status. Increased intracellular ratios of AMP to
ATP results in its activation (McNeil, 1984). 40% and 50% higher levels of
AMPK and AMP, respectively, were found in the gastrocnemius muscle
harvested from GF mice than CONV-D mice fed a ‘western diet’. This
indicates that GF mice are sheltered from diet induced obesity by two
mechanisms that result in increased fatty acid metabolism i.e. elevated levels
of Fiaf and AMPK (Backhed et al., 2007).
As discussed briefly above, (Hildebrandt et al., 2009) investigated the
effects of a high fat diet on WT and RELMβ KO mice. Higher levels of
RELMβ expression were observed in high fat diet mice when compared to
mice fed a standard chow diet. It was also noted that oral treatment of mice
with antibiotics reduced the expression of colonic RELMβ in both mice fed a
standard chow or a high fat diet. Thus it was concluded that the induction of
RELMβ expression by a high fat diet is dependent upon the commensal gut
microbiota. It was noted that although KO and wild type mice weighed the
same at 13 weeks of age when fed a standard chow diet, following 21 weeks
on a high fat diet RELMβ KO mice displayed diminished weight gain due to a
decreased build up of fat mass compared with the wild type controls. This
difference was not due to an alteration in food intake, fat absorption or core
body temperature and it was also established that RELMβ KO mice did not
exhibit any differences with respect to physical activity when compared to
wild type controls during the period. However, indirect calorimetry revealed
that the relative reduction in diet induced obesity in KO mice was caused by
an increase in energy expenditure. Further analysis also revealed that the
expression of a collection of genes encoding ABC transporters was
increased in wild type mice fed the high fat diet when compared to
expression of the same genes in wild type mice on a standard chow diet. The
corresponding proteins are responsible for the transport of lipids, sugars and
peptides as well as metals. Expression of genes for amino acid metabolism
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and carbohydrate metabolism were relatively decreased. In summary, the
results from this study demonstrate the importance of diet as a determinant
of gut microbiome composition and suggest the need to control for dietary
variation when evaluating the composition of the human gut microbiome.
The possibility that manipulation of the gut microbiota with B. breve
might influence the fatty acid composition of host tissues has been
investigated by (Wall et al., 2009). In this study different animal models were
fed with B. breve NCIMB 702258, which was selected because of its ability to
synthesize bioactive isomers of conjugated linoleic acid (CLA) from free
linoleic acid. The authors hypothesised that the administration of NCIMB
702258 could have an anti inflammatory impact by virtue of this metabolite.
An 8 week dietary intervention study involving BALB/c mice showed that the
cis-9, trans-11 CLA (c9,t11 CLA) content of the livers of mice fed the B.
breve and a linoleic acid substrate was 2.4-fold higher than in the control
mice. This CLA isomer has been previously shown to exhibit a number of
beneficial activities in experimental animal models and human cell culture
studies including the ability to reduce body fat and to bring about anti-
diabetic effects (Terpstra, 2004, de Roos et al., 2005, Moloney et al., 2007).
These studies should be distinguished from those involving the cis-12, trans-
10 CLA isomer, which can have negative effects (Poirier et al., 2005, Poirier
et al., 2006). The c9,t11 CLA content of the large intestine, small intestine,
caecal contents and faeces of these test mice was also higher than that of
controls. In the same study, the supplementation of the diet of severe
combined immunodeficient (SCID; most frequently employed as animal
models of inflammatory bowel disease) mice with B. breve and linoleic acid
resulted in 4-fold higher levels of c9,t11 CLA in the liver than the group
receiving linoleic acid alone. Examination of the former group also revealed
3.0- and 2.0-fold higher levels of c9,t11 CLA in the large intestines and ceca,
respectively. Indeed, all tissues from SCID mice fed pure c9,t11 CLA had
higher levels of this compound when compared with those fed linoleic acid
alone. It was also noted that levels of eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA) in adipose tissue in mice supplemented with B.
breve alone were 3 fold higher than the corresponding tissue from control
mice. EPA and DHA are also known to exert anti-inflammatory properties.
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From corresponding porcine studies it was established that the livers of pigs
fed the B. breve strain and linoleic acid had 1.5-fold greater c9,t11 CLA
levels than those from unsupplemented controls. Overall this study showed
that the fatty acid composition of host tissue can be positively influenced by
the oral administration of a metabolically active commensal acting on a
dietary substrate.
The occurrence of sexual dimorphism in the mouse model in relation
to total body fat content (TBFC) was observed in a recent study (Mestdagh et
al., 2011). It was demonstrated that male mice had a significantly higher
TBFC than female mice. Interestingly GF male and female mice did not
display this sexual dimorphism. GF animals showed lower brown adipose
tissue lactate levels and circulating levels of very low density lipoprotein
while greater levels of (D)-3-hydroxybutyrate in liver, plasma and brown
adipose tissue. These results imply that the gut microbiota adjust the lipid
metabolism in brown adipose tissue as the loss of gut microbiota inhibits
lipogenesis while also promoting hepatic and brown adipose tissue lipolysis.
1.7.2 Short chain fatty acids
Faecal SCFAs are predominantly produced from the fermentation of fibre in
the large intestine by bacteria. In the absence of these intestinal microbes,
the host would not be able to completely hydrolyse this fibre. These SCFAs,
consisting mainly of acetate, propionate and butyrate, represent an additional
source of energy and, indeed, it is estimated that microbially generated
SCFAs provide 10% of the total dietary energy supply in humans (McNeil,
1984). SCFA levels were investigated in the previously referred to study by
(Schwiertz et al., 2009). In total, 98 volunteers (34 males and 64 females)
were analyzed and their stool samples revealed the presence of acetate,
propionate, butyrate and valerate as well as iso-valerate and iso-butyrate. It
was noted that the samples from obese volunteers had 20% higher mean
total SCFA concentrations than those from lean volunteers. Of the SCFA,
propionate levels were most dramatically increased in this group (41%),
followed by levels of butyrate (28%), valerate (21%) and acetate (18%). In
contrast, the iso-SCFAs concentrations did not differ considerably. In 2007
(Duncan et al.) measured the changes in faecal SCFA in response to
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changes in dietary intake of carbohydrates. Volunteers were given a
maintenance (M) (13% protein, 52% carbohydrate and 35% fat) diet for 3
days. After this they were given a high protein (30%), low carbohydrate (4%)
(HPLC) diet or a high protein (30%), moderate carbohydrate (35%) (HPMC)
diet for 4 weeks. The analysis of faecal samples revealed that concentrations
of SCFA were lower when the volunteers were in receipt of the HPLC and
HPMC diets than when they consumed the M diet. While the concentrations
of the predominant SCFAs, i.e. acetate, propionate and valerate, decreased
due to the shift from the maintenance to the low carbohydrate diets (50%),
butyrate levels decreased even more dramatically (75%). Notably, a linear
relationship existed between carbohydrate intake and butyrate concentration.
In contrast, although (Murphy et al., 2010) did find that the faecal energy
content of ob/ob mice was decreased and caecal SCFA concentrations
increased at 7 weeks of age relative to lean controls, these patterns did not
continue with time and were not observed in DIO mice. The (Murphy et al.,
2010) study also indicated that SCFA concentrations were unrelated to
changes in proportions of Firmicutes, Bacteroidetes or Actinobacteria. These
findings suggest that the connection between the microbial composition and
energy harvest capacity is more complex than previously thought.
1.7.3 LPS-mediated impacts on obesity
Obesity and metabolic syndrome are associated with low grade
inflammation, and data from several studies provides evidence that the
lipopolysaccharide (LPS) endotoxin derived from certain components of the
gut microbiota contributes to the increased development of adipose tissue
and impaired glucose tolerance in obesity. LPS is a component of the Gram
negative bacterial cell wall and is composed of lipid and a polysaccharide.
The impact of LPS on the host is mediated through the toll-like receptor 4
(TLR4)/MyD88/NF-κB signalling pathway. Endogenous LPS is continuously 
produced in the gut as a consequence of the death of Gram-negative
bacteria and is absorbed into capillaries of the intestine through a TLR4-
dependant mechanism. In 2007, (Cani et al.) showed that LPS could be an
early factor in the triggering of high-fat diet induced metabolic diseases. More
specifically, their data showed that high fat feeding caused plasma LPS
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concentrations to remain high throughout the whole day compared with
controls which showed dinural variations in plasma LPS concentrations. Due
to the fact that high fat feeding induced plasma LPS concentrations were
lower than values associated with septicemia and infections, the authors
defined this phenomenon as metabolic endotoxemia. To causally link high fat
diet increased LPS concentrations to metabolic disease, the authors
mimicked LPS concentrations of high fat feeding by implanting a
subcutaneous osmotic minipump in mice and continuously infused LPS or
saline for a month. It was then revealed that fasted glycemia, blood glucose,
fasted insulinemia, liver triglyceride content and body weight levels were
greater in mice infused with LPS than those infused with saline. Furthermore,
the magnitude of weight gain and visceral and subcutaneous adipose depots
in LPS infused mice was similar to that observed in mice fed a high fat diet. It
was also apparent that mRNA concentrations corresponding to the genes for
the main inflammatory factors involved in metabolic disease (i.e. tumor
necrosis factor (TNF)-α, interleukin (IL)-1, IL-6 and plasminogen activator
inhibitor (PAI)-1) were increased in both high fat diet and LPS infused mice.
In a further study, WT and CD14 mutant mice were intravenously infused
with LPS for 3 hours. It was noted that, as a consequence, levels of IL-6,
PAI-1, IL-1, phosphorylated nuclear factor-kB and IkappaB kinase (Claesson
et al., 2009) forms increased in WT mice whereas levels of the same factors
decreased or were unchanged in CD14 mutant mice. In addition, the body
weight, visceral and subcutaneous adipose depot weight and liver weight of
WT mice were increased but were unchanged in CD14 mutant mice.
The possibility that metabolic endotoxemia could be controlled by
changes of the gut microbiota has been examined by (Cani et al., 2008). This
involved a 4 week study during which mice were fed a control, or a high fat,
carbohydrate-free diet. While mice fed a high fat diet had increased plasma
LPS levels relative to controls, plasma LPS levels were not increased in high
fat diet mice treated with the antibiotics ampicillin and neomycin. This study
also revealed that the high fat diet significantly increased intestinal
permeability through a mechanism that resulted in reduced expression of
ZO-1 and occludin, i.e. tight junction proteins. Antibiotic treatment reversed
this effect, suggesting that gut bacteria affected by antibiotic administration
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are involved in the control of intestinal permeability and hence the
occurrence of metabolic endotoxemia.
A link may also exist between serum amyloid A (SAA) proteins and
LPS. SAA proteins are suspected mediators of inflammation and
atherosclerosis (Lewis et al., 2004, Yang et al., 2006, Urieli-Shoval et al.,
2000). Increased serum levels of SAA proteins have been linked with
obesity, chronic hyperglycemia, insulin resistance and cardiovascular
disease (Andersson et al., 2008, Johnson et al., 2004, Lin et al., 2001,
Ogasawara et al., 2004, Scheja et al., 2008, Yang et al., 2006). Four
functional SAA isoforms have been identified in mice i.e. SAA1-4. SAA3 is
the most abundant SAA isoform and, significantly with respect to the link
between LPS and obesity, its expression is induced in adipose tissue after
intraperitoneal administration of LPS (Reigstad et al., 2009). The human
isoform, SAA1, is most similar to the mouse SAA3 when their amino acid
sequences are compared. The expression of human SAA1 has been shown
to augument lipolysis in adipocytes (Yang et al., 2006) and increased
expression is observed in hypertrophic adipocytes of obese humans
(Sjoholm et al., 2005). (Scheja et al., 2008) showed that SAA3 is also up-
regulated in the adipose tissue of mice fed a high-fat diet and proposed that
SAA3 could be a mediator of the chronic inflammation associated with insulin
resistance in obesity. (Reigstad et al., 2009) took these investigations a step
further by comparing levels of SAA3 mRNA in adipose and intestinal tissue
from GF and CONV-R mice to determine if components of the gut microbiota
impacted on SAA3 levels. It was established that SAA3 mRNA levels in
adipose tissue were significantly higher (9.9 fold) in CONV-R mice than in
GF mice, whereas SAA1 and SAA2 levels did not increase significantly in
these tissues. With respect to the gut, an analysis of cDNAs from the
duodenum, jejunum, ileum and proximal colon revealed that SAA3 mRNA
levels were highest in the colon of both GF and CONV-R mice and that, here
too, SAA3 mRNA levels were significantly higher (7.0 fold) in CONV-R mice
than GF controls. Expression of TNF-α, a commonly expressed cytokine with
a likely role in chronic inflammatory disease and a known regulator of SAA3
expression, was also found to be significantly higher in the colon of CONV-R
mice. Co-staining of colonic sections from CONV-R mice revealed that SAA3
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is expressed by the intestinal epithelial cells and intraepithelial macrophages
which may contribute to the elevated SAA3 levels identified in the colon of
these animals. Indeed, the treatment of CMT-93 colonic epithelial cell lines
and RAW 264.7 mouse macrophages with increasing concentrations of
purified E. coli LPS caused a concentration-dependent increase in SAA3
mRNA levels. More specifically, a 27-fold increase was observed in the
CMT-93 cells upon the addition of 1µg/ml LPS. Furthermore, SAA3 mRNA
levels also increased in RAW 264.7 macrophages treated with 1µg/ml LPS,
but only to a maximum of 1.6 fold. The authors speculated that mouse SAA3
might be functionally similar to human SAA1 and could represent a link
between low grade microbiota-induced inflammation and obesity.
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1.8 CONCLUSION
The debate regarding the significance of the Firmicutes:Bacteroidetes ratio
with respect to obesity is still ongoing, and the basis for differences between
the various studies investigating this phenomenon has not yet been
established. While differences in host genetics represent an obvious
variable, other factors such as the degree of weight change, the severity of
calorie restriction and/or the duration of the study are just some of a number
of other important factors. Possibly the most important of these factors
relates to diet associated differences in the composition of the gut
microbiota. The question as to whether specific populations are responsible
for weight gain or are simply flourishing as a consequence of the diet being
consumed (i.e. are these populations a ‘cause’ or an ‘effect’) remains a key
one. The use of GF mice and mice conventionalized with known microbial
species should help to reveal the influence of specific populations on host
health and in turn reveal therapeutic targets in the fight against obesity.
Further investigations, combined with the ever increasing capacity of next
generation sequencing technologies, and the standardization of methods to
facilitate comparisons between studies will overcome the inconsistencies that
have plagued investigations into the link between human gut microbiota and
obesity. Such developments are crucial as the obesity epidemic is showing
no sign of abating and all possible treatments, including potentially the
targeting of specific components of the gut microbiota of overweight and
obese individuals, need to be considered.
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Table 1. Molecular methods used in studies discussed in this review.
Approach Description
Sequencing strategies employed to study
eubacterial (bacterial) populations
Shotgun sequencing Metagenomic DNA is randomly sheared into smaller fragments and sequenced at random to reveal information
regarding the functional potential and, to a lesser extent, composition of a microbial population.
16S rRNA amplicon sequencing Amplification of the 16S rRNA gene from eubacteria using degenerate PCR primers and sequencing thereof to
reveal information regarding the bacterial population present in the environment.
Sequencing Platforms
Sanger sequencing Dideoxy chain termination method in which fluorescent labelled ddNTPs or dNTPs are incorporated into the newly
synthesised DNA thereby preventing further synthesis and leaving products of different lengths. Products are
separated by size by gel or capillary electrophoresis.
Pyrosequencing Sequence by synthesis method involving the detection of pyrophosphate release upon incorporation of a known
nucleotide. A number of sequencing platforms, including the Roche-454 sequencers, employ this technology.
Illumina sequencing Sequence by synthesis method in which small DNA fragments are bound to a slide and amplified in clusters.
Double stranded DNA in the clusters is separated and sequenced. Lasers detect nucleotide addition and from this
the sequence of the DNA fragment is generated.
Other technologies employed to
investigate microbial ecosystems
Fluorescent in situ Hybridization Fluorescent labelled oligonucleotide probes used to identify taxa in situ through hybridization.
Denaturing Gradient Gel Electrophoresis
(DGGE)
Separation of DNA (usually 16S amplicons) based on GC content using gel electrophoresis and a denaturing agent
to differentiate between microbial populations.
Terminal Restriction Fragment Length
Polymorphism (T-RFLP) Separation of terminally labelled PCR amplicons that have been enzymatically digested with restriction enzymes.
Quantitative Real Time Polymerase Chain
Reaction (qPCR)
Modified form of PCR which allows for detection and quantification of fluorescent PCR amplicons or amplicons to
which fluorescent probes have attached, the fluorescence of which increases in line with increasing DNA
concentrations.
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Table 2. Culture independent methods used by studies in this review.*
Cohort/model Method Reference
ob/ob, ob/+ and +/+ mice 16S by Sanger (Ley et al., 2005)
Obese human on low calorie diets 16S by Sanger (Ley et al., 2006)
ob/ob, ob/+ and +/+ mice
16S by Sanger &
Pyrosequencing (Turnbaugh et al., 2006)
Humans on weight loss diets FISH (Duncan et al., 2007)
CD14 -/- and Wt mice FISH (Nadal et al., 2009)
ob/ob, +/+, CD14-/- and ob/ob CD14-/- mice DGGE and qPCR (Cani et al., 2008)
Children FISH and qPCR (Kalliomaki et al., 2008)
DIO mice and WT mice 16S by Sanger (Turnbaugh et al., 2008)
Overweight and normal weight pregnant women qPCR and FISH (Collado et al., 2008)
Adolescents on diets and exercise FISH (Santacruz et al., 2009)
Monozygotic and dizygotic human twins and mothers
16S by Sanger &
Pyrosequencing (Turnbaugh et al., 2009)
ob/ob mice DGGE and qPCR (Cani et al., 2009)
Lean, obese and post gastric bypass humans
16S by Sanger &
Pyrosequencing (Zhang et al., 2009b)
NMRI-KI mice on LF/HS, HF/HS or LF/PP diets qPCR (Zhang et al., 2009a)
Adolescents on diets and exercise qPCR (Walker et al., 2011)
Lean, overweight and obese humans qPCR (Schwiertz et al., 2009)
Hamsters
16S by Pyrosequencing,
DGGE & qPCR (Martinez et al., 2009)
Children qPCR
(Balamurugan et al.,
2009)
RELMβ Knockout and Wild type mice 16S by Pyrosequencing (Hildebrandt et al., 2009)
* Table done in chronological order
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Table 2. (continued)
Cohort/model Method Reference
Syrian hamsters DGGE, 16S Sanger and qPCR (Sonoyama et al., 2009)
Obese, lean and anorexic humans qPCR (Armougom et al., 2009)
Apoa-I-/- and Wt C57BL/6J mice
16S on DGGE, T-RFLP &
Pyrosequencing (Cani et al., 2007)
African Americans and Caucasian Americans DGGE, FISH and qPCR (Mai et al., 2009)
Humanized gnotobiotic mice 16S by Pyrosequencing (Turnbaugh et al., 2009 )
Overweight and normal weight pregnant women qPCR (Santacruz et al., 2010)
C57bI6/J mice DGGE and qPCR (Dewulf et al., 2011)
Lean and obese humans qPCR (Li et al., 2011)
HF-fed, ob/ob and Wt mice Pyrosequencing (Murphy et al., 2010)
Overweight and normal weight children FISH (Luoto et al., 2011)
Humans of different nationalities Sanger & Pyrosequencing (Arumugam et al., 2011)
Gnotobiotic mice Illumina shotgun sequencing ((Faith et al., 2011)
Wistar rats 16S Pyrosequencing (Furet et al., 2010)
Mammals Shotgun Pyrosequencing (Muegge et al., 2011)
JCR:LA-cp rats qPCR
(Parnell and Reimer,
2011)
Healthy humans
16S by Pyrosequencing & shotgun
metagenomics (Wu et al., 2011)
In vitro three stage colonic model FISH & DGGE (Shen et al., 2011))
* Table done in chronological order
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Table 3. Dietary related influences on gut microbiota.
Human
Diet Populations increasing Populations decreasing
Fat restricted Bacteroidetes (Ley et al., 2006) Firmicutes(Ley et al., 2006)
Carbohydrate restriction Bacteroidetes (Ley et al., 2006) Firmicutes (Ley et al., 2006)
Low carbohydrate/high protein Oscillibacter valerigens (Walker et
al., 2011)
Roseburia, E. rectale (Walker et al., 2011) &
Bifidobacterium (Duncan et al., 2007)
Calorie restriction & exercise Bacteroides fragilis, Lactobacillus
(Santacruz et al., 2009) &
Bacteroides (Nadal et al., 2009)
C. coccoides, B. longum, B. adolescentis
(Santacruz et al., 2009), C. histolyticum & E.
rectale-C. coccoides (Nadal et al., 2009)
Resistant starch Ruminococcus bromii, Oscillibacter
valerigens, Roseburia & E. rectale
(Walker et al., 2011)
High dietary fibre Bifidobacterium, Ruminococcus,
Lactobacillus-Enterococcus,
Faecalibacterium prausnitzii & E.
rectale-C. coccoides (Shen et al.,
2011)
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Table 3. (continued)
Animal
Diet Populations increasing Populations decreasing
High fat Mollicutes M2 cluster (Zhang et al.,
2009a)
Mollicutes M1 & M3 cluster,
Bifidobacteriaceae, (Zhang et al., 2009a)
Bacteroides, E. rectale-C. coccoides &
Bifidobacterium (Cani et al., 2007)
Western diet (high fat/high sugar) C. innocuum, E. dolichum, C.
mitsuokai & Bacilli (Turnbaugh et
al., 2009 )
Bacteroidetes (Turnbaugh et al., 2009 ) & E.
rectale (Mahowald et al., 2009)
Western diet reduced fat Bacteroidetes (Turnbaugh et al.,
2008)
Mollicutes (Turnbaugh et al., 2008) & E.
rectale (Mahowald et al., 2009)
Western diet reduced
carbohydrate
Bacteroidetes (Turnbaugh et al.,
2008)
Mollicutes (Turnbaugh et al., 2008)
Fasting Desulfovibrionaceae (Sonoyama et
al., 2009)
Clostridium (Sonoyama et al., 2009)
Increased casein E. rectale, D. piger & M. formatexigens (Faith
et al., 2011)
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Figure 1. The study of the role of the gut microbiota in obesity can be
subdivided into four broad areas.
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Figure 2. Next generation sequencing (NGS) – High throughput. Left – 16S
rRNA gene amplification using specific PCR primers followed by sequencing
to reveal eubacterial composition. Right – Random shearing of metagenomic
DNA into small fragments followed by sequencing to reveal functional
potential of bacterial population.
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Figure 3. Comparison of germ free and Conventionally raised mice with
respect to weight gain and associated biomarkers. Fasting induced adipose
factor (Fiaf), phosphorylated AMP activated protein kinase (AMPK),
lipoprotein lipase (LPL) and western diet (WD).
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2.1 ABSTRACT
Objective The gut microbiota is an environmental regulator of fat storage
and adiposity. Whether the microbiota represents a realistic therapeutic
target for improving metabolic health is unclear. This study explored two
antimicrobial strategies for their impact on metabolic abnormalities in murine
diet-induced obesity: oral vancomycin and a bacteriocin-producing probiotics
(Lactobacillus salivarius UCC118Bac+).
Design Male (7-week-old) C57BL/J6 mice (9-10/ group) were fed a low-fat
(lean) or a high-fat diet for 20 weeks with/without vancomycin by gavage at 2
mg/day, or with L. salivarius UCC118Bac+ or the bacteriocin negative
derivative L. salivarius UCC118Bac- (each at a dose of 1x109 cfu/day by
gavage). Compositional analysis of the microbiota was by 16S rDNA
amplicon pyrosequencing.
Results Analysis of the gut microbiota showed that vancomycin treatment
led to significant reductions in the proportions of Firmicutes and
Bacteroidetes and a dramatic increase in Proteobacteria, with no change in
Actinobacteria. Vancomycin-treated high-fat-fed mice gained less weight
over the intervention period despite similar caloric intake, and had lower
fasting blood glucose, plasma TNF-α and triglyceride levels compared with
diet-induced obese controls. The bacteriocin producing probiotic had no
significant impact on the proportions of Firmicutes but resulted in a relative
increase in Bacteroidetes and Proteobacteria and a decrease in
Actinobacteria compared with the non bacteriocin-producing control. No
improvement in metabolic profiles was observed in probiotic-fed diet-induced
obese mice.
Conclusion Both vancomycin and the bacteriocin-producing probiotic
altered the gut microbiota in diet induced obese mice, but in distinct ways.
Only vancomycin treatment resulted in an improvement in the metabolic
abnormalities associated with obesity thereby establishing that while the gut
microbiota is a realistic therapeutic target, the specificity of the antimicrobial
agent employed is critical.
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2.2 SIGNIFICANCE OF THIS STUDY
What is already known about this subject?
 The gut microbiota is an environmental regulator of fat storage and
adiposity.
 We and others have shown the primacy of diet in influencing the
microbiota in obesity.
 The composition of the gut microbiota is significantly altered in obesity
and diabetes in both animal and human studies.
 It has been suggested that alteration in microbial composition
increases the risk of obesity because of enhanced energy harvest
from dietary intake.
What are the new findings?
 Vancomycin and the bacteriocin-producing probiotic produced
distinctive modifications in the gut microbiota in diet-induced obese
mice at the phylum, family and genus levels.
 To our knowledge, this is the first report to establish that a bacteriocin
produced by a probiotic can substantially alter the composition of the
gut microbiota in vivo.
 However, only vancomycin treatment resulted in an improvement in
the metabolic abnormalities associated with obesity.
 Our findings provide further confirmation for the role of the microbiota
in metabolic dysregulation and a supporting rationale for altering the
microbiota as a prophylactic strategy using antimicrobial agents,
including bacteriocins, but specificity of action will be crucial.
How might it impact on clinical practice in the foreseeable future?
 These findings indicate that therapeutic manipulation of the microbiota
may be a useful strategy in the prevention or management of obesity
and metabolic disorders.
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2.3 INTRODUCTION
The basis of the modern obesity epidemic in developed societies is complex
and involves a contribution from genetic susceptibility and, more importantly,
changes in diet and other lifestyle elements. In addition, the molecular event
underlying the pathogenesis of the metabolic abnormalities of obesity are
incompletely understood and interventions to treat them are poorly
developed. A body of work has recently implicated alterations of the gut
microbiota as a contributory factor to obesity-related metabolic dysregulation
(Ley, 2010, Tilg and Kaser, 2011).
The composition of the gut microbiota is significantly altered in obesity
and diabetes in both animal and human studies and is characterised by
reduced diversity (Larsen et al., 2010, Ley et al., 2005, Ley et al., 2006,
Turnbaugh et al., 2008, Turnbaugh and Gordon, 2009, Turnbaugh et al.,
2006). It has been suggested that this alteration in microbial composition
increases the risk of obesity because of enhanced energy harvest from
dietary intake (Turnbaugh et al., 2008, Turnbaugh and Gordon, 2009,
Turnbaugh et al., 2006). We and others have demonstrated that, in murine
models, changes in the gut microbiota in response to diet and obesity are
dissociated from markers of energy harvest over time, suggesting that
mechanisms other than energy harvest may contribute to microbiota-induced
susceptibility to obesity and metabolic diseases (Bajzer and Seeley, 2006,
Hildebrandt et al., 2009, Murphy et al., 2010). In this regard, the gut
microbiota and associated products such as lipopolysaccharides and short-
chain fatty acids have been reported to regulate gene expression, and
thereby alter energy expenditure and storage through host related
mechanisms (Cani et al., 2007a, Cani et al., 2008, Cani et al., 2007b,
Samuel et al., 2008). However, it is unclear if the microbiota represents a
realistic therapeutic target for improving metabolic health.
The composition of the microbiome is dynamic and adaptable, and a
number of strategies including antibiotics, prebiotics and probiotics have the
potential to influence host metabolism favourably by targeting the gut
microbiota. In this study, we explored two antimicrobial strategies for their
impact on metabolic abnormalities in murine diet-induced obesity: oral
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vancomycin and a bacteriocin-producing probiotics Lactobacillus.
Vancomycin exhibits anti-Firmicutes activity and has limited systemic effects
(Moellering, 2006, Pultz et al., 2005, Yap et al., 2008), while Lactobacillus
salivarius UCC118 is a genetically well characterised probiotic strain that
produces a broad-spectrum class II bacteriocin, Abp118, and has previously
been shown to protect mice from infection by Listeria monocytogenes (Corr
et al., 2007, Claesson et al., 2006, Flynn et al., 2002). The availability of a
bacteriocin-negative (Bac-) derivative of L. salivarius UCC118 allowed for the
direct assessment of the effect of the bacteriocin on the gut microbiota and
its impact on metabolic dysregulation. The results show that the antimicrobial
agents modulated the gut microbiota in different ways, but only vancomycin
treatment resulted in an improvement in metabolic markers in diet-induced
obesity. These findings indicate that therapeutic manipulation of the
microbiota may be a useful strategy in the prevention or management of
obesity and metabolic disorders.
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2.4 MATERIALS AND METHODS
2.4.1 Animals
C57BL/6J male mice, aged 3-4 weeks, were obtained from Harlan (Oxon,
UK) and housed under barrier-maintained conditions within the biological
services unit, University College Cork (UCC). Mice were allowed to
acclimatise for 3-4 weeks before the start of the study. All experiments were
approved by the UCC Animal Ethics Committee and experimental
procedures were conducted under licence from the Irish government.
2.4.2 Experimental design
To assess the impact of the two antimicrobial strategies on metabolic
abnormalities in murine diet-induced obesity, 7-week old male C57BL/J6
mice (9-10 per group) were fed either a low fat diet (control; 10% calories
from fat; Research Diets, New Jersey, USA; #D12450B), a high-fat diet (diet-
induced obesity; 45% calories from fat; Research Diets; #D12451) for 20
weeks or a high-fat diet for 20 weeks including an 8 week oral treatment from
weeks 12 to 20 with either 2 mg/day of vancomycin (Sigma Aldrich, UK), the
bacteriocin-producing probiotic L. salivarius UCC118Bac+ at 1x109 cfu/day,
or L. salivarius UCC118Bac- at 1x109 cfu/day. All mice were gavaged and
phosphate-buffered saline was used as the vehicle control for the
vancomycin-treated group. An initial study was undertaken to establish that
vancomycin at a dose of 2 mg/day did not alter the health status of mice and
was effective at altering the components of the gut microbiota in mice, using
traditional plating methods, as outlined in the supplementary materials and
methods.
2.4.3 Probiotic production
The bacteriocin-negative derivative L. salivarius UCC118Bac- was generated
as described by Corr et al., 2007. Both the L. salivarius UCC118Bac+ and the
L. salivarius UCC118Bac- were grown in MRS broth media for 24 h at 37oC,
harvested by centrifuge and freeze dried. The powders were resuspended in
water for delivery to the mice.
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2.4.4 Weights and tissue sampling
Body weight and food intake were assessed weekly. At the end of the study,
fat and lean body mass were measured using a Minispec mq benchtop NMR
spectrometer (Bruker Instruments, Rheistetten, Germany), after which they
were killed and necropsied. Internal organs (liver and spleen) and fat pads
(reproductive, renal, mesenteric and inguinal) were removed, weighed and
stored at -80oC.
2.4.5 DNA extractions and amplicon sequencing
Total metagenomic DNA was extracted from individual faecal samples and
16S ribosomal RNA gene tags of the V4 region were amplified, sequenced
and subjected to in-silico analysis as described in the supplementary
materials and methods and by Murphy et al., 2010. Real-time quantitative
PCR was used to determine total bacterial numbers (16S rRNA gene
copies), and hierarchical clustering was used to provide an overview of the
data, as outlined in the supplementary materials and methods.
2.4.6 Metabolic markers
Mice were fasted for 5-6 h and blood glucose was determined using a
Coutour glucose meter (Bayer, UK) on 1 ml of blood collected from the tip of
the tail vein. Blood was collected by cardiac puncture from fasted mice and
plasma obtained. Tumour necrosis factor alpha (TNF-α) was measured in 25
ml of plasma using an ultrasensitive kit from MesoScale Discovery
(Gaithersburg, Maryland, USA), and plasma insulin concentrations were
determined in 5 ml of plasma using an ELISA kit (Mercodia, Uppsala,
Sweden) as per the manufacturer’s instructions. Plasma free fatty acids were
determined using a Wako kit (Wako, Germany) and plasma triglyceride
levels were determined on 3 ml of plasma using infinity triglyceride liquid
stable reagent (Thermo Scientific, Middletown, Virginia, USA). The lipids
from 50 mg of frozen liver were extracted according to the Folch method
(Folch et al., 1957), and triglyceride levels were determined using infinity
triglyceride liquid stable reagent (Thermo Scientific).
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2.4.7 Statistical analysis
Data for all variables were normally distributed and allowed for parametric
tests of significance. Data are presented as mean values with their SEM.
Statistical analysis was performed by analysis of variance and Student’s t
test (Graph-Pad Software, San Diego, CA, USA).
63
2.5 RESULTS
2.5.1 Diet-induced obesity alters the composition of the gut microbiota
As expected, diet-induced obese mice gained significantly more body weight
compared with lean controls over the 20-week feeding period, and this
increase in body weight (41.75±1.12 vs 33.22±0.92 g; p<0.001) was
attributable to an increase in fat mass alone (16.03±0.77 vs 6.27±0.61;
p<0.001). Diet-induced obese mice consumed significantly more calories
than lean controls, as measured by the cumulative caloric intake over the 20-
week period of the study (7212±35 vs 6136±27 kJ/mouse; p<0.001).
At the end of the 20-week study, the composition of the gut microbiota
of individual mice was investigated by DNA sequencing (Roche-454 titanium,
Roche Diagnostics Ltd, West Sussex, UK) of 16S rRNA (V4) amplicons
generated from total faecal DNA. A total of 212,655 sequence reads was
generated, averaging 4,340 reads per faecal sample. Species richness,
coverage and diversity estimations were calculated for each dataset
(Supplementary Fig 1). Rarefaction curves for each group indicated that the
total bacterial diversity present was well represented. Of the reads, 173,444
(82%) were assigned at the phylum level, 100,282 (47%) at the family level
and 80,899 (38%) at the genus level. In agreement with previous studies, the
mouse faecal microbiota was dominated by Firmicutes and Bacteroidetes at
the phylum level (Table 1). Actinobacteria, Proteobacteria and
Deferribacteria were also detected but at lower proportions. Consistent with
the high levels of Firmicutes and Bacteroidetes detected, the most dominant
bacteria at the genus level were Clostridium, Lactobacillus and Bacteroides
(Table 1).
A comparison of the composition of the gut microbiota of lean and
diet-induced obese mice showed that high-fat feeding for 20 weeks was
associated with an increase in the relative proportions of Firmicutes (p<0.05)
and a decrease in Bacteroidetes proportions (p<0.05) compared with lean
controls (Table 1 and Supplementary Fig 2). At the family level, diet-induced
obesity in mice was associated with a relative increase in the proportions of
the Firmicutes class Lactobacillaceae (p<0.01) and a decrease in the
Bacteroidetes class Bacteroidaceae (p<0.05), while the abundance of
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Streptococcaceae (p<0.05) and Alcaligenaceae (p<0.05) increased and
decreased, respectively (Table 1 and Supplementary Fig 2). At the genus
level, the proportions of Lactobacillus (p<0.01) and Lactococcus spp.
(p<0.05) increased, while Bacteroides (p<0.001), Odoribacter (p<0.05) and
Sutterella (p<0.05) decreased in abundance (Table 1 and Supplementary Fig
2).
2.5.2 Vancomycin does not alter the health status of chow-fed mice
A preliminary investigation (outlined in the supplementary materials and
methods) was undertaken to determine if vancomycin treatment was
associated with any adverse health effects in healthy mice. The results
confirmed that vancomycin did not negatively affect body weight, appearance
or consistency of the stool in chow-fed C57BL/6 male mice at a dose of 2
mg/day over 4 weeks. In addition, culture-based microbial analysis of the
faeces of healthy mice confirmed that, at this dose, vancomycin impacted
specific microbiota elements, with a decrease in Enterococcus spp. (phylum
Firmicutes), an increase in total Enterobacteriaceae (phylum Proteobacteria)
and no change in either total anaerobes or Lactobacillus spp. (phylum
Firmicutes; see Supplementary Fig 3).
2.5.3 Vancomycin treatment alters the composition of the gut
microbiota in diet-induced obese mice
DNA sequencing-based analysis of the microbiota revealed that treatment of
diet-induced obese mice for 8 weeks with vancomycin at 2 mg/day resulted
in a significant reduction in the relative proportions of Firmicutes (p<0.01),
Bacteroidetes (p<0.001) and Deferribacteres (p<0.05), and a dramatic
increase in the proportions of Proteobacteria (p<0.001) compared with diet-
induced obese mice (Table 1 and Supplementary Fig 2). The increased
proportion of Proteobacteria was largely accounted for by an increased
percentage of Enterobacteriaceae (p<0.001), while the decrease in
Firmicutes and Bacteroidetes corresponded to a decrease in the proportions
of Clostridiaceae (p<0.001) and Bacteroidaceae (p<0.001), respectively, at
the family level (Table 1 and Supplementary Fig 2). Vancomycin treatment of
diet-induced obese mice also resulted in changes among less common
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families, such as a relative decrease in the proportions of
Porphyromonadaceae (p<0.001) and increases in the proportions of
Streptococcaceae (p<0.01), Desulfovibrionaceae (p<0.01) and
Alcaligenaceae (p<0.001). At the genus level, the proportions of Lactococcus
(p<0.001), Sutterella (p<0.001) and Desulfovibrio spp. (p<0.01) increased,
while Bacteroides (p<0.001), Clostridium (p<0.001) and Odoribacter spp.
(p<0.05) decreased (Table 1 and Supplementary Fig 2). The overall
proportions of Lactobacillus spp. were unchanged by vancomycin treatment
of diet-induced obese mice. Clustering of the data showed that diet-induced
obese mice treated with vancomycin grouped together at the phylum level
and separated well from lean and diet-induced obese mice (see
Supplementary Fig 4). Better separation of lean and diet-induced obese mice
was observed at the family and genus level (data not shown) than at the
phylum level.
2.5.4 L. salivarius UCC118 alters the composition of the gut microbiota
in diet-induced obese mice by a mechanism involving bacteriocin
production
Comparison of the L. salivarius UCC118Bac+ with the non bacteriocin-
producing strain, L. salivarius UCC118Bac-, showed that the production of
the antimicrobial agent altered the composition of the gut microbiota in diet-
induced obese mice. While the proportions of Firmicutes did not change,
feeding of L. salivarius UCC118Bac+ for 8 weeks resulted in a significant
increase in the relative proportions of Bacteroidetes and Proteobacteria, and
a decrease in the proportions of Actinobacteria compared with the
bacteriocin-negative derivative, L. salivarius UCC118Bac- (Table 2 and
Supplementary Fig 5). Consistent with these results, the increase in
Bacteroidetes corresponded to an increase in the Bacteroidaceae family and
the genus Bacteroides (Table 2 and Supplementary Fig 5). The decrease in
Actinobacteria corresponded to a decrease in Bifidobacteriaceae at the
family level and Bifidobacterium at the genus level (Table 2 and
Supplementary Fig 5). Hierarchical clustering showed that, consistent with
small changes, separation was not apparent between L. salivarius
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UCC118Bac+ and the non bacteriocin-producing strain, L. salivarius
UCC118Bac-, using this technique (see Supplementary Fig 6).
2.5.5 Total bacterial counts were altered by diet-induced obesity and
vancomycin treatment, but not by bacteriocin-production by L.
salivarius UCC118, in diet-induced obese mice
Quantitative PCR analysis revealed that total bacterial counts (16S rRNA
gene copies/g of stool) were significantly lower in the faeces of diet-induced
obese mice compared with lean controls (p<0.001; Fig 1A). Treatment of
diet-induced obese mice with vancomycin resulted in a further large
decrease in absolute faecal bacterial numbers compared with their diet-
induced obese counterparts (p<0.001; Fig 1A). In contrast, comparison of
treatment with L. salivarius UCC118Bac+ and its bacteriocin negative
derivative showed that bacteriocin production did not alter the total bacterial
numbers in the faeces of diet-induced obese mice (Fig 1B).
2.5.6 Antimicrobial strategies alter weight gain in diet-induced obese
mice
Treatment of diet-induced obese mice with vancomycin resulted in a
significant reduction in weight gain (p<0.05; Fig 2A) compared with diet-
induced obese mice, despite a large increase in caecum weight (p<0.0001)
relative to the caeca of diet induced obese controls (see Supplementary
Table 1). However, a recovery in the rate of body weight gain in the
vancomycin-treated diet-induced obese mice was evident after day 28 of the
intervention. For probiotic-fed mice, a statistically significant reduction in
weight gain was observed on treatment with L. salivarius UCC118Bac+ in
diet-induced obese mice compared with L. salivarius UCC118Bac- at days
14, 21 and 28 of the 8-week intervention period, but this effect did not persist
over time (Fig 2B). In addition, calorie intake was not altered by treatment
with vancomycin, L. salivarius UCC118Bac+ or L. salivarius UCC118Bac- in
diet-induced obese mice (Fig 2C).
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2.5.7 Vancomycin treatment, but not bacteriocin-production by L.
salivarius UCC118, improves metabolic markers in diet-induced obese
mice
We next investigated the metabolic consequences of perturbing the gut
microbiota using the two antimicrobial strategies. Comparison of lean and
diet-induced obese mice after 20 weeks of feeding showed that diet-induced
obese mice had elevated fasting blood glucose (p<0.001) and plasma insulin
(p<0.05), while there was no change in plasma triglycerides compared with
lean controls (see Supplementary Table 1). Treatment of diet-induced obese
mice with vancomycin for 8 weeks resulted in an improvement in fasting
blood glucose levels (p<0.05) and plasma triglyceride levels (p=0.06)
compared with diet-induced obese mice, while there was no change in
fasting insulin levels (see Supplementary Table 1). Diet-induced obese mice
were characterised by elevated liver weight (p<0.01) and liver triglyceride
levels (p<0.001) compared with lean controls. Interestingly, there was a trend
towards a reduction in liver weight (p=0.06) in vancomycin treated diet-
induced obese mice relative to diet-induced obese mice. However, liver
triglyceride levels were unaltered by vancomycin in diet-induced obese mice.
In contrast, comparison of L. salivarius UCC118Bac+ with the bacteriocin-
negative derivative showed that the bacteriocin-induced alterations in the gut
microbiota did not alter metabolic parameters in diet induced obese mice
(see Supplementary Table 2).
2.5.8 Vancomycin treatment is associated with reduced plasma TNFα
levels and TNFα mRNA levels in liver and visceral adipose tissues of
diet-induced obese mice
To investigate further the effect of vancomycin on metabolic health, the
plasma levels of TNFα and the gene expression of TNF-α, monocyte
chemoattractant protein 1 (MCP-1) and the macrophage differentiation
marker (F4+80) were assessed in the visceral adipose tissue and liver as
markers of inflammation. Diet-induced obesity in mice was associated with
an increase in plasma TNF-α (p<0.05) and an increase in the gene
expression of F4+80 (p<0.001), MCP-1 (p<0.001) and TNF-α (p<0.05) in
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visceral adipose but not liver tissue (Fig 3A,B). Treatment of diet-induced
obese mice with vancomycin resulted in a decrease in plasma TNF-α levels
(p<0.05) compared with diet-induced obese mice (Fig 3A), and this was
associated with a tendency towards a reduction in the gene expression of
TNF-α in both adipose (p=0.06) and liver (p=0.09) tissue. The gene
expression levels of F4+80 and MCP-1 in adipose or liver tissues were
unchanged in vancomycin-treated diet-induced obese mice compared with
diet-induced obese controls (Fig 3B).
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2.6 DISCUSSION
The findings show that although vancomycin and the bacteriocin-producing
probiotic, L. salivarius UCC118, altered the gut microbiota in diet-induced
obese mice in distinct ways, only vancomycin treatment resulted in an
improvement in the metabolic abnormalities associated with diet-induced
obesity.
In the present study, vancomycin was chosen for its ability to target
the Gram-positive component of the gut microbiota and its limited systemic
impact (Moellering, 2006, Pultz et al., 2005, Yap et al., 2008). In addition,
vancomycin exposure has been shown to alter significantly the host
metabolome in healthy mice (Yap et al., 2008) and the main components of
the gut microbiota in a human distal colon model (Rea et al., 2010). In the
current study, vancomycin treatment of diet-induced obese mice resulted in a
major alteration in the composition of the gut microbiota whereby the
respective proportions of the three dominant phyla were altered dramatically
with respect to each other, with a large reduction in Firmicutes, and in
particular the Bacteroidetes, and a dramatic increase in Proteobacteria.
These alterations were associated with a reduction in body weight gain and
an improvement in inflammatory and metabolic health of the host. In
particular, plasma TNF-α levels were reduced in vancomycin-treated diet-
induced obese mice compared with diet-induced obese controls, and this
corresponded to a trend towards a reduction in the gene expression of TNF-
α levels in the liver and visceral adipose tissues. In both in-vitro and in animal
models, an increase in TNF-α has been linked to tissue insulin resistance
(Yap et al., 2008, Hotamisligil et al., 1995, Hotamisligil et al., 1996,
Hotamisligil and Spiegelman, 1994). Other studies have shown that
modulation of the microbiota by broad-spectrum antibiotics results in a
reduction in metabolic endotoxaemia in both high-fat-fed and ob/ob mice,
and is associated with improvements in inflammation, glucose tolerance and
hepatic steatosis, possibly through a mechanism involving Toll-like receptors
(Ley et al., 2005, Cani et al., 2008, Membrez et al., 2008). However, whether
the effect on weight gain is sustained or is overcome by microbial
compensatory adjustments is unclear, and more long term studies in animal
70
models and humans are required. These data suggest that the ability of the
gut microbiota to regulate inflammatory responses in diet-induced obesity is
important in the interaction between gut microbes and obesity-related
metabolic dysfunction.
To our knowledge, this is the first report to establish that a bacteriocin
produced by a probiotic can substantially alter the composition of the gut
microbiota in vivo. We have also recently shown that the bacteriocin
produced by L. salivarius UCC118 alters the microbiota of pigs and healthy
chow-fed mice (Riboulet-Bisson et al., 2012). Bacteriocin production is
thought to confer a competitive advantage on the producing strain, enabling
it to dominate complex microbial populations (Abee, 1995, Cotter et al.,
2005, Klaenhammer, 1993). In this study, the bacteriocin produced by L.
salivarius UCC118 significantly altered the gut microbiota in diet-induced
obese mice by increasing the relative proportions of Bacteroidetes and
Proteobacteria and decreasing Actinobacteria compared with a bacteriocin-
negative derivative. While these observations suggest that bacteriocins can
play a significant role in determining the composition of gut bacterial
populations in vivo, the alterations did not confer beneficial effects on
metabolic health. Interestingly, the bacteriocin produced by L. salivarius
UCC118 reduced the proportions of Bifidobacteria in diet-induced obese
mice. A partial inhibition of Bifidobacteria by L. salivarius UCC118 has
previously been observed in in-vitro studies (Dunne et al., 1999).
Bifidobacteria have been shown to be positively correlated with improved
glucose tolerance and normalised inflammatory tone in high-fat-fed mice
(Cani et al., 2007b). These results suggest that while the gut microbiota is a
realistic target for addressing obesity-related metabolic dysfunction, the
specificity of the antimicrobial agent employed may be critical. Indeed,
distinct clusters or enterotypes in the human microbiome have been
described (Arumugam et al., 2011) and support the use of targeted
strategies.
While the proximate microbiota-related biomarkers of risk for obesity
and metabolic dysregulation remain to be determined, recent reports have
suggested an association between lactobacilli and the development of
obesity (Angelakis and Raoult, 2010, Armougom et al., 2009, Raoult, 2008).
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Indeed, Lactobacillus populations have been shown to be elevated in obese
subjects (Armougom et al., 2009) and subjects with diabetes (Larsen et al.,
2010). In addition, vancomycin treatment of patients with infective
endocarditis was associated with a significant increase in weight gain (Thuny
et al., 2010), leading the authors to speculate that this may be due to the
selection of Lactobacillus spp. by vancomyin in the gut. However, in the
present study, the introduction of L. salivarius UCC118 did not contribute to
weight gain in diet-induced obese mice. In addition, although higher levels of
Lactobacillus spp. were detected in diet-induced obese compared with lean
mice, treatment of diet-induced obese mice with vancomycin reduced the
rate of weight gain, without significantly affecting the proportions of
Lactobacillus spp. Other studies using lactobacilli as probiotics have shown
beneficial effects on metabolic health in animals (Aronsson et al., 2010, Kang
et al., 2010, Takemura et al., 2010) and humans (Kadooka et al., 2010,
Andreasen et al., 2010). These observations suggest that lactobacilli are not
related to the risk of obesity and strain-specific effects need to be taken into
account.
Recent reports have shown that the relationship between obesity, gut
microbiota and the risk of obesity is more complex than previously
considered (Bajzer and Seeley, 2006, Murphy et al., 2010, Schwiertz et al.,
2009, Duncan et al., 2008). In the present study, in agreement with others
(Ley et al., 2005, Ley et al., 2006, Turnbaugh et al., 2006) diet-induced
obesity was characterised by a relative increase in the proportions of
Firmicutes and a decrease in Bacteroidetes, and was also associated with a
decrease in total bacterial numbers. These results suggest that in addition to
altering the composition of the gut microbiota, obesity and diet may also alter
the total intestinal microbial load or ‘density’. Indeed, diet has been shown to
alter diversity and induce large and rapid changes in the gut microbiota
(Jumpertz et al., 2011, Turnbaugh et al., 2009). Furthermore, vancomycin
treatment of diet-induced obese mice resulted in a further large decrease in
total bacterial numbers, while the bacteriocin produced by L. salivarius
UCC118 did not alter microbial loads in diet-induced obese mice. Further
work is required to understand the role of variations in the total microbial load
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and diversity in obesity and related conditions and the significance of
changes in phylum proportions when the total bacterial load also varies.
In conclusion, our data demonstrate that while vancomycin and the
bacteriocin-producing probiotic produced distinctive modifications in the gut
microbiota in diet-induced obese mice, vancomycin treatment alone resulted
in an improvement in the metabolic abnormalities associated with obesity.
Our findings provide further confirmation for the role of the microbiota in
metabolic dysregulation, and a supporting rationale for altering the
microbiota as a prophylactic strategy using antimicrobial agents, including
bacteriocins, but specificity of action will be crucial.
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Table 1 Vancomycin treatment of diet-induced obese mice results in a major
disturbance in the gut microbiota.
Lean DIO DIO + vancomycin
Phylum‡
Firmicutes 60.7±2.8 70.2±2.4* 53.9±0.4†††
Bacteroidetes 30.0±2.3 19.5±1.4* 3.5±1.9†††
Deferribacteria 7.1±2.2 4.7±1.6 0.7±0.3†
Proteobacteria 2.7±0.4 3.5±1.0 37.7±2.5†††
Actinobacteria 2.5±0.7 2.1±0.5 4.1±1.6
Family
Clostridaceae 30.6±4.1 25.4±3.0 3.9±1.5†††
Bacteroidaceae 16.0±1.2 11.6±1.0* 1.5±0.6†††
Lactobacillaceae 4.9±0.9 13.6±2.7** 19.3±4.3
Bifidobacteriaceae 2.4±0.7 1.2±0.5 4.1±1.6
Porphyromonadaceae 2.3±0.5 1.4±0.2 0.1±0.1†††
Alcaligenaceae 1.0±0.4 0.0±0.0* 6.9±0.9†††
Streptococcaceae 0.4±0.1 0.6±0.1* 2.0±0.5††
Desulfovibrionaceae 0.8±0.3 0.6±0.1 1.7±0.4††
Enterobacteriaceae 0.0±0.0 0.0±0.0 28.0±0.9†††
Genus
Clostridium 30.1±4.1 25.1±3.1 3.8±1.3†††
Bacteroides 7.4±0.7 3.3±0.5*** 0.3±0.1†††
Lactobacillus 4.9±0.9 13.5±2.7** 19.6±4.2
Odoribacter 2.5±0.5 1.1±0.2* 0.0±0.0†††
Bifidobacterium 2.4±0.7 1.2±0.5 4.1±1.6
Lactococcus 0.4±0.1 0.6±0.1* 1.6±0.2†††
Desulfovibrio 0.8±0.3 0.6±0.1 1.7±0.4††
Sutterella 1.0±0.4 0.0±0.0* 6.9±0.9†††
Statistical significance was determined using a two-tailed unpaired t test; p value ≤0.05*;
≤0.01**; ≤0.001*** between lean and diet-induced obese (DIO mice and p<0.05†; p<0.01††;
p<0.001††† between diet-induced obesity and Vancomycin-treated diet induced obese
mice. ‡Values are mean percentage read number ±SEM, n=9-10.
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Table 2 L. salivarius UCC118 alters the composition of the gut microbiota in
diet-induced obese mice by a mechanism involving bacteriocin production.
DIO + UCC118Bac+ DIO + UCC118Bac-
Phylum†
Firmicutes 66.9±3.3 72.4±1.6
Bacteroidetes 23.9±2.1 17.6±1.9*
Deferribacteria 6.1±2.2 3.4±1.0
Proteobacteria 1.6±0.2 1.1±0.2
Actinobacteria 1.5±0.4 5.2±1.4*
Family
Clostridaceae 15.5±2.6 22.0±2.5
Bacteroidaceae 14.4±1.3 8.0±0.7*
Lactobacillaceae 16.9±4.4 12.4±2.5
Bifidobacteriaceae 1.4±0.4 5.1±1.4*
Porphyromonadaceae 2.3±0.4 2.5±0.4
Streptococcaceae 0.8±0.1 0.7±0.1
Desulfovibrionaceae 0.7±0.2 1.2±0.7
Enterobacteriaceae 0.4±0.1 0.2±0.1
Genus
Clostridium 16.9±4.4 11.4±2.7
Bacteroides 4.4±0.5 2.1±0.5**
Lactobacillus 16.9±4.4 11.4±2.7
Odoribacter 2.3±0.4 2.5±0.4
Bifidobacterium 1.4±0.4 5.1±1.4*
Lactococcus 0.8±0.1 0.7±0.1
Statistical significance was determined using a two-tailed unpaired t test; p value ≤0.05*;
≤0.01**. †Values are mean percentage read number ±SEM, n=9-10. DIO, diet-induced
obese.
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Figure 1 Numbers of 16S rRNA gene copies/g stool in lean, diet-induced
obese (DIO) and vancomycin (vanco)- treated diet-induced obese mice (A)
and in diet-induced obese mice treated with the bacteriocin-producing
probiotic strain L. salivarius UCC118Bac+ and a non-bacteriocin-producing
derivative L. salivarius UCC118Bac– (B). Data represented as mean ±SME,
n=9-10, ***p<0.001.
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Figure 2 Weight gain (g) (A and B) and cumulative energy intake (KJ/mouse)
(C) over the 8-week intervention period in lean, diet-induced obese (DIO)
and vancomycin (vanco)-treated diet-induced obese mice and in diet-induced
obese mice treated with the bacteriocin-producing probiotic strain L.
salivarius UCC118Bac+ (1x109 cfu/day) and a non-bacteriocin-producing
derivative L. salivarius UCC118Bac- (1x109 cfu/day). Data represented as
mean ±SEM, n=9-10. *p<0.05.
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Figure 3 Vancomycin (vanco) treatment improves the inflammatory tone of
diet-induced obese (DIO) mice. Plasma tumour necrosis factor alpha (TNFα)
(pg/ml) (A) and gene expression levels of the macrophage differentiation
marker (F4+80), monocyte chemoattractant protein (MCP-1) and TNFα in
visceral adipose tissue and liver (B) in lean and diet-induced obese mice
(12weeeks of high-fat feeding followed followed by 8-week intervention with
vancomycin (2mg/day)). Data represented as mean ±SEM, n=9-10. *p<0.05;
***p<0.001. Values for gene expression are fold change ±SEM, n=9-10.
Expression is relative to β-actin.
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SUPPORTING INFORMATION
Supplementary Materials And Methods
The effect of vancomycin on the health status of chow-fed mice
An initial study was undertaken to establish that vancomycin at a dose of 2
mg/day does not alter the health status of mice and is effective at altering the
components of the gut microbiota in mice, using traditional plating methods.
Briefly, 7- week old male chow-fed C57BL/J6 mice (n=4) were gavaged with
PBS or 2 mg/d of vancomycin for 4 weeks. A clinical score sheet based on
weight, appearance, stool, physical signs and behaviour was kept daily. After
4 weeks of treatment, fresh faecal samples were collected under anaerobic
conditions and the total numbers of culturable Enterococcus spp.,
Enterobacteriaciae, total anaerobes and Lactobacillus spp. were determined
using Kenner Faecal Streptococcal (KF-Strep), Violet Red Bile Dextrose
(VRBD), Wilkins-Chalgren (WC) and Lactobacillus selection (LBS) agar,
respectively. Bacterial numbers were expressed as colony forming units
(CFU)/g faecal content.
DNA extractions and amplicon sequencing
Total metagenomic DNA was extracted from individual faecal samples using
the QIAamp DNA Stool Mini Kit (Qiagen, West Sussex, UK) coupled with an
initial bead-beating step. The microbial composition of these samples was
determined by pyrosequencing of 16S rRNA tags (V4 region; 239 nt long)
amplified using universal 16S rRNA primers predicted to bind to 94.6% of all
16S genes i.e. the forward primer F1 (5’-AYTGGGYDTAAAGNG) and a
combination of four reverse primers R1 (5’-TACCRGGGTHTCTAATCC), R2
(5’-TACCAGAGTATCTAATTC), R3 (5’-CTACDSRGGTMTCTAATC) and R4
(5’-TACNVGGGTATCTAATC) (RDP's Pyrosequencing Pipeline:
http://pyro.cme.msu.edu/pyro/help.jsp). The primers incorporated the
proprietary 19-mer sequences at the 5’-end to allow emulsion-based clonal
amplification for the 454 pyrosequencing system. Unique molecular identifier
(MID) tags were incorporated between the adaptamer and the target-specific
primer sequence, to allow identification of individual sequences from pooled
amplicons. Amplicons were cleaned using the AMPure purification system
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(Agencourt) and sequenced on a 454 Genome Sequencer FLX platform
(Roche Diagnostics Ltd, West Sussex, UK) according to 454 protocols.
Sequences were trimmed and quality checked with RDP pyrosequencing
pipeline. Reads with low quality scores (quality scores below 40) and short
length (less than 150bp for 16S rRNA V4 region) were removed as well as
reads that did not have exact matches with the primer sequence. Clustering
and statistical analysis of sequence data was performed using the MOTHUR
software package (Schloss and Handelsman, 2008). Trimmed fasta
sequences were then BLASTed (Altschul et al., 1997) against a previously
published 16S rRNA-specific database (Urich et al., 2008) using default
parameters. The resulting BLAST output was parsed using MEGAN (Huson
et al., 2007). MEGAN assigns reads to NCBI taxonomies by employing the
Lowest Common Ancestor algorithm which assigns each RNA-tag to the
lowest common ancestor in the taxonomy from a subset of the best scoring
matches in the BLAST result. Bit scores were used from within MEGAN for
filtering the results prior to tree construction and summarization (absolute
cutoff: BLAST bitscore 86, relative cutoff: 10% of the top hit) (Urich et al.,
2008). Unsupervised hierarchical cluster analyses were computed using
Pearson's correlation coefficient and Ward linkage (Ward Jr, 1963) and
applied to data that was dual scaled to the limits of -3 and 3. The heatplots
were generated using the "made4" library in R (Culhane et al., 2005).
Real-time quantitative PCR
RNA was isolated from liver tissue using the Absolute RNA Miniprep Kit from
Stratagene (Texas, US) and from adipose tissue using the RNeasy Lipid
Tissue Mini Kit from Qiagen (Maryland, US). Total RNA was quantified using
the Nanodrop (Thermoscientific, Wilmington, Delware, US) and the quality
assessed using the Bioanalyzer 2100 (Agilent Technologies, Palo Alto,
California, US). Single-stranded complementary DNA (cDNA) was
synthesisized from 1 μg total RNA using the reverse-transcription system
from Promega (Leiden, the Netherlands) according to the manufacturer’s
protocol. Quantitative reverse-transcription polymerase chain reaction (qRT-
PCR) was performed using 1 μl cDNA on the LightCycler 480 System using
the thermal cycling conditions as per the manufacturer's instructions (Roche
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Diagnostics GmbH, Germany). Polymerase chain reaction (PCR) primers
and probes were designed using the Universal Probe Library Assay Design
Centre (https://www.roche-applied-science.com/sis/rtpcr/upl/adc.jsp). All
samples were analyzed in duplicate and normalized to β-actin (as a
constitutively expressed control gene).
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Supplementary Table 1 Tissue weights and metabolic profiles of lean, diet-
induced (DIO) mice and in response to treatment of DIO mice with
vancomycin.
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Supplementary Table 2 Metabolic profiles of diet-induced (DIO) mice fed
the bacteriocin-producing probiotic L. salivarius UCC118Bac+ and a non-
bacteriocin-producing derivative L. salivarius UCC118Bac-.
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Supplementary Figure 1 Rarefaction curves for each group at 97%
similarity levels indicated that the total bacterial diversity present was well
represented. Number of operational taxonomic units (OTUs) identified as a
function of the number of sequence tags sampled.
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Supplementary Figure 2 Composition of the gut microbiota at the phylum,
family and genus level as determined by pyrosequencing of 16S rRNA tags
(V4 region) of lean, DIO and DIO mice treated with for 8 weeks with
vancomycin (2mg/day). Data outside the pie charts represent the mean
percentage read number for the corresponding colour coded family (n=9-10
per group).
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Supplementary Figure 3 Impact of the administration of 2mg/day of
vancomycin (V) compared to PBS (control (C)) for 4 weeks on components
of the murine faecal microbiota (n=3-4 per group) as determined using
culture-based approaches. The selective media employed were FK
Streptococcus (KF-Strep) agar for Enterococcus spp. (black bars), Violet
Red Bile Dextrose (VRBD) agar for Enterobacteriaciae (white bars), Wilkins-
Chalgren agar (WCA) for total anaerobes (dark grey bars) and Lactobacillus
selection agar (LBS) for Lactobacillus spp. (light grey bars). Data are
expressed as mean ± SD (n=3-4 per group; *p≤0.05 as determined by the
Mann- Whitney non-parametric test.
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Supplementary figure 4 Clustering of microbiota composition at phylum
level of lean, DIO and DIO mice treated with for 8 weeks with vancomycin
(2mg/day).
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Supplementary Figure 5 Composition of the gut microbiota at the phylum,
family and genus level of DIO mice treated with the bacteriocin-producing
probiotic strain L. salivarius UCC118Bac+ (1x109 cfu/day) compared to DIO
mice treated with a non-bacteriocin-producing derivative L. salivarius
UCC118Bac- (1x109 cfu/day). Data outside the pie charts represent the
mean percentage read number for the corresponding colour coded family
(n=10 per group).
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Supplementary figure 6 Clustering of microbiota composition at phylum
level of DIO mice treated with the bacteriocin-producing probiotic strain L.
salivarius UCC118Bac+ (1x109 cfu/day) compared to DIO mice treated with a
non-bacteriocin-producing derivative L. salivarius UCC118Bac- (1x109
cfu/day).
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Chapter 3
Targeting the microbiota to address diet-induced obesity:
a time dependent challenge
PloS One (2013) 8(6) e65790
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3.1 ABSTRACT
Links between the gut microbiota and host metabolism have provided
new perspectives on obesity. We previously showed that the link between
the microbiota and fat deposition is age- and time-dependent subject to
microbial adaptation to diet over time. We also demonstrated reduced
weight gain in diet-induced obese (DIO) mice through manipulation of the
gut microbiota with vancomycin or with the bacteriocin-producing
probiotic Lactobacillus salivarius UCC118 (Bac+), with metabolic
improvement achieved in DIO mice in receipt of vancomycin. However,
two phases of weight gain were observed with effects most marked early
in the intervention phase. Here, we compare the gut microbial populations
at the early relative to the late stages of intervention using a high
throughput sequencing-based analysis to understand the temporal
relationship between the gut microbiota and obesity. This reveals several
differences in microbiota composition over the intervening period.
Vancomycin dramatically altered the gut microbiota composition, relative
to controls, at the early stages of intervention after which time some
recovery was evident. It was also revealed that Bac+ treatment initially
resulted in the presence of significantly higher proportions of
Peptococcaceae and significantly lower proportions of Rikenellaceae and
Porphyromonadaceae relative to the gut microbiota of L. salivarius
UCC118 bacteriocin negative (Bac-) administered controls. These
differences were no longer evident at the later time. The results highlight
the resilience of the gut microbiota and suggest that interventions may
need to be monitored and continually adjusted to ensure sustained
modification of the gut microbiota.
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3.2 INTRODUCTION
Obesity is due to a surplus of energy intake over expenditure, resulting in
storage of excess energy as fat. However, this is only part of a bigger
story; an emerging theme is the relationship between the composition
and functionality of microorganisms in the gut with obesity (Cani and
Delzenne, 2011, Clarke et al., 2012, Flint, 2011, Greiner and Bäckhed,
2011, Ley, 2010). A corollary to this is the potential for manipulation of the
gut microbiota in the prevention and management of obesity and
associated metabolic disorders.
We previously showed that compositional changes in the faecal
microbiota associated with diet-induced obesity are time-dependent and
unrelated to markers of energy harvest, which change over time (Murphy
et al., 2010). Furthermore, we have previously investigated the impact of
administering the glycopeptide antibiotic vancomycin and the bacteriocin-
producing probiotic Lactobacillus salivarius UCC118 (Bac+) to diet-
induced obese (DIO) mice. Vancomycin resulted in an improvement in
the metabolic abnormalities associated with obesity, including a
significant reduction in weight gain, by the end of the intervention period.
In contrast, when compared with an isogenic non-bacteriocin producing
control (Bac-), the L. salivarius UCC118 Bac+ strain alters the gut
microbiota but did not significantly alter metabolic markers or weight gain
as measured at the end of the intervention period (Murphy et al., 2012).
While our initial report focused on the metabolic changes evident
upon completion of the intervention strategies, the temporal changes in
the microbiota need to be addressed further. The impact of vancomycin
intervention on weight gain was most considerable during the early
stages of intervention and a significant reduction in weight gain in mice
fed with the Bac+ strain was apparent when compared with their Bac- fed
counterparts (Murphy et al., 2012). Here, we analyse and compare the
gut microbial populations of these animals at the early (week 2) with the
late (week 8) intervention period. The results reflect the resilience of the
gut microbiota and show that therapeutic manipulation of the microbiota is
96
likely to be more complex than anticipated with sustained adjustment
likely to require multiple interventions over time.
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3.3 MATERIALS AND METHODS
3.3.1 Animals
3-4 week old male C57BL/6j mice were acquired from Harlan (oxon, UK)
and housed within the biological services unit, University College Cork.
UCC Animal Ethics Committee approved all experiments and
experimental procedures were conducted under licence from the Irish
government.
3.3.2 Experimental design
A low fat (lean) or high fat (DIO) diet was fed to male C57BL/J6 mice
(aged 7 weeks) for 12 weeks followed by an intervention period during
which the high fat diet was supplemented with the glycopeptide antibiotic
vancomycin, the bacteriocin producing (Bac+) L. salivarius UCC118, its
bacteriocin negative derivative (Bac-) or was unsupplemented (9-10
mice/cohort) for a period of 8 weeks. For full experimental design see
supplementary Fig 1 and Murphy et al., 2012.
3.3.3 DNA extraction and high-throughput amplicon sequencing
Individual mouse faecal samples were collected and DNA was extracted
on the same day of collection from fresh samples using the QIAmp DNA
Stool Mini Kit (Qiagen, Crawley, West Sussex, UK) combined with an
additional bead-beating step (30s x 3) and stored at -20oC. The
microbiota composition of the samples was established by amplicon
sequencing; universal 16S rRNA primers estimated to bind to 94.6% of all
16S genes (i.e. the forward primer F1 (5’-AYTGGGYDTAAAGNG) and a
combination of four reverse primers R1 (5’-TACCRGGGTHTCTAATCC),
R2 (TACCAGAGTATCTAATTC), R3 (5’-CTACDSRGGTMTCTAATC) and
R4 (5’-TACNVGGGTATCTAATC) (RDP’S Pyrosequencing Pipeline:
http://pyro.cme.msu.edu/pyro/help.jsp) were employed for PCR
amplification. Molecular identifier tags were attached between the 454
adaptor sequence and the target-specific primer sequence, allowing for
identification of individual sequences from the pooled amplicons. Ampure
purification system (Beckman Coulter, Takeley, UK) was used to clean
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the amplicons before being sequenced on a 454 Genome Sequencer
FLX platform (Roche Diagnostics Ltd, Burgess Hill, West Sussex, UK) in
line with 454 protocols at the Teagasc high throughput sequencing
centre. The amplicon sequences were deposited in the European
bioinformatics institute sequence read archive (EBI-SRA) accession
number ERP002448.
3.3.4 Real time quantitative PCR
Total bacterial numbers (16S rRNA gene copies per gram of wet stool
(Zhang et al., 2009)) were determined using real time quantitative PCR.
The 16S rRNA gene sequence of E. coli EPI300 was amplified using the
universal 16S primers 802R and 520F (Claesson et al., 2009). The
amplified products purified using the High Pure PCR Cleanup Micro Kit
(Roche Diagnostics Ltd, Burgess Hill, West Sussex, UK) were inserted
into the pCR4-TOPO Vector (Invitrogen, Bio-Sciences, Dublin Ireland)
and transformed into One Shot TOP10 Chemically Competent E. coli
(Invitrogen, Bio-Sciences, Dublin, Ireland). Plasmids were extracted using
the PureYield™ Plasmid Miniprep System (Promega, Madison,
Wisconsin, USA) and quantified on the NanoDrop™ 1000
Spectrophotometer (Thermo Fisher Scientific, Waltham, Massachusetts,
USA). Quantitative real time PCR (QPCR) was performed with SYBER-
green (Roche Diagnostics Ltd, Burgess Hill, West Sussex, UK) on the
lightcycler 480 (Roche Diagnostics Ltd, Burgess Hill, West Sussex, UK).
The standard curve was generated using dilutions of the plasmid DNA.
The following program was used to quantify total bacterial numbers: 95°C
for 5 min followed by 40 cycles of 95°C for 20 s, 51°C for 20s and 72°C
for 20 s followed by melting curve analysis of 95°C for 5 s, 46°C for 1 min,
and 97°C continuously and a final cooling at 40°C for 10 s. Samples
contained 2 μl of PCR grade water, 1 μl of 520F (0.15 μM), 1 μl of the
802R (0.15 μM), 1 μl template DNA, and 5 μl of SYBR green. Samples
and standards were run in triplicate. Negative controls were added to
each plate with template DNA being replaced with PCR-grade water. The
copy numbers of each sample were calculated from the standard curve
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and copies of 16S rRNA/g wet stool was calculated using a previously
outlined calculation (Zhang et al., 2009).
3.3.5 Bioinformatics sequence analysis
A locally installed RDP pyrosequencing pipeline was used to quality trim
the raw sequence data. Reads were removed that were shorter than the
main distribution (150bp for the 16S rRNA V4 region), of low quality and
not exact matches to barcoded tags and primer sequence. A locally
installed version of SILVA 16S rRNA database (Pruesse et al., 2007) was
used to BLAST (Altschul et al., 1997) the trimmed fasta sequence files
using default parameters. Resulting BLAST output files were parsed
through MEGAN (Huson et al., 2007a) which uses a lowest common
ancestor algorithm to assign reads to NCBI taxonomies. Prior to tree
construction and summarization filtering was carried out within MEGAN
using bit scores, similar to previous studies a bit-score cut-off of 86 was
selected (Urich et al., 2008, Rea et al., 2011). Alpha diversity indices
were generated using MOTHUR software (Schloss et al., 2009).
Clustering of sequence reads into operational taxonomical units (OTUs)
at 97% identity was achieved using QIIME suite software tools (Caporaso
et al., 2010). The ChimeraSlayer program was used to remove chimeric
OTUs from aligned OTUs and the FastTreeMP tool generated a
phylogenetic tree (Price et al., 2010, Haas et al., 2011). Beta diversities
were also calculated on the sequence reads based on weighted and
unweighted unifrac and bray curtis distances; subsequently principal
coordinate analysis (PCoA) and unweighted pair group method with
arithmetic mean (UPGMA) clustering was performed on the samples.
UPGMA clustering was visualised using Dendroscope software (Huson et
al., 2007b) while PCoA plots were viewed with KiNG viewer (Chen et al.,
2009). The nonparametric Kruskal-Wallis test (Kruskal and Wallis, 1952)
in the Minitab statistical package was employed to establish statistical
significance (significance taken to be p ≤0.05).
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3.4 RESULTS
3.4.1  diversity of the murine gut microbiota increases during the
intervention period
There is a significant reduction in weight gain in DIO mice at intervention
weeks 2-4 (early intervention period) in the Bac+ intervention, when
compared to Bac- intervention, but this does not persist with time (Fig 1A)
(Murphy et al., 2012). Vancomycin administration results in a two phase
reduction in weight gain in DIO mice. In phase one (early intervention
weeks 1-4) a significant reduction in weight gain relative to the initial start
weight is observed. In the second phase, DIO mice receiving vancomycin
gain weight relative to the initial start weight but weight change continues
to be significantly less than that in DIO controls (Fig 1B) (Murphy et al.,
2012). The relationship between these early intervention period-specific
observations and the gut microbiota were investigated through high
throughput DNA sequencing. A total of 86,103 V4 16S sequence reads,
corresponding to faecal pellets from mice at intervention week 2 of the
study, were generated. These corresponded to an average of 14,978
reads per group or 1,757 per mouse. These reads were analysed and
compared with 212,655 16S sequence reads generated from the mice at
intervention week 8 (Murphy et al., 2012). Shannon diversity, simpson
diversity and species richness estimations were calculated for each data
set (Fig 2). The Chao1 estimator of species richness reveals significant
differences in species richness with time in all populations, including lean
and DIO animals not exposed to interventions. Shannon diversity data
revealed a high level of biodiversity in all groups along with a significant
increase in diversity with time in all cohorts except those in receipt of a
lean diet only (Fig 2). The Simpson diversity index-based analysis, which
also takes account the number of species present and the relative
abundance of each species, particularly highlighted the significant
increase in diversity in animals in receipt of vancomycin as the
intervention period continued. Thus while a general increase in gut
microbial diversity was apparent as the mice aged, it was apparent that
exposure to vancomycin brought about an initially considerable reduction
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in diversity which was diminished with time. Goods coverage ranged
between 95% and 98% at week 2 and from 84% to 86% at week 8.
Rarefaction curves were seen to be approaching parallel or parallel
(Supplementary Fig 2) signifying that extra sampling would yield a limited
increase in species richness. Of the reads at week 2, 74,686 (87%) were
assigned at phylum level, 59,720 (69%) at the family level and 40,947
(48%) at genus level.
3.4.2 Taxonomical analysis highlights the temporal impact of
vancomycin on specific components of the gut microbiota
Analysis of the gut microbiota composition after 2 weeks established that
the major difference, at the phylum level, between the microbiota of the
lean and diet induced obese (DIO) mice is the presence of relatively
greater proportions of Firmicutes and relatively lower proportions of
Bacteroidetes in DIO mice when compared with lean mice (p value
≤0.05). At family level, significantly greater proportions of
Rhodospirillaceae, Lachnospiraceae, Streptococcaceae,
Lactobacillaceae, and Clostridiaceae in DIO mice were apparent when
compared to lean mice (p value ≤0.05), whereas significantly lower
proportions of Alcaligenaceae, Rikenellaceae, Bacteroidaceae and
Coriobacterineae were evident when DIO mice were compared with lean
mice (p value ≤0.05). At genus level, when the microbiota of DIO mice
were compared with that of lean mice, significantly more, Thalassospira,
Alistipes, Odoribacter and Bacteroides and significantly less Sutterella
Lactococcus, Turicibacter, Lactobacillus, Clostridium and Anaeroplasma
were observed (p value ≤0.05; Fig 3 & Supplementary Table 1).
High-throughput DNA sequence based analysis of the gut
microbiota at week 2 also revealed statistically significant differences at
phylum level between DIO and DIO vancomycin treated mice. Significant
decreases in proportions of Bacteroidetes and Deferibacteres (p value
≤0.05), but not Firmicutes, were noted in vancomycin treated DIO mice
compared with DIO mice. An increase in proportions of Proteobacteria (p
value ≤0.05) in DIO vancomycin treated mice was also evident. At family
level, proportions of Rhodospirillaceae, Rikenellaceae,
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Porphyromonadaceae, Bacteroidaceae, Ruminococcaceae,
Peptostrepococcaceae, Peptococcaceae, Erysipelotrichaceae, and
Deferribacteraceae (p value ≤0.05) were all relatively lower in the
vancomycin treated mice relative to DIO controls whereas proportions of
Alcaligenaceae, Enterobacteriaceae, Streptococcaceae, Lactobacillaceae
and Leuconostocaceae (p value ≤0.05) were all relatively greater in the
former group. At genus level relatively lower proportions of Thalassospira,
Alistipes, Rikenella, Parabacteroides, Odoribacter, Bacteroides,
Lachnospiraceae Incertae Sedis, Coprococcus, Ruminococcaceae
Incertae Sedis, Oscillibacter, Anaerotruncus, Turicibacter, Allobaculm,
Mucispirillum, uncultured Lachnospiraceae genus members,
Peptostreptococcaceae Incertae Sedis, Peptococcus, Clostridium and
Anaeroplasma (p value ≤0.05) were detected in DIO vancomycin treated
mice compared with DIO mice. These were accompanied by the
presence of relatively greater proportions of Sutterella, Lactococcus,
Lactobacillus, Weissella and members of Enterobactereaceae-associated
genera in the antibiotic treated group (p value ≤0.05) (Fig 3 &
Supplementary Table 1).
The sequence data generated was investigated from a temporal
perspective. As suggested from  diversity values, the six weeks which
passed from intervention week 2 to 8 of the study impacted on microbiota
composition even in animals where no intervention occurred, i.e. the lean
and DIO controls, presumably as a consequence of the aging of the
animals. At week 8, among the lean animals, it was noted that significant
increases in proportions of the phyla Deferribacteres and
Verrucomicrobia (p value ≤0.05) occurred and, at family level, the relative
proportions of Rhodospirillaceae, Desulfovibrionaceae,
Deferribacteraceae, Lactobacillaceae, Verrucomicrobiaceae and
Eubacteriaceae (p value ≤0.05) were all significantly increased when
compared with microbiota from the same animals at week 2. At genus
level proportions of Thalassospira, Desulfovibrio, Allobaculm,
Mucispirillum, Lactobacillus, Akkermansia, Bilophila and Blautia (p value
≤0.05) all increased between weeks 2 and 8. In contrast, proportions of
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Bacteroidetes (phylum, p value ≤0.05), Porphyromonadaceae,
Bacteroidaceae, Ruminococcaceae (family, p value ≤0.05) and Alistipes,
Bacteroide, Coprococcus and Ruminococcaceae Incertae Sedis (genus,
p value ≤0.05) all decreased between the two time points.
Among DIO mice there were relative increases in the proportions
of Proteobacteria, Actinobacteria, Deferribacteres and Verrucomicrobia (p
value ≤0.05) at the week 8, relative the week 2 time point. This
corresponded to significant increases in Rhodospirillaceae,
Desulfovibrionaceae, Bifidobacteriaceae, Deferribacteraceae and
Verrucomicrobiaceae at the family level (p value ≤0.05) and
Desulfovibrio, Mucispirillum, uncultured Lachnospiraceae, Akkermansia,
Bilophila and Catabacter (p value ≤0.05) at the genus level. In contrast,
proportions of Ruminococcaceae, Clostridiaceae (p value ≤0.05) and
Coprococcus, Ruminococcaceae Incertae Sedis, Turicibacter and
Clostridium decreased between the two time points (p value ≤0.05).
Comparison of the impacts of vancomycin treatment at week 2
relative to those at week 8 had the potential to be particularly revealing
given that the relative extent to which the antibiotic impacted on weight
gain was greater at the earlier time point and that  diversity also
increased during the intervening period. This suggested that a
compensatory effect, possibly due to the recovery of specific populations,
occurred between the two time points. Analysis revealed that several taxa
increased in relative proportions during this interval. These included
Bacteroidetes, Actinobacteria, Defferibacteres and Verrucomicrobia (p
value ≤0.05) at the phylum level, Desulfovibrionaceae, Rikenellaceae,
Porphyromonadaceae, Ruminococcaceae, Erysipelotrichaceae,
Bifidobacteriaceae, Deferribacteraceae, Verrucomicrobiaceae and
Enterobacteriaceae (p value ≤0.05) at the family level and
Ruminococcaceae Incertae Sedis, Turicibacter, Clostridium,
Akkermansia, Allobaculum, Desulfovibrio, Alistipes, Bifidobacterium,
Mucispirillum, Anaeroplasma and members of Enterobacteriaceae-
associated genera (p value ≤0.05) at the genus level. Of the genus level
changes, only the Ruminococcaceae Incertae Sedis, Turicibacter,
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Clostridium and Akkermansia associated changes corresponded with
temporal changes which were evident in the DIO control group and thus
the other genera which underwent relative increases in proportions likely
represent the populations which have most successfully adapted to
vancomycin exposure. Within the vancomycin treatment group the only
phylum to decrease significantly, from a temporal perspective, in the gut
microbiota of the vancomycin administered mice was the Firmicutes (p
value ≤0.05), which corresponded with a significant decrease in the
relative proportions of the family Streptococcaceae (p value ≤0.05) and
the genus Lactococcus (p value ≤0.05). A significant decrease over time
was also apparent within the genus Weissella (p value ≤0.05)
(Supplementary Table 1).
3.4.3 UCC118 Bac+ associated reductions in weight gain
correspond to reductions in Rikenellaceae and
Porphyromonadaceae and increases in Peptococcaceae
populations
While the impact of vancomycin administration on weight gain decreased
from intervention week 2 to week 8 of the study, this impact continued to
be significant throughout. However, the impact on weight gain of
employing the bacteriocin producing probiotic relative to its isogenic non-
bacteriocin producing equivalent changed from being significant to non-
significant over the same duration. Comparison of the impact of the two
strains at week 2 revealed no significant differences at the phylum level
between the two groups. However, at family level, a relative decrease in
proportions of Rikenellaceae and Porphyromonadaceae (p value ≤0.05)
was noted in Bac+ mice relative to their Bac- counterparts. At genus level,
a relative reduction was observed in Alistipes (p value ≤0.05) in Bac+
mice compared with Bac- mice. Furthermore, a relative increase in
proportions of the family Peptococcaceae (p value ≤0.05) and the
corresponding genus Peptococcus (p value ≤0.05) was noted in Bac+
mice compared with Bac- mice (Fig 4 & Supplementary Table 2).
Continued exposure to the bacteriocin producing UCC118 strain
brought about a variety of changes. At phylum level the relative
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proportions of Firmicutes, Candidate Division TM7, Deferribacters and
Verrucomicrobia (p value ≤0.05) were significantly increased by week 8.
Proportions of the families Desulfovibrionaceae, Erysipelotrichaceae,
Deferribacteraceae, Verrucomicrobiaceae and Eubacteriaceae (p value
≤0.05) and the genera Desulfovibrio, Lactococcus, Akkermansia,
Clostridium, Bilophila, Mucispirillum, Turicibacter and Catabacter (p value
≤0.05) also increased. Over the same period relative reductions in the
phylum Bacteroidetes (p value ≤0.05), the families Rikenellaceae,
Porphyromonadaceae and Bacteroidaceae (p value ≤0.05) as well as the
genera Alistipes, Parabacteroides and Bacteroides (p value ≤0.05) also
occurred (Fig 4 & Supplementary Table 2).
The impact of administering the bacteriocin negative UCC118
strain also changed between the two time points. At phylum level relative
increases in the proportions of the Firmicutes, Actinobacteria and
Candidate Division TM7 (p value ≤0.05) were seen which corresponded
with increases at family level in Desulfovibrionaceae, Lachnospiraceae,
Peptococcaceae, Erysipelotrichaceae, Bifidobacteriaceae,
Coriobacterineae and Lactobacillaceae (p value ≤0.05). At genus level
increases in Desulfovibrio, Turicibacter, Bifidobacterium, uncultured
Lachnospiraceae, Peptococcus, Bilophila and Catabacter (p value ≤0.05)
were also noted. Relative reductions in the phylum Bacteroidetes (p value
≤0.05), families Rikenellaceae, Porphyromonadaceae and
Bacteroidaceae (p value ≤0.05) as well as the genera Alistipes, Rikenella,
Parabacteroides and Bacteroides (p value ≤0.05) also occurred (Fig 4 &
Supplementary Table 2). It should also be noted that the proportions of
Rikenellaceae, Porphyromonadaceae and Peptococcaceae in Bac+ fed
mice relative to that in Bac- fed controls did not differ significantly at the
later time point (intervention week 8).
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3.4.4 Vancomycin administration reduces total bacterial numbers in
the gut
As high throughput sequencing reveals information with respect to
relative proportions of populations rather than relative numbers,
quantitative PCR was employed to determine if the antimicrobial
employed, i.e. vancomcyin or the bacteriocin Abp118, impacted on the
total number of gut microbes present. Analysis revealed that there were
no significant differences in total bacterial numbers in the faeces of diet
induced obese mice compared with lean controls (p <0.96) at week 2.
While treatment of the diet-induced obese mice with vancomycin resulted
in a decrease in absolute faecal bacteria compared with their diet-induced
obese counterparts (p <0.006 Fig 5), bacteriocin production did not alter
the total bacterial numbers in the diet induced obese mice. The significant
impact of vancomycin, but not other interventions, on total bacterial
counts is also apparent at week 8 (Murphy et al., 2012).
3.4.5 Beta diversity highlights temporal variation in microbial
populations
Principal coordinate analysis (based on unweighted unifrac distances) of
the 16S rRNA sequences further highlights the temporal changes in the
microbial populations from intervention week 2 to 8 with samples clearly
clustering according to time point (Fig 6). In line with the  diversity and
taxonomical data presented above, it is apparent that data points
corresponding to DIO mice who received vancomycin (purple) cluster
away from those corresponding to the other groups. The degree to which
these data points are removed is more apparent at week 2, again
suggesting that a recovery occurs during the subsequent weeks (Fig 6).
At week 8, data points corresponding to the DIO controls (red) cluster
tightly together within a larger cluster. Such tight clustering is not
apparent at week 2 (Fig 6). It would also appear that the Bac+ (green) and
Bac- (orange) mice are more distinct at week 2 (Fig 6). Hierarchical
clustering of the OTUs from each dataset also highlights the temporal
instability in the mouse microbiota between the two time points. However
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the unweighted pair group method with arithmetric mean (UPGMA) tree
shows that, at specific time points, the microbiota of mice within each
treatment group are generally more similar to each other than they are to
those from the other groups (Supplementary Fig 3). Hierarchical
clustering again highlights the separation of the vancomycin-exposed
populations from the other groups. In addition to clustering away from the
other groups, it is also clear that these populations differ at the respective
time points. At week 8, the ‘lean’ OTUs cluster into two groups on either
side of the DIO OTUs, this separation was not observed at week 2. No
significant difference in weight was observed between these respective
lean subgroups. At week 2 Bac+ OTUs are divided into two groups on
either side of DIO OTUs. This separation did not persist with time.
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3.5 DISCUSSION
This analysis of the gut microbiota of animals subjected to either
vancomcyin or the bacteriocin producing probiotic L. salivarius UCC118
intervention provides valuable information regarding the temporal nature
of the resultant changes. The results reflect microbial adaptation over
time and the resilience of the microbiota. Principal coordinate analysis
(PCoA) and hierarchical clustering analysis reveal that clustering occurs
as a feature of time and to a lesser extent, treatment groups, rather than
between microbial populations from within the same animal. In agreement
with previous studies (Turnbaugh et al., 2006, Ley et al., 2006, Ley et al.,
2005), we established that the diet-induced obesity-associated murine gut
microbiota differed from that of lean controls. More specifically, a
significant increase in the proportion of Firmicutes and a decrease in the
proportion of Bacteroidetes. Vancomycin was selected because of its
limited systemic impact and its apparent ability to specifically target the
low GC Gram-positive organisms i.e. Firmicutes (Murphy et al., 2012).
Here, we establish that treatment of mice on a high fat diet with
vancomycin resulted in significant alterations in the composition of the gut
microbiota; including a decrease in the relative proportions of
Bacteroidetes and Deferribacteres and a relative increase in the
proportions of Proteobacteria relative to DIO controls. This vancomycin-
induced effect on Proteobacteria populations has been noted before (Rea
et al., 2011, Ubeda et al., 2010). In contrast to week 8, the proportion of
Firmicutes was not reduced between animals receiving vancomycin and
controls at intervention week 2. At this time point, the corresponding
increased proportions of the families Streptococcaceae, Lactobacillaceae
and Leuconostocaceae (all members of the Firmicutes phylum) might
negate the detrimental impact of vancomycin on other Firmicutes
members, resulting in the absence of an overall net change. The
glycopeptide antibiotic vancomycin is traditionally known to be active
against Gram-positive bacteria such as Staphylococcus aureus and
Clostridium difficile through the inhibition of cell wall synthesis (Howden et
al., Rea et al., 2011a, Chang et al., 2003). The cell wall of Gram-negative
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bacteria is protected by the presence of an outer membrane that blocks
the effects of vancomycin (Barna and Williams, 1984). Nevertheless, here
we found that eight genera (Thalassospira, Alistipes, Rikenella,
Parabacteroides, Odiorbacter, Bacteroides, Oscillibacter and
Mucispirillum) of Gram-negative bacteria were significantly reduced in
vancomycin treated DIO mice at week 2. Also three Gram-positive genus
(Lactococcus, Lactobacillus and Weissella) increased at week 2 in
vancomycin treated mice. While the innate vancomycin resistance of
many lactobacilli has been well established, there have been rare reports
of resistant Lactococcus and Weissella isolates (Salimnia et al., 2011,
Zhang et al., 2013, D'Aimmo et al., 2007). Other differences between the
gut microbial populations of these mice at week 2 and week 8 were also
apparent. These included significant increases in the relative proportions
of Bacteroidetes, Actinobacteria, Deferribacteres and Verrucomicrobia
and a significant decrease in the relative proportions of Firmicutes at the
later time points. The recovery of both Gram-positive (Turicibacter,
Ruminococcaceae Incertae Sedis, Clostridium, Allobaculum and
Anaeroplasma) and Gram-negative bacteria by week 8 (Alistipes and
Mucispirillum) highlights the resilience of the gut bacteria. On the basis of
PCoA and hierarchical clustering these temporal changes seems to
represent a recovery of/development of resistance among the gut
microbiota such that it less considerably differs from that of controls.
While it is tempting to speculate that this reflects the emergence of
resistant strains from among these populations, further investigations are
required to definitively establish the basis for this recovery. This recovery
coincides with vancomycin having a relatively less dramatic impact on
weight gain by week 8 of the study but the identity of the population that
may be contributing to this phenomenon is difficult to ascertain due to the
numbers of different taxa which are altered, however it is also apparent
that the total number of bacteria did not alter between the two time points.
These results highlight the resilience of the microbiota to change,
demonstrating that after the initial impact from vancomycin they start to
revert back to their original profile. This highlights the challenge faced
when utilising antimicrobials, prebiotics (Dewulf et al., 2012), microbial
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transplantation (Vrieze et al., 2012) or other interventions in order to bring
about long-term changes to the obesity-associated (and other) gut
microbial populations. Indeed, the temporal resilience of the gut
microbiota following exposure to antibiotics has been highlighted in
previous studies (Cotter et al, 2012, Fouhy et al., 2012, Lozupone et al.,
2012, Rea et al., 2011, Tims et al., 2012, Zhang et al., 2012).
The comparison of the impact of Bac+ and Bac- on the murine
microbiota may be more revealing as a consequence of the number of
changes being fewer and the fact that the impact of Bac+ intervention
changed from being significant to non-significant as the study continued.
While previous studies with bacteriocin-producing UCC118 strain have
shown it to be active against representatives of several Gram-positive
taxa, including Bacillus, Listeria monocytogenes, Enterococcus,
Staphylococcus and Clostridium perfringens (Flynn et al., 2002,
O'Mahony et al., 2001), high throughput sequencing again provided
unexpected results with respect to compositional changes, at family level,
relative to Bac- controls at week 2. Specifically a relative reduction in the
proportions of the Gram-negative families Rikenellaceae and
Porphyromonadaceae and a relative increase in the proportions of the
Gram-positive Peptococcaceae occurred. Interestingly, a recent study
has suggested a link between the Porphyromonadaceae with the
development of metabolic syndrome (Henao-Mejia et al., 2012). While the
decrease in weight gain observed in Bac+, relative to Bac-, mice at week
2 and the reduction in relative numbers of this family is notable, the
proportions of this family decreased even further in Bac+ mice by week 8
despite the fact that the impact of the probiotic with respect to weight gain
was no longer significant by this time. Notably the proportions of
Rikenellaceae, Porphyromonadaceae and Peptococcaceae in Bac+ and
Bac- fed mice did not differ significantly at week 8. Further studies are
needed to explore the role these families play in the link between the gut
microbial ecosystem and obesity.
In conclusion, the data demonstrate that though vancomycin
distinctively modified the gut microbiota composition, the growth of some
bacterial families over time may be responsible for this intervention
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having a less dramatic impact on weight gain by the end of the 8 week
intervention period. There also exist a number of changes in the microbial
population of animals administered Bac+ which, if successfully targeted
over a longer period, could potentially extend the duration over which
weight gain is significantly reduced. These results provide further
rationale for altering the gut microbiota using antimicrobials but the
specific identification of the populations involved and the specificity of
action of the antimicrobials will be essential and may require continual
modification to ensure a sustained impact and to overcome
compensatory effects.
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Figure 1. Delta weight gain over the eight week intervention period.
(A) Bac+ intervention, when compared to Bac- intervention, causes a
significant reduction in weight gain in diet induced obese mice at weeks
2-4 (early intervention period) but this does not persist with time. (B)
Vancomycin treatment results in a two phase reduction in weight gain in
diet induced obese mice. In phase one (early; weeks 1-4) a significant
reduction in weight gain relative to the initial start weight is observed. In
the second phase, diet induced obese mice receiving vancomycin gain
weight relative to the initial start weight but weight change continues to be
significantly less than that in diet induced obese controls. Data
represented as mean ±SEM n=9-10 *p<0.05.
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Figure 2.  diversity of the gut microbiota within each time point. In
a number of instances significant increases in diversity are observed
between intervention week 2 and week 8. Statistical significance was
determined by Kruskal Wallis. * Statistical significant difference (p <0.05).
Data represented as mean ±SEM (n=9-10).
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Figure 3. Microbial distribution at phylum level. Phylum level microbial
distribution in all data sets at intervention week 2 and week 8. The pie
charts represent total percentage read number for the corresponding
colour coded phylum (n=9-10 per group).
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Figure 4. Microbial distribution at family level. Family level microbial
distribution in all data sets at intervention week 2 and week 8. The pie
charts represent total percentage read number for the corresponding
colour coded family (n=9-10 per group).
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Figure 5. Total bacterial number observed in all treatment groups at
both time points. Quantitative PCR reveals that the changes occurring
are qualitative not quantitative as no significant difference is observed
between time points. Total bacterial numbers calculated as copies of 16S
rRNA/g wet stool. Statistical significant difference between treatment
groups is denoted by ***. p value based on Kruskal Wallis analysis with
statistical significant determined as p ≤0.05. Error bars represent the
standard error of the mean.
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Figure 6. Principal coordinate analysis of unweighted unifrac
reveals temporal shift. Vancomycin treated diet induced obese mice
(purple) cluster away from other groups at both time points, however the
distance between these mice and other treatment groups at week 8 is
less than at week 2. Data sets: purple vancomycin, blue lean, red DIO,
green Bac+ and orange Bac-.
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SUPPORTING INFORMATION
Table S1. Vancomycin treatment alters gut microbiota in diet induced obese mice
Lean
Wk 2
Lean
Wk 8
DIO
Wk 2
DIO
Wk 8
Vancomycin
Wk 2
Vancomycin Wk
8
Phylum
Proteobacteria 1.51± 0.22 2.43±0.37 1.28±0.28† 3.18±0.83 24.63±6.90* 31.74±1.90
Bacteroidetes 42.89± 2.48# 21.50±2.13## 22.13±4.69 16.82±1.26 0.67±0.45* 2.24±0.76**
Firmicutes 52.92± 2.65# 60.03±2.90 74.96±4.54 72.06±2.05 74.18±7.15 61.49±2.61**
Actinobacteria 1.54± 0.66 2.20±0.61 0.58±0.22† 1.86±0.46 0.34±0.31 3.06±1.39**
Candidate Devision TM7 0.22± 0.09 0.27±0.05 0.09±0.06 0.15±0.08 0.0±0.0 0.01±0.01
Deferribacteres 0.53± 0.25 5.42±1.62## 0.61±0.18† 3.86±1.28 0.0±0.0* 0.60±0.27**
Verrucomicrobia 0.10±0.10 7.90±3.11## 0.0±0.0† 1.65±0.45 0.0±0.0 0.20±0.08**
4COd 2 0.0±0.0 0.0±0.0 0.07±0.07 0.14±0.05 0.0±0.0 0.0±0.0
Family
Rhodospirillaceae 0.16±0.06# 0.54±.08## 0.87±0.28† 2.38±0.77 0.0±0.0* 0.01±0.01
Alcaligenaceae 0.94± 0.22# 0.99±0.42 0.0±0.0 0.03±0.02 7.74±3.09* 6.87±0.91
Desulfovibrionaceae 0.24±0.11 0.82±0.22## 0.09±0.07† 0.71±0.14 0.07±0.05 1.42±0.29**
Rikenellaceae 10.55±1.01# 7.61±1.18 5.93±1.46 5.38±0.79 0.20±0.20* 1.10±0.36**
Porphyromonadaceae 5.50±0.59 3.72±0.42## 4.71±1.44 3.92±0.54 0.0±0.0* 3.81±3.68**
Bacteroidaceae 10.40±1.65# 4.38±0.45## 4.46±2.08 2.45±0.45 0.17±0.17* 5.85±5.74
Lachnospiraceae 20.83±2.03# 24.97±2.61 32.50±4.25 29.87±2.09 48.27±11.82 27.52±5.98
Ruminococcaceae 12.13±0.97 5.62±0.99## 13.58±1.46† 7.02±1.17 0.20±0.13* 1.14±0.45**
Peptostreptococcaceae 0.96±0.23 0.51±0.24 1.67±05.6 1.19±0.41 0.0±0.0* 0.04±0.03
Peptococcaceae 0.39±0.09 0.36±0.05 0.56±0.15 0.51±0.11 0.0±0.0* 0.06±0.03
Streptococcaceae 0.37±0.09# 0.34±0.05 0.78±0.16 0.58±0.07 4.88±1.69* 1.34±0.14**
Erysipelotrichaceae 0.09±0.06 0.16±0.08 1.43±0.74 0.11±0.06 0.0±0.0* 0.63±0.29**
Statistical significance was determined using Kruskal Wallis. Values are mean percentage read number ± standard error. *p value ≤0.05 between DIO and
DIO vancomycin mice at week 2; **p value ≤0.05 between DIO vancomycin mice at week 2 and DIO vancomycin mice at week 8; #p value ≤0.05 between
Lean and DIO mice at week 2; ##p value ≤0.05 between Lean week 2 and Lean week 8; †p value ≤0.05 between DIO week 2 mice and DIO week 8 mice.
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Table S1. (continued)
Lean
Wk 2
Lean
Wk 8
DIO
Wk 2
DIO
Wk 8
Vancomycin
Wk 2
Vancomycin Wk
8
Bifidobacteriaceae 1.33±0.61 2.03±0.60 0.56±0.22† 1.67±0.40 0.34±0.31 3.45±1.34**
Deferribacteraceae 0.53±0.25 5.42±1.62## 0.48±0.17† 3.86±1.28 0.0±0.0* 0.61±0.27**
Coriobacterineae 0.13±0.07# 0.14±0.04 0.0±0.0† 0.18±0.06 0.0±0.0 0.0±0.0
Lactobacillaceae 1.970±0.51# 3.88±0.69## 6.27±1.67 11.82±2.43 19.27±6.21* 16.52±3.54
Leuconostocaceae 0.05±0.05 0.04±0.02 0.0±0.0 0.04±0.02 0.40±0.13* 0.08±0.03
Verrucomicrobiaceae 0.10±0.10 7.90±3.11## 0.0±0.0† 1.65±0.45 0.0±0.0 0.20±0.08**
Clostridiaceae 0.0±0.0# 0.01±0.01 0.82±0.33† 0.0±0.0 0.13±0.09 0.73±0.31
Enterobacteriaceae 0.0±0.0 0.02±0.02 0.0±0.0 0.01±0.01 16.64±3.87* 23.32±1.20**
EU622698 0.0±0.0 0.0±0.0 0.06±0.06 0.09±0.03 0.0±0.0 0.0±0.0
Eubacteriaceae 0.0±0.0 0.06±0.03## 0.0±0.0 0.02±0.01 0.0±0.0 0.0±0.0
Genus
Thalassospira 0.16±0.06# 0.47±0.07## 0.87±0.28 1.59±0.33 0.0±0.0* 0.01±0.01
Sutterella 0.94±0.22# 0.99±0.42 0.0±0.0 0.03±0.02 7.74±3.09* 6.87±0.91
Desulfovibrio 0.20±0.10 0.65±0.21## 0.04±0.04† 0.50±0.11 0.07±0.05 1.41±0.28**
Alistipes 7.53±0.88# 4.01±0.42## 3.52±0.98 2.43±0.25 0.13±0.13* 0.77±0.26**
Rikenella 2.06±0.32 2.82±0.76 1.71±0.67 1.89±0.63 0.0±0.0* 0.0±0.0
Parabacteroides 1.82±0.47 1.67±0.12 3.45±1.14 2.75±0.50 0.0±0.0* 0.03±0.02
Odoribacter 3.68±0.66# 2.05±0.39 1.24±0.34 1.16±0.16 0.0±0.0* 0.04±0.03
Bacteroides 10.40±1.65# 4.38±0.45## 4.46±2.08 2.45±0.45 0.17±0.17* 0.13±0.07
Lachnospiraceae Incertae Sedis 0.66±0.13 0.41±0.07 0.70±0.20 0.59±0.10 0.0±0.0* 0.10±0.06
Coprococcus 0.40±0.11 0.10±0.04## 0.58±0.14† 0.17±0.04 0.0±0.0* 0.02±0.02
Ruminococcaceae Incertae Sedis 6.66±0.62 2.12±0.36## 7.16±0.74† 3.09±0.43 0.0±0.0* 0.56±0.22**
Statistical significance was determined using Kruskal Wallis. Values are mean percentage read number ± standard error. *p value ≤0.05 between DIO and
DIO vancomycin mice at week 2; **p value ≤0.05 between DIO vancomycin mice at week 2 and DIO vancomycin mice at week 8; #p value ≤0.05 between
Lean and DIO mice at week 2; ##p value ≤0.05 between Lean week 2 and Lean week 8; †p value ≤0.05 between DIO week 2 mice and DIO week 8 mice.
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Table S1. (continued)
Lean
Wk 2
Lean
Wk 8
DIO
Wk 2
DIO
Wk 8
Vancomycin
Wk 2
Vancomycin Wk
8
Oscillibacter 0.54±0.14 0.73±0.19 0.84±0.16 0.99±0.16 0.0±0.0* 0.12±0.07
Anaerotruncus 1.54±0.24 1.06±0.20 2.27±0.37 1.47±0.24 0.0±0.0* 0.12±0.06
Lactococcus 0.35±0.08# 0.33±0.05 0.74±0.15 0.56±0.07 4.76±1.67* 1.33±0.14**
Turicibacter 0.09±0.06# 0.16±0.08 1.73±0.70† 0.11±0.06 0.0±0.0* 0.63±0.29**
Allobaculum 12.77±1.61 21.18±3.34## 10.94±2.80 17.09±2.94 0.13±0.13* 2.63±1.00**
Bifidobacterium 1.36±0.61 2.03±0.60 0.56±0.22 1.46±0.42 0.34±0.31 3.45±1.34**
Mucispirillum 0.53±0.25 5.42±1.62## 0.61±0.18† 3.86±1.28 0.0±0.0* 0.61±0.27**
Lactobacillus 1.97±0.51# 3.85±0.69## 6.26±1.67 11.74±2.41 19.27±6.21* 16.49±3.53
uncultured Lachnospiraceae 0.19±0.08 0.57±0.22 0.33±0.17† 2.57±0.81 0.0±0.0* 0.22±0.10**
Weissella 0.03±0.03 0.0±0.0 0.0±0.0 0.02±0.01 0.29±0.1* 0.02±0.02**
Leuconostoc 0.02±0.02 0.0±0.0 0.0±0.0 0.0±0.0 0.04±0.04 0.03±0.02
Peptostreptococcaceae Incertae Sedis 0.11±0.06 0.20±0.16 0.52±0.22 0.33±0.11 0.0±0.0* 0.04±0.03
Peptococcus 0.09±0.10 0.0±0.0 0.34±0.15 0.21±0.10 0.0±0.0* 0.0±0.0
Akkermansia 0.10±0.10 7.90±3.11## 0.0±0.0† 1.65±0.45 0.0±0.0 0.20±0.08**
Clostridium 0.0±0.0# 0.01±0.01 0.82±0.33† 0.0±0.0 0.08±0.08* 0.73±0.13**
Anaeroplasma 0.0±0.0# 0.02±0.02 0.65±0.31 0.06±0.03 0.0±0.0* 0.07±0.04
Bilophila 0.0±0.0 0.13±0.05## 0.03±0.03† 0.21±0.04 0.0±0.0 0.0±0.0
Enterobacteriaceae genus 0.0±0.0 0.02±0.02 0.0±0.0 0.01±0.01 16.58±3.83* 23.31±1.20**
Veillonella 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.02±0.02 0.0±0.0
Streptococcus 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0
Catabacter 0.0±0.0 0.04±0.02 0.0±0.0† 0.05±0.02 0.0±0.0 0.0±0.0
Anaerovorax 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0
Acinetobacter 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0
Blautia 0.0±0.0 0.05±0.02## 0.0±0.0 0.05±0.02 0.0±0.0 0.0±0.0
Eubacterium 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0
Enterococcus 0.0±0.0 0.0±0.0 0.0±0.0 0.01±0.01 0.0±0.0 0.0±0.0
Statistical significance was determined using Kruskal Wallis. Values are mean percentage read number ± standard error. *p value ≤0.05 between DIO and
DIO vancomycin mice at week 2; **p value ≤0.05 between DIO vancomycin mice at week 2 and DIO vancomycin mice at week 8; #p value ≤0.05 between
Lean and DIO mice at week 2; ##p value ≤0.05 between Lean week 2 and Lean week 8; †p value ≤0.05 between DIO week 2 mice and DIO week 8 mice.
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Table S2. Effects of L salivarius UCC118 bacteriocin production on the gut microbiota of DIO mice over time.
BAC-
wk 2
BAC-
wk 8
BAC+
wk 2
BAC+
wk 8
Phylum
Proteobacteria 0.94±0.23 1.00±0.12 0.93± 0.30 2.43±0.37
Bacteroidetes 48.66±4.0 13.4±1.6‡ 41.70± 1.67† 21.50±2.13
Firmicutes 47.17±3.82 70.65±7.29‡ 53.84± 1.61† 60.03±2.90
Actinobacteria 0.97±0.30 4.20±1.27‡ 1.85± 0.54 2.20±0.61
Candidate Devision TM7 0.0±0.0 0.43±0.10‡ 0.0±0.0† 0.27±0.05
Deferribacteres 1.23±0.56 2.40±0.72 1.25± 0.31† 5.42±1.62
Verrucomicrobia 0.49±0.29 1.17±1.02 0.16± 0.14† 7.90±3.11
4COd2 0.0±0.0 0.02±0.02 0.01±0.01† 0.0±0.0
Family
Desulfovibrionaceae 0.10±0.07 0.58±0.10‡ 0.07±0.05† 0.82±0.22
Rikenellaceae 20.99±1.88* 6.31±0.85‡ 14.62±0.78† 7.61±1.18
Porphyromonadaceae 11.15±1.43* 3.14±0.57‡ 6.83±0.87† 3.72±0.42
Bacteroidaceae 9.42±1.60 0.68±0.18‡ 12.23±1.50† 4.38±0.45
Lachnospiraceae 19.65±2.69 33.38±3.55‡ 24.54±2.20 24.97±2.61
Peptococcaceae 0.09±0.09* 1.21±0.21‡ 0.69±0.14 0.36±0.05
Streptococcaceae 0.62±0.39 0.60±0.11 0.33±0.14† 0.34±0.05
Erysipelotrichaceae 0.0±0.0 1.24±0.46‡ 0.09±0.06† 0.16±0.08
Bifidobacteriaceae 0.95±0.30 4.04±1.22‡ 1.78±0.52 2.03±0.60
Deferribacteraceae 1.23±0.56 2.46±0.70 1.25±0.31† 5.42±1.62
Coriobacterineae 0.0±0.0 0.13±0.06‡ 0.02±0.02 0.14±0.04
Lactobacillaceae 3.73±0.95 9.71±2.16‡ 6.27±1.88 3.88±0.69
Leuconostocaceae 0.0±0.0 0.05±0.03 0.0±0.0† 0.04±0.02
Verrucomicrobiaceae 0.49±0.29 1.17±1.02 0.16±0.14† 7.90±3.11
Clostridiaceae 0.28±0.19 0.04±0.03 0.02±0.02† 0.01±0.01
Anaeroplasmataceae 0.17±0.12 0.29±0.22 0.03±0.03 0.02±0.02
Enterobacteriaceae 0.43±0.19 0.16±0.03 0.45±0.18 0.02±0.02
Eubacteriaceae 0.0±0.0 0.01±0.01 0.0±0.0† 0.06±0.03
Statistical significance was determined using Kruskal Wallis. Values are mean percentage read number ± standard error. *p value ≤0.05 between BAC+ and
BAC- at week 2; † p value ≤0.05 between BAC+ week 2 and BAC+ week 8; ‡p value ≤0.05 between BAC- week 2 and BAC- week 8.
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Table S2. (continued)
BAC-
wk 2
BAC-
wk 8
BAC+
wk 2
BAC+
wk 8
Genus
Desulfovibrio 0.05±0.05 0.25±0.09‡ 0.02±0.02† 0.56±0.11
Alistipes 13.92±1.18* 2.97±0.53‡ 8.35±0.66† 3.60±0.39
Rikenella 3.18±0.42 2.00±0.43‡ 2.64±0.48 2.55±0.67
Parabacteroides 6.80±1.11 1.22±.034‡ 3.74±0.75† 1.38±0.19
Bacteroides 9.42±1.60 0.68±0.18‡ 12.23±1.50† 2.87±0.54
Lactococcus 0.28±0.10 0.68±0.18 0.17±0.12† 0.62±0.09
Turicibacter 0.0±0.0 1.24±0.46‡ 0.09±0.06† 1.68±0.70
Bifidobacterium 0.95±0.30 4.04±1.22‡ 1.78±0.25 1.17±0.38
Mucispirillum 1.23±0.56 1.82±0.49 1.25±0.31† 4.91±1.73
uncultured Lachnospiraceae 0.32±0.16 1.46±0.55‡ 0.54±0.19 1.36±0.49
Peptococcus 0.08±0.08* 0.76±0.19‡ 0.47±0.13 0.51±0.14
Akkermansia 0.49±0.29 1.17±1.02 0.16±0.14† 2.85±1.05
Clostridium 0.23±0.15 0.05±0.03 0.02±0.02† 0.82±0.35
Bilophila 0.0±0.0 0.22±0.06‡ 0.01±0.01† 0.36±0.11
Enterobacteriaceae genus 0.28±0.16 0.15±0.03 0.30±0.17 0.29±0.05
Catabacter 0.0±0.0 0.08±0.03‡ 0.0±0.0† 0.11±0.04
Uncultured Bacteria 0.0±0.0 0.07±0.03‡ 0.01±0.01† 0.21±0.05
Statistical significance was determined using Kruskal Wallis. Values are mean percentage read number ± standard error. *p value ≤0.05 between BAC+ and
BAC- at week 2; † p value ≤0.05 between BAC+ week 2 and BAC+ week 8; ‡p value ≤0.05 between BAC- week 2 and BAC- week 8.
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Supplementary Figure 1. Experimental design: Seven week old
C57BL/J6 mice were fed a high fat or low fat diet for 20 weeks, after 12
weeks intervention began. Sequencing was performed at intervention
week 2 and week 8 of the study.
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Supplementary Figure 2. Rarefaction curves for each group at 97%
similarity levels for intervention week 2 (A) and week 8 (B) data sets.
Amount of operational taxonomic units (OUT’s) found as a function of the
number of sequence tags sampled.
129
Supplementary Figure 3. Unweighted pair group method with
arithmetic mean (UPGMA) tree of all samples at both time point’s.
Highlights temporal shift and clustering by treatment group. Vancomycin
treated DIO mice present as outliers from both time points.
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Chapter 4
Isogenic strains producing different bile salt hydrolases
differ in their impact on weight gain and the composition
of the gut microbiota of mice
Siobhan Clarke Chapter Contributions:
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4.1 ABSTRACT
Conjugated bile acids (CBAs) are thought to repress gut microbiota
through direct antimicrobial effects and/or up-regulation of host defences.
Here we investigate the impact of the production of specific bile salt
hydrolases on the gut microbiota and weight gain using a commensal
Escherichia coli strain that produces bile salt hydrolase (BSH) from either
Lactobacillus salivarius JCM1046 (BSH1) or UCC118 (BSH2) in the same
isogenic background. To facilitate this, the streptomycin-treated mouse
model was employed as it provides a less competitive niche for
colonization. A significant reduction in weight gain was observed in mice
administered the BSH1-producing strain fed either high and low fat diets,
relative to the BSH2-producing strain. These results were accompanied
by changes in microbiota composition and diversity, including an increase
in the proportions of Bacteroidetes in the cecum of mice administered the
BSH1-producing strain relative to those receiving the BSH2-producing
strain. The study highlights the impact of the production of different BSHs
on gut microbiota communities and, in turn, health.
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4.2 INTRODUCTION
The human gastrointestinal tract is inhabited by a complex population of
microorganisms. This community contains approximately 3 million genes
(Qin et al., 2010), which contrasts with the approximately 23,000 genes
that comprise the human genome (Yang et al., 2009). Recent advances
in sequence based technologies have considerably enhanced our
understanding of the composition and functional potential of the human
gut microbiota and, in turn, facilitated studies to assess the role of specific
microbiota populations and activities on human health, both beneficial
and harmful (Qin et al., 2012, Kurokawa et al., 2007, Turnbaugh et al.,
2006).
The human liver secretes approximately one litre of bile into the
intestinal tract every day (Hofmann, 1994). The main constituents of this
bile include bile acids, cholesterol, phospholipids and the pigment
biliverdin (Hofmann, 1999). Bile acids are synthesized de novo in the liver
from cholesterol and are then conjugated with either glycine or taurine,
which increase solubility, before secretion (Claus et al., 2011). These
CBAs promote the breakdown of dietary fat (Begley et al., 2005b). It has
been suggested that CBAs repress bacterial growth in the small intestine
through direct antimicrobial effects and/or the up-regulation of host
mucosal defences (Jones et al., 2008). The deconjugation of CBAs by
specific gut microbes is catalyzed by enzymes called bile salt hydrolases
(BSHs) which hydrolyze the amide bond to liberate the glycine/taurine
component from the side chain of the steroid core and release the bile
acids (cholic acid or chenodeoxycholic acid and amino acids) (Begley et
al., 2005a). Other components of the gut microbiota can modify these bile
acids through dehydroxylation, dehydrogenation and sulfation into
secondary and tertiary forms (Jones et al., 2008). Metagenomic analysis
has identified functional BSHs from all major bacterial divisions and
archaeal species in the gut, while also establishing that BSH-encoding
genes are enriched within the human gut microbiome (Jones et al., 2008).
It has been suggested that the gut microbiota can regulate secondary bile
acid metabolism and inhibit bile acid synthesis in the liver (Sayin et al.,
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2013). BSH activity may also impact on host physiology through
perturbations of bile acid controlled endocrine functions, influencing the
risks of metabolic diseases such as obesity, diabetes and atherosclerosis
(Jones et al., 2008).
Here we investigate the respective impacts of two BSHs from
different strains of Lactobacillus salivarius on gut microbiota composition
and weight gain through two pilot studies. First, we establish a suitable
experimental animal model and, second, use this model to investigate the
effects of BSH-production on weight gain and the gut microbiota in a
murine model of diet induced obesity.
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4.3 MATERIAL AND METHODS
4.3.1 Bile salt hydrolase cloning and manipulation.
Known bile salt hydrolases from Lactobacillus salivarius JCM1046
(BSH1) (accession number FJ591091) and L. salivarius UCC118 (BSH2)
(accession number FJ591081), which differ with respect to their affinity
for tauro-conjugated bile acids in vitro (Fang et al., 2009), were cloned
independently into pBKminiTn7GM2 (Koch et al., 2001) under the control
of the constitutive P44 promoter (McGrath et al., 2001) to create plasmids
pTn7GMBSH1UCC118 and pTn7GMBSH1JCM1046. E. coli MG1655StrR (20
mg-1) was transformed using standard methods with helper plasmid
pBUX13 then conjugated with one of pBKminiTn7GM2,
pTn7GMBSH1UCC118 and pTn7GMBSH1JCM1046. Transformants were
selected on the basis of gentamicin resistance (10 mg-1) and the helper
plasmid was removed by sodium dodecyl sulfate (SDS) treatment. PCR
and sequence analysis (GATC Biotech) confirmed the integrity of these
constructs. These strains were negative for growth defects in minimal
media and were named EC, ECBSH1 and ECBSH2 for those containing
GM cassette, GMBSH1JCM1046 and GMBSH1UCC118 insertions,
respectively. Primers applied are listed in supplementary information
Table 1.
4.3.2 Animal studies
C57Bl/6J male mice aged 4 weeks were sourced from Harlan (Oxon, UK)
and housed under barrier maintained conditions at University College
Cork (UCC). Mice were allowed to acclimatise for 2 weeks prior to
commencement of the study. The UCC Animal Ethics Committee
approved all of the experiments performed. All procedures were
conducted under license from the Irish government.
4.3.2.1 Experimental design - study 1
To reduce/remove resident Proteobacteria from the gastrointestinal (GI)
tract, food was removed from 6 week old male C57Bl/6J mice for 24
hours and mice were immediately supplied with streptomycin-treated
135
drinking water (5 g/L final concentration) for the duration of the
experiment. Water was changed every two days. After 24 hours mice
were fed either a low fat diet (LFD) ((n=5) 10% calories from fat,
Research Diets, New Jersey, USA D12450B) or a high fat diet (HFD)
((n=10) 45% calories from fat, Research Diets, New Jersey, USA
D12451) for 10 weeks. The high fat diet group was further divided into
two treatment groups (n=5 for each group) and were treated as follows (i)
no treatment or (ii) gavage with 1x107 cfu streptomycin resistant (StrR),
gentamicin resistant (GMR) E. coli MG1655 without a bile salt hydrolase
insert (BSH) for 2 consecutive days. Faecal samples were collected,
pooled and stored at -80oC at time points T=0, T=1, T=8 and T=10
weeks. At the end of the study, after culling of the mice, the caecum was
removed and stored at -80oC.
4.3.2.2 Experimental design - study 2
Food was removed from 6 week old male C57Bl/6J mice for 24 hours and
mice were immediately supplied with streptomycin treated drinking water
(5g/L final concentration) for the duration of the experiment. After this 24
hour period, mice were fed either a LFD ((n=6) 10% calories from fat,
Research Diets, New Jersey, USA D12450B) or a HFD ((n=6) 45%
calories from fat, Research Diets, New Jersey, USA D12451) for 8
weeks. These two diet groups were further divided into parallel treatment
groups (n=3 for each group) and 1x107 cfu ECBSH1 or ECBSH2 were
introduced by gavage on two consecutive days. Faecal samples were
collected, pooled and stored at -80oC at time points T=0, T=1 and T=8
weeks. At the end of the study, after culling of the mice, the caecum was
removed and stored at -80oC.
4.3.3 DNA extraction and high-throughput DNA sequencing
Metagenomic DNA was extracted from murine faecal or caecal samples
using the QIAmp DNA Stool Mini Kit (Qiagen, Crawley, West Sussex, UK)
using a protocol modified to include an additional bead beating step (30 s
x3) (Murphy et al., 2012) and stored at -20oC. Microbiota composition was
established by 16S rRNA amplicon sequencing; PCR amplification of the
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16S rRNA gene was performed using the universal primers F1 (F1 (5’-
AYTGGGYDTAAAGNG) and a combination of four reverse primers R1
(5’-TACCRGGGTHTCTAAAGNG), R2 (TACCAGAGTATCTAATTC), R3
(5’-CTACDSRGGTMTCTAATC) and R4 (5’-TACNVGGGTATCTAATC)
(RDP’S Pyrosequencing Pipeline: http://pyro.cme.msu.edu/pyro/help.jsp).
Unique multiplex identifier tags were attached between the 454 adaptor
sequence and the target-specific primer sequence, to facilitate the
pooling and subsequent differentiation of samples. Amplicons generated
from triplicate PCR reactions were pooled and cleaned using the
Agencourt AMpure® purification system (Beckman Coulter, Takeley, UK)
prior to being sequenced on a 454 Genome Sequencer FLX platform
(Roche Diagnostics Ltd, Burgess Hill, West Sussex, UK) in line with 454
protocols at the Teagasc high-throughput sequence centre.
4.3.4 Analysis of high-throughput DNA sequence data
A locally installed RDP pipeline for high-throughput DNA sequence data
was used to quality trim and filter raw sequence data. Reads were
removed that did not meet the quality criteria of a minimum quality score
of 40 and sequence length shorter than 150bps for 16S amplicon reads.
A locally installed version of SILVA 16S rRNA database (Pruesse et al.,
2007) was employed to BLAST (Altschul et al., 1997) the trimmed fasta
sequence files using default parameters. BLAST output files were parsed
using MEGAN (Huson et al., 2007) which uses a lowest common
ancestor algorithm to assign reads to NCBI taxonomies. Filtering was
carried out within MEGAN using bit scores of 86 similar to previous
studies (Rea et al., 2011, Urich et al., 2008). Clustering of sequence
reads into operational taxonomical units (OTUs) at 97% identity level was
achieved using Qiime (Caporaso et al., 2010). Chimeric OTU’s were
removed from the aligned OTU’s using the ChimeraSlayer program (Haas
et al., 2011) and a phylogenetic tree was generated with the FastTreeMP
tool (Price et al., 2010). Alpha diversity indices and rarefaction curves
were generated using Qiime. Beta diversities were also calculated on the
sequence reads based on weighted and unweighted Unifrac and Bray
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Curtis distance matrices; subsequently principal coordinate analysis
(PCoA) plots were visualised using KiNG (Chen et al., 2009).
4.3.5 Statistical analysis
Statistical analysis was carried out using GraphPad Prism version 5.04
(La Jolla, California, USA) and SPSS software package version 18
(SPSS Inc., Chicago, USA). Mann–Whitney tests and unpaired Student t
test were used to find significant differences. p≤0.05 was considered as
statistically significant.
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4.4 RESULTS
4.4.1 HFD-EC mice gain more weight than controls
Initially, the effect of continuous streptomycin treatment on weight gain
and gut microbiota composition in both high and low fat fed mice over a
ten week period was assessed. Streptomycin treatment was required in
order to remove resident Proteobacteria from the GI tract to facilitate the
subsequent establishment of the streptomycin resistant E. coli strain
MG1655. In addition, the impact of introducing MG1655 on the gut
microbiota composition of HFD mice (HFD-EC) was investigated prior to
a second study, in which the effects (weight and microbiota) of utilising
MG1655 derivatives that expressed heterologous BSH genes were
assessed.
In the case of the first study, it was established that, as expected,
HFD controls gained significantly more weight than LFD controls
(p<0.0001). HFD mice that received 1x107 cfu StrR GMR E. coli MG1655
(HFD-EC) for two consecutive days at the start of the trial also gained
significantly more body weight than the LFD controls (p<0.0001). HFD-EC
mice gained more body weight than HFD controls and while this
difference was not significant, a trend was noted (p=0.08) (Fig 1). HFD-
EC mice consumed significantly more calories on average than both LFD
and HFD controls, as measured by the average cumulative caloric intake
per week (Fig 2).
4.4.2 Caecum microbiota diversity is higher in LFD mice than HFD
controls
The composition of the gut microbiota of LFD, HFD and HFD-EC mice
was investigated. Post quality filtering a total of 171,127 V4 16S rRNA
sequence reads were generated, equating to an average of 1,321 reads
per mouse for each time point and an average of 6,126 reads per cecum.
Rarefaction curves were calculated at 97% similarity and were
approaching parallel to the x-axis for all samples, again indicating extra
sampling would yield a limited increase in species richness
(Supplementary Fig 1). Shannon diversity, Simpson diversity and Chao1
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values of species richness as well as Phylogenetic diversity and
Observed species numbers were calculated for each sample
(Supplementary Table 2). Analysis of the alpha diversity of the faecal
microbiota over the course of the study revealed that treatment with
streptomycin resulted in a reduction in Chao1 values in all three groups
from T0 to T1. However diversity increased over time with recovery
found to be greatest in the HFD-EC mice (Supplementary Fig 2). This
pattern was also apparent when alpha diversity was quantified with
respect to Phylogenetic diversity and Observed species, but not Simpson
and Shannon diversity (Supplementary Fig 2).
Analysis of the alpha diversity of cecum microbiota revealed
Observed species, Phylogenetic diversity and Chao1 values were
significantly greater for the LFD caecal microbiota relative to that of HFD
controls. A similar pattern was observed in the case of Shannon and
Simpson values but in these instances the differences were not
significant (Supplementary Fig 3). It was also noted that the number of
Observed species was significantly greater in the caecum of LFD mice
than in the HFD-EC controls, but that these populations did not differ
significantly when other alpha diversity-related metrics were assessed
(Supplementary Fig 3).
A shift in the beta diversity of the microbiota, as assessed using
unweighted Unifrac, was observed in all three groups of mice following
the administration of streptomycin i.e. between T0 and T1 (Fig 3). By the
end of the trial, caecal microbiota and T10 faecal samples of all three
groups clustered separately from each other (Fig 3)
4.4.3 Diet effects microbiota composition in streptomycin treated
mice
Assignment of the 16S rRNA amplicons revealed the presence of six
phyla, Bacteroidetes, Firmicutes, Actinobacteria, Deferribacteres,
Proteobacteria and Verrucomicrobia, in the faecal samples of the LFD fed
mice whereas just five phyla were detected in the corresponding caecal
samples despite caecal samples being sequenced to a greater depth.
The Proteobacterium phylum was not identified within the LFD caecal
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samples and was detected in the faecal samples collected at T8 only. In
both faecal and caecal samples the two dominant phyla were the
Bacteroidetes and Firmicutes. Initially, the Bacteroidetes dominated but,
by week eight, the Firmicutes became dominant. Bacteria corresponding
to the phylum Actinobacteria were detected in low proportions in samples
collected at T8 (0.5%) and in caecal samples (0.02%).
When the LFD 16S reads were assigned at family level, only
fourteen families were detected in the caecal samples, whereas twenty
were detected in the faecal samples. At T0, the faecal samples was
dominated by a variety of families that could not be accurately identified
(57%), with the most dominant ‘assigned’ families being
Ruminococcaceae (22%) and Erysipelotrichaceae (9%) (Supplementary
Table 3). After one week of intervention with streptomycin-treated water
and a LFD, Peptostreptococcaceae (24%) and Lactobacillaceae (8%)
became the most dominant ‘assigned’ families. By T10, this pattern had
changed with a large reduction in unassigned families, making
Erysipelotrichaceae (42%) the most dominant family followed by
Lactobacillaceae (11%) and Peptostreptococcaceae (8%). This final
pattern was also evident in the caecal samples (Supplementary Table 3).
It is noteworthy that the Enterobacteriaceae were not detected throughout
the study.
Compositional sequencing revealed the presence of four phyla in
the faecal and caecal samples in the HFD fed mice. These were
Bacteroidetes, Firmicutes, Deferribacteres and Verrucomicrobia. Of
these, Verrucomicrobia were not identified at T1. In both faecal and
caecal samples, the two most dominant phyla were the Bacteroidetes and
Firmicutes. As with the LFD group, Bacteroidetes were initially the more
dominant of the two phyla before a shift in favour of Firmicutes occurred.
Unlike LFD group mice, reads corresponding to the phylum
Actinobacteria were not detected.
The number of families detected was again lower than was the
case for LFD mice i.e. only 14 families were detected in faecal samples
and 13 were detected in caecal samples. After one week of intervention
with streptomycin treated water and a HFD, unassigned families
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dominated the composition (44%) with Erysipelotrichaceae (21%),
Peptostreptococcaceae (20%), Verrucomicrobiaceae (3%) and
Rikenellaceae (3%) being the most dominant ‘assigned’ families. By T10,
a reduction in unassigned families was seen, with Erysipelotrichaceae
(28%) and Peptostreptococcaceae (16%) continuing to be abundant. This
pattern was also evident in the caecal samples. It is again noteworthy that
Enterobacteriaceae were not detected throughout the study
(Supplementary Table 4).
Pairwise comparison of caecal microbiota of the streptomycin-
treated HFD and LFD mice using Mann-Whitney revealed that the
proportions of Bacteroidaceae and Peptostreptococcaceae were
significantly greater, and the proportions of Eubacteriaceae were
significantly lower, in HFD mice.
Compositional sequencing of the microbiota of HFD mice in receipt
of 1x107 cfu StrR GMR E. coli MG1655 (HFD-EC) for two consecutive
days revealed the presence of seven phyla in the faecal samples and six
phyla in the caecal samples. These were Proteobacteria, Bacteroidetes,
Firmicutes, Actinobacteria, Deferribacteres, 4C0d-2 and Verrucomicrobia
with reads corresponding to the 4C0d-2 being detected in T8 faecal
samples only. In both faecal and caecum samples the most dominant
phyla were Bacteroidetes and Firmicutes. Initially, the Bacteroidetes
dominated but, by the T10, Firmicutes were the most dominant phyla.
Bacteria corresponding to the phylum Proteobacteria were not initially
detected but were detected in increasing proportions over subsequent
time points.
As was the case for the LFD mice, there were a greater number of
different families detected in the HFD-EC faecal (21) and caecal (14)
samples than in HFD mice. After one week of intervention 63% of reads
were ‘unassigned’. Among the assigned families Erysipelotrichaceae
(14%), Verrucomicrobiaceae (13%), Rikenellaceae (2%),
Lactobacillaceae (2%) and Ruminococcaceae (2%) were the most
dominant. As noted for both of the other groups, a reduction in
unassigned families was observed at T10 and, as with the HFD mice, the
Erysipelotrichaceae (51%) and Peptostreptococcaceae (13%) were still
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the most dominant families. It is also noteworthy that Enterobacteriaceae
were detected at T1, T8 and in the caecum (Supplementary Table 5).
Pairwise comparisons of the caecal microbiota of HFD and HFD-
EC mice using Mann-Whitney revealed the presence of significantly
greater proportions of Eubacteriaceae and significantly smaller
proportions of Rikenellaceae and Bacteroidaceae in HFD-EC mice. A
trend towards significantly greater Proteobacteria and associated family
was seen in HFD-EC mice compared to HFD mice (p=0.054).
4.4.4 ECBSH1 mice gain less body weight than ECBSH2 mice
The streptomycin-treated DIO mouse model described above was
employed to evaluate the consequences of administering E. coli MG1655
derivatives expressing L. salivarius BSH1 (accession number FJ591091)
or BSH2 (accession number FJ591081) genes on weight gain and gut
microbiota composition. LFD and HFD mice receiving ECBSH1 gained
significantly less body weight than their ECBSH2-fed counterparts (Fig 4)
despite the fact that there was no significant difference in average calorie
consumption between the cohorts (Fig 5).
4.4.5 Reduced diversity in low fat diet mice in receipt of EC-BSH1
164,581 quality filtered V4 16S sequence reads were generated to
investigate the gut microbiota composition of the LFD and HFD mice in
receipt of either ECBSH1 or ECBSH2. This equated to an average of
2,478 reads per mouse at each time point and on average 6,919 reads
per cecum. Alpha diversities were calculated in each case
(Supplementary Table 6). Rarefaction curves were calculated at 97%
similarity and were saturating for all samples, indicating extra sampling
would yield only a limited increase in species richness (Supplementary
Fig 4). Bar graph analysis of caecal alpha diversity reveals that the caecal
bacteria of LFD mice receiving ECBSH1 was numerically less than that
present in the other three treatment groups (Supplementary Fig 5 & 6).
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4.4.6 Analysis of microbiota beta diversity highlights the dominant
impact of BSH1 over diet
Principal coordinate analysis of microbial beta diversity, as determined by
unweighted Unifrac, again highlights the dramatic effects that
streptomycin and diet have on the microbiota population over time
(Supplementary Fig 7). Tight clustering of the data points is observed
prior to antibiotic treatment and dietary change but following one week of
antibiotic treatment and a change in diet there is a considerable shift in
the microbiota (Supplementary Fig 7). The faecal microbiota of LFD mice
receiving ECBSH2 is separated from the other three treatment groups at
all time points. By T8 of the trial, the faecal microbiota shifts again and
clusters together with the caecal samples, with the microbiota of both
LFD and HFD mice receiving ECBSH1 clustering together. Among the
caecal samples, it is apparent that mice fed a LFD and receiving
ECBSH2 cluster together, there is no clustering among the microbiota of
HFD mice receiving ECBSH2 while all ECBSH1 receiving mice cluster
together regardless of diet (Supplementary Fig S7).
4.4.7 BSH1 and 2 differ in their impacts on bacterial taxa
Although numerous changes in composition were observed following
administration of the BSH1 and 2 producing strains, here we focus on
family level assignments. Data with respect to the impact of introduction
of these strains on phylogeny at the phylum and genus level can be found
in supplementary tables 7, 8, 9 & 10. Compositional sequencing of the
gut microbiota of HFD fed mice receiving ECBSH1 for two consecutive
days revealed a greater number of families in faecal samples (23) than in
caecal samples (16) despite greater depth of sequencing in caecal
samples. Initially, faecal samples were predominantly composed of
unassigned families (44%), with the most common assigned families
detected similar to study 1 being Lachnospiraceae (17%), Rikenellaceae
(13%), Ruminococcaceae (12%) and Bacteroidaceae (6%). However,
after one week of intervention, a shift in the microbiota was evident with
Enterobacteriaceae (13%), Erysipelotrichaceae (12%),
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Erysipelotrichaceae Incertae Sedis (8%), Ruminococcaceae (3%) and
Lachnospiraceae (3%) becoming the most dominant of the assigned
families. Eight weeks of intervention further altered the microbiota
composition with Bacteroidaceae (44% and 42%), Erysipelotrichaceae
(15% and 16%), Bifidobacteriaceae (6% and 8%) and Ruminococcaceae
(4% in both) being the most dominant families in both faecal and caecum
samples, respectively. Staphylococcaceae were detected at a level of
16% after eight weeks but were not detected in caecum samples.
Lactobacillaceae and Porphyromonadaceae were detected at 8% and 6%
in caecal samples but only at 0.1% and 0.8% in T8 faecal samples
(Supplementary Table 7).
Compositional sequencing of the gut microbiota of LFD fed mice
receiving ECBSH1 detected twenty two families of bacteria in faecal
samples whereas only fifteen were detected in caecal samples. On the
basis of assigned reads, the most dominant families detected similar to
study 1, were Rikenellaceae (17%), Lachnospiraceae (15%),
Ruminococcaceae (6%) and Bacteroidaceae (6%) however here,
Porphyromonadaceae (6%) were also dominant. After one week of
intervention a shift in the microbiota was observed with Lactobacillaceae
(18%), Thermaceae (18%), Erysipelotrichaceae (15%),
Enterobacteriaceae (10%), Ruminococcaceae (4%) and Lachnospiraceae
(2%) becoming the most dominant families. After eight weeks of
intervention the microbiota composition shifted again, with
Bacteroidaceae (27% and 40%) and Erysipelotrichaceae (23% and 17%)
being the most dominant families in the faecal and caecal samples,
respectively (Supplementary Table 8).
Compositional sequencing of the gut microbiota of LFD fed mice
that received ECBSH2 revealed fourteen families of bacteria in caecal
samples and nineteen were detected in faecal samples. As noted above,
at T0, the faecal samples were predominantly composed of
Lachnospiraceae (18%), Ruminococcaceae (12%) and Rikenellaceae
(10%), however Streptococcaceae (31%) was also seen to be dominant
in this instance. After one week of intervention, this changed such that the
Bacteroidaceae (74%), Enterobacteriaceae (13%), Rikenellaceae (6%)
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and Lactobacillaceae (3%) became the most dominant families. After
eight weeks of intervention Bacteroidaceae (54%) were still the most
dominant family, followed by Rikenellaceae (17%), Erysipelotrichaceae
(12%), Bifidobacteriaceae (5%) and Ruminococcaceae (4%). The caecal
microbiota was again quite different, being dominated by
Lactobacillaceae (28%), Bacteroidaceae (25%), Erysipelotrichaceae
(15%) and Rikenellaceae (11%) (Supplementary Table 9).
Compositional sequencing of the gut microbiota of HFD mice that
received ECBSH2 revealed twenty five families of bacteria in the faecal
samples whereas only fifteen were detected in caecal samples. At T0 like
the initial study faecal samples consisted of Rikenellaceae (18%),
Lachnospiraceae (18%), Ruminococcaceae (11%) and Bacteroidaceae
(6%) however unlike study 1 Streptococcaceae (11%) was also dominant.
After one week of intervention the proportions of the different families
changed with Bacteroidaceae (53%), Lactobacillaceae (22%),
Streptococcaceae (12%) and Erysipelotrichaceae (8%) being the most
dominant families. After eight weeks the composition changed further with
Erysipelotrichaceae (25%), Bacteroidaceae (22%), Moraxellaceae (17%)
and Vibrionaceae (11%) being the most dominant families. Similarly, the
Erysipelotrichaceae (30%) and Bacteroidaceae (25%) were the most
dominant families in the caecal samples. Bifidobacteriaceae were also
detected at 13% (Supplementary Table 10).
4.4.8 Caecal comparisons reveal that both diet and type of BSH
impact on microbiota composition
While phylogenetic data can be viewed in the context of changes within
specific groups over time, it is also of value to assess differences that
occur between groups. Here we will assess separately the effects both
diet and the type of BSH expressed have on caecum microbiota
composition. Unlike faecal samples, caecum samples were sequenced
for each individual mouse which is why they were chosen for this
analysis.
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4.4.8.1 BSH activity influences microbiota composition in a strain
specific manner
The impact that the two respective BSH activities had on the caecal
microbiota was assessed by comparing data from animals administered
identical diets but supplemented with either ECBSH1 or ECBSH2. In the
case of the LFD fed animals, it is interesting to note that Bacteroidetes
was the dominant phylum in mice receiving ECBSH1 whereas Firmicutes
dominated in mice receiving ECBSH2 mice. Increases and decreases in
the proportions of a number of families were evident throughout the
study. In particular, there was a large increase in the proportions of the
family Bacteroidaceae, and the genera Bacteroides and Allobaclum, in
ECBSH1 mice. In contrast, increases in the proportions of
Lactobacillaceae and Streptococcaceae, and the corresponding genera
Lactobacillus and Streptococcus, were seen in ECBSH2. It is also
interesting to note that representatives of the phylum Deinococcus-
Thermus, and its corresponding family and genus, Thermaceae and
Thermus, and the family Erysipelotrichales Incertae Sedis were found in
ECBSH1 mice but not ECBSH2 mice. Similarly, the family Prevotellaceae
and its corresponding genus, Prevotella, were detected in mice receiving
ECBSH2, but not ECBSH1.
The impact of expression of the BSH genes was also assessed by
comparing the caecal microbiota of HFD-fed animals that received
ECBSH1 or ECBSH2. As was the case for the corresponding LFD fed
animals, reads corresponding to the phylum Deinococcus-Thermus and
its corresponding family and genus (Thermaceae and Thermus) were
detected in mice that received ECBSH1, but not those that received
ECBSH2. It was also noted yet again that Bacteroidetes were dominant in
ECBSH1-administered mice whereas Firmicutes were dominant BSH2-
administered mice. It was also noted that Vibrionaceae, and its
corresponding genus Vibrio, were detected in mice receiving ECBSH1
only. In contrast, the families Porphyromadaceae and Leuconostocaceae
and the genera Faecalibacterium and Leuconostoc were only detected in
ECBSH2 mice. Differences in the proportions of other taxa were also
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noted. In ECBSH1 mice the proportions of the families Bacteroidaceae,
Lactobacillaceae and Erysipelotrichales Incertae Sedis and the genera
Bacteroides and Lactobacillus were greater in ECBSH1-administered
mice compared to ECBSH2 mice. In contrast, the proportions of the
phylum Actinobacteia and its corresponding family and genus,
Bifidobacteriaceae and Bifidobacterium, the families Lachnospiraceae,
Erysipelotrichaceae and Enterobacteriaceae as well as Lachnospiraceae
Incertae Sedis and Enterobacteriaceae associated genera were greater
in ECBSH2-adminsitered mice.
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4.5 DISCUSSION
Effective colonization of the intestine with newly introduced strains of E.
coli can be problematic due to colonization resistance from the natural
microbiota (Lawley and Walker, 2013). For this reason, the streptomycin-
treated mouse model (Leatham-Jensen et al., 2012, Leatham et al., 2005,
Cronin et al., 2012) was employed in this study. Effects of streptomycin
on the gut have previously been investigated using FISH, which revealed
that streptomycin treatment increases the numbers of Cytophage-
Flavobacterium-Bacteroidetes, while traditional culture methods revealed
a reduction in the abundance of Lactobacillus, Enterobacteriaceae and
enterococci/group D streptococci (Sekirov et al., 2008).
On the basis of principle coordinate analysis, a clear shift in the
microbiota population was apparent after one week of streptomycin
treatment. While this shift could be attributed to age and diet, it is likely
that antibiotic intervention plays a big part in this change. Unlike our
previous study, in which a recovery of the microbiota with time was
observed in HFD mice receiving the antibiotic vancomycin (Clarke et al.,
2013), no recovery was observed here after 10 weeks of streptomycin
treatment. It is not clear why this is the case but may be due to the
different antimicrobial spectra or mechanisms of action of these
antibiotics. This highlights the varying and lasting effects that antibiotics
can have on our gut microbiota communities. As expected, and in line
with previous studies (Clarke et al., 2013, Garner et al., 2009, Murphy et
al., 2012), a reduction in microbiota diversity due to antibiotic treatment
was noted in all three cohorts. Diet induced obesity in streptomycin-
treated mice resulted in a gut microbiota composition, as revealed by
unweighted unifrac, that was clearly distinct from that of LFD
streptomycin-treated mice. Initially, and in agreement with previous
studies, treatment of LFD fed animals with streptomycin for one week did
not alter the proportions of Bacteroidetes. However, 10 weeks of
streptomycin treatment brought about a reduction in Bacteroidetes and a
bloom in Firmicutes, and of Erysipelotrichaceae in particular, in faecal
and caecal samples. Though the blooming of Mollicutes (equivalent to
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Erysipelotrichaceae in this study) has been previously associated with
diet induced obesity (Turnbaugh et al., 2008), this was not observed in
our previous study which employed the same HFD employed here
(Murphy et al., 2012). Multiple antibiotics (ampicillin, gentamycin,
metronidazole, neomycin and vancomycin) have been found to increase
the numbers of Erysipelotrichaceae (Hill et al., 2009), with the species
Erysipelothrix rhusiopathiae being resistant to streptomycin (Lee et al.,
2011). In contrast to studies investigating the impact of streptomycin on
the murine microbiota (Sekirov et al., 2008), but in line with diet induced
obesity studies (Murphy et al., 2012), a decrease in Bacteroidetes
abundance and an increase in Firmicutes abundance in faecal and caecal
samples was noted after 10 weeks of HFD mice receiving streptomycin.
In this case, increases in the families Erysipelotrichaceae and
Peptostreptococcaceae were primarily responsible for the increase in
Firmicutes whereas, in our previous study, diet induced obesity did not
alter the levels of Erysipelotrichaceae or Peptostreptococcaceae (Clarke
et al., 2013). This is presumably a phenomenon driven by the additional
presence of streptomycin. Streptomycin also successfully reduced
Proteobacteria to below detectable levels in the faecal and caecal
samples of HFD and LFD mice after 10 weeks.
While the first animal trial described in this study provided
information with respect to the impact of streptomycin on mice fed a HFD
or LFD diet, it also revealed the impact of the colonization of the
streptomycin-treated HFD fed mouse model with E. coli MG1655.
Colonization of HFD fed animals with E. coli MG1655 resulted in
significant changes to the microbiota from that of control HFD fed animals
as revealed by unweighted Unifrac. Pairwise comparison of the caecal
microbiota revealed significantly greater proportions of Eubacteriaceae,
and significantly lower proportions of Rikenellaceae and Bacteroidaceae
in HFD-EC mice compared to HFD mice. Critically, the detection of
Enterobacteriaceae in the caecum of HFD-EC mice reflected the
successful colonization of the mouse intestinal tract with E. coli MG1655
and suggested that this was a suitable model for investigating the
influence of BSH production on the gut microbiota.
150
It has been noted that bile acids have a direct effect on the host
with increased levels protecting against obesity in leptin deficient mice
(Zhang et al., 2012) and reduced levels of eight bile acids species noted
in humanized obese mice (Ridaura et al., 2013). Bile acid administration
has also been previously noted to alter microbiota composition (Islam et
al., 2011). Deconjugation of bile acids by BSHs has been hypothesised to
impact on gut microbiota composition as the liberated amino acids taurine
and glycine could potentially be used as carbon, nitrogen and energy
sources (Begley et al., 2005a). Previous characterisation of BSH1JCM1046
and BSH1UCC118 (ECBSH1 and ECBSH2, respectively) has shown that
ECBSH1 is more active than ECBSH2, detoxifying primary bile acids and
producing more secondary and tertiary bile acids (Fang et al., 2009). We
hypothesised that ECBSH1 and ECBSH2 can modulate the gut
microbiota as bacteria that are normally sensitive to bile acids can now
flourish and bacteria that are sensitive to secondary and tertiary bile acids
will be reduced. ECBSH1 has a greater affinity for tauro-conjugated bile
(TCBA) acids than ECBSH2. As the level of TCBA is increased by dietary
fat (Devkota et al., 2012), we used both a LFD and HFD to determine if
the effects of BSH activity on the microbiota population differed in a diet-
dependent manner.
E. coli MG1655 expressing either ECBSH1 or ECBSH2 was
administered to LFD or HFD fed animals for two consecutive days at the
beginning of the trial. Although no significant difference in energy
consumption by the respective groups was observed, significant
differences in percentage weight gain were apparent. As expected, LFD
mice in receipt of either ECBSH1 or ECBSH2 gained significantly less
weight than their HFD counterparts. It is interesting, however, to note that
ECBSH1 receiving mice gained significantly less weight than mice that
received ECBSH2. This reduction could be due to increased activity of
ECBSH1 altering the microbiota composition and in turn weight gain,
though host related factors such as hormones and genotype could also
be involved.
As with our previous trial (Clarke et al., 2013) and the initial pilot
study, streptomycin causes a shift in microbiota composition visualised by
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PCoA. Neither diet nor BSH treatment appear to play a role in this shift
with all four cohorts clustering together at each time point. However, this
changed by the end of the study with caecum microbiota composition
clustering by treatment group. Mice receiving ECBSH1 clustered closely
together regardless of diet and LFD ECBSH2 mice clustered away from
HFD ECBSH2 mice.
We speculated that comparing the gut microbiota of LFD mice
receiving ECBSH1 and ECBSH2 might highlight differences that could
explain the significant reduction in weight gain seen in mice receiving
ECBSH1 but not in mice receiving ECBSH2. It was therefore interesting
to note that the caecal samples from ECBSH1 mice had a high
Bacteroidetes to Firmicutes ratio whereas the opposite was the case in
mice receiving ECBSH2. A high Firmicutes to Bacteroidetes ratio has
previously been associated with obesity (Murphy et al., 2012, Ley et al.,
2005, Ley et al., 2006), albeit not in all cases (Clarke et al., 2013,
Schwiertz et al., 2009, Duncan et al., 2007). Actinobacteria, specifically
Bifidobacteriaceae, were detected in larger numbers in week eight faecal
samples from LFD ECBSH1 administered mice relative to samples from
LFD ECBSH2 mice. Bifidobacterium has previously been associated with
anti-obesity effects i.e. reducing body and fat weight (An et al., 2011),
albeit in a strain specific manner (Yin et al., 2010). A large increase in
Lactobacillus was noted in ECBSH2 mice cecum samples. The species
Lactobacillus reuteri has previously been found to be enriched in obese
humans (Million et al., 2011, Million et al., 2013), but this remains highly
controversial (Delzenne and Reid, 2009, Ehrlich, 2009, Raoult, 2009). As
for LFD mice, HFD ECBSH1 mice gained significantly less weight than
HFD ECBSH2 mice. Comparisons again reveal a high Bacteroidetes to
Firmicutes ratio in HFD ECBSH1 mice (corresponding to high
Bacteroidaceae numbers) compared to a high Firmicutes to
Bacteroidetes ratio observed in ECBSH2 mice (corresponding to high
Erysipelotrichaceae numbers). Given that a high Firmicutes to
Bacteroidetes ratio and greater Erysipelotrichi levels have previously
been observed in mice administered cholic acid (Islam et al., 2011) it
would seem that this phenomenon results from instances where bile salt
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breakdown is greater, i.e. reflecting the greater activity of ECBSH1 over
ECBSH2, or where increased substrate, i.e. cholic acid, is available for
the gut microbiota to act on.
These pilot studies highlight the effect diet, antibiotics and BSH
can have on gut microbiota communities. Though the reduction in weight
gain associated with ECBSH1 and the composition changes are
promising, further investigations using larger groups of mice and
additional controls are required to determine the significance of these
phenomena.
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Figure 1
HFD and HFD-EC mice gain significantly more weight than LFD
mice.
158
Figure 2
HFD and HFD-EC consume more calories on average than LFD mice
per week.
159
Figure 3
Principal coordinate analysis of unweighted Unifrac for each diet
group.
Colour codes; low fat diet fed mice, shades of red with T1 being the
darkest and getting lighter with time; high fat diet fed mice, shades of blue
with T1 being the darkest and getting lighter with time and high fat diet
fed mice receiving 1x107 cfu StrR GMR E. coli MG1655 with no bile salt
hydrolase, shades of green with T1 being the darkest and getting lighter
with time.
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Figure 4
ECBSH1 mice gain significantly less weight than ECBSH2 mice.
161
Figure 5
No significant difference in average weekly calorie intake between
the cohorts.
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SUPPLEMENTARY INFORMATION
Supplementary Table 1
Primer Sequence 5’-3’ Purpose
P44FAflII 5'-ATAATACTTAAGACCCATCCAGGAGACGGGACGATAGC-3' p44 Promoter
amplification
p44RNcoI 5'-
GCAGTACCCATGGTTTGGCCTCCTAAGCGCCTCCTTTCCCTCA
CAC ATC-3'
p44 Promoter
amplification
GMF 5'-GATCCTCTAGAGTCGACCTGCAGGCATG-3' Plasmid
sequencing
from GM
cassette
glmSattnF 5'-GATGCTGGTGGCGAAGCTGT-3' Chromosome
integration
check
glmSattnR 5'-GATGACGGTTTGTCACATGGA-3' Chromosome
integration
check
p44OLRBSH1 5'-
TAAAGTAATTGCTGTACACATGGTTTGGCCTCCTAAGCGCCTC
CTTTCCC-3'
Amplification
of p44
promoter with
overlap of
BSH1
BSH1OLF 5'-
GGGAAAGGAGGCGCTTAGGAGGCCAAACCATGTGTACAGCAA
TTACTTTA-3'
Amplification
of BSH1 with
overlap of
p44
BSH1R 5'-ATATATCCGCGGTTAATTCAACTTATTTATTACTTGTTT-3' Amplification
of BSH1
BSH2OLF 5'-
GGGAAAGGAGGCGCTTAGGAGGCCAAACCATGTGTACAGCAA
TTACTTTA-3'
Amplification
of BSH2 with
overlap of
p44
BSH2R 5'-TATATAGGTACCTTAATTTTGCATATTAATTGATTGGTGGC-3' Amplification
of BSH2
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Supplementary Table 2 Alpha diversity
Chao1 Simpson Shannon
Phylogenetic
Diversity
Observed
Species
Low Fat Diet
T0 885.5 0.953 5.589 24.147 368
T1 580.5 0.872 4.281 17.140 294
T8 845.5 0.715 4.012 30.080 443
T10 554.6 0.811 4.008 19.077 306
caecal 559.1 0.904 4.697 17.092 348
caecal 706.0 0.919 4.770 18.326 352
caecal 564.2 0.799 3.896 14.941 297
caecal 649.6 0.799 3.964 21.308 319
caecal 614.1 0.912 4.634 17.652 304
High Fat Diet
T0 885.5 0.953 5.589 24.147 368
T1 493.0 0.877 4.220 18.211 285
T8 492.0 0.872 4.304 17.514 303
T10 536.8 0.841 4.145 16.060 290
caecal 401.6 0.926 4.793 13.949 249
caecal 487.3 0.932 4.847 14.693 270
caecal 495.1 0.916 4.696 15.097 281
caecal 464.6 0.886 4.302 15.045 284
caecal 445.7 0.896 4.517 16.243 278
High Fat Diet + MG1655
T0 885.5 0.953 5.589 24.147 368
T1 473.9 0.889 4.373 17.658 268
T8 874.5 0.757 4.223 32.855 501
T10 700.1 0.747 3.599 21.252 338
caecal 477.1 0.913 4.738 17.044 298
caecal 541.1 0.900 4.533 15.310 296
caecal 679.3 0.888 4.391 16.858 291
caecal 614.2 0.882 4.430 14.050 282
caecal 445.7 0.915 4.663 14.719 279
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Supplementary Table 3 Percentage read number Low fat diet mice
LFD
T0
LFD
T1
LFD
T8
LFD
T10
LFD
caecal
Phylum
Proteobacteria 0.000 0.000 0.140 0.000 0.000
Bacteroidetes 52.690 53.141 12.495 22.120 35.019
Firmicutes 42.172 43.094 81.804 70.432 56.270
Actinobacteria 0.000 0.000 0.490 0.000 0.021
Deferribacteres 4.614 0.000 0.084 2.509 1.751
Candidate division TM7 0.000 0.000 0.000 0.000 0.000
4C0d-2 0.000 0.000 0.000 0.000 0.000
Verrucomicrobia 0.000 3.688 4.931 4.834 6.789
Deinococcus-Thermus 0.000 0.000 0.000 0.000 0.000
other 0.524 0.078 0.056 0.105 0.150
Family
Rhodospirillaceae 0.000 0.000 0.000 0.000 0.000
Alcaligenaceae 0.000 0.000 0.000 0.000 0.000
Rikenellaceae 1.975 0.094 3.026 0.946 2.251
Porphyromonadaceae 0.121 0.000 0.784 0.000 0.000
Bacteroidaceae 1.350 0.375 5.379 0.171 0.141
Lachnospiraceae 1.632 3.141 1.849 4.019 1.646
Eubacteriaceae 0.222 0.125 0.616 0.355 0.563
Ruminococcaceae 22.063 1.953 4.356 2.706 5.385
Peptococcaceae 0.000 0.000 0.000 0.000 0.000
Lactobacillaceae 1.592 7.875 5.477 11.296 12.372
Erysipelotrichales Incertae Sedis 0.000 0.000 0.000 0.000 0.000
Bifidobacteriaceae 0.000 0.000 0.280 0.000 0.000
Deferribacteraceae 4.614 0.000 0.084 2.509 1.751
Erysipelotrichaceae 9.248 1.078 55.456 42.073 24.874
Coriobacterineae 0.000 0.000 0.210 0.000 0.018
Clostridiaceae 0.000 0.000 0.098 0.000 0.000
Verrucomicrobiaceae 0.000 3.688 4.917 4.834 6.789
Enterobacteriaceae 0.000 0.000 0.000 0.000 0.000
Streptococcaceae 0.181 0.359 1.961 0.328 0.545
Anaeroplasmataceae 0.000 0.000 0.000 0.000 0.000
Prevotellaceae 0.302 0.172 0.630 0.118 0.039
Moraxellaceae 0.000 0.000 0.000 0.000 0.000
Vibrionaceae 0.000 0.000 0.000 0.000 0.000
Thermaceae 0.000 0.000 0.000 0.000 0.000
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LFD
T0
LFD
T1
LFD
T8
LFD
T10
LFD
caecal
Brevibacteriaceae 0.000 0.000 0.000 0.000 0.000
Staphylococcaceae 0.000 0.000 0.000 0.000 0.000
Pseudoalteromonadaceae 0.000 0.000 0.000 0.000 0.000
Leuconostocaceae 0.000 0.000 0.098 0.000 0.015
Bacillaceae 0.000 0.000 0.000 0.000 0.000
Desulfovibrionaceae 0.000 0.000 0.000 0.000 0.000
Peptostreptococcaceae 0.000 23.750 8.012 7.894 9.942
Planococcaceae 0.000 1.109 0.000 0.000 0.000
Paenibacillaceae 0.000 0.344 0.000 0.000 0.000
Veillonellaceae 0.000 0.000 0.112 0.000 0.000
Other 56.700 55.938 6.654 22.751 33.669
Genus
Thalassospira 0.000 0.000 0.000 0.000 0.000
Sutterella 0.000 0.000 0.000 0.000 0.000
Alistipes 1.612 0.000 0.896 0.946 2.230
Rikenella 0.000 0.000 0.000 0.000 0.000
Parabacteroides 0.000 0.000 0.588 0.000 0.000
Odoribacter 0.000 0.000 0.126 0.000 0.000
Bacteroides 1.350 0.375 5.379 0.171 0.177
Lachnospiraceae Incertae Sedis 0.000 0.000 0.532 0.131 0.180
uncultured Lachnospiraceae 0.000 0.000 0.000 0.000 0.000
Ruminococcus 0.000 0.000 0.350 0.000 0.000
Ruminococcaceae Incertae Sedis 16.845 0.141 0.434 2.075 4.643
Oscillibacter 0.000 0.000 0.000 0.000 0.000
Anaerotruncus 1.229 1.344 0.196 0.066 0.186
Lactobacillus 1.592 7.875 0.546 11.296 12.372
Allobaculum 0.000 1.063 0.000 0.000 0.000
Bifidobacterium 0.000 0.000 0.280 0.000 0.000
Mucispirillum 4.614 0.000 0.084 2.509 1.751
Turicibacter 0.000 0.000 0.000 0.000 0.000
Clostridium 0.000 0.000 0.098 0.000 0.000
Coprococcus 0.000 0.000 0.000 0.000 0.000
Akkermansia 0.000 3.688 0.490 4.834 6.789
Brenneria-Yersinia 0.000 0.000 0.000 0.000 0.000
Streptococcus 0.000 0.000 0.000 0.000 0.000
Prevotella 0.302 0.172 0.630 0.118 0.039
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LFD
T0
LFD
T1
LFD
T8
LFD
T10
LFD
caecal
Marvinbryantia - Bryantella 0.000 0.000 0.000 0.000 0.000
Anaeroplasma 0.000 0.000 0.000 0.000 0.000
Lactococcus 0.181 0.344 1.933 0.328 0.545
Faecalibacterium 0.101 0.000 0.798 0.000 0.000
Psychrobacter 0.000 0.000 0.000 0.000 0.000
Vibrio 0.000 0.000 0.000 0.000 0.000
Thermus 0.000 0.000 0.000 0.000 0.000
Staphylococcus 0.000 0.000 0.000 0.000 0.000
Pseudoalteromonas 0.000 0.000 0.000 0.000 0.000
Leuconostoc 0.000 0.000 0.084 0.000 0.000
Anoxybacillus 0.000 0.000 0.000 0.000 0.000
Desulfovibrio 0.000 0.000 0.000 0.000 0.000
Paenibacillus 0.000 0.344 0.000 0.000 0.000
Lysinibacillus 0.000 1.094 0.000 0.000 0.000
Peptostreptococcaceae Incertae Sedis 0.000 0.391 0.224 0.276 0.287
Anaerovorax 0.000 0.000 0.000 0.000 0.000
Catenibacterium 0.000 0.000 0.210 0.000 0.000
Barnesiella 0.000 0.000 0.000 0.000 0.000
Blautia 0.000 0.000 0.154 0.000 0.000
Subdoligranulum 0.000 0.000 0.126 0.000 0.000
uncultured Ruminococcaceae 0.000 0.000 0.084 0.000 0.000
Phascolarctobacterium 0.000 0.000 0.084 0.000 0.000
Lachnospira 0.000 0.000 0.000 0.000 0.000
Megamonas 0.000 0.000 0.000 0.000 0.000
Weissella 0.000 0.000 0.000 0.000 0.000
Uncultured bacteria 0.201 0.000 2.717 1.497 1.159
Other 71.973 83.172 82.953 75.752 69.642
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Supplementary Table 4 Percentage read number high fat diet mice
HFD
T0
HFD
T1
HFD
T8
HFD
T10
HFD
caecal
Phylum
Proteobacteria 0.000 0.000 0.000 0.000 0.000
Bacteroidetes 52.690 44.919 22.180 22.832 34.456
Firmicutes 42.172 48.591 70.171 69.128 51.592
Actinobacteria 0.000 0.000 0.000 0.000 0.000
Deferribacteres 4.614 2.981 1.480 4.145 5.097
Candidate division TM7 0.000 0.000 0.000 0.000 0.000
4C0d-2 0.000 0.000 0.000 0.000 0.000
Verrucomicrobia 0.000 3.399 6.073 3.843 8.760
Deinococcus-Thermus 0.000 0.000 0.000 0.000 0.000
other 0.524 0.109 0.096 0.053 0.095
Family
Rhodospirillaceae 0.000 0.000 0.000 0.000 0.000
Alcaligenaceae 0.000 0.000 0.000 0.000 0.000
Rikenellaceae 1.975 3.072 1.385 3.395 2.598
Porphyromonadaceae 0.121 0.000 0.000 0.000 0.000
Bacteroidaceae 1.350 0.418 0.411 0.737 0.699
Lachnospiraceae 1.632 0.891 3.578 4.461 1.451
Eubacteriaceae 0.222 0.000 0.452 0.000 0.122
Ruminococcaceae 22.063 1.963 3.619 3.224 6.101
Peptococcaceae 0.000 0.091 0.000 0.000 0.000
Lactobacillaceae 1.592 1.545 3.578 1.500 9.285
Erysipelotrichales Incertae Sedis 0.000 0.000 0.000 0.000 0.000
Bifidobacteriaceae 0.000 0.000 0.000 0.000 0.000
Deferribacteraceae 4.614 2.981 1.480 4.145 5.097
Erysipelotrichaceae 9.248 21.196 28.430 37.163 16.814
Coriobacterineae 0.000 0.000 0.000 0.000 0.000
Clostridiaceae 0.000 0.000 0.000 0.000 0.000
Verrucomicrobiaceae 0.000 3.399 6.073 3.843 8.760
Enterobacteriaceae 0.000 0.000 0.000 0.000 0.000
Streptococcaceae 0.181 0.818 0.699 1.000 0.821
Anaeroplasmataceae 0.000 0.000 0.000 0.000 0.000
Prevotellaceae 0.302 0.345 0.000 0.000 0.024
Moraxellaceae 0.000 0.000 0.000 0.000 0.000
Vibrionaceae 0.000 0.000 0.000 0.000 0.000
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HFD
T0
HFD
T1
HFD
T8
HFD
T10
HFD
caecal
Thermaceae 0.000 0.000 0.000 0.000 0.000
Brevibacteriaceae 0.000 0.000 0.000 0.000 0.000
Staphylococcaceae 0.000 0.000 0.000 0.000 0.000
Pseudoalteromonadaceae 0.000 0.000 0.000 0.000 0.000
Leuconostocaceae 0.000 0.000 0.000 0.000 0.020
Bacillaceae 0.000 0.000 0.000 0.000 0.000
Desulfovibrionaceae 0.000 0.000 0.000 0.000 0.000
Peptostreptococcaceae 0.000 19.760 24.907 15.857 15.861
Planococcaceae 0.000 0.000 0.000 0.000 0.000
Paenibacillaceae 0.000 0.000 0.000 0.000 0.000
Veillonellaceae 0.000 0.000 0.000 0.000 0.000
Other 56.700 43.519 25.387 24.674 32.346
Genus
Thalassospira 0.000 0.000 0.000 0.000 0.000
Sutterella 0.000 0.000 0.000 0.000 0.000
Alistipes 1.612 0.491 0.795 1.908 1.882
Rikenella 0.000 0.000 0.000 0.000 0.000
Parabacteroides 0.000 0.000 0.000 0.000 0.000
Odoribacter 0.000 0.000 0.000 0.000 0.000
Bacteroides 1.350 0.418 0.411 0.737 0.699
Lachnospiraceae Incertae Sedis 0.000 0.000 0.000 0.000 0.000
uncultured Lachnospiraceae 0.000 0.000 0.000 0.000 0.000
Ruminococcus 0.000 0.000 0.000 0.000 0.000
Ruminococcaceae Incertae Sedis 16.845 1.254 1.974 2.027 3.951
Oscillibacter 0.000 0.000 0.000 0.000 0.000
Anaerotruncus 1.229 0.109 1.179 0.711 1.716
Lactobacillus 1.592 1.545 3.578 1.500 9.285
Allobaculum 0.000 0.000 0.000 0.000 0.000
Bifidobacterium 0.000 0.000 0.000 0.000 0.000
Mucispirillum 4.614 2.981 1.480 4.145 5.097
Turicibacter 0.000 0.000 0.000 0.000 0.000
Clostridium 0.000 0.000 0.000 0.000 0.000
Coprococcus 0.000 0.000 0.000 0.000 0.000
Akkermansia 0.000 3.381 6.073 3.843 8.760
Brenneria-Yersinia 0.000 0.000 0.000 0.000 0.000
Streptococcus 0.000 0.000 0.000 0.000 0.000
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HFD
T0
HFD
T1
HFD
T8
HFD
T10
HFD
caecal
Prevotella 0.302 0.345 0.000 0.000 0.024
Marvinbryantia - Bryantella 0.000 0.000 0.000 0.000 0.000
Anaeroplasma 0.000 0.000 0.000 0.000 0.000
Lactococcus 0.181 0.818 0.685 0.974 0.807
Faecalibacterium 0.101 0.000 0.000 0.000 0.000
Psychrobacter 0.000 0.000 0.000 0.000 0.000
Vibrio 0.000 0.000 0.000 0.000 0.000
Thermus 0.000 0.000 0.000 0.000 0.000
Staphylococcus 0.000 0.000 0.000 0.000 0.000
Pseudoalteromonas 0.000 0.000 0.000 0.000 0.000
Leuconostoc 0.000 0.000 0.000 0.000 0.000
Anoxybacillus 0.000 0.000 0.000 0.000 0.000
Desulfovibrio 0.000 0.000 0.000 0.000 0.000
Paenibacillus 0.000 0.000 0.000 0.000 0.000
Lysinibacillus 0.000 0.000 0.000 0.000 0.000
Peptostreptococcaceae Incertae
Sedis 0.000 0.491 0.315 0.355 0.424
Anaerovorax 0.000 0.000 0.000 0.000 0.000
Catenibacterium 0.000 0.000 0.000 0.000 0.000
Barnesiella 0.000 0.000 0.000 0.000 0.000
Blautia 0.000 0.000 0.000 0.000 0.000
Subdoligranulum 0.000 0.000 0.000 0.000 0.000
uncultured Ruminococcaceae 0.000 0.000 0.000 0.000 0.000
Phascolarctobacterium 0.000 0.000 0.000 0.000 0.000
Lachnospira 0.000 0.000 0.000 0.000 0.000
Megamonas 0.000 0.000 0.000 0.000 0.000
Weissella 0.000 0.000 0.000 0.000 0.000
Uncultured bacteria 0.201 0.000 1.398 2.211 0.868
Other 71.973 88.166 82.111 81.590 66.487
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Supplementary Table 5 Percentage read number High fat diet mice
receiving E. coli MG1655
HFD-EC
T0
HFD-EC
T1
HFD-EC
T8
HFD-EC
T10
HFD-EC
caecal
Phylum
Proteobacteria 0.000 0.154 0.382 0.059 0.200
Bacteroidetes 52.690 58.773 21.229 19.841 36.000
Firmicutes 42.172 27.664 77.396 73.671 53.218
Actinobacteria 0.000 0.289 0.186 0.237 0.021
Deferribacteres 4.614 0.096 0.142 3.883 4.084
Candidate division TM7 0.000 0.000 0.000 0.000 0.000
4C0d-2 0.000 0.000 0.327 0.000 0.000
Verrucomicrobia 0.000 12.967 0.273 2.285 6.336
Deinococcus-Thermus 0.000 0.000 0.000 0.000 0.000
other 0.524 0.058 0.065 0.024 0.141
Family
Rhodospirillaceae 0.000 0.000 0.186 0.000 0.000
Alcaligenaceae 0.000 0.000 0.000 0.000 0.000
Rikenellaceae 1.975 1.693 1.572 0.533 1.359
Porphyromonadaceae 0.121 0.000 0.830 0.000 0.000
Bacteroidaceae 1.350 0.269 7.160 0.189 0.017
Lachnospiraceae 1.632 0.539 1.790 0.675 3.449
Eubacteriaceae 0.222 0.943 0.982 0.758 0.479
Ruminococcaceae 22.063 1.501 4.224 2.084 6.243
Peptococcaceae 0.000 0.866 0.055 0.000 0.000
Lactobacillaceae 1.592 1.885 2.107 1.350 4.725
Erysipelotrichales Incertae Sedis 0.000 0.000 0.000 0.000 0.000
Bifidobacteriaceae 0.000 0.000 0.120 0.000 0.000
Deferribacteraceae 4.614 0.096 0.142 3.883 4.084
Erysipelotrichaceae 9.248 14.313 50.437 50.681 20.671
Coriobacterineae 0.000 0.289 0.065 0.225 0.017
Clostridiaceae 0.000 0.000 0.000 0.000 0.000
Verrucomicrobiaceae 0.000 12.967 0.273 2.285 6.336
Enterobacteriaceae 0.000 0.154 0.065 0.000 0.179
Streptococcaceae 0.181 1.077 2.434 2.013 0.797
Anaeroplasmataceae 0.000 0.000 0.120 0.095 0.000
Prevotellaceae 0.302 0.115 4.410 0.000 0.000
Moraxellaceae 0.000 0.000 0.000 0.000 0.000
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HFD-EC
T0
HFD-EC
T1
HFD-EC
T8
HFD-EC
T10
HFD-EC
caecal
Vibrionaceae 0.000 0.000 0.000 0.000 0.000
Thermaceae 0.000 0.000 0.000 0.000 0.000
Brevibacteriaceae 0.000 0.000 0.000 0.000 0.000
Staphylococcaceae 0.000 0.000 0.000 0.000 0.000
Pseudoalteromonadaceae 0.000 0.000 0.000 0.000 0.000
Leuconostocaceae 0.000 0.000 0.000 0.000 0.038
Bacillaceae 0.000 0.000 0.000 0.000 0.000
Desulfovibrionaceae 0.000 0.000 0.055 0.000 0.000
Peptostreptococcaceae 0.000 0.289 10.194 12.490 15.290
Planococcaceae 0.000 0.000 0.000 0.000 0.000
Paenibacillaceae 0.000 0.000 0.000 0.000 0.000
Veillonellaceae 0.000 0.000 0.393 0.000 0.000
Other 56.700 63.005 12.388 22.742 36.313
Genus
Thalassospira 0.000 0.000 0.186 0.000 0.000
Sutterella 0.000 0.000 0.000 0.000 0.000
Alistipes 1.612 1.654 1.222 0.474 1.352
Rikenella 0.000 0.000 0.000 0.000 0.000
Parabacteroides 0.000 0.000 0.458 0.000 0.000
Odoribacter 0.000 0.000 0.175 0.000 0.000
Bacteroides 1.350 0.269 7.160 0.189 0.017
Lachnospiraceae Incertae Sedis 0.000 0.000 0.502 0.000 0.252
uncultured Lachnospiraceae 0.000 0.000 0.000 0.000 0.000
Ruminococcus 0.000 0.000 0.600 0.000 0.000
Ruminococcaceae Incertae Sedis 16.845 0.750 0.666 1.705 5.050
Oscillibacter 0.000 0.000 0.000 0.000 0.000
Anaerotruncus 1.229 0.000 0.000 0.000 0.000
Lactobacillus 1.592 1.885 2.107 1.350 4.725
Allobaculum 0.000 0.000 0.000 0.000 0.000
Bifidobacterium 0.000 0.000 0.120 0.000 0.000
Mucispirillum 4.614 0.096 0.142 3.883 4.084
Turicibacter 0.000 0.000 0.000 0.000 0.000
Clostridium 0.000 0.000 0.000 0.000 0.000
Coprococcus 0.000 0.000 0.000 0.000 0.000
Akkermansia 0.000 12.967 0.273 2.285 6.336
Brenneria-Yersinia 0.000 0.154 0.000 0.000 0.179
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HFD-EC
T0
HFD-EC
T1
HFD-EC
T8
HFD-EC
T10
HFD-EC
caecal
Streptococcus 0.000 0.000 0.000 0.000 0.000
Prevotella 0.302 0.115 4.388 0.000 0.000
Marvinbryantia - Bryantella 0.000 0.000 0.000 0.000 0.000
Anaeroplasma 0.000 0.000 0.120 0.095 0.000
Lactococcus 0.181 1.077 2.434 1.989 0.773
Faecalibacterium 0.101 0.000 0.775 0.000 0.000
Psychrobacter 0.000 0.000 0.000 0.000 0.000
Vibrio 0.000 0.000 0.000 0.000 0.000
Thermus 0.000 0.000 0.000 0.000 0.000
Staphylococcus 0.000 0.000 0.000 0.000 0.000
Pseudoalteromonas 0.000 0.000 0.000 0.000 0.000
Leuconostoc 0.000 0.000 0.000 0.000 0.000
Anoxybacillus 0.000 0.000 0.000 0.000 0.000
Desulfovibrio 0.000 0.000 0.000 0.000 0.000
Paenibacillus 0.000 0.000 0.000 0.000 0.000
Lysinibacillus 0.000 0.000 0.000 0.000 0.000
Peptostreptococcaceae Incertae Sedis 0.000 0.000 0.240 0.284 0.335
Anaerovorax 0.000 0.308 0.000 0.000 0.000
Catenibacterium 0.000 0.000 0.000 0.000 0.000
Barnesiella 0.000 0.000 0.196 0.000 0.000
Blautia 0.000 0.000 0.098 0.000 0.000
Subdoligranulum 0.000 0.000 0.338 0.000 0.000
uncultured Ruminococcaceae 0.000 0.000 0.076 0.000 0.000
Phascolarctobacterium 0.000 0.000 0.218 0.000 0.000
Lachnospira 0.000 0.000 0.055 0.000 0.000
Megamonas 0.000 0.000 0.098 0.000 0.000
Weissella 0.000 0.000 0.000 0.000 0.017
Uncultured bacteria 0.201 0.846 3.515 2.687 1.018
Other 71.973 79.877 73.838 85.060 75.862
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Supplementary Table 6 Alpha diversities
Chao1 Simpson Shannon
Phylogenetic
Diversity
Observed
Species
Low Fat Diet + MG1655
BSH1
T0 2557.2 0.989 8.170 60.124 1139
T1 740.1 0.920 5.100 21.554 394
T8 1030.4 0.923 5.258 23.891 425
caecal 626.3 0.924 5.089 19.430 371
caecal 240.9 0.689 2.627 10.407 156
High Fat Diet + MG1655
BSH1
T0 2911.7 0.989 8.239 68.437 1277
T1 1083.4 0.916 5.127 25.681 366
T8 657.3 0.885 4.639 19.864 343
caecal 695.3 0.824 4.449 18.077 304
caecal 517.7 0.860 4.416 19.014 318
caecal 1298.4 0.935 5.497 26.521 574
Low Fat Diet + MG1655
BSH2
T0 2841.5 0.901 6.670 62.629 1209
T1 665.0 0.905 4.822 16.715 335
T8 510.0 0.931 5.211 14.848 263
caecal 819.5 0.894 4.841 22.899 470
caecal 871.1 0.906 4.839 21.684 437
caecal 565.1 0.772 3.804 19.164 312
High Fat Diet + MG1655
BSH2
T0 2594.4 0.981 7.770 62.072 1213
T1 629.7 0.822 3.813 19.675 268
T8 776.1 0.933 5.432 22.954 420
caecal 839.7 0.929 5.248 19.144 394
caecal 731.4 0.869 4.690 24.455 370
caecal 719.7 0.953 5.820 24.319 426
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Supplementary Table 7 Percentage read number high fat diet mice
receiving E. coli MG1655 BSH1
HFD
ECBSH1
T0
HFD
ECBSH1
T1
HFD
ECBSH1
T8
HFD
ECBSH1
Caecal
Phylum
Proteobacteria 2.333 13.441 0.650 1.235
Bacteroidetes 61.173 48.418 54.100 55.195
Firmicutes 34.279 36.031 38.493 31.975
Actinobacteria 0.798 1.791 5.895 8.608
Deferribacteres 0.222 0.221 0.749 2.774
Candidate division TM7 0.133 0.000 0.000 0.000
4C0d-2 0.089 0.000 0.000 0.000
Verrucomicrobia 0.606 0.000 0.000 0.000
Deinococcus-Thermus 0.000 0.000 0.000 0.030
Other 0.369 0.098 0.113 0.183
Family
Rhodospirillaceae 0.798 0.000 0.000 0.000
Alcaligenaceae 1.374 0.000 0.000 0.000
Rikenellaceae 12.509 0.294 0.848 6.273
Porphyromonadaceae 1.521 0.123 0.000 0.000
Bacteroidaceae 5.716 0.883 43.780 41.709
Lachnospiraceae 17.250 2.674 0.410 0.474
Eubacteriaceae 0.177 0.000 0.000 0.809
Ruminococcaceae 11.786 2.698 4.085 4.408
Peptococcaceae 0.428 0.000 0.000 0.000
Lactobacillaceae 1.521 0.172 0.141 8.012
Erysipelotrichales Incertae Sedis 0.502 7.849 0.184 0.417
Bifidobacteriaceae 0.650 0.123 5.697 8.138
Deferribacteraceae 0.222 0.221 0.749 2.774
Erysipelotrichaceae 0.694 12.436 15.196 15.955
Coriobacterineae 0.133 1.619 0.198 0.461
Clostridiaceae 0.118 0.000 0.000 0.000
Verrucomicrobiaceae 0.606 0.000 0.000 0.000
Enterobacteriaceae 0.103 12.975 0.551 1.087
Streptococcaceae 0.000 2.821 0.947 1.213
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HFD
ECBSH1
T0
HFD
ECBSH1
T1
HFD
ECBSH1
T8
HFD
ECBSH1
Caecal
Anaeroplasmataceae 0.000 0.000 0.000 0.000
Prevotellaceae 0.000 0.172 0.000 0.000
Moraxellaceae 0.000 0.147 0.071 0.052
Vibrionaceae 0.000 0.123 0.000 0.039
Thermaceae 0.000 0.000 0.000 0.030
Brevibacteriaceae 0.000 0.000 0.000 0.000
Staphylococcaceae 0.000 0.000 16.087 0.000
Pseudoalteromonadaceae 0.000 0.000 0.000 0.000
Leuconostocaceae 0.000 0.000 0.000 0.000
Bacillaceae 0.000 0.000 0.000 0.000
Desulfovibrionaceae 0.000 0.000 0.000 0.000
Peptostreptococcaceae 0.000 0.000 0.000 0.000
Planococcaceae 0.000 0.000 0.000 0.000
Paenibacillaceae 0.000 0.000 0.000 0.000
Veillonellaceae 0.000 0.000 0.000 0.000
Other 43.893 54.673 11.055 8.147
Genus
Thalassospira 0.738 0.000 0.000 0.000
Sutterella 1.374 0.000 0.000 0.000
Alistipes 10.767 0.196 0.848 6.247
Rikenella 1.536 0.000 0.000 0.000
Parabacteroides 0.738 0.000 0.000 0.000
Odoribacter 0.783 0.000 0.000 0.000
Bacteroides 5.716 0.883 43.780 41.709
Lachnospiraceae Incertae Sedis 3.161 0.123 0.000 0.213
uncultured Lachnospiraceae 0.192 0.000 0.000 0.000
Ruminococcus 0.340 0.123 0.000 0.000
Ruminococcaceae Incertae Sedis 5.642 1.055 3.195 3.734
Oscillibacter 0.428 0.000 0.000 0.000
Anaerotruncus 0.177 0.000 0.608 0.230
Lactobacillus 1.521 0.172 0.141 8.012
Allobaculum 0.000 0.000 0.000 0.000
Bifidobacterium 0.650 0.123 5.697 8.138
Mucispirillum 0.222 0.221 0.749 2.774
Turicibacter 0.207 0.000 0.000 0.000
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HFD
ECBSH1
T0
HFD
ECBSH1
T1
HFD
ECBSH1
T8
HFD
ECBSH1
Caecal
Clostridium 0.089 0.000 0.000 0.000
Coprococcus 0.222 0.000 0.000 0.000
Akkermansia 0.606 0.000 0.000 0.000
Brenneria-Yersinia 0.103 12.902 0.551 1.078
Streptococcus 0.000 0.000 0.254 0.713
Prevotella 0.000 0.172 0.000 0.000
Marvinbryantia - Bryantella 0.000 0.000 0.000 0.000
Anaeroplasma 0.000 0.000 0.000 0.000
Lactococcus 0.000 2.821 0.664 0.500
Faecalibacterium 0.000 0.147 0.000 0.000
Psychrobacter 0.000 0.123 0.000 0.052
Vibrio 0.000 0.123 0.000 0.035
Thermus 0.000 0.000 0.000 0.030
Staphylococcus 0.000 0.000 16.087 0.000
Pseudoalteromonas 0.000 0.000 0.000 0.000
Leuconostoc 0.000 0.000 0.000 0.000
Anoxybacillus 0.000 0.000 0.000 0.000
Desulfovibrio 0.000 0.000 0.000 0.000
Paenibacillus 0.000 0.000 0.000 0.000
Lysinibacillus 0.000 0.000 0.000 0.000
Peptostreptococcaceae Incertae Sedis 0.000 0.000 0.000 0.000
Anaerovorax 0.000 0.000 0.000 0.000
Catenibacterium 0.000 0.000 0.000 0.000
Barnesiella 0.000 0.000 0.000 0.000
Blautia 0.000 0.000 0.000 0.000
Subdoligranulum 0.000 0.000 0.000 0.000
uncultured Ruminococcaceae 0.000 0.000 0.000 0.000
Phascolarctobacterium 0.000 0.000 0.000 0.000
Lachnospira 0.000 0.000 0.000 0.000
Megamonas 0.000 0.000 0.000 0.000
Weissella 0.000 0.000 0.000 0.000
Uncultured bacteria 0.354 0.417 0.226 0.204
Other 64.437 80.402 27.198 26.328
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Supplementary Table 8 Percentage read number low fat diet mice
receiving E. coli MG1655 BSH1
LFD
ECBSH1
T0
LFD
ECBSH1
T1
LFD
ECBSH1
T8
LFD
ECBSH1
Caecal
Phylum
Proteobacteria 3.191 9.683 0.902 1.101
Bacteroidetes 71.011 20.663 47.350 59.945
Firmicutes 24.460 46.590 28.712 26.905
Actinobacteria 0.478 3.841 21.657 7.643
Deferribacteres 0.268 1.209 1.214 3.967
Candidate division TM7 0.000 0.000 0.000 0.000
4C0d-2 0.000 0.000 0.000 0.000
Verrucomicrobia 0.000 0.000 0.000 0.000
Deinococcus-Thermus 0.000 17.871 0.000 0.108
Other 0.592 0.142 0.164 0.331
Family
Rhodospirillaceae 2.580 0.000 0.000 0.000
Alcaligenaceae 0.554 0.053 0.000 0.000
Rikenellaceae 17.332 0.223 7.613 12.421
Porphyromonadaceae 6.363 0.080 0.000 0.000
Bacteroidaceae 5.924 1.024 27.482 39.523
Lachnospiraceae 15.020 2.021 1.247 0.972
Eubacteriaceae 0.191 0.525 0.919 1.246
Ruminococcaceae 6.115 3.793 2.789 6.248
Peptococcaceae 0.325 0.000 0.000 0.000
Lactobacillaceae 0.936 18.378 0.000 0.341
Erysipelotrichales Incertae Sedis 0.306 0.321 0.000 0.042
Bifidobacteriaceae 0.440 0.000 21.559 7.461
Deferribacteraceae 0.268 1.211 1.214 3.980
Erysipelotrichaceae 0.325 15.493 22.888 16.658
Coriobacterineae 0.000 3.820 0.000 0.208
Clostridiaceae 0.000 0.080 0.000 0.000
Verrucomicrobiaceae 0.000 0.000 0.000 0.000
Enterobacteriaceae 0.000 9.518 0.771 1.039
Streptococcaceae 0.000 0.695 0.082 0.125
Anaeroplasmataceae 0.000 0.000 0.000 0.000
Prevotellaceae 0.000 0.000 0.000 0.000
Moraxellaceae 0.000 0.000 0.000 0.000
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LFD
ECBSH1
T0
LFD
ECBSH1
T1
LFD
ECBSH1
T8
LFD
ECBSH1
Caecal
Vibrionaceae 0.000 0.000 0.000 0.000
Thermaceae 0.000 17.897 0.000 0.108
Brevibacteriaceae 0.000 0.000 0.000 0.000
Staphylococcaceae 0.000 0.000 0.000 0.000
Pseudoalteromonadaceae 0.000 0.000 0.000 0.000
Leuconostocaceae 0.000 0.045 0.000 0.000
Bacillaceae 0.000 0.000 0.000 0.042
Desulfovibrionaceae 0.000 0.062 0.000 0.000
Peptostreptococcaceae 0.000 0.080 0.000 0.000
Planococcaceae 0.000 0.000 0.000 0.000
Paenibacillaceae 0.000 0.000 0.000 0.000
Veillonellaceae 0.000 0.000 0.000 0.000
Other 43.321 24.824 13.437 9.920
Genus
Thalassospira 2.083 0.000 0.000 0.000
Sutterella 0.554 0.053 0.000 0.000
Alistipes 16.167 0.187 7.613 12.372
Rikenella 0.459 0.000 0.000 0.000
Parabacteroides 5.733 0.053 0.000 0.000
Odoribacter 0.631 0.000 0.000 0.000
Bacteroides 5.924 1.022 27.482 39.392
Lachnospiraceae Incertae Sedis 1.242 0.000 0.000 0.000
uncultured Lachnospiraceae 0.096 0.053 0.000 0.000
Ruminococcus 0.478 0.000 0.000 0.000
Ruminococcaceae Incertae Sedis 2.159 2.685 2.199 5.449
Oscillibacter 0.248 0.222 0.000 0.000
Anaerotruncus 0.325 0.000 0.394 0.389
Lactobacillus 0.936 18.352 0.000 0.340
Allobaculum 0.325 0.000 0.000 4.058
Bifidobacterium 0.440 0.000 21.559 7.436
Mucispirillum 0.268 1.209 1.214 3.967
Turicibacter 0.000 0.053 0.000 0.000
Clostridium 0.000 0.080 0.000 0.000
Coprococcus 0.000 0.000 0.000 0.000
Akkermansia 0.000 0.000 0.000 0.000
Brenneria-Yersinia 0.000 9.505 0.771 1.035
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LFD
ECBSH1
T0
LFD
ECBSH1
T1
LFD
ECBSH1
T8
LFD
ECBSH1
Caecal
Streptococcus 0.000 0.071 0.000 0.050
Prevotella 0.000 0.000 0.000 0.000
Marvinbryantia - Bryantella 0.000 0.000 0.000 0.000
Anaeroplasma 0.000 0.000 0.000 0.000
Lactococcus 0.000 0.622 0.082 0.050
Faecalibacterium 0.000 0.000 0.000 0.000
Psychrobacter 0.000 0.000 0.000 0.000
Vibrio 0.000 0.000 0.000 0.000
Thermus 0.000 17.871 0.000 0.108
Staphylococcus 0.000 0.000 0.000 0.000
Pseudoalteromonas 0.000 0.000 0.000 0.000
Leuconostoc 0.000 0.044 0.000 0.000
Anoxybacillus 0.000 0.000 0.000 0.041
Desulfovibrio 0.000 0.044 0.000 0.000
Paenibacillus 0.000 0.000 0.000 0.000
Lysinibacillus 0.000 0.000 0.000 0.000
Peptostreptococcaceae Incertae Sedis 0.000 0.000 0.000 0.000
Anaerovorax 0.000 0.000 0.000 0.000
Catenibacterium 0.000 0.000 0.000 0.000
Barnesiella 0.000 0.000 0.000 0.000
Blautia 0.000 0.000 0.000 0.000
Subdoligranulum 0.000 0.000 0.000 0.000
uncultured Ruminococcaceae 0.000 0.000 0.000 0.000
Phascolarctobacterium 0.000 0.000 0.000 0.000
Lachnospira 0.000 0.000 0.000 0.000
Megamonas 0.000 0.000 0.000 0.000
Weissella 0.000 0.000 0.000 0.000
Uncultured bacteria 0.248 1.574 0.870 0.480
Other 61.685 46.297 37.818 24.834
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Supplementary Table 9 Percentage read number low fat diet mice
receiving E. coli MG1655 BSH2
LFD
ECBSH2
T0
LFD
ECBSH2
T1
LFD
ECBSH2
T8
LFD
ECBSH2
Caecal
Phylum
Proteobacteria 0.636 13.312 0.981 1.146
Bacteroidetes 34.969 80.143 75.234 38.750
Firmicutes 63.230 4.572 18.536 50.287
Actinobacteria 0.589 1.672 4.688 7.479
Deferribacteres 0.106 0.060 0.467 2.195
Candidate division TM7 0.000 0.000 0.000 0.000
4C0d-2 0.000 0.000 0.000 0.000
Verrucomicrobia 0.000 0.000 0.000 0.000
Deinococcus-Thermus 0.000 0.181 0.000 0.000
Other 0.471 0.060 0.093 0.142
Family
Rhodospirillaceae 0.341 0.000 0.000 0.000
Alcaligenaceae 0.224 0.000 0.000 0.000
Rikenellaceae 10.287 5.820 16.869 11.101
Porphyromonadaceae 0.824 0.000 0.000 0.000
Bacteroidaceae 3.060 74.192 54.159 25.003
Lachnospiraceae 17.538 0.151 1.760 0.341
Eubacteriaceae 0.000 0.000 0.000 0.793
Ruminococcaceae 11.452 0.211 4.097 4.203
Peptococcaceae 0.094 0.000 0.000 0.000
Lactobacillaceae 0.577 3.414 0.000 27.596
Erysipelotrichales Incertae Sedis 0.212 0.000 0.000 0.000
Bifidobacteriaceae 0.589 0.070 4.595 7.211
Deferribacteraceae 0.106 0.060 0.467 2.195
Erysipelotrichaceae 0.400 0.081 11.682 14.955
Coriobacterineae 0.000 1.591 0.093 0.268
Clostridiaceae 0.000 0.000 0.000 0.000
Verrucomicrobiaceae 0.000 0.000 0.000 0.000
Enterobacteriaceae 0.000 12.980 0.935 1.110
Streptococcaceae 31.356 0.564 0.125 1.512
Anaeroplasmataceae 0.000 0.000 0.000 0.000
Prevotellaceae 0.000 0.000 0.000 0.024
Moraxellaceae 0.000 0.141 0.000 0.000
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LFD
ECBSH2
T0
LFD
ECBSH2
T1
LFD
ECBSH2
T8
LFD
ECBSH2
Caecal
Vibrionaceae 0.000 0.081 0.000 0.000
Thermaceae 0.000 0.181 0.000 0.000
Brevibacteriaceae 0.000 0.000 0.000 0.000
Staphylococcaceae 0.000 0.000 0.000 0.000
Pseudoalteromonadaceae 0.000 0.000 0.000 0.000
Leuconostocaceae 0.000 0.000 0.000 0.000
Bacillaceae 0.000 0.000 0.000 0.106
Desulfovibrionaceae 0.000 0.000 0.000 0.000
Peptostreptococcaceae 0.000 0.000 0.000 0.000
Planococcaceae 0.000 0.000 0.000 0.000
Paenibacillaceae 0.000 0.000 0.000 0.000
Veillonellaceae 0.000 0.000 0.000 0.000
Other 22.940 0.463 5.218 3.581
Genus
Thalassospira 0.235 0.000 0.000 0.000
Sutterella 0.224 0.000 0.000 0.000
Alistipes 9.911 5.800 16.869 11.097
Rikenella 0.259 0.000 0.000 0.000
Parabacteroides 0.129 0.000 0.000 0.000
Odoribacter 0.694 0.000 0.000 0.000
Bacteroides 3.060 74.192 54.159 25.003
Lachnospiraceae Incertae Sedis 1.271 0.000 0.000 0.000
uncultured Lachnospiraceae 0.071 0.000 0.000 0.000
Ruminococcus 0.282 0.000 0.000 0.000
Ruminococcaceae Incertae Sedis 2.519 0.141 3.302 3.341
Oscillibacter 0.435 0.000 0.000 0.000
Anaerotruncus 0.259 0.000 0.343 0.305
Lactobacillus 0.565 3.414 0.000 27.588
Allobaculum 0.400 0.081 0.000 1.512
Bifidobacterium 0.589 0.070 4.595 7.211
Mucispirillum 0.106 0.060 0.467 2.195
Turicibacter 0.000 0.000 0.000 0.000
Clostridium 0.000 0.000 0.000 0.000
Coprococcus 0.129 0.000 0.000 0.000
Akkermansia 0.000 0.000 0.000 0.000
Brenneria-Yersinia 0.000 12.969 0.935 1.106
182
LFD
ECBSH2
T0
LFD
ECBSH2
T1
LFD
ECBSH2
T8
LFD
ECBSH2
Caecal
Streptococcus 31.321 0.091 0.000 1.427
Prevotella 0.000 0.000 0.000 0.024
Marvinbryantia - Bryantella 0.000 0.000 0.000 0.000
Anaeroplasma 0.000 0.000 0.000 0.000
Lactococcus 0.000 0.443 0.125 0.041
Faecalibacterium 0.000 0.000 0.000 0.000
Psychrobacter 0.000 0.141 0.000 0.000
Vibrio 0.000 0.060 0.000 0.000
Thermus 0.000 0.181 0.000 0.000
Staphylococcus 0.000 0.000 0.000 0.000
Pseudoalteromonas 0.000 0.000 0.000 0.000
Leuconostoc 0.000 0.000 0.000 0.000
Anoxybacillus 0.000 0.000 0.000 0.081
Desulfovibrio 0.000 0.000 0.000 0.000
Paenibacillus 0.000 0.000 0.000 0.000
Lysinibacillus 0.000 0.000 0.000 0.000
Peptostreptococcaceae Incertae Sedis 0.000 0.000 0.000 0.000
Anaerovorax 0.000 0.000 0.000 0.000
Catenibacterium 0.000 0.000 0.000 0.000
Barnesiella 0.000 0.000 0.000 0.000
Blautia 0.000 0.000 0.000 0.000
Subdoligranulum 0.000 0.000 0.000 0.000
uncultured Ruminococcaceae 0.000 0.000 0.000 0.000
Phascolarctobacterium 0.000 0.000 0.000 0.000
Lachnospira 0.000 0.000 0.000 0.000
Megamonas 0.000 0.000 0.000 0.000
Weissella 0.000 0.000 0.000 0.000
Uncultured bacteria 0.494 0.000 0.109 0.183
Other 47.046 2.356 19.097 18.885
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Supplementary Table 10 Percentage read number high fat diet mice
receiving E. coli MG1655 BSH2
HFD
ECBSH2
T0
HFD
ECBSH2
T1
HFD
ECBSH2
T8
HFD
ECBSH2
Caecal
Phylum
Proteobacteria 2.251 2.144 31.723 2.617
Bacteroidetes 53.133 53.960 30.498 36.468
Firmicutes 43.414 43.001 31.874 41.995
Actinobacteria 0.379 0.227 4.462 13.848
Deferribacteres 0.065 0.000 0.436 4.651
Candidate division TM7 0.336 0.000 0.000 0.000
4C0d-2 0.000 0.000 0.000 0.000
Verrucomicrobia 0.065 0.000 0.000 0.000
Deinococcus-Thermus 0.000 0.580 0.000 0.000
Other 0.357 0.088 1.007 0.420
Family
Rhodospirillaceae 1.948 0.000 0.000 0.000
Alcaligenaceae 0.206 0.303 0.000 0.000
Rikenellaceae 17.913 0.113 2.617 6.130
Porphyromonadaceae 1.764 0.000 0.000 0.037
Bacteroidaceae 6.397 53.014 21.758 25.207
Lachnospiraceae 17.772 0.315 0.503 2.386
Eubacteriaceae 0.000 0.000 0.000 0.000
Ruminococcaceae 11.311 0.517 1.258 5.740
Peptococcaceae 0.130 0.000 0.000 0.000
Lactobacillaceae 1.526 21.803 0.000 1.637
Erysipelotrichales Incertae Sedis 0.000 0.227 0.000 0.037
Bifidobacteriaceae 0.379 0.000 1.745 12.856
Deferribacteraceae 0.065 0.000 0.436 4.651
Erysipelotrichaceae 0.260 8.020 24.677 30.089
Coriobacterineae 0.000 0.139 0.000 0.980
Clostridiaceae 0.000 0.000 0.000 0.000
Verrucomicrobiaceae 0.065 0.000 0.000 0.000
Enterobacteriaceae 0.000 1.652 0.235 2.435
Streptococcaceae 10.943 11.349 3.389 0.895
Anaeroplasmataceae 0.065 0.000 0.000 0.000
Prevotellaceae 0.054 0.000 0.000 0.000
Moraxellaceae 0.000 0.088 17.245 0.067
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HFD
ECBSH2
T0
HFD
ECBSH2
T1
HFD
ECBSH2
T8
HFD
ECBSH2
Caecal
Vibrionaceae 0.000 0.063 11.206 0.000
Thermaceae 0.000 0.580 0.000 0.000
Brevibacteriaceae 0.000 0.000 0.352 0.000
Staphylococcaceae 0.000 0.000 0.000 0.000
Pseudoalteromonadaceae 0.000 0.000 2.869 0.000
Leuconostocaceae 0.000 0.000 0.252 0.134
Bacillaceae 0.000 0.000 0.000 0.000
Desulfovibrionaceae 0.000 0.000 0.000 0.000
Peptostreptococcaceae 0.000 0.000 0.000 0.000
Planococcaceae 0.000 0.000 0.000 0.000
Paenibacillaceae 0.000 0.000 0.000 0.000
Veillonellaceae 0.000 0.000 0.000 0.000
Other 29.202 1.816 11.458 6.720
Genus
Thalassospira 1.537 0.000 0.000 0.000
Sutterella 0.206 0.303 0.000 0.000
Alistipes 17.296 0.088 2.583 6.075
Rikenella 0.487 0.000 0.000 0.000
Parabacteroides 0.216 0.000 0.000 0.000
Odoribacter 1.548 0.000 0.000 0.000
Bacteroides 6.397 53.014 21.758 25.207
Lachnospiraceae Incertae Sedis 1.223 0.000 0.151 1.017
uncultured Lachnospiraceae 0.206 0.000 0.000 0.000
Ruminococcus 0.541 0.000 0.000 0.000
Ruminococcaceae Incertae Sedis 3.561 0.277 0.000 4.937
Oscillibacter 0.303 0.000 0.000 0.000
Anaerotruncus 0.346 0.000 0.101 0.110
Lactobacillus 1.526 21.765 0.000 1.637
Allobaculum 0.260 0.000 0.000 0.000
Bifidobacterium 0.379 0.000 1.745 12.856
Mucispirillum 0.065 0.000 0.436 4.651
Turicibacter 0.000 0.000 0.000 0.000
Clostridium 0.000 0.000 0.000 0.000
Coprococcus 0.184 0.000 0.000 0.000
Akkermansia 0.065 0.000 0.000 0.000
Brenneria-Yersinia 0.000 1.652 0.201 2.423
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HFD
ECBSH2
T0
HFD
ECBSH2
T1
HFD
ECBSH2
T8
HFD
ECBSH2
Caecal
Streptococcus 10.943 10.668 0.000 0.365
Prevotella 0.054 0.000 0.000 0.000
Marvinbryantia - Bryantella 0.108 0.000 0.000 0.000
Anaeroplasma 0.065 0.000 0.000 0.000
Lactococcus 0.000 0.681 3.355 0.481
Faecalibacterium 0.000 0.000 0.000 0.037
Psychrobacter 0.000 0.088 17.245 0.055
Vibrio 0.000 0.063 10.552 0.000
Thermus 0.000 0.580 0.000 0.000
Staphylococcus 0.000 0.000 0.000 0.000
Pseudoalteromonas 0.000 0.000 2.869 0.000
Leuconostoc 0.000 0.000 0.252 0.134
Anoxybacillus 0.000 0.000 0.000 0.000
Desulfovibrio 0.000 0.000 0.000 0.000
Paenibacillus 0.000 0.000 0.000 0.000
Lysinibacillus 0.000 0.000 0.000 0.000
Peptostreptococcaceae Incertae Sedis 0.000 0.000 0.000 0.000
Anaerovorax 0.000 0.000 0.000 0.000
Catenibacterium 0.000 0.000 0.000 0.000
Barnesiella 0.000 0.000 0.000 0.000
Blautia 0.000 0.000 0.000 0.000
Subdoligranulum 0.000 0.000 0.000 0.000
uncultured Ruminococcaceae 0.000 0.000 0.000 0.000
Phascolarctobacterium 0.000 0.000 0.000 0.000
Lachnospira 0.000 0.000 0.000 0.000
Megamonas 0.000 0.000 0.000 0.000
Weissella 0.000 0.000 0.000 0.000
Uncultured bacteria 0.660 0.895 0.151 0.280
Other 51.824 9.924 38.601 39.737
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Supplementary Figure 1
Rarefaction curve for each group at 97% similarity levels. Amount of
operational taxonomic units (OTU’s) found as a function of the number of
sequence tags sampled.
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Supplementary Figure 2
Bar graph of α diversity of faecal gut microbiota within each group
over time.
Colour codes blue, LFD fed mice; red, HFD fed mice; green, HFD fed
mice receiving 1x107 cfu StrR GMR E. coli MG1655 with no bile salt
hydrolase insert.
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Supplementary Figure 3
Bar graph of α diversity of caecum microbiota within each group.
Colour codes blue, LFD fed mice; red, HFD fed mice; green, HFD fed
mice receiving 1x107 cfu StrR GMR E. coli MG1655 with no bile salt
hydrolase insert. Statistical significance was determined using a two-
tailed unpaired t test; p value ≤0.05*; ≤0.01**.
189
Supplementary Figure 4
Rarefaction curve for each group at 97% similarity levels. Amount of
operational taxonomic units (OTU’s) found as a function of the number of
sequence tags sampled.
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Supplementary Figure 5
Bar graph of α diversity of caecum microbiota within each diet
group.
Colour codes; LFD ECBSH1, yellow; HFD ECBSH1, blue; LFD ECBSH2,
red; HFD ECBSH2, green.
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Supplementary Figure 6
Bar graph of alpha diversity from faecal gut microbiota within each
group over time.
Colour codes; LFD ECBSH1, yellow; HFD ECBSH1, blue; LFD ECBSH2,
red; HFD ECBSH2, green.
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Supplementary Figure 7
Principal coordinate analysis plot of unweighted Unifrac colour
coded by diet group. Colour codes, LFD ECBSH1, yellow; HFD
ECBSH1, blue; LFD ECBSH2, red; HFD ECBSH2, green. Faceal time
points highlighted in image. Cecum data point unlabelled.
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High fat feeding of mice alters their gut microbiota and
protects against colitis and colitis-associated colorectal
cancer
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5.1 ABSTRACT
Environmental factors such as diet and gut microbiota composition,
together with immune dysregulation are thought to trigger inflammatory
bowel diseases (IBD) in genetically susceptible individuals. Long term
chronic inflammation increases the risk of IBD patients developing colitis-
associated colorectal cancer (CAC). This study aimed to assess the
effect of diet on colitis, CAC progression and microbiota composition.
Mice were fed high fat (HF-45% Kcal from fat) or low fat (LF-10% Kcal
from fat) diet, followed by one azoxymethane (AOM) injection and 3x
Dextran Sodium Sulphate (DSS) cycles (1.5%DSS-5days & water-
14days) or 3xDSS cycles alone. HF-feeding protected mice from
developing colitis and CAC on the basis of weight and cytokine profile,
tumour numbers and incidence and colon length and weight. Analysis of
the murine gut microbiota showed a reduction in gut microbiota diversity
in LF-colitis and LF-CAC mice relative to their HF-fed counterparts. This
data reveals that a HF-diet provides a protective effect against colitis and
CAC progression and is accompanied by alterations in gut microbiota
populations. These results highlight a far more complex interaction
between high fat diet on microbiota-host responses in these models
warranting further investigations in patients with IBD and CAC.
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5.2 INTRODUCTION
The human gut microbiota is a large and diverse population of
microorganisms, the activities of which contribute to health as well as
disease. Disruption of the normal gut microbiota is associated with a
number of diseases including Inflammatory Bowel Diseases (IBD) (Ott et
al., 2004, Manichanh et al., 2006), diabetes (Qin et al., 2012), obesity
(Flint, 2011), Irritable Bowel Syndrome (IBS) (Carroll et al., 2011), autism
(Kang et al., 2013), Alzheimer’s disease (Bhattacharjee and Lukiw, 2013)
and colorectal cancer (CRC) (Sobhani et al., 2011), although the quality
of evidence varies considerably. Ulcerative colitis (UC) and Crohn’s
disease (CD) are two major phenotypes of IBD. In UC the mucosal lining
of the colon and the rectum are primarily affected while in CD any part of
the gastrointestinal tract can be affected (Podolsky, 2002). It has been
suggested that an excessive immune response to gut microbiota-
associated antigens is the main trigger of inflammation and the
subsequent mucosal tissue damage in both diseases (Sartor, 2006).
Furthermore, individuals with IBD have an increased risk of developing
colon cancer (Jess et al., 2006, Bernstein et al., 2001), particularly colitis
associated cancer (CAC) (Grivennikov, 2013, Danese et al., 2011). CAC
is a form of CRC that is preceded by IBD-like UC and CD (Grivennikov,
2013). CRC is the third most common cancer and second leading cancer
killer in the United States (CDC, 2009). It has also been revealed that the
risk of CRC increases by 7% as body mass index (BMI) increases by 2
(Calle and Kaaks, 2004). Diets low in fruit and vegetables and high in red
meat have previously been associated with an increased risk of CRC
(Mai et al., 2007, Giovannucci et al., 1994, Willett et al., 1990, Potter,
1996), while the high fat ‘western diet’ has been associated with the
development of CRC in mouse models (Mai et al., 2007, Singh et al.,
1997, Newmark et al., 2001). Diet-induced obesity in the mouse model of
CAC (chemically induced using AOM and DSS) has also been found to
increases the number colonic tumours (Flores et al., 2012, Kim et al.,
2010, Park et al., 2012). AOM is a metabolite of dimethylhydrazine (DMH)
that induces colon tumours while DSS has been suggested to exert toxic
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effects on colonic epithelium creating a chronic inflammatory state
(Robertis et al., 2011, Thaker et al., 2012). When combined, these
chemicals shorten the latency time for the induction of CAC, resulting in
the rapid growth of colonic tumours (Thaker et al., 2012). In a recent
study, feeding of a ‘western style diet’, where 37% of calories were from
saturated milk derived fat, to IL-10-/- mice resulted in an increased onset
and severity of colitis relative to controls fed a polyunsaturated (safflower
oil) diet or low fat (5% Kcal from lard) diet (Devkota et al., 2012).
Examinations of the effect of high fat diets in other experimental models
of colitis and CAC have provided conflicting outcomes, showing either no
effect, protection or worsening of disease (Hyland et al., 2009, Gäbele et
al., 2011, Park et al., 2012)
A number of other dietary components have been shown to have
an impact on the incidence of CAC. For example, high fat rice bran oil-
based, as well as omega 3 fatty acids, diets have been associated with
reducing the risk of CAC (Shih et al., 2011, Nowak et al., 2007, Jia et al.,
2008) while nobiletin, a polymethoxylated flavonoid in citrus fruit peels,
has been shown to reduce colon tumour development (Miyamoto et al.,
2008). Studies into CRC have also noted that consumption of probiotics
have an inhibitory effect on the development of colon cancer in animal
models (Brady et al., 2000, Saikali et al., 2004, Appleyard et al., 2011).
The role of microbiota composition in colitis has been the subject
of much attention since the reports that germ free mice do not develop
colitis (Sellon et al., 1998). Antibiotic treatment can also alleviate colitis-
associated symptoms in animal models of colitis (Hoentjen et al., 2003)
and in humans, especially in a sub group of patients with CD (Nomura et
al., 2005). With respect to CAC specifically, it has been shown that
infection with Helicobacter spp. can result in CAC development
(Chichlowski et al., 2008, Fox et al., 1999) and that antibiotic treatment to
remove this bacterium prevented CAC development (Chichlowski et al.,
2008). Advances in next generation sequencing technology have allowed
researchers to gain an even better insight into the altered gut microbiota
populations that are associated with CD, UC and CRC. Increased
proportions of Proteobacteria have consistently been noted in UC, CD
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and CRC (Gophna et al., 2006, Frank et al., 2011, Lepage et al., 2011,
Arthur et al., 2012, Wang et al., 2012). While reductions in abundance of
the bacterium Faecalibacterium prausnitzii (phylum Firmicutes) has been
observed in patients with CD (Sokol 2008, wiling 2008) and UC (Sokol
2009), this association has been challenged by others (Hansen 2012).
Similarly, although it has been reported that Bacteroides/Prevotella are
enriched in the gut microbiota of CRC patients (Sobhani et al., 2011),
others have reported the opposite (Kostic et al., 2012, Wang et al., 2012).
Genomic analysis of the microbiome of CRC patients revealed the
enrichment of the bacterium Fusobacterium (Kostic et al., 2012) with the
presence of Fusobacterium nucleatum accelerating the onset of colonic
tumors in Apcmin-/- mice (Kostic et al., 2013). However this association
was not seen in CAC models (Kostic et al., 2013).
Here, we use Dextran Sodium Sulphate (DSS, a model of colitis)
and Azoxymethane/DSS (AOM/DSS, a model of CAC) treated mice in
receipt of a high fat (45% calories from fat) or low fat (10% of calories
from fat) diets, in order to better understand the relationship between diet,
the gut microbiota, colitis and CAC progression.
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5.3 MATERIALS AND METHODS
5.3.1 Animals
Male C57BL/6OlaHsD mice, 5-9 weeks old and weighing 20-22 g, were
obtained from Harlan, UK. The mice were housed in a semi-conventional
environment (temperature 21°C, 12h light: 12h darkness, humidity 50%)
in a dedicated animal holding facility. All mice were provided with water
ad libitum and were fed a low fat diet (LF, 10% Kcal from fat, Research
Diets, New Jersey, USA; #D12450B) for 2 wk to acclimatize before
entering the study. Animal husbandry and experimental procedures were
approved by the UCC Animal Ethics Committee and experimental
procedures were conducted under licence from the Irish government.
5.3.2 Induction of colitis and colitis-associated colorectal cancer
and diet
Induction of colitis and CAC was performed as described with minor
changes (Wirtz et al., 2007). After acclimatization, mice were randomly
divided in groups of 8-12 and received a high fat diet (HF, 45% Kcal from
fat (lard), Research Diets, New Jersey, USA; #D12451) or LF for 4-5
weeks. After this period, the mice were further divided into a total of 6
groups i.e. LF-Control (Ctr), LF-colitis (3x DSS cycle), LF-CAC (AOM/3x
DSS cycle), HF-Ctr, HF-colitis and HF-CAC. The CAC groups were
injected intraperionatally (i.p.) once with 8mg AOM (Sigma, Aldrich, UK),
and rested for 1 week after which the CAC and Colitis groups were
administered 1.5% DSS (w/v, TdB Consultancy, Uppsala, Sweden) in
their drinking water for 5 days, followed by 14 days of DSS-free drinking
water. This DSS-cycle was repeated a total of 3 times and the mice were
culled thereafter (Fig 1). Food intake, weight and general health condition
was monitored once per week.
5.3.3 Weights and tissue sampling
For microbiota composition analysis, faecal samples were collected on 3
occasions; 1) immediately before DSS treatment started in the CAC and
colitis groups (i.e. week 12), 2) 1 week after the first DSS treatment (i.e.
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week 14) and 3) at the end of the study (i.e. week 21). Faecal samples
were collected from individual mice at the specified time point and stored
at -80oC until processing. On the day on which the mice were to be
sacrificed, they were first subjected to whole body composition using a
Bruker MRI Body composition analyser to measure fat and lean body
mass. Mice were then sedated under isoflurane anaesthesia and blood
collected in EDTA-containing tubes, centrifuged, serum aliquoted, frozen
and kept at -80oC until analysis. Mice were sacrificed and the cecum was
dissected, weighed and the contents frozen in liquid nitrogen until
processed for high-throughput sequencing. The colon was dissected and
its length and weight measured. The distal colon was divided into tumour
bearing (tumour+) and non-tumour bearing (tumour-) tissues. A piece (1-
2cm) of distal tumour+ was rolled as “Swiss rolls” (Moolenbeek and
Ruitenberg, 1981), embedded in OCT and frozen in liquid nitrogen. The
rest of the colonic tissue (tumour-) was frozen in liquid nitrogen, and
stored at -80oC until processing.
5.3.4 Cytokine analysis
Plasma serum and colon homogenates were assayed for the cytokines
IFN-γ, TNF-α, IL-1β, IL-6, IL-10, IL-12p70, keratinocyte chemoattractant
[KC] using the 7-proinflammatory-plex kit (MesoScale Discovery, USA)
and IL-17 were examined using ELISA (R&D Systems, Minnesota, USA).
Colons were homogenised as described previously (Murphy et al., 2010).
All assays were performed according to the manufacturers’ instructions.
Colonic cytokine levels are expressed as pg cytokine/100mg colonic
tissue.
5.3.5 DNA extraction and 16S rRNA gene amplicon sequencing
DNA was extracted from faecal and cecum samples using the QIAmp
DNA Stool Mini Kit (Qiagen, Crawley, West Sussex, UK) combined with
an additional bead-beating step (30s x 3) and stored at -20oC. The
microbiota composition of the samples was established by high-
throughput DNA sequencing of 16S rRNA amplicons generated using the
universal 16S rRNA primers (i.e. the forward primer F1 (5’-
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AYTGGGYDTAAAGNG) and reverse primer V5 (5’-
CCGTCAATTYYTTTRAGTTT) (RDP’S Pyrosequencing Pipeline:
http://pyro.cme.msu.edu/pyro/help.jsp). Molecular identifier tags were
attached between the 454 adaptor sequence and the target-specific
primer sequence, allowing for identification of individual sequences from
the pooled amplicons. Ampure purification system (Beckman Coulter,
Takeley, UK) was used to clean the amplicons before being sequenced
on a 454 Genome Sequencer FLX platform (Roche Diagnostics Ltd,
Burgess Hill, West Sussex, UK) in line with 454 protocols at the Teagasc
high throughput sequencing centre.
5.3.6 Bioinformatic analysis of 16s rRNA sequence data
A locally installed RDP pyrosequencing pipeline was used to quality trim
the raw sequence data. Reads were removed that were shorter than the
main distribution (150bp for the 16S rRNA V4 region), of low quality or not
exact matches to barcoded tags and primer sequence. A locally installed
version of SILVA 16S rRNA database (Pruesse et al., 2007) was used to
BLAST (Altschul et al., 1997) the trimmed fasta sequence files using
default parameters. Resulting BLAST output files were parsed through
MEGAN (Huson et al., 2007) which uses a lowest common ancestor
algorithm to assign reads to NCBI taxonomies. Prior to tree construction
and summarization filtering was carried out within MEGAN using bit
scores, similar to previous studies a bit-score cut-off of 86 was selected
(Urich et al., 2008, Rea et al., 2011). Alpha diversity indices were
generated using MOTHUR software (Schloss et al., 2009). Clustering of
sequence reads into operational taxonomical units (OTUs) was achieved
using QIIME suite software tools (Caporaso et al., 2010). The
ChimeraSlayer program was used to remove chimeric OTUs from aligned
OTUs (Haas et al., 2011) and the FastTreeMP tool generated a
phylogenetic tree (Price et al., 2010). Beta diversities were also
determined based on weighted and unweighted Unifrac and bray curtis
distances. Principal coordinate analysis (PCoA) was performed on the
samples. PCoA plots were visualised with KiNG viewer (Chen et al.,
2009). The nonparametric Kruskal-Wallis test (Kruskal and Wallis, 1952)
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in the Minitab statistical package was employed to establish statistical
significance (significance taken to be p ≤0.05).
5.3.7 Statistics
All statistical tests were performed using commercially available statistic
software (GraphPad Software, CA, USA) unless otherwise stated.
Statistical significance was determined with one-way analysis of variance
(ANOVA) with post-hoc analysis and the unpaired Student’s t-test. Data
are presented as Mean ±SEM. A p value of <0.05 was considered
significant.
202
5.4 RESULTS
5.4.1 High fat feeding protects mice from inflammation of tumour
development
Mice were randomised and fed LF and HF diets for 4-5 weeks, with mice
that consumed a HF diet gaining more weight than LF-mice i.e. 45 to 51%
body weight increase from start of feeding in HF-groups compared 20 to
25% increase in body weight in LF-groups (Fig 2). Injection of AOM did
not affect weight gain in either LF or HF-fed mice. Mice in the LF-CAC
group (treated with AOM and one DSS cycle and thus predicted to
develop CAC) lost 14.5% body weight and mice with LF-colitis group
(treated with one DSS cycle and thus predicted to develop colitis) lost
17.8% body weight in line with previous reports (Thaker et al., 2012). In
contrast, mice fed a HF diet lost significantly less weight (p<0.05; Fig 2),
i.e. 3.9% lost in HF-CAC mice and 4.6% lost in HF-colitis animals. Similar
body weight changes were observed after the 2nd and 3rd cycle of DSS-
treatment with a significant difference in the final body weight at W21 in
the HF-CAC and HF-colitis groups compared to the LF-CAC and LF-
colitis equivalents (Fig 2). Reductions in colon length and increased colon
weight are indicative of inflammation and were apparent in LF-colitis
(p<0.05) and LF-CAC (p<0.05 and p<0.001 respectively), when
compared to LF-Ctr, mice (Fig 3). HF-CAC mice had significantly longer
intestines (p<0.01) and lower colon weights (p<0.01) than LF-CAC mice
(Fig 3). A trend was observed in the intestinal length and a significant
difference in colon weight (p<0.05) of the HF-colitis group when
compared with those of LF-colitis mice. As noted above, combined
AOM/DSS treatment is known to result in accelerated tumour
development (Robertis et al., 2011, Rosenberg et al., 2009). Here, we
observed that mice fed LF and treated with AOM/DSS (LF-CAC)
presented on average with 6.75 tumours per mouse. The corresponding
HF diet fed mice developed significantly fewer tumours (p<0.01), i.e. on
average 2.7 per mouse (Fig 4). In addition to the reduced number of
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tumours, the size of the tumours was, on the basis of visual observation
(Fig.4), smaller in the HF-CAC mice.
5.4.2 High fat diet reduces plasma and colonic cytokines in colitis
and CAC model animals
We also examined the effect of the LF- and HF-diet on the local and
mucosal inflammatory response in mice with colitis and CAC. IL-1β
(p<0.05), IFNγ (p<0.05) and IL-12 (p<0.001) levels were significantly
higher in LF-colitis, compared to LF-Ctr, mice. The increase in IL-1β
(p<0.001) was sustained in LF-CAC relative to LF-Ctr mice and a
significant increase in IL-4 (p<0.001) levels was also apparent (Fig 5). IL-
1β (p<0.001) was also significantly increased in HF-CAC, relative to HF-
Ctr mice, with significantly greater levels of IL-2 (p<0.05) and IL-10
(p<0.05) also being apparent in the former group. In contrast to the LF
groups, no significant differences in plasma cytokines were detected
when HF-colitis and HF-Ctr groups were compared. Comparisons
between HF and LF colitis and CAC data revealed that plasma IL-1β
(p<0.05), IL-12 (p<0.001) and IFNγ (p<0.05) levels were significantly
reduced in HF-colitis relative to LF-colitis animals and IL-4 (p<0.01) was
also significantly reduced in HF-CAC relative to LF-CAC animals. No
other significant differences were observed between the HF-CAC and LF-
CAC groups (Fig 5). No difference in plasma levels of IL-5, IL-17, TNFα
and mKC were detected between any of the groups. Thus, at the
systemic level, the HF diet reduces the inflammatory tone in animals with
DSS-induced colitis relative to their LF diet fed counterparts.
We next examined the effect of diet on cytokine levels in colon
tissue devoid of tumours. A significant increase in the levels of colonic IL-
1β (p<0.001), IFNγ (p<0.05) and mKC (p<0.05) was found in LF-colitis,
compared to LF-Ctr mice (Fig 6). IL-1 and mKC, in addition to IL-6
(p<0.05), were significantly greater in LF-CAC relative to LF-Ctr mice. HF-
colitis mice also had significantly greater levels of colonic IFNγ (p<0.05),
IL-6 (p<0.05) and mKC (p<0.05) compared to HF-Ctr mice. HF-CAC mice
had significantly higher levels of mKC (p<0.05) compared to HF-Ctr mice.
HF-CAC mice had significantly less IL-6 (p<0.05) than HF-colitis mice.
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There were no significant differences in the levels of colonic cytokines
between HF-colitis and LF-colitis mice or HF-CAC and LF-CAC mice,
although the cytokine levels were in general lower in HF-group compared
to their LF fed counterparts (Fig 5). Overall, a lower inflammatory tone
was found in HF-diet mice with colitis and CAC relative to their LF-fed
counterparts.
5.4.3 Microbiota diversity is reduced in LF-colitis and LF-CAC mice
The composition of the gut microbiota in these mice was investigated.
Faecal samples were collected at 3 different time points i.e. 1 week after
CAC mice were injected with AOM (week 12 – W12), after the first DSS
cycle (week 14, W14) and immediately prior to culling (week 21, W21) to
explore the changes that diet and the different onslaughts exerts on the
microbiota. A total of 477,108 V4 16S rRNA sequence reads were
generated. These corresponded to an average of 17,211 reads per group
or 1,912 per mouse. Rarefaction curve analysis established that extra
sampling would yield only a limited increase in species richness
(Supplementary Fig 1). α diversity metrics were calculated for each data
set (Supplementary Table 1). In almost all cases diet did not affect the
diversity in the control LF and HF mice. One cycle of DSS (W14)
significantly reduced α diversity in LF-colitis mice relative to HF-colitis
mice. While this difference was not apparent in subsequent faecal
samples, lower Simpson (p=0.0015) and Shannon (p=0.0026) values
were attributed to cecum samples of LF-colitis mice relative to HF-colitis
mice. No significant difference in α diversity was found between the
faecal samples from HF-CAC and LF-CAC mice faecal samples but a
significantly greater (p=0.035) Shannon diversity was noted in HF-CAC
cecum samples relative to those of LF-CAC mice.
Principal coordinate analysis (PCoA) based on unweighted Unifrac
distances highlights the clear separation of the microbiota populations in
a treatment-specific manner (Fig 10A). It can be clearly seen that data
points cluster according to treatment groups and away from the HF and
LF controls. Data points corresponding to the LF-colitis and LF-CAC
microbiota cluster together and, in general, diverged considerably from
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the data points corresponding to controls. The data points corresponding
to the HF-colitis and HF-CAC microbiota are generally located between
those corresponding to the controls and the LF-colitis/CAC populations
(Fig 10A). When the PCoA is visualised as a function of time, regardless
of treatment, clustering of the data points at week 12 and in the cecum is
most evident (Fig 10B).
5.4.4 Altered gut microbiota composition in animals fed a high fat,
rather than a low fat, diet.
Of the reads, 413,069 (87%) were assigned at phylum level, 365,218
(76%) at family level and 281,785 (59%) at genus level. Comparisons
between the gut microbiota compositions of many of the different groups
of mice were possible. First, we compared the microbiota composition of
control animals fed a LF or HF diet. At 12 weeks of age, i.e. 6 weeks after
being divided into HF and LF diet groups, significantly lower proportions
of the phyla Actinobacteria and Verrucomicrobia, the families
Alcaligenaceae, Bifidobacteriaceae and Verrucomicrobiaceae and the
genera Sutterella, Allobaculum, Bifidobacterium and Akkermansia were
observed in HF-fed compared to LF-fed control mice (Fig 7). Significantly
greater proportions of the families Lachnospiraceae, Ruminococcaceae
and Erysipelotrichaceae and genera Lachnospiraceae Incertae Sedis,
uncultured Lachnospiraceae, Ruminococcaceae Incertae Sedis,
Oscillibacter and Turicibacter were also observed among HF-fed
compared to LF-fed control mice (Supplementary Fig 2).
When the microbiota was assessed two weeks later (W14),
significantly higher proportions of reads corresponding to the phylum
Firmicutes, the family Ruminococcaceae and the genus uncultured
Lachnospiraceae, Ruminococcaceae Incertae Sedis and Oscillibacter
were detected among HF-fed relative to LF-fed animals. Significantly
lower proportions of the phylum Proteobacteria, the families
Alcaligenaceae and Rikenellaceae and the genera Sutterella and
Alistipes were also evident in the HF-fed group.
At 21 weeks of age (W21), no significant differences were seen
between HF-fed and LF-fed mice microbiota at phylum level (Fig 7).
206
However, significantly greater proportions of, at family level,
Streptococcaceae, and, at genus level, Oscillibacter, Turicibacter and
Lactococcus were observed in HF-fed animals. Among the same animals,
significantly lower proportions of the genera Alistipes and
Parabacteroides were evident in HF-fed, relative to LF-fed, animals.
Analysis of cecal samples revealed the presence of significantly
greater proportions of, at phylum level, Deferribacteres, at family level,
Lachnospiraceae, Deferribacteraceae and Desulfovibrionaceae and, at
genus level, Mucispirillum and Desulfovibrio in HF-fed compared to LF-
fed mice. In the same samples, it was noted that proportions of
Bacteroidetes (phylum). Rikenellaceae (family) and Alistipes and
Thalassospira (genus) were lower in HF-fed mice than in the LF-fed
equivalents (Fig 7; Supplementary Fig 2 & 3 and Supplementary Tables 2
& 3).
5.4.5 The abundance of Proteobacteria in the colitis mouse model
is lower in animals fed a high fat diet
At W14, when the mice present the highest degree of acute inflammation,
analysis of the gut microbiota composition revealed specific DSS effects
(Fig 8) (i.e. significant changes not previously found in our control mice at
W14). Significantly lower proportions of Bacteroidaceae,
Ruminococcaceae (family) and Bacteroides (genus) were detected in the
HF-colitis mice relative to LF-colitis mice (Supplementary Fig 4 and 5). In
contrast, significantly greater proportions of the phylum Deferribacteres
and the genera Anaerotruncus and Odoribacter were seen in the HF-
colitis mice relative to LF-colitis mice (Fig 8, Supplementary Fig 4 and 5).
Analysis of the gut microbiota composition at W21, revealed there
was significantly lower proportions of the phylum Proteobacteria, the
family Alcaligenaceae and in the corresponding genus Sutterella in HF-
colitis mice compared to LF-colitis counterparts (Fig 8). Significantly
greater proportions of the phylum Verrucomicrobia, the families
Bifidobacteriaceae, Verrucomicrobiaceae, Peptostreptococcaceae and
the genera Lachnospiraceae Incertae Sedis, Akkermansia and
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Peptostreptococcaceae Incertae Sedis were noted in the HF-colitis mice
compared to the LF-colitis mice.
Analysis of the microbiota composition of the murine cecal
samples revealed that, at phylum level, as for the corresponding faecal
samples, proportions of Proteobacteria were also greater in LF-fed mice,
but in this instance not to a significant degree (p=0.2). At family level,
significantly greater proportions of Rikenellaceae, Ruminococcaceae,
Peptococcaceae, Veillonellaceae and of the genera Alistipes,
Ruminococcaceae Incertae Sedis and Oscillibacter were apparent in HF-
colitis mice, while significantly reduced proportions of the family
Porphyromonadaceae and the genus Parabacteroides, were noted in HF-
colitis mice compared to their LF-colitis equivalents (Fig 8;
Supplementary Fig 4 & 5 and Supplementary Tables 3 & 4).
5.4.6 Proportions of Proteobacteria are also lower in the colitis
associated cancer mouse model fed a high fat diet
Analysis of the gut microbiota composition after six weeks of diet (W12)
and one week post AOM injection (but prior to DSS exposure) between
the HF-CAC mice and the LF-CAC mice revealed the presence of
relatively lower proportions of the phyla Proteobacteria and
Bacteroidetes, the family Prophyromonadaceae and the genera Sutterella
and Rikenella in HF-CAC mice compared to LF-CAC mice. Significantly
greater proportions of the phylum Firmicutes, the family Lactobacillaceae
and the genus Lactobacillus were apparent in these HF-CAC animals.
After eight weeks of dietary intervention (W14 i.e. three weeks
after AOM injection and 5 days post DSS cycle one), the proportions of
the phylum Bacteroidetes, the families Bacteroidaceae,
Peptostreptococcaceae and Prophyromonadaceae were significantly
lower in HF-CAC mice compared to LF-CAC controls. Only the family
Erysipelotrichaceae were present in significantly greater proportions
within the gut microbiota of the HF-CAC, relative to LF-CAC mice.
After 15 weeks of dietary intervention (W21 i.e. 10 weeks post
AOM and two weeks post the third DSS cycle), a significantly lower
proportion of the phylum Proteobacteria and the corresponding family
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Alcaligenaceae and genus Sutterella was found in HF-fed, relative to LF-
fed mice.
Analysis of the cecal microbiota composition established that at
phylum level a significantly lower proportion of Proteobacteria were
observed in HF-CAC mice compared to their LF-fed equivalents.
Significant reductions at family level in Alcaligenaceae,
Peptostreptococcaceae, Clostridiaceae and at genus level in Sutterella
and Clostridium were noted in HF-CAC mice relative to LF-CAC mice (Fig
9; Supplementary Fig 6 & 7 Supplementary Tables 3 & 5).
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5.5 DISCUSSION
The ‘western diet’, characterised by high fat and calorie rich content, and
its contribution to colorectal cancer, has been the focus of much attention.
Previous studies examining ‘western diet’ in experimental models of
colitis and colitis associated cancer (CAC) have been inconclusive. Here
we assessed the relative effects of high and low fat diets on the
development of colitis and CAC in the widely used DSS and AOM/DSS
murine models (Rosenberg et al., 2009, Thaker et al., 2012, Robertis et
al., 2011). AOM induces colon tumours while DSS has been suggested to
exert toxic effects on colonic epithelium creating a chronic inflammatory
state (Robertis et al., 2011, Thaker et al., 2012) and, when combined,
they result in rapid growth of colon tumours shortening the latency time
for induction of CAC (Thaker et al., 2012). Here we found that, in contrast
to previous studies in CRC mice fed a high fat diet (Singh et al., 1997,
Newmark et al., 2001) a high lard based fat diet protected mice from
colitis and colitis associated cancer when compared to a low fat diet.
Though there are differences seen between this study and those cited,
this study does follow a similar design to that employed by Flores et al.
(2012). These results are in line with reports by Hyland and colleagues in
the TNBS-model of colitis and Gäbele and colleagues in chronic DSS-
colitis, both studies using similar lard-containing HF-diet (Hyland et al.,
2009, Gäbele et al., 2011). In addition, two other studies reported HF diet
reduction in a colon carcinogenesis but in these cases the high fat diets
were rice bran oil-based or were olive oil-based and supplemented with
fruit and vegetable extract (Shih et al., 2011, Mai et al., 2007). Major
differences between this study and previous studies reporting that HF
diets induced colitis and CAC are the strain used (BALB/c, A/J (Kim et al.,
2010, Park et al., 2012)), the concentration of AOM (10-12.5mg/kg
(Flores et al., 2012, Park et al., 2012, Kim et al., 2010)), the DSS-provider
(Laroui et al., 2012, Park et al., 2012, Kim et al., 2010), percentage
(Laroui et al., 2012, Flores et al., 2012, Park et al., 2012, Kim et al., 2010)
and time of exposure of DSS (Laroui et al., 2012, Park et al., 2012, Kim et
al., 2010), the concentration of HF diet (Flores et al., 2012, Kim et al.,
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2010, Laroui et al., 2012) and the provider of the mice (Flores et al.,
2012, Kim et al., 2010, Park et al., 2012).
Similar to other conditions, including obesity and diabetes, IBD has
an increasing incidence worldwide suggesting that environmental factors
such as diet might be important. There are currently no studies that
correlate obesity with the increased incidence of IBD and one recent
study did not find a correlation between BMI and incidence for CD or UC
(Chan et al., 2013). Obesity is associated with an increased pro-
inflammatory cytokine production and infiltration of macrophages into the
adipose tissue suggesting an interaction between the adipose tissue and
the immune system. In the current study, the protective effect of high fat
diet was already noticed after the first cycle of DSS (based on body
weight loss), suggesting that diet positively regulates responses from
other non-mucosal organ such as the adipose tissue as well as the
microbiota. Recent reports have suggested that the crosstalk between
mesenteric adipose tissue and immune cells is of a protective nature with
the adipose tissue being a barrier for microbiota translocation (Kredel et
al., 2013, Batra et al., 2012). We are currently examining the response of
the adipose tissue in these models with a view to identifying novel
mechanisms associated with the protective effect.
It is well accepted that diet regulates the microbiota. Analysis of
the murine gut microbiota composition was particularly revealing in this
current study, since no such analysis were performed in the previous
reports. Principal coordinate analysis revealed a shift in the microbiota
composition in colitis and CAC mice which was influenced by diet. High
gut microbiota diversity is considered desirable with low diversity
associated with UC and CD (Ott et al., 2004). The current study revealed
a reduction in gut microbiota diversity of LF-colitis and LF-CAC mice
relative to their HF counterparts. It was revealed that in both controls and
experimental groups, HF-fed mice had significantly lower proportions of
the phylum Proteobacteria relative to LF-fed comparators. The phylum
Proteobacteria, as previously stated, has been found to be associated
with CD, UC and CRC patients (Lepage et al., 2011, Gophna et al., 2006,
Frank et al., 2011). Phylogenetic analysis of the faecal microbiota of
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colitis model mice revealed numerous differences between HF-fed and
LF-fed mice. Of particular interest was the increase in proportions of the
genus Ordoribacter in HF-fed mice. Ordoribacter was found previously to
be reduced in CD and DSS colitis mice (Samanta et al., 2012, Morgan et
al., 2012). Notably, the genus Akkermansia was increased in the “HF-fed
colitis mice” given that a member of this genus, Akkermansia muciniphila,
has been previously reported to be reduced in CD and UC patients (Png
et al., 2010). A recent report also highlighted the regulatory role of A.
muciniphila in a model of diet-induced obesity whereby administration of
A. muciniphila reduced the metabolic profile of the disease by improving
gut barrier function (Everard et al., 2013). In cecum samples, a reduction
in Prophyromonadaceae and increase in Ruminococcaceae was noted.
These two families have previously been shown to be increased and
decreased, respectively, in CRC and UC patients (Wang et al., 2012,
Lepage et al., 2011, Kostic et al., 2012, Chen et al., 2012, Bibiloni et al.,
2006). Analysis of the gut microbiota composition of CAC mice revealed,
like colitis mice, numerous differences between HF-fed and LF-fed
animals. Of particular interest is the greater proportion of the phylum
Firmicutes in HF-fed CAC mice, as others have reported the presence of
relatively low proportions of Firmicutes in CRC patients (Kostic et al.,
2012). It is interesting that reductions in the families
Porphyromonadaceae and Peptostreptococcaceae were noted in HF-fed
CAC mice given that two corresponding genera, Porphyromonas and
Peptostreptococcus, have previously been found to be increased in CRC
patients (Wang et al., 2012, Chen et al., 2012) while an unclassified
member of the family Porphyromonadaceae was detected in UC patients,
but not healthy controls (Bibiloni et al., 2006).
Ultimately, this data reveals that a high fat diet protected against
the progression of colitis and CAC and highlights changes to the gut
microbiota that accompany this phenomenon. The data also highlight a
far more complex outcome of high fat diet on microbiota-host responses
warranting further investigations on these factors in patients with IBD and
CAC.
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Figure 1. Schematic of experimental design. Male C57BL/6 mice were
fed a low fat (LF, 10% fat) or high fat (HF, 45% fat) diet for 15 weeks
(Control group). Male C57BL/6 mice were fed with LF or HF diet for 15
weeks including 3 cycles of DSS, 5 days 1.5% DSS and 14 days of water
(Colitis group). Male C57BL/6 mice were fed a LF or HF diet for 15
weeks, after 4 weeks injected intraperitoneally with axozymethane (AOM,
8mg) and 1 week later supplied with 3 cycles of DSS, 5 days 1.5% DSS
and 14 days of water (Colitis-associated cancer (CAC)-group).
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Figure 2. Reduced body weight loss in HF diet colitis and CAC
model mice relative to LF diet counterparts. Body weight change was
monitored twice a week and the relative change is depicted as
percentage of starting day zero. Significance differences were determined
using ANOVA with post-hoc corrections unless otherwise stated: %%%
p<0.001 for differences between HF-CAC vs HF-Ctr; $$$ p<0.001 for
differences between HF-colitis vs LF-Colitis; &&& p<0.001 for differences
between HF-Ctr vs LF-Ctr. Data are mean ±SEM. n=8–12 mice per
group, representative of 2 experiments.
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Figure 3. Colonic macroscopic signs of disease. Colon Length and
weight were measured at time of necropsy. Significance differences were
determined using ANOVA with post-hoc corrections unless otherwise
stated: **p<0.01 for differences between HF-CAC vs LF-CAC; # p< 0.05
for differences between LF-colitis vs LF-Ctr; ## p< 0.05 (p<0.001 relative
colon weight) for differences between LF-CAC and LF-Ctr; ### p<0.05 for
differences between LF-colitis vs LF-CAC; $ p<0.05 for differences
between LF-colitis vs HF-colitis and % p<0.05 for differences between
HF-CAC vs HF-Ctr. Data are mean ±SEM. n=8–12 mice per group,
representative of 2 experiments.
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Figure 4. Tumor number and incidence. Representative images of
intestine with tumours from mice with LF-CAC and HF-CAC at 20x and a
close up of tumours at 40x. Number of tumours per mouse fed LF and HF
diet. Data are mean ±SEM. n = 9–12 mice per group, representative of
two experiments. Significance differences were determined using ANOVA
with post-hoc corrections - **p<0.01 for differences between HF-CAC vs
LF-CAC.
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Figure 5. Reduced plasma cytokines in HF fed colitis and CAC
model animals relative to LF diet counterparts. Plasma was collected
at the end of the study from mice exposed to LF and HF-diet (LF/HF-Ctr),
diets and DSS (LF/HF-colitis) and diets and AOM/DSS (LF/HF-CAC).
Plasma levels of IL-1β, IFN-γ, IL-12, IL-2, IL-10 and IL-4 were measured
using MSD-technology. Data are mean ±SEM. n=8–12 mice per group,
representative of 2 experiments. Significance differences were
determined using ANOVA with post-hoc corrections - ***p<0.001 for
differences between HF-CAC vs LF-CAC; # p<0.05 and ### p<0.001 for
differences between LF-colitis or LF-CAC vs LF-Ctr; ## p<0.05 for
differences between LF-colitis and LF-CAC; % p<0.05 and %%%
p<0.001 for differences between HF-CAC or HF-colitis vs HF-Ctr; %%
p<0.05 between HF-CAC and HF-Colitis; $$ p<0.05 and $$$ p<0.001 for
differences between HF-colitis vs LF-colitis.
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Figure 6. Reduced colon cytokines in HF fed colitis and CAC model
animals relative to LF diet counterparts. Proximal colon was collected
at necropsy from mice exposed to LF and HF-diet (LF/HF-Ctr), and DSS
(LF/HF-colitis) and AOM/DSS (LF/HF-CAC). Colon homogenates were
measured for IL-1β, IFN-γ, IL-6 and mKC using MSD technology. Data
are mean ±SEM. n=8–12 mice per group. Significance differences were
determined using ANOVA with post-hoc corrections unless otherwise
stated - # p<0.05 and ### p<0.001 for differences between LF-colitis or
LF-CAC vs LF-Ctr; ## p<0.05 for differences between LF-colitis and LF-
CAC; % p<0.05 for differences between HF-CAC or HF-colitis vs HF-Ctr;
%% p<0.05 between HF-CAC and HF-colitis.
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Figure 7. Faecal microbiota composition at phylum level in Control
mice. Faecal samples were collected at week 12 (W12, before DSS
start), W14 (after 5 days DSS and 1 week of water) and W21 (at time of
necropsy). DNA extracted and microbiota composition determined. (a)
Microbiota distribution at phylum level in LF- and HF-diet control mice as
determined by pyrosequencing of 16rRNA tags (V4) region. Data outside
the pie charts represent the mean percentage read number for the
corresponding colour coded family (n=8 mice/group).
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Figure 8. Faecal microbiota composition at phylum level in mice
with colitis. The gut microbiota composition at phylum level of mice fed a
HF diet is altered in colitis conditions compared to mice on a LF diet as
determined by pyrosequencing of 16rRNA tags (V4) region. Data outside
the pie charts represent the mean percentage read number for the
corresponding colour coded family (n=7-11 mice/group).
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Figure 9. Faecal microbiota composition at phylum level in mice
with colitis-associated colorectal cancer (CAC). The gut microbiota
composition at phylum level of mice fed a HF diet is altered in CAC
compared to mice on a LF diet as determined by pyrosequencing of
16rRNA tags (V4) region. Data outside the pie charts represent the mean
percentage read number for the corresponding colour coded family (n=7-
10 mice/group)
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Figure 10. Microbiota composition. Principal coordinate analysis of
unweighted Unifrac reveals separation by treatment group. Data sets A:
Yellow - low fat diet control, Purple - high fat diet control, Red - CAC high
fat diet, Blue - CAC low fat diet, Orange - Colitis high fat diet and Green -
Colitis low fat diet. Data sets B: Blue - week 12, Orange - week 14, Green
- week 21 and Red - cecum.
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SUPPLEMENTARY INFORMATION
Supplementary Table 1 -  Diversity of the gut microbiota in each group within
each time point
Statistical significance was determined using Mann Whitney. *p value ≤0.05 ** p value <0.005 and *** p value
<0.0005 between HF-fed and LF-fed mice within each treatment group.
Group AMODSSHF AMODSSLF DSSHF DSSLF HF LF
W
ee
k
12
Simpson 0.78 0.85 0.87 0.86 0.93 0.79**
CHao1 239.58 306.33 395.67 465.49 589.53 389.53
Shannon 3.96 4.41 4.66 4.79 5.52 4.15
Observed Species 121.86 138 159.88 219.55 257.5 193.13
Phylogenetic Diversity 14.21 15.46 16.60 20.10 21.98 18.48
W
ee
k
14
Simpson 0.75 0.84 0.85 0.82 0.75 0.77
CHao1 302.93 209.28 405.21 172.85** 303.48 364.02
Shannon 3.70 3.97 4.42 3.60** 3.86 4.04
Observed Species 144.2 104.25 175.5 81.73*** 163.67 170.4
Phylogenetic Diversity 15.03 12.10 17.65 10.44*** 17.14 17.40
W
ee
k
21
Simpson 0.77 0.87 0.83 0.85 0.83 0.81
CHao1 285.60 344.08 319.23 237.65 468.31 408.20
Shannon 3.91 4.50 4.14 4.33 4.50 4.40
Observed Species 143.22 163.4 149.63 123.30 217.63 187.25
Phylogenetic Diversity 15.70 16.98 15.34 14.10 20.04 18.35
C
ec
um
Simpson 0.94 0.93 0.93 0.88** 0.93 0.93
CHao1 529.30 371.40 554.60 451.43 721.32 804.34
Shannon 5.46 5.14* 5.40 4.65** 5.55 5.58
Observed Species 203.22 178.4 228 189.73 271.5 310.38
Phylogenetic Diversity 19.70 18.21 20.78 18.67 22.60 25.87
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Supplementary Table 2. Gut microbiota changes in the control mouse model over time
WK 12
HF
WK 12
LF
WK 14
HF
WK 14
LF
WK 21
HF
WK 21
LF
Phylum
Proteobacteria 1.116 1.487 0.617 1.098* 0.91 1.95
Firmicutes 58.931 60.205 72.764 60.128* 66.51 60.87
Actinobacteria 2.243 10.146* 2.806 3.901 1.32 1.33
Verrucomicrobia 1.417 1.497* 0.172 0.067 0.16 0.65
Family
Alcaligenaceae 0.000 0.995* 0.043 0.652* 0.00 0.90
Rikenellaceae 9.196 8.721 3.954 14.338* 5.46 8.06
Lachnospiraceae 21.500 8.536* 8.957 8.520 14.73 11.29
Ruminococcaceae 13.004 4.696* 11.389 5.139* 6.54 7.97
Bifidobacteriaceae 2.205 10.095* 2.641 3.761 1.26 1.24
Verrucomicrobiaceae 1.417 1.497* 0.172 0.067 0.16 0.65
Erysipelotrichaceae 17.791 39.81* 45.737 41.856 36.304 37.631
Streptococcaceae 0.224 0.000 0.000 0.000 0.10 0.00*
Note only significant changes in % read number shown. Statistical significance was determined using Kruskal Wallis. *Pvalue ≤0.05 between high fat and low fat within each time point.
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Supplementary Table 2 (continued)
WK 12
HF
WK 12
LF
WK 14
HF
WK 14
LF
WK 21
HF
WK 21
LF
Genus
Sutterella 0.000 0.995* 0.043 0.652* 0.00 0.90
Alistipes 6.631 6.942 2.727 12.294* 3.37 6.39*
Lachnospiraceae Incertae Sedis 1.198 0.441* 0.581 0.459 0.68 0.76
uncultured Lachnospiraceae 0.624 0.077* 0.746 0.160* 0.19 0.07
Ruminococcaceae Incertae Sedis 6.078 1.933* 6.301 2.689* 3.25 4.26
Oscillibacter 1.346 0.272* 1.593 0.379* 0.90 0.53*
Allobaculum 16.905 39.810* 45.464 41.856 34.85 37.63
Bifidobacterium 2.205 10.095* 2.641 3.761 1.26 1.24
Akkermansia 1.417 1.405* 0.172 0.067 0.16 0.62
Turicibacter 0.886 0.000* 0.273 0.000 1.45 0.00*
Lactococcus 0.148 0.000 0.050 0.000 0.09 0.00*
Other 38.137 24.076* 20.906 24.256 33.56 30.74
Note only significant changes in % read number shown. Statistical significance was determined using Kruskal Wallis. *Pvalue ≤0.05 between high fat and low fat within each time point.
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Supplementary Table 3. Cecum composition within each cohort at W21
Cecum
HF
Cecum
LF
Cecum
DSS HF
Cecum
DSS LF
Cecum
AMO DSS HF
Cecum
AMO DSS LF
Phylum
Proteobacteria 4.110 3.890 4.990 7.420 4.460 8.250*
Bacteroidetes 24.530 33.620* 23.690 29.030 34.170 36.500
Deferribacteres 7.500 3.880* 7.440 3.050* 5.130 3.630
Family
Alcaligenaceae 0.100 1.460 2.390 6.020 2.280 6.010*
Rikenellaceae 5.710 10.200* 5.260 2.200* 6.580 4.510
Porphyromonadaceae 4.220 4.450* 2.130 3.940* 2.920 4.270
Lachnospiraceae 31.350 17.240* 24.350 20.470 20.060 17.290
Ruminococcaceae 15.010 16.860 15.600 10.130* 16.470 10.630
Deferribacteraceae 7.500 3.880* 7.440 3.050* 5.130 3.630
Desulfovibrionaceae 3.700 1.670* 2.000 0.910* 1.730 1.550
Peptostreptococcaceae 0.050 0.110 0.320 0.150 0.000 0.260*
Peptococcaceae 0.720 0.510 0.700 0.250* 0.560 0.690
Clostridiaceae 0.000 0.000 0.000 0.020 0.000 0.150*
Veillonellaceae 0.000 0.000 0.090 0.00* 0.040 0.000
Note only significant changes in % read number shown. Statistical significance was determined using Kruskal Wallis. *Pvalue ≤0.05 between high fat and low fat within group
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Supplementary Table 3 (continued)
Cecum
HF
Cecum
LF
Cecum
DSS HF
Cecum
DSS LF
Cecum
AMO DSS HF
Cecum
AMO DSS LF
Genus
Sutterella 0.100 1.460 2.390 6.020 2.280 6.010*
Alistipes 4.050 8.550* 3.900 1.550* 5.240 3.540
Parabacteroides 1.990 3.010 0.950 2.830* 1.850 3.610
Ruminococcaceae Incertae Sedis 8.450 10.060 8.020 4.890* 9.930 5.610
Oscillibacter 2.770 1.470 1.730 1.020* 1.370 1.300
Mucispirillum 7.500 3.880* 7.440 3.050* 5.130 3.630
Desulfovibrio 3.430 1.530* 1.580 0.770* 1.410 1.410
Thalassospira 0.210 0.520* 0.370 0.420 0.230 0.310
Clostridium 0.000 0.000 0.000 0.020 0.000 0.150*
Note only significant changes in % read number shown. Statistical significance was determined using Kruskal Wallis. *Pvalue ≤0.05 between high fat and low fat within each group.
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Supplementary Table 4. Gut microbiota changes in the colitis mouse model overtime
WK12
colitis HF
WK12
colitis LF
WK14
colitis HF
WK14
colitis LF
WK21
colitis HF
WK21
colitis LF
Phylum
Proteobacteria 2.519 1.913 5.033 9.476* 4.19 7.96*
Firmicutes 59.266 64.608 61.548 40.730* 54.49 53.79
Deferribacteres 5.568 5.247 0.566 0.091* 2.97 3.85
Verrucomicrobia 0.592 1.777 0.364 1.385 0.52 0.24*
Family
Alcaligenaceae 0.318 1.053 4.528 8.608 2.63 6.07*
Rikenellaceae 7.097 5.501 1.280 3.602* 4.91 2.35
Bacteroidaceae 11.012 4.921 14.230 27.494* 12.03 10.15
Lachnospiraceae 16.792 19.514 12.700 2.181* 9.38 14.64
Ruminococcaceae 8.988 8.668 8.779 1.531* 4.30 5.94
Bifidobacteriaceae 3.535 1.898 2.062 0.231 3.05 0.54*
Verrucomicrobiaceae 0.592 1.777 0.364 1.385 0.52 0.24*
Peptostreptococcaceae 0.106 0.178 0.640 1.841 0.65 0.00*
Peptococcaceae 0.186 0.246 0.371 0.061 0.35 0.00*
Note only significant changes in % read number shown. Statistical significance was determined using Kruskal Wallis. *Pvalue ≤0.05 between high fat and low fat within each time point.
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Supplementary Table 4 (continued)
WK12
colitis HF
WK12
colitis LF
WK14
colitis HF
WK14
colitis LF
WK21
colitis HF
WK21
colitis LF
Genus
Sutterella 0.318 1.053 4.528 8.608 2.63 7.97*
Parabacteroides 0.097 1.879* 1.348 2.570 0.60 2.60
Bacteroides 11.012 4.921 14.230 27.494* 12.03 10.15
Lachnospiraceae Incertae Sedis 1.149 1.315 1.961 0.383* 1.67 0.22*
uncultured Lachnospiraceae 0.000 0.269* 0.155 0.000 0.00 0.32
Ruminococcaceae Incertae Sedis 4.490 4.262 5.195 0.589* 1.71 1.91
Oscillibacter 0.946 0.754 0.445 0.140* 0.37 0.28
Anaerotruncus 0.928 1.489 0.364 0.000* 0.68 1.37
Akkermansia 0.592 1.777 2.244 4.459 2.43 0.51*
Odoribacter 1.918 1.424 0.404 1.233* 0.45 0.00
Peptostreptococcaceae Incertae Sedis 0.000 0.045 0.061 0.000 0.37 0.00*
uncultured bacteria 0.362 0.000 0.418 0.000* 0.00 0.00
Other 30.040 34.039 31.573 23.545* 26.66 35.54
Note only significant changes in % read number shown. Statistical significance was determined using Kruskal Wallis. *Pvalue ≤0.05 between high fat and low fat within each time point.
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Supplementary Table 5 Gut microbiota changes in the colitis associated cancer mouse model (CAC) overtime
WK 12
CAC HF
WK 12
CAC LF
WK 14
CAC HF
WK 14
CAC LF
WK 21
CAC HF
WK 21
CAC LF
Phylum
Proteobacteria 0.855 3.014* 2.586 8.112* 3.430 8.130*
Bacteroidetes 23.055 35.969* 21.959 38.381* 31.330 41.200
Firmicutes 67.640 52.702* 66.839 48.117* 59.610 45.200
Family
Alcaligenaceae 0.342 1.587* 2.255 6.898* 2.270 6.710*
Porphyromonadaceae 1.539 3.382* 0.952 2.686* 2.190 3.570
Bacteroidaceae 8.218 12.358 10.074 25.219* 12.620 20.290
Lactobacillaceae 8.475 2.513* 1.634 3.766 2.640 1.800
Peptostreptococcaceae 0.000 0.000 0.217 2.588* 0.030 0.170
Erysipelotrichaceae 42.569 33.759 41.963 23.898* 44.133 24.980
Note only significant changes in % read number shown. Statistical significance was determined using Kruskal Wallis. *Pvalue ≤0.05 between high fat and low fat within each time point.
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Supplementary Table 5 (continued)
WK 12
CAC HF
WK 12
CAC LF
WK 14
CAC HF
WK 14
CAC LF
WK 21
CAC HF
WK 21
CAC LF
Genus
Sutterella 0.342 1.587* 2.255 6.898* 2.270 6.710*
Parabacteroides 0.550 1.663 0.652 2.650* 1.470 3.120
Bacteroides 8.218 12.358 10.074 25.219* 12.620 20.290
uncultured Lachnospiraceae 0.220 0.047 0.434 0.080* 0.200 0.230
Allobaculum 42.569 33.692 41.963 23.737* 44.130 24.980
Lactobacillus 8.426 2.513* 1.634 3.757 2.060 1.790
Peptostreptococcaceae Incertae Sedis 0.000 0.000 0.134 1.303* 0.000 0.060
Rikenella 0.000 0.595* 0.000 0.000 0.310 0.060
Note only significant changes in % read number shown. Statistical significance was determined using Kruskal Wallis. *Pvalue ≤0.05 between high fat and low fat within each time point.
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Supplementary Figure 1. Rarefaction curves for each group at 97%
similarity levels for all twenty four data sets. Amount of operational
taxonomic units (OTU’s) found as a function of the number of sequence
tags sampled.
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Supplementary Figure 2. Faecal microbiota composition at family
level in control mice. Microbiota distribution at family level in high fat
diet and low fat diet mice as determined by pyrosequencing of 16rRNA
tags (V4) region. Data outside the pie charts represent the mean
percentage read number for the corresponding colour coded family (n=8
mice/group).
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Supplementary Figure 3. Faecal microbiota composition at genus
level in control mice. Microbiota distribution at genus level in high fat
diet and low fat diet mice as determined by pyrosequencing of 16rRNA
tags (V4) region. Data outside the pie charts represent the mean
percentage read number for the corresponding colour coded family (n=8
mice/group).
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Supplementary Figure 4. Faecal microbiota composition at family
level in colitis mice. The gut microbiota composition at family level of
mice fed a HF diet is altered in colitis conditions compared to mice on a
LF diet as determined by pyrosequencing of 16rRNA tags (V4) region.
Data outside the pie charts represent the mean percentage read number
for the corresponding colour coded family (n=7-11 mice/group).
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Supplementary Figure 5. Faecal microbiota composition at genus
level in colitis mice. The gut microbiota composition at genus level of
mice fed a HF diet is altered in colitis conditions compared to mice on a
LF diet as determined by pyrosequencing of 16rRNA tags (V4) region.
Data outside the pie charts represent the mean percentage read number
for the corresponding colour coded family (n=7-11 mice/group).
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Supplementary Figure 6. Faecal microbiota composition at family
level in mice with colitis-associated colorectal cancer (CAC). The gut
microbiota composition at family level of mice fed a HF diet is altered in
CAC conditions compared to mice on a LF diet as determined by
pyrosequencing of 16rRNA tags (V4) region. Data outside the pie charts
represent the mean percentage read number for the corresponding colour
coded family (n=7-10 mice/group).
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Supplementary Figure 7. Faecal microbiota composition at genus
level in mice with colitis-associated colorectal cancer (CAC). The gut
microbiota composition at genus level of mice fed a HF diet is altered in
CAC compared to mice on a LF diet as determined by pyrosequencing of
16rRNA tags (V4) region. Data outside the pie charts represent the mean
percentage read number for the corresponding colour coded family (n=7-
10 mice/group).
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6.1 ABSTRACT
The commensal microbiota, host immunity and metabolism participate in a
signalling network, with diet influencing each component of this triad. In
addition to diet, many elements of a modern lifestyle influence the gut
microbiota but the degree to which exercise affects this population is unclear.
Since extremes of exercise often accompany extremes of diet, we addressed
the issue by studying professional athletes from an international rugby union
squad. Two groups were included to control for physical size, age and gender.
As expected, athletes and controls differed significantly with respect to plasma
creatine kinase (a marker of extreme exercise), inflammatory and metabolic
markers. More importantly, athletes had a higher diversity of gut
microorganisms, which in turn positively correlated with protein consumption.
The results provide evidence for a beneficial impact of exercise on the
microbiota but also indicate that the relationship is complex and related to
accompanying dietary extremes. The results provide rationale for a
prospective controlled study.
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6.2 INTRODUCTION
The commensal human gut microbiota has become the focus of converging
interest from diverse disciplines, primarily because of its contribution to health
and risk of disease throughout life (Sommer and Bäckhed, 2013, Sekirov et
al., 2010). The changing composition of the human microbiota is linked with
changes in human behaviour (Shanahan, 2012). Many of the elements of a
modern lifestyle, particularly in early life, influence the composition of the
microbiota (O'Toole and Claesson, 2010). Disturbances of the microbiota at
various ages may confer disease risk. In the elderly, the diversity and
composition of the microbiota has been linked with various health parameters,
including levels of inflammatory cytokines (Claesson et al., 2012). The
microbiota may also be a risk or protective factor in relation to immunoallergic
and metabolic disorders (Le Chatelier et al., 2013, Larmonier et al., 2013,
Bisgaard et al., 2011, Sha et al., 2012). Thus, a signalling network among the
microbiota, host immunity and host metabolism has become evident, with diet
influencing each component of this triad (Cotillard et al., 2013, Jeffery and
O'Toole, 2013).
Although obesity-related disorders have been linked with alterations in
the microbiota (Qin et al., 2012), the relationship between the microbiota and
exercise or a sedentary lifestyle has received less attention. Some evidence
suggests that exercise may modify the microbiota (Queipo-Ortuño et al.,
2013); therefore, we predicted that athletes should have a more diverse
microbiota than their sedentary counterparts. To address this, we studied a
professional rugby team while in the regulated environment of pre-season
camp and performed a high-throughput DNA sequencing-based analysis of
faecal microbiota with contemporaneous measurements of inflammatory
cytokines and metabolic health. Since extremes of exercise are often
associated with dietary extremes, the findings were correlated with diet.
Because of the physical size of modern rugby players, two control groups
were assessed; one matched for athlete size with a comparable body mass
index (BMI) and another reflecting the background age- and gender-matched
population. The results confirm differences in composition and diversity of the
microbiota of athletes when compared to both control groups which correlate
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with dietary differences, and which are linked with a more favourable
metabolic and inflammatory profile.
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6.3 RESULTS
6.3.1 Athletes have lower inflammatory and improved metabolic
markers relative to controls
Subject characteristics are shown in Table 1. Despite increased levels of
creatine kinase (CK) (Fig. 1), the athletes studied had a lower inflammatory
status than controls (Supplementary Figs S1 and S2). Metabolic markers in
athletes and low BMI controls were improved relative to the high BMI cohort
(Supplementary Table S1 and Supplementary Figs S3 and S4).
6.3.2 The gut microbiota of athletes is more diverse than that of
controls
A total of 1,217,954 (1.2 million) 16S rRNA reads were generated from faecal
samples provided by elite athletes and controls, with an average of 14,736
(±6,234 s.d.) reads per athlete and 11,941 (±4,515 s.d.) reads per control. In
both cases rarefaction curves established that extra sampling would be of
limited benefit (Supplementary Fig. S5). Analysis of this data revealed that the
alpha diversity of the elite athlete microbiota was significantly higher than that
of the high BMI (Shannon index, Simpson) or both control groups
(Phylogenetic diversity, Chao1, Observed species) (Fig. 2). The alpha
diversity of the two control groups did not differ significantly from each other.
Principal coordinate analysis based on unweighted Unifrac distances of the
16S rRNA sequences highlighted a clear clustering of the microbial
populations of athletes away from that of controls (Fig. 3). This was further
confirmed using hierarchical clustering (Supplementary Fig. S6). No
separation was observed between control groups. None of the previously
reported enterotypes were identified.
6.3.3 Proportions of several taxa are significantly higher in the gut
microbiota of elite athletes relative to controls
Reads corresponding to 22 phyla, 68 families and 113 genera were detected
in athlete faecal samples. In contrast, just 11 phyla, 33 families and 65 genera
were detected in low BMI samples and 9 phyla, 33 families and 61 genera in
high BMI samples. Pairwise comparisons of the elite athlete gut microbiota
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and the high BMI controls revealed that athletes had significantly greater
proportions of 48 taxa than high BMI controls while only one taxon,
Bacteroidetes was significantly (P=0.022) less abundant in athletes
(Supplementary Fig.S7). The top six flux changes in relative abundance were
in the Firmicutes, Ruminococcaceae, S24-7, Succinivibrionaceae, RC9 gut
group and Succinivibrio. Notably, there were significantly higher proportions of
Akkermansiaceae (family; P=0.049) and Akkermansia (genus; P=0.035) in
elite athletes compared to the high BMI controls. A comparison of the elite
athlete gut microbiota with that of low BMI controls revealed significantly
higher proportions of 40 taxa and lower proportions of only three taxa,
Lactobacillaceae (P=0.001) Bacteroides (P=0.035) and Lactobacillus
(P=0.001), in the former (Supplementary Fig. S8). The top six flux changes in
relative abundance were noted among the Prevotellaceae,
Erysipelotrichaceae, S24-7, Succinivibrionaceae, Prevotella and Succinivibrio.
Pairwise comparisons of the microbiota of the control groups revealed
differences in the proportions of seven taxa (Supplementary Fig. S9). At
genus level, significantly greater proportions of Dorea (P=0.026) and
Pseudobutyrivibrio (P=0.022) and significantly lower proportions of
Ruminococcaceae Incertae Sedis (P=0.021) and Akkermansia (P=0.006)
were observed in the high BMI, relative to low BMI, controls.
6.3.4 Protein accounted for considerably more of the total energy
intake of athletes than of controls
As expected, total energy intake was significantly higher in athletes than
either control group (Table 2). Athletes consumed significantly higher
quantities of calories, protein, fat, carbohydrates, sugar and saturated fat per
day than either of the control groups and consumed significantly higher
quantities of fibre, monounsaturated fat and polyunsaturated fat than the high
BMI control group (Table 2). Protein accounted for considerably more (22%)
of the total energy intake of athletes, than of the low BMI (16%) and high BMI
(15%) control groups (Table 2). While meat/meat products were the top
contributors of dietary protein across all groups, supplements were the
second highest (15%) contributor to protein in athletes and did not contribute
considerably to protein consumption in controls (Supplementary Fig. S10).
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Visualisation of dietary data with correspondence analysis highlighted a clear
separation between the types of foods consumed by athletes and controls
(Fig. 4a). The most discriminating food types were fruit, vegetables (athletes)
and snacks (controls), whose consumption changes in a gradual manner
along the y axis (Fig. 4b).
6.3.5 Exercise and protein intake as drivers of increased gut microbiota
diversity in athletes
Correlations between health parameters (BMI, waist hip ratio, metabolic and
inflammatory markers) or diet with the respective taxa or microbial diversity
were examined using Pearson correlations. Significantly positive correlations
were revealed between leptin levels and BMI, body fat percentage and waist
hip measurement, while significant negative correlations between leptin and
lean body mass (Supplementary Fig. S11), as well as between adiponectin
levels and both BMI and lean body mass (Supplementary Fig. S2), were
observed. Significantly positive associations was noted between microbial
diversity and protein intake (Fig. 5), CK levels (Fig. 6) and urea
(Supplementary Fig. S13). No correlations were observed after adjustment for
multiple testing using FDR values between microbial taxa and health
parameters.
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6.4 DISCUSSION
Although the relationship between diet, the gut microbiota, host immunity and
host metabolism is becoming more evident (Cotillard et al., 2013, Jeffery and
O'Toole, 2013), the relationship between the microbiota and exercise has not
been fully explored. Our findings show that a combination of exercise and diet
impact on gut microbial diversity. In particular, the enhanced diversity of the
microbiota correlates with exercise and dietary protein consumption in the
athlete group.
Diversity is important in all ecosystems to promote stability and
performance. Microbiota diversity may become a new biomarker or indicator
of health (Shanahan, 2010). Loss of biodiversity within the gut has been
linked to an increasing number of conditions such as autism, gastrointestinal
diseases and obesity associated inflammatory characteristics (Claesson et al.,
2012, Kang et al., 2013, Ott et al., 2004, Le Chatelier et al., 2013, Chang et
al., 2008). In this study, the diversity of the athlete gut microbiota was
significantly higher than both control groups matched for physical size, age
and gender. The proportions of several gut microbial taxa were also altered in
athletes relative to controls. However, few differences were seen between the
two control cohorts. Of note, the athletes and low BMI group had significantly
higher proportions of the genus Akkermansia levels than the high BMI group.
Akkermansia muciniphilla has been identified as a mucin-degrading bacteria
that resides in the mucus layer and its abundance has been shown to
inversely correlate with obesity and associated metabolic disorders in both
mice and humans (Everard et al., 2013, Karlsson et al., 2012). Everard et al.,
2013 recently showed that feeding Akkermansia, or restoration of
Akkermansia levels by prebiotic treatment in diet-induced obese mice,
correlated with an improved metabolic profile possibly due to enhanced
barrier function. Interestingly, the athletes had lower inflammatory and
improved metabolic markers relative to controls, and in particular the high BMI
controls, demonstrating the enhanced health profile of this group. While the
microbiota diversity of the two control groups did not differ significantly, it was
noted that alpha diversity in the high BMI controls was numerically, although
not significantly, lower than that of their low BMI counterparts. Reductions in
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the diversity of microbial populations in high BMI individuals has been
reported in a recent study with a larger cohort size (Le Chatelier et al., 2013)
which also showed that dietary intervention can increase microbiota diversity
in an obese cohort (Cotillard et al., 2013).
Rugby is a vigorous contact sport requiring considerable fitness and
increased dietary requirements (Lundy et al., 2006). The levels of plasma CK
(a marker of extreme exercise) and creatinine were significantly elevated in
the elite athlete group consistent with the high exercise loads (Brancaccio et
al., 2007, Lazarim et al., 2009, McLellan et al., 2010). Furthermore, diet was
significantly different from that of controls, with increased intake of calories,
protein, fat and carbohydrate. Diversity in the diet has been linked to
microbiota diversity (Claesson et al., 2012). In our study, microbiota diversity
indices positively correlated with protein intake and CK suggesting that both
diet and exercise are drivers of biodiversity in the gut. The protein and
microbiota diversity relationship is further supported by a positive correlation
between urea levels, a by-product of diets that are rich in protein, and
microbiota diversity. Long-term diets have been linked to clusters in the gut
microbiota with protein and animal fat associated with Bacteroides and simple
carbohydrates with Prevotella (Wu et al., 2011). Fermentation of protein has
also been suggested to result in the production of various potentially toxic
products, such as amines and NH3, and in one report, with growth of potential
pathogens (Rist et al., 2013). In contrast, feeding of whey protein to mice
mediates against the negative effects of a high fat diet (McAllana et al.,
submitted, Tranberg et al., 2013). Indeed, in athletes, whey protein
supplements represented a significant component of the protein intake in
athletes but not controls. Whey protein has been associated with reductions in
body weight and increased insulin sensitivity in the past and is frequently a
major component of the athlete diet (Tipton and Wolfe, 2004, Belobrajdic et
al., 2004). Taken together, our results suggest that the relationship between
exercise, diet and the gut microbiota warrants further investigation.
In conclusion, exercise seems to be another important factor in the
relationship between the microbiota, host immunity and host metabolism, with
diet playing an important role. Further, intervention-based studies to tease
apart this relationship will be important and provide further insights into
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optimal therapies to influence the gut microbiota and its relationship to health
and disease.
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6.5 MATERIALS AND METHODS
6.5.1 Subjects characteristics
Male elite professional rugby players (n=40) were recruited for this study; the
mean age of the athletes was 29 (±4) years and they had a mean BMI of 29.1
(±2.9). Healthy male controls were recruited from the Cork city and county
region of Ireland; the mean age of controls was 29 (±6) years. Two groups of
control were specifically recruited based on their physical size (BMI) relative
to the athletes, with group 1 (n=23) having a BMI of less than or equal to 25
and group 2 (n=23) having a BMI of greater than 28 (Supplementary Table 2).
All subjects except one (Indian ethnicity) were of Irish ethnicity and all
subjects gave written informed consent prior to the beginning of the study.
This study was approved by the Cork Clinical Research Ethics Committee.
Exclusion criteria included having a BMI between 25 and 28, antibiotic
treatment within the previous 2 months or suffering from any acute or chronic
cardiovascular, gastrointestinal or immunological condition.
6.5.2 Experimental design
Faecal and blood samples were collected from all participants. DNA was
extracted from fresh stool samples which were stored on ice prior to use.
Each participant was interviewed by a nutritionist and completed a detailed
food frequency questionnaire (FFQ). Body composition analysis data from
dual-energy X-ray absorptiometry (DXA) scans were received from the Irish
Rugby Football Union (IRFU) for all athletes, DXA scans for controls were
performed in University Hospital Cork, waist:hip measurements were taken for
both athletes and controls.
6.5.3 Nutritional and clinical data collection
Dietary data were collected by means of a FFQ which was administered by a
research nutritionist. The FFQ was an adapted version of that used in the UK
arm of the European Prospective Investigation into Cancer (EPIC) study
(Bingham et al., 1997) which in turn, is based on the original Willett FFQ
(Willett et al., 1988, Willett et al., 1985). To more comprehensively reflect the
Irish diet, the 130-food item EPIC FFQ was extended to include an additional
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57 food items. Participants were asked to recall dietary intakes over the
previous 4-weeks. A photographic food atlas was used to pictorially quantify
foods and beverages (Nelson et al., 1997). Manufacturer’s weights on
packaging and household measures were also used to quantify foods. Intakes
of nutritional supplements were recorded. Completed FFQ’s were coded and
quantified by researchers and entered in the Weighed Intake Software
Package (WISP©) (Tinuviel Software, Anglesey, UK), which uses McCance
and Widdowson’s The Composition of Foods, sixth edition plus all
supplemental volumes to generate nutrient intake data (Roe et al., 2002).
Data were subsequently imported into SPSS© version 18 (SPSS Inc.,
Chicago, USA) for analysis. Dietary data was visualised with correspondence
analysis (R statistical package version 2.13.1) (RDevelopmentCoreTeam,
2010). Fasting blood samples were collected and analysed at the Cork Mercy
University Hospital clinical laboratories. Commercial multi-spot microplates
(Meso Scale Diagnostics) were used to measure cytokines.
6.5.4 Control physical activity levels
As the athletes were involved in a rigorous training camp we needed to
assess the physical activity levels of both control groups. To determine this
we used an adapted version of the EPIC-Norfolk questionnaire (Wareham et
al., 2002). T-tests were carried out to compare high BMI and low BMI controls.
6.5.5 DNA extraction and high-throughput amplicon sequencing
Stool samples were stored on ice until processed. DNA was purified from
fresh stool samples using the QIAmp DNA Stool Mini Kit (Qiagen, Crawley,
West Sussex, UK) according to manufacture’s instructions with addition of a
bead-beating step (30s x 3) and stored at -20oC. The microbiota composition
of the samples was established by amplicon sequencing of the 16S rRNA
gene V4; universal 16S rRNA primers estimated to bind to 94.6% of all 16S
genes (i.e. the forward primer F1 (5’-AYTGGGYDTAAAGNG) and a
combination of four reverse primers R1 (5’-TACCRGGGTHTCTAAAGNG), R2
(TACCAGAGTATCTAATTC), R3 (5’-CTACDSRGGTMTCTAATC) and R4 (5’-
TACNVGGGTATCTAATC) (RDP’S Pyrosequencing Pipeline:
http://pyro.cme.msu.edu/pyro/help.jsp) were employed for PCR amplification.
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Molecular identifier tags were attached between the 454 adaptor sequence
and the target-specific primer sequence, allowing for identification of individual
sequences from the pooled amplicons. Ampure purification system (Beckman
Coulter, Takeley, UK) was used to clean the amplicons before being
sequenced on a 454 Genome Sequencer FLX platform (Roche Diagnostics
Ltd, Burgess Hill, West Sussex, UK) in line with 454 protocols at the Teagasc
high throughput sequencing centre. DNA sequence reads from this study are
available from the Sequence Read Archive (accession numbers PRJEB4609)
6.5.6 Bioinformatic analysis
The Stoney supercomputer at the Irish Centre for High End Computing
(ICHEC) was used for the following analysis. Raw sequences were quality
trimmed using the Qiime Suite of programmes (Caporaso et al., 2010), any
reads not meeting the quality criteria of a minimum quality score of 25 and
sequence length shorter than 150bps for 16S amplicon reads. The SILVA 16S
rRNA (version 106) database was employed to BLAST the trimmed fasta
sequence files using default parameters (Altschul et al., 1997, Pruesse et al.,
2007). Parsing of the resulting BLAST output files was achieved through
Megan which uses a lowest common ancestor algorithm to assign reads to
NCBI taxonomies (Huson et al., 2007). Filtering was carried out within
MEGAN using bit scores prior to tree construction and summarization, similar
to previous studies a bit-score cut-off of 86 was selected (Urich et al., 2008).
Clustering of sequence reads into operational taxonomical units (OTUs) at
97% identity level was achieved using Qiime. The ChimeraSlayer program
was used to remove chimeras from aligned OTU and the FastTreeMP tool
generated a phylogenetic tree (Haas et al., 2011, Price et al., 2010). Alpha
diversity indices and rarefaction curves were generated using Qiime. Beta
diversities were also calculated on the sequence reads based on weighted
and unweighted Unifrac and bray curtis distance matrices; subsequently
principal coordinate analysis (PCoA) and unweighted pair group method with
arithmetic mean (UPGMA) clustering was performed on the samples. KiNG
viewer and Dendroscope software were used to visualise PCoA plots and
UPGMA clustering respectively (Chen et al., 2009). Enterotype clustering was
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carried out according to the approach previously described (Arumugam et al.,
2011).
6.5.7 Statistical methods
Statistical analysis was carried out using GraphPad Prism version 5.04 (La
Jolla, California, USA) R statistical package (version 2.13.1), and SPSS
software package version 18 (SPSS Inc., Chicago,
USA)(RDevelopmentCoreTeam, 2010). Kruskal–Wallis and Mann–Whitney
tests were used to find significant differences in microbial taxa, alpha
diversity, clinical and biochemical measures. Adjustment for multiple testing
was estimated using the FDR functions (phylum and family level) in the R
statistical package (version 2.13.1) using the Benjamini & Hochberg method
(Benjamini and Hochberg, 1995).
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Table 1 Subject Characteristics
Elite Athletes Low BMI Controls High BMI Controls
(n = 40) (n = 23) (n = 23)
Age (years) 28.8±3.8 28.1± 5.1 30.8±5.6
BMI (kg/m2) 29.1±3.0+ 22.7±1.8** 31.2±3.0¥
Body mass (Kg) 101.3±13.8 74.3±6.3 103.1±13.8
Body Fat % (Kg) 16.9±6.1++ 15±4.6* 33.9±8.8¥
Lean body mass (Kg) 80±8.9++ 55.4±5.6** 65±8¥
Waist/Hip Ratio 0.8±0.04++ 0.8±0.05 0.9±0.07¥
Data shown as mean ± SD, *P<0.01 or **P<0.0005 athletes versus low BMI
controls +P<0.01 or ++P<0.0005 athletes versus high BMI controls ¥P<0.0005
high BMI versus low BMI controls. Note only data for 39 athletes was
available for waist hip ratio while only data for 22 controls was assessed for
fat (Kg) and lean (Kg).
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Table 2 Macronutrient intake in study participants
Athletes Control BMI <25 Control BMI >28
(n=40) (n=23) (n=23)
Macronutrients Recommended daily intakes Median IQR Median IQR Median IQR
Energy (Kcal) 2400-2800(FSAI, 2011) 4449** 3610-5656 2937 2354-3917 2801 2358-3257
Protein (g) 248** 192-305 117 83-144 105 88-131
Protein (g/kg bw) 2.36** 0.99-4.42 1.55† 0.88-2.82 1.1 0.55-1.66
Fat (g) 131** 113-186 100 80-152 101 78-127
Saturated fat (g) 44** 35-55 37 28-45 33 30-49
Monounsaturated fat (g) 41* 32-57 35 25-48 32 25-42
Polyunsaturated fat (g) 18* 16-31 17 12-29 15 11-22
Carbohydrate (g) 572** 442-875 375 288-529 316 266-423
Sugars (g) ≤10% TE (FSAI, 2011) 330** 250-569 163 131-256 159 102-247
Fibre (g) ≥25g (FSAI, 2011) 39* 32-51 30 25-36 25 19-33
% Total energy from protein 10-35% TE (FNB, 2005) 22 17-27 16 11-20 15 13-19
% Total energy from total fat 20-35% TE (FSAI, 2011) 27 23-37 31 25-47 32 25-41
% Total energy from saturated fat ≤10% TE (FSAI, 2011) 9 7-11 11 9-14 11 10-16
% Total energy from carbohydrate 45-65% TE (FNB, 2005) 49 39-79 51 40-72 45 38-60
** P value ≤ 0.05 between athletes and both control groups. * P value ≤ 0.05 between athletes and >28 controls. † P value ≤ 0.05
between control groups.
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Figure 1. Creatine kinase levels elevated in athletes compared to
controls. Plasma creatine kinase levels are significantly elevated in athletes
(n=39) compared to low (n=23) and high (n=23) BMI controls. Results are
expressed as mean value ± SEM. Statistical significance was determined by
Mann-Whitney for each pair-wise comparison.
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Figure 2. Increased  diversity in athletes compared to controls.
Comparison of microbiota indices across the three cohorts. a, Phylogenetic
diversity; b, Shannon index; c, Simpson; d, Chao1 and e, Observed species.
Mann-Whitney tests were performed for each pair-wise comparison. * p<0.05
** p<0.009 *** p<0.009. Kruskal Wallis p values refer to tests performed
across all three groups.
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Figure 3. Unweighted UniFrac separates the athlete and control
microbiota. Unweighted UniFrac PCoA of faecal microbiota from 86 subjects.
Subject colour coding: black, elite athletes; green, high BMI controls; and red,
low BMI controls.
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Figure 4. Dietary patterns separate elite athletes from controls. Food
correspondence analysis, A, Food frequency data visualised by
correspondence analysis. By describing subjects’ responses according to
their dominant sources of variation (food types), correspondence analysis can
produce a single score for a subject from multiple measurements. Colour
codes green-high BMI controls, red-low BMI controls and black-elite athletes.
B, Driving food types. Using the same scoring system, food can be evaluated
and plotted on the same axis, providing a visual aid to get an overall view of
how food drives the clustering. Colour codes green-meat, red-fish, blue-bread
and cereal, brown-eggs, yellow-carbohydrates, cyan-dairy, maroon-spreads
and sauces, orange-fruit and vegetables, black-snacks, violet-non alcoholic
beverages and dark grey-alcohol.
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Figure 5. Protein intake positively correlates with  diversity. Subject
colour coding: black, elite athletes; green, high BMI controls; and red, low BMI
controls.
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Figure 6. Creatine kinase positively correlates with  diversity. Subject
colour coding: black, elite athletes; green, high BMI controls; and red, low BMI
controls.
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SUPPLEMENTARY INFORMATION
Supplementary Table S1 Metabolic, inflammatory and other markers
Athletes Control Controls
n=40 BMI >28 BMI <25
n=23* n=23*
Glucose (mmol/L) 4.94±0.1 4.95±0.1* 4.69±0.1*
CRP (mg/dL) 1.12±0.1 1.94±0.5 2.18±0.7
Adiponectin (ug/ml) 7.02±0.39 8.5±0.6 9.8±0.6#
Insulin (pg/ml) 227.88±24.6▲ 469.1±84.9 490.3±123.04#
Leptin (pg/ml) 1411.01±234.5▲ 10382.5±2117.9† 4237.1±1937.6
IFN-γ (pg/ml) 5.2±2.6 1.88±0.2 1.7±0.2
IL-10 (pg/ml) 8.78±3.8 2.67±0.3 63.5±53.4
IL-12p70 (pg/ml) 7.2±3.1 1.97±0.2 11.47±5.9
IL-1B (pg/ml) 0.5±0.05▲ 1.56±0.4 5.6±4.8
IL-6 (pg/ml) 0.79±0.19▲ 0.82±0.1 4.2±3.5
IL-8 (pg/ml) 10.45±5.8▲ 2.79±0.4 3.2±0.3#
TNF-α (pg/ml) 4.86±0.2▲ 6.68±0.4 32.7±27.6
Sodium (mmol/L) 139±0.2▲ 139.2±0.7 139.52±0.6
Potassium (mmol/L) 5.89±0.1▲ 4.2±0.1† 4.62±0.3#
Urea (mmol/L) 8.57±0.2▲ 5.2±0.2† 6.07±0.2#
Creatine (μmol/L) 97.42±2▲ 82.44±2 88.48±3.9#
CK (IU/L) 1038.17±112▲ 159.44±26.9† 389.52±105.7#
AST (IU/L) 45.65±2.4▲ 23.95±3.2 26.57±2.3#
YGT (IU/L) 27.90±3.2 32.0±5.2† 23.44±4.8#
Alkaline Phosphatase (IU/L) 68.15±2.2 64.7±2.7 64.22±4.2
Total Bilirubin (μmol/L) 15.97±0.8 14.44±1.2 16.74±2.57
Total Cholesterol (mmol/L) 4.91±0.2 7.11±2.3 4.5±0.2
HDL (mmol/L) 1.44±0.04▲ 1.2±0.4† 1.39±0.05
LDL (mmol/L) 3.07±0.1 2.94±0.1 2.73±0.2
Triglycerides (mmol/L) 0.86±0.05▲ 7.6±5.9† 0.84±0.1
Total Protein (g/L) 71.03±0.5▲ 73.95±0.9 73.74±0.8#
Albumin (g/L) 41.45±0.3▲ 43.8±0.6 44.44±0.4#
Globulin (g/L) 29.58±0.43 30.2±0.7 29.3±0.7
Calcium (mmol/L) 2.43±0.01 2.41±0.2 2.34±0.1
Data is expressed as mean value ± standard error of mean. All intergroup
comparisons were made using the Mann Whitney U test. *n=22, # P<0.05
between athletes and low BMI controls. ▲ P<0.05 between athletes and high
BMI controls. † P<0.05 between high BMI and low BMI controls.
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Supplementary Table S2 Control physical activity assessment
BMI<25 BMI >28
Walking
winter (hours per week) 6.26 4.30
summer (hours per week) 7.04 5.07
Cycling
winter (hours per week) 3.00 0.39
summer (hours per week) 3.61 0.98
Gardening
winter (hours per week) 0.28 0.21
summer (hours per week) 0.98 0.53
Physical exercise e.g. aerobics, dancing swimming etc
winter (hours per week) 1.16 0.61
summer (hours per week) 3.74 2.61
DIY (hours per week) 4.22 3.41
Housework (hours per week) 4.41 4.13
How many hours weekly of vigorous activity (sweating/ ↑ heart 
rate) 7.21 3.85
No. flights of stairs per day 7.17 9.09
Values shown are expressed as mean. t-test comparisons between low BMI
and high BMI controls was undertaken.
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Supplementary Figure S1. Cytokine levels vary between cohorts. Scatter
plot of A, Interlukin-1β; B, Interlukin-8; C, Interlukin-6; and D, TNF-α. (n=40
Athletes; n=23 low BMI control and n=23 high BMI control). Data expressed
as mean value ± SEM. Statistical significance was determined by Mann-
Whitney for each pair-wise comparison. Note one low BMI control was
removed from these graphs due to elevated cytokine values associated with
completion of a marathon prior to blood collection. Removal of this control
changes the p value between athletes and low BMI controls to p=0.0051 for
IL-8. Two new significant results also appear between athletes and low BMI
controls in IL-6 p=0.0373 and low BMI controls and high BMI controls in TNF-
α p=0.0121.
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Supplementary Figure S2. Differences in the blood biochemistry of
athletes and controls. Scatter plot of A, creatinine; B, sodium; C, potassium;
D, urea; E, AST; and F, YGT. Mann- (n=40 Athletes; n=23 low BMI control
and n=23 high BMI control). Data expressed as mean value ± SEM. Statistical
significance was determined by Mann-Whitney for each pair-wise comparison.
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Supplementary Figure S3. Study participants blood biochemistry. Scatter
plot of A, HDL; B, triglycerides; C, total protein; and D, albumin. (n=40
Athletes; n=23 low BMI control and n=23 high BMI control). Data expressed
as mean value ± SEM. Statistical significance was determined by Mann-
Whitney for each pair-wise comparison.
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Supplementary Figure S4. Significantly lower leptin and insulin levels
seen in elite athletes. Scatter plot of A, insulin; B, adiponectin and C, leptin
across the three cohorts. (n=40 Athletes; n=23 low BMI control and n=23 high
BMI control). Data expressed as mean value ± SEM. Statistical significance
was determined by Mann-Whitney for each pair-wise comparison.
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Supplementary Figure S5. Rarefaction curves for a, controls and b,
athletes at 97% similarity levels. Amount of operational taxonomic units
(OUT’s) found as a function of the number of sequence tags sampled.
281
Supplementary Figure S6. Unweighted pair group method with
arithmetric mean (UPGMA) tree of all subjects. Subject colour coding:
black, elite athletes; green, high BMI controls; and red, low BMI controls.
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Supplementary Figure S7. Relative change in the abundance of selected
taxa in athletes relative to high BMI controls. Only taxa with significant
differences in population numbers are illustrated.
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Supplementary Figure S8. Relative change in the abundance of selected
taxa in athletes relative to low BMI controls. Only taxa with significant
differences in population numbers are illustrated.
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Supplementary Figure S9. Relative change in the abundance of selected
taxa in low BMI controls relative to high BMI controls. Only taxa with
significant differences in population numbers are illustrated.
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Supplementary Figure S10. Top 5 food groups contributing to protein in
all subjects. A, athletes: b, low BMI controls and c, high BMI controls.
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Supplementary Figure S11. Leptin levels positively correlate with
percentage body fat, BMI, waist:hip ratio and negatively correlate with
lean body mass. Subject colour coding: black, elite athletes; green, high BMI
controls; and red, low BMI controls.
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Supplementary Figure S12. Adiponectin levels negatively correlate with
BMI and lean body mass. Subject colour coding: black, elite athletes; green,
high BMI controls; and red, low BMI controls.
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Supplementary Figure S13. Urea levels positively correlates with 
diversity. Subject colour coding: black, elite athletes; green, high BMI
controls; and red, low BMI controls.
289
APPENDIX I
Composition and energy harvesting capacity of the gut
microbiota: relationship to diet, obesity and time in mouse
models
Siobhan Clarke Chapter Contributions:
Experimental:
 Generated amplicons for 454 pyrosequencing.
Results interpretation:
 Analysed all data in relation to 16S compositional sequencing analysis.
GUT (2010) 59: (12) 1635-1642
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7.1 ABSTRACT
Background and Aims Increased efficiency of energy harvest, due to
alterations in the gut microbiota (increased Firmicutes and decreased
Bacteroidetes), has been implicated in obesity in mice and humans.
However, a causal relationship is unproven and contributory variables
include diet, genetics and age. Therefore, we explored the effect of a
high-fat (HF) diet and genetically determined obesity (ob/ob) for changes
in microbiota and energy harvesting capacity over time.
Methods Seven-week-old male ob/ob mice were fed a low-fat (LF) diet
and wild-type mice were fed either a LF-diet or a HF-diet for 8 weeks
(n=8/group). They were assessed at 7, 11 and 15 weeks of age for: fat
and lean body mass (by NMR); faecal and caecal short-chain fatty acids
(SCFA, by gas chromatography); faecal energy content (by bomb
calorimetry) and microbial composition (by metagenomic
pyrosequencing).
Results A progressive increase in Firmicutes was confirmed in both HF-
fed and ob/ob mice reaching statistical significance in the former, but this
phylum was unchanged over time in the lean controls. Reductions in
Bacteroidetes were also found in ob/ob mice. However, changes in the
microbiota were dissociated from markers of energy harvest. Thus,
although the faecal energy in the ob/ob mice was significantly decreased
at 7 weeks, and caecal SCFA increased, these did not persist and faecal
acetate diminished over time in both ob/ob and HF-fed mice, but not in
lean controls. Furthermore, the proportion of the major phyla did not
correlate with energy harvest markers.
Conclusion The relationship between the microbial composition and
energy harvesting capacity is more complex than previously considered.
While compositional changes in the faecal microbiota were confirmed,
this was primarily a feature of high fat feeding rather than genetically
induced obesity. In addition, changes in the proportions of the major
phyla were unrelated to markers of energy harvest which changed over
time. The possibility of microbial adaptation to diet and time should be
considered in future studies.
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7.2 SIGNIFICANCE OF THE STUDY
What is already known about this subject?
 Increased efficiency of energy harvest, due to alterations in the gut
microbiota (increased Firmicutes and decreased Bacteroidetes)
has been implicated in obesity in mice and humans.
 Studies in humans have provided variable finding with respect to
changes in the gut microbiota in obese individuals and placed less
emphasis on changes in the proportions of Firmicutes and
Bacteroidetes in obesity
 Recent studies in mice suggest that diet plays an important role in
modulating the gut microbiota.
 Further mouse studies have highlighted the role of the gut
microbiota in the regulation of energy homeostasis, in the
pathogenesis of insulin resistance, in fatty liver, in lipid and amino
acid metabolism and as a modulator of host fatty acid composition.
What are the new findings?
 While compositional changes in the faecal microbiota were
confirmed, this was primarily a feature of high-fat feeding rather
than genetically-induced obesity.
 The relationship between the microbial composition and energy
harvesting capacity is more complex than previously considered.
 The changes in proportions of Firmicutes and Bacteroidetes were
unrelated to markers of energy harvest which changed over time.
 The mouse gut microbiota was dominated not only by Firmicutes
and Bacteroidetes, but also by a third major phylum, the
Actinobacteria.
How might it impact on clinical practice in the foreseeable future?
 Our findings suggest that microbial adaptation to diet over time,
and perhaps with age, is an important variable in the complex
relationship between the composition of the microbiota, energy
harvesting capacity and obesity and should be taken into account
in the design and interpretation of future clinical studies.
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7.3 INTRODUCTION
Obesity, one of the great pandemics of our time, is a major threat to
public health and to healthcare resources. This complex syndrome is
influenced by host susceptibility and by environmental or lifestyle factors,
such as diet and sedentary behaviour. At one level, obesity is frequently
thought as the outcome of a relative imbalance in energy intake versus
energy expenditure. Recently, enhanced energy harvest from dietary
intake, due to an alteration in microbial composition, has been highlighted
as a potential contributor to the pathogenesis of obesity (Ley et al., 2005,
Ley et al., 2006, Turnbaugh et al., 2008, Turnbaugh et al., 2006, Ley,
2010).
Sequencing of the gut microbiota of the caecum of genetically
obese ob/ob mice revealed a 50% lower relative abundance of
Bacteroidetes, whereas the Firmicutes were correspondingly higher (Ley
et al., 2005). Similarly, the provision of a high-calorie, high-fat/simple
carbohydrate, obesity-inducing ‘Western’ diet to wild-type mice brought
about an overall decrease in the diversity of the gut microbiota, a
decrease in Bacteroidetes and a bloom of a single class of Firmicutes -
the Mollicutes (Turnbaugh et al., 2008). On the basis of these
investigations it was suggested that the obese microbiome possesses
metabolic pathways that are highly efficient at extracting energy from food
(Turnbaugh et al., 2008, Turnbaugh et al., 2006). This has been
supported by the observation that transplantation of the microbiota of
chow-fed ob/ob or ‘Western’ diet-fed wild-type mice into germ-free wild-
type mouse recipients resulted in mice receiving an ‘obese’ microbiota
gaining more fat than recipients of a ‘lean’ microbiota (Turnbaugh et al.,
2006, Turnbaugh et al., 2008). Furthermore, Ley et al., 2006 showed a
decrease in the Firmicutes/Bacteroidetes ratio in obese human subjects
in response to weight loss following dietary intervention. In a larger follow
up study in obese and lean twins, Turnbaugh and colleagues reported
that while the faecal microbiome of obese subjects had significantly lower
proportions of Bacteroidetes and higher levels of Actinobacteria
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compared to lean individuals, there was no change in the proportion of
Firmicutes (Turnbaugh et al., 2009).
Further mouse studies have highlighted the role of the gut
microbiota in the regulation of energy homeostasis (Backhed et al., 2004,
Backhed et al., 2007), in the pathogenesis of insulin resistance (Cani et
al., 2007a, Cani et al., 2008a, Cani et al., 2008b, Cani et al., 2007b,
Membrez et al., 2008), in fatty liver (Dumas et al., 2006), in lipid and
amino acid metabolism (Martin et al., 2007) and as a modulator of host
fatty acid composition (Wall et al., 2009). These studies suggest that
interventions which target the metabolic activity of the gut microbiota may
have efficacy in obesity and associated disorders. However, a variety of
intrinsic and environmental factors, such as age, diet and host physiology
and genotype are considered to significantly affect the structure and
functionality capabilities of gut microbial communities (Hopkins et al.,
2001, Kurokawa et al., 2007, McGarr et al., 2005, Stewart et al., 2005).
Indeed, it has been suggested that the Firmicutes/Bacteroidetes ratio of
the human microbiota changes with age (Mariat et al., 2009).
A recent study in mice has shown that a high-fat diet determines
the composition of the gut microbiota independent of obesity (Hildebrandt
et al., 2009). Furthermore, switching from a low-fat to a high-fat diet
resulted in a rapid and dramatic shift in the structure of the gut microbiota
in mice in a single day (Turnbaugh and Gordon, 2009). These studies
suggest that diet plays an important role in modulating the gut microbiota.
In addition, a number of follow-up studies in humans have provided
variable findings with respect to changes in the gut microbiota in obese
individuals and placed less emphasis on changes in the proportions of
Firmicutes and Bacteroidetes in obesity (Ley, 2010, Turnbaugh et al.,
2009, Schwiertz et al., 2009, Duncan et al., 2008, Santacruz et al., 2009,
Zhang et al., 2009, Collado et al., 2008). Moreover, few reports have
examined the composition of the gut microbiota over time. Therefore, we
examined the energy harvesting capacity and composition of the gut
microbiota over time in murine models in response to high fat (HF)
feeding and genetically determined obesity. The results confirm the
compositional changes in the faecal microbiota, particularly in response
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to diet rather than genetically determined obesity, but these are unrelated
to markers of energy harvest, which change over time.
7.4 MATERIALS AND METHODS
7.4.1 Animals and diets
ob/ob (leptin deficient) and wild-type C57BL/6J mice were obtained from
Charles River (L’arbresle, France) and housed under barrier-maintained
conditions within the biological services unit, University College Cork
(UCC). Mice were received at 5 weeks of age and allowed to acclimatise
for 2 weeks on a low-fat diet (10% calories from fat; Research Diets, New
Brunswick, New Jersey, USA; #D12450B) to ‘normalise’ the gut
microbiota. Seven-week-old male ob/ob mice, wild-type controls fed a
low-fat diet and wild-type mice fed a HF-diet (45% calories from fat;
Research Diets; #D12451) were housed individually for 8 weeks (n=8 per
group). Body weight was assessed weekly. Precautions were taken to
ensure that food intake and faecal collections were performed as
accurately as possible. Food intake was measured weekly taking account
of residual spillage. Faecal output per mouse was measured over 48 h at
age 7, 11 and 15 weeks and weights recorded. Fat and lean body mass
were measured at age 15 weeks using a Minispec mq benchtop NMR
spectrometer (Bruker Instruments, Rheinstetten, Germany).
7.4.2 Experimental design
To examine the relationship between the composition of the gut
microbiota and the efficiency of energy harvest, the effects of diet and
obesity on the composition and the energy harvesting capacity of the gut
microbiota were determined over time (age 7, 11 and 15 weeks). The
levels of short-chain fatty acids (SCFA), the major fermentation end-
products and source of energy for the host, and the energy content of the
faeces were used as markers of energy harvesting.
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7.4.3 Analysis of the composition of the gut microbiota in response
to diet and obesity over time
For these studies, fresh faecal pellets (n=8 per group) were collected at 7,
11 and 15 weeks of age from lean, HF-fed and ob/ob mice. As a
consequence of the number of samples that required processing, the
samples were stored at -80oC prior to DNA extraction. As it has been
suggested that freezing may adversely affect the levels of Bacteroidetes
in stored human faecal samples (Duncan et al., 2008), an initial study
was undertaken to determine the impact of freezing on the microbial
populations of mouse faeces. Faecal pellets were collected from
C57BL/J6 mice on the same day (n=20) and divided into two groups.
Faecal samples in the first group were stored on ice and DNA was
extracted from these fresh samples on the day of collection (n=10) while
in the second group, faecal samples were stored at -80oC and DNA was
extracted (n=10) after 1 month of freezing.
7.4.4 DNA extractions and pyrosequencing
Total metagenomic DNA was extracted from individual faecal samples
using the QIAamp DNA Stool Mini Kit (Qiagen, Crawley, West Sussex,
UK) coupled with an initial bead-beating step. The microbial composition
of these samples was determined by pyrosequencing of 16S rRNA tags
(V4 region; 239 nt long) amplified using universal 16S primers predicted
to bind to 94.6% of all 16S genes; that is, the forward primer F1 (59-
AYTGGGYDTAAAGNG) and a combination of four reverse primers R1
(59-TACCRGGGTHTCTAATCC), R2 (59-TACCAGAGTATCTAATTC),
R3 (59-CTACDSRGGTMTCTAATC) and R4 (59-
TACNVGGGTATCTAATC) (RDP’s Pyrosequencing Pipeline:
http://pyro.cme.msu.edu/pyro/help.jsp). The primers incorporated the
proprietary 19-mer sequences at the 59-end to allow emulsion-based
clonal amplification for the 454 pyrosequencing system. Unique molecular
identifier (MID) tags were incorporated between the adaptamer and the
target-specific primer sequence, to allow identification of individual
sequences from pooled amplicons. Amplicons were cleaned using the
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AMPure purification system (Beckman Coulter, Takeley, United Kingdom)
and sequenced on a 454 Genome Sequencer FLX platform (Roche
Diagnostics Ltd, Burgess Hill, West Sussex, UK) according to 454
protocols. De-noising was performed using traditional techniques
implemented in the RDP pyrosequencing pipeline. Reads with low quality
scores (quality scores below 40) and short length (less than 150 bp for
the 16S rRNA V4 region) were removed as well as reads that did not
have exact matches with the primer sequence. Clustering and statistical
analysis of sequence data were performed using the MOTHUR software
package (Schloss and Handelsman, 2008). Trimmed fasta sequences
were then BLASTed (Altschul et al., 1997) against a previously published
16S-specific database (Urich et al., 2008) using default parameters. The
resulting BLAST output was parsed using MEGAN (Huson et al., 2007).
MEGAN assigns reads to NCBI taxonomies by employing the lowest
common ancestor algorithm which assigns each RNA-tag to the lowest
common ancestor in the taxonomy from a subset of the best scoring
matches in the BLAST result. Bit scores were used from within MEGAN
for filtering the results prior to tree construction and summarisation
(absolute cut-off: BLAST bitscore 86, relative cut-off: 10% of the top hit)
(Urich et al., 2008).
7.4.5 Bomb calorimetry
Faecal samples were collected over 48 h from individual mice at 7, 11
and 15 weeks of age and used for bomb calorimetry and SCFA analysis.
For bomb calorimetry analysis, the samples were weighed and oven-
dried at 60oC for 48 h. The energy content of the faeces was assessed
with a Parr 6100 calorimeter using an 1109 semi-micro bomb (Parr
Instruments & Co., Moline, Illinois, USA). The calorimeter energy
equivalent factor was determined using benzoic acid standards and each
sample (100 mg) was analysed in triplicate.
7.4.6 SCFA analysis
SCFA analysis was performed according to previously published methods
(Bakker-Zierikzee et al., 2005, Costabile et al., 2008, Pereira et al., 2003).
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Mice were killed at 7, 11 and 15 weeks of age and the contents of the
caecum from individual mice were collected for SCFA analysis. To have
sufficient quantity for gas chromatography, the caecum contents were
pooled with an n=3-4 per pool. SCFA were extracted from the caecal and
faecal contents using 2.0 ml Milli-Q water per 0.1 g fresh weight. The
solution was centrifuged for 5 min at 10 000 g to pellet bacteria and other
solids. The supernatant was collected and added to 3.0 mM 2-ethylbutyric
acid in formic acid, used as the internal standard. Calibration was done
using standard solutions containing 10.0 mM, 8.0 mM, 6.0 mM, 4.0 mM,
2.0 mM, 1.0 mM and 0.5 mM of acetic acid, propionic acid and butyric
acid. The concentration of SCFA was determined by gas chromatography
using a Varian 3500 GC system, fitted with a TRB-FFAP column (30 m x
0.32 mm x 0.50 mm; Teknokroma, Barcelona, Spain) and a flame
ionisation detector. Helium was supplied as the carrier gas at an initial
flow rate of 1.3 ml/min. The initial oven temperature was 100oC,
maintained for 0.5 min, raised to 180oC at 8oC/min and held for 1.0 min,
then increased to 200oC at 20oC/min, and finally held at 200oC for 5.0
min. The temperatures of the detector and the injection port were set at
250oC and 240oC, respectively. The injected sample volume was 0.5 mL.
Peaks were integrated using Varian Star Chromatography Workstation
version 6.0 software. Additional phials containing standards were
included in each run to maintain calibration and a cleaning injection of
1.2% formic acid was used before each analysis.
7.4.7 Statistical analysis
Data for all variables were normally distributed and allowed for parametric
tests of significance. Data are presented as mean values with their
standard errors (SEM). Statistical analysis was performed by ANOVA and
the Student t test (Graph-Pad Software, San Diego, CA, USA).
Correlations analysis was performed using Pearson’s (r) correlation test.
p<0.05 was considered as statistically significant.
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7.5 RESULTS
7.5.1 ob/ob and HF-fed mice gain more weight than lean mice and
vary in body composition
ob/ob mice gained significantly more body weight compared to lean
controls (p<0.001) while a modest although statistically significant
increase in body weight was observed for mice fed a high-fat diet
compared to lean mice (p<0.05) over 8 weeks (Fig 1A,B). The increase in
body weight was associated with an increase in fat mass and a decrease
in lean mass in ob/ob mice compared to lean mice, while the increase in
body weight in HF-fed mice was attributable to an increase in fat mass
alone (Fig 1C). In agreement with previous studies, ob/ob mice
consumed significantly more calories than lean controls, as measured by
the cumulative caloric intake over the 8 week period of the study (Fig 1D).
There were no differences in cumulative caloric intake between lean and
HF-fed mice.
7.5.2 Freezing of murine faecal samples for 1 month does not
significantly alter compositional analysis
It has been suggested that freezing may reduce the levels of
Bacteroidetes in stored human faecal samples (Duncan et al., 2008).
High throughput sequencing and phylogenetic assignment of the resultant
amplicons revealed that, at both the phylum and genus levels, there was
no significant alteration in the composition of the gut microbiota between
fresh and frozen samples (Supplementary Fig 1). Therefore, for
processing large numbers of samples, frozen storage was deemed
acceptable prior to DNA isolation for the purposes of the present study.
7.5.3 The mouse gut microbiota is dominated by Firmicutes,
Bacteroidetes and Actinobacteria
A total of 249,409 V4 16S sequence reads were generated,
corresponding to an average of 31,176 reads per group or 3,897 per
mouse. Species richness, coverage and diversity estimations were
calculated for each data set (Supplementary Table 1 and Supplementary
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Fig 2). Rarefaction curves for each group indicated that the total bacterial
diversity present was well represented. Of the reads, 208,202 (83%) were
assigned at the phylum level, 148,363 (59.5%) at the family level and
130,950 (52.5%) at the genus level. Taxonomy-based analysis of the
assigned sequences showed that, at the phylum level, the mouse gut
microbiota was dominated by Firmicutes, Bacteroidetes and
Actinobacteria (Fig 2 and Table 1). The high proportion of Actinobacteria
detected may reflect differences in the DNA extraction protocol employed
or advances in primer design (primers employed match perfectly to
94.6% of sequences within RDP release 9.53
[http://pyro.cme.msu.edu/pyro/help.jsp]). Proteobacteria, Tenericutes,
Spirochaetes and Deferribacteria were detected but at considerably lower
levels. Consistent with the high levels of Firmicutes and Actinobacteria
detected, the most dominant bacteria at the genus level were Clostridium
and Bifidobacterium (Table 1).
7.5.4 The composition of the murine gut microbiota changes over
time in response to diet and obesity
In lean mice, from age 7 through 11 to 15 weeks, there were no
significant changes in the proportions of bacteria at the level of phylum
(Fig 2A and Table 1) or genus (Table 1). In contrast, there was a
progressive increase in the proportions of Firmicutes in both HF-fed and
ob/ob mice, reaching statistical significance in the former (p<0.05).
Reductions in Bacteroidetes over time were evident in all three groups of
mice but reached statistical significance only in the ob/ob mice (p<0.001).
The levels of Actinobacteria, and of the associated genus
Bifidobacterium, fluctuated in all three groups with significant increases
observed in ob/ob and HF-fed mice from age 7 to 11 weeks (p<0.05) but
not between 7-15 or 11-15 weeks of age.
While the proportions of other phyla and genera were very low,
changes were detectable. Proteobacteria were found to decrease in
abundance over time in HF-fed mice (p<0.001); Deferribacteria and
lactococci increased and decreased, respectively, from age 7 to 11
(p<0.001) and from 7 to 15 (p<0.001) weeks in ob/ob mice (Table 1).
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7.5.5 Energy harvesting changes in response to diet and obesity
over time and does not correlate with the proportions of Firmicutes,
Bacteroidetes and Actinobacteria
To examine the relationship between the composition of the gut
microbiota and the efficiency of energy harvest, the levels of SCFA, the
major fermentation end-products and source of energy for the host, and
the energy content of the faeces were used as markers of energy
harvesting. Faecal SCFA and energy content were then correlated with
the levels of Firmicutes, Bacteroidetes and Actinobacteria in lean, ob/ob
and HF-fed mice.
As reported by others (Turnbaugh et al., 2006), the energy content
of faeces from ob/ob mice, as assessed by bomb calorimetry, was
modestly but significantly lower at 7 weeks than that of lean controls
(Table 2 and Fig 3A). However, this relationship did not persist at ages 11
and 15 weeks. In contrast, in mice on a high-fat diet, the faecal energy
content increased from age 7 to 11 weeks without any further increase at
15 weeks (Table 2 and Fig 3A). Faecal output was similar in lean and HF-
fed mice over time and there was no significant changes in faecal output
between lean and HF-fed mice at age 7 (0.31 vs 0.32 g/day), 11
(0.30±0.01 vs 0.34±0.01 g/day) and 15 (0.29±0.01 vs 0.32±0.01 g/day)
weeks. ob/ob mice produced significantly more faeces (0.47±0.02 vs
0.31±0.01 g/day; p<0.001) at age 7 weeks compared to lean controls.
However, faecal production decreased over time in ob/ob mice from age
7 to 11 (0.47±0.02 to 0.34±0.02 g/ day; p<0.001) and from 7 to 15
(0.47±0.02 to 0.30±0.01; p<0.001) weeks of age. Calculation of energy
assimilation (data not shown) suggests that the energy excreted is a
function of food intake and the contribution of the gut microbiota to energy
extraction is very small as suggested by Bajzer and Seeley, 2006.
Faecal and caecal SCFA analysis showed that while acetate,
propionate and butyrate were detected in the caecum, only acetate was
detected in the faeces of the lean, HF-fed and ob/ob groups (Table 2 and
Fig 3B). Faecal acetate concentration was higher in ob/ob compared to
lean mice at age 7 and 11 weeks. However, faecal acetate levels
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decreased progressively over time in both the ob/ob and HF-fed mice.
Analysis of caecal SCFA showed that, at 7 weeks, caecal acetate and
propionate levels were significantly higher in ob/ob mice compared to
lean controls (Table 2). However, this observation did not persist with
time and no further pattern in caecal SCFA levels was observed in lean,
HF-fed and ob/ob groups.
Correlation analysis revealed that the proportions of Firmicutes,
Bacteroidetes and Actinobacteria did not correlate with energy harvesting
markers (Table 3). Furthermore, while a positive correlation between
faecal energy content and acetate levels in lean mice was observed
(r=0.50; p<0.01), there was no relationship between these parameters in
ob/ob and HF-fed mice suggesting a more complex relationship between
faecal energy and faecal SCFA levels in obesity (Fig 3C).
7.6 DISCUSSION
The results confirmed the compositional changes in the microbiota
previously linked with obesity, particularly in response to a high-fat diet,
but these were unrelated to energy harvesting capacity, which changed
over time. Furthermore, markers of energy harvesting were not correlated
with the proportions of the major phyla. The study also showed that the
mouse gut microbiota was dominated not only by Firmicutes and
Bacteroidetes, but also by a third major phylum, the Actinobacteria.
This is the first report to detect high levels of the phylum
Actinobacteria and the associated genus Bifidobacterium in the mouse
gut microbiota using a pyrosequencing approach. There appears to be
discordance in detection rates and levels of Bifidobacterium between
pyrosequencing (Ley et al., 2005, Ley, 2010, Hildebrandt et al., 2009,
Eckburg et al., 2005, Palmer et al., 2007, Suau et al., 1999, Wang et al.,
2003) and other techniques such as fluorescence in-situ hybridisation
(FISH) and traditional culture-based methods (Rajilić-Stojanović et al.,
2007, Vrieze et al., 2010, Zoetendal et al., 2006). The low percentage of
Actinobacteria in some studies has been attributed to difficulties
associated with extracting the associated DNA, a difference in the GC
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content of the template or the accuracy of PCR primers (Turroni et al.,
2008). In this study, the particular DNA extraction protocol employed
and/or the use of primers predicted to bind to 94.6% of all 16S genes,
may account for the greater proportion of Actinobacteria reads.
Another potential pitfall in studies of this type is the impact of
freeze storage prior to DNA extraction (Duncan et al., 2008). In our
hands, a preliminary assessment revealed that storage of frozen samples
over 1 month had no major influence on the DNA-based compositional
analysis. It is noteworthy that a recent large metagenomics study in
Europe (MetaHIT) also used frozen stool samples (Qin et al., 2010).
The evidence supporting the concept that the gut microbiota in
obesity facilitates the extraction of additional calories from ingested food
has been reviewed elsewhere (DiBaise et al., 2008, Tilg et al., 2009, Tilg,
2010). Although we were able to confirm that the energy content of
faeces from ob/ob mice was reduced and that caecal SCFA were
increased at 7 weeks (consistent with increased harvest), as reported by
others (Turnbaugh et al., 2006), this did not persist with time and was not
found in HF-fed mice. It is noteworthy that faecal acetate levels
decreased in both ob/ob and HF-fed mice over time but not in lean
controls. The decrease in faecal acetate may be due to the observed
alterations in the gut microbiota or an increase in its uptake/absorption in
response to diet and obesity. Interestingly, it has been reported that,
while obese individuals have higher faecal SCFA levels, these changes
were not associated with a higher proportion of Firmicutes leading the
authors to speculate that the amount of SCFA produced and not the ratio
of Firmicutes and Bacteroidetes is important in obesity (Schwiertz et al.,
2009). It is unlikely that the Firmicutes/Bacteroidetes ratio is solely
responsible for obesogenic shifts in the microbiota as indicated by
Turnbaugh and colleagues (Turnbaugh et al., 2009) suggesting that
altered proportions of other phyla including the Actinobacteria should also
be further investigated. Indeed, the critical biomarker of obesity is
uncertain (Firmicutes, Bacteroidetes, Firmicutes/Bacteroidetes ratio
thereof and other phyla) and remains to be determined.
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The primacy of diet in determining the composition of the gut
microbiota independent of obesity has been elegantly demonstrated by
Hildebrandt et al., 2009. Moreover, Turnbaugh and Gordon, 2009
demonstrated that the structure of the microbiota changes in a rapid and
dramatic manner after switching from a low-fat polysaccharide-rich diet to
a high-fat, high-sugar ‘Western’ diet. In our study, while time-dependent
decreases in Bacteroidetes in ob/ob mice were observed, the levels of
Firmicutes significantly increased in HF-fed but not ob/ob mice over time.
This observation suggests that a high-fat diet and not the obese genotype
of ob/ob mice exerts the greater influence on the composition of the gut
microbiota, in agreement with the results by Hildebrandt et al., 2009.
Furthermore, Duncan et al., 2008 demonstrated a significant diet-
dependent reduction in Firmicutes levels in faecal samples from obese
individuals on a low-carbohydrate diet. Taken together, these
observations suggest that diet plays an important role in modulating the
gut microbiota and suggests that dietary variations must be taken into
account in human studies.
In the present study, there was no significant change in the
composition and energy harvesting of the gut microbiota of lean mice
over the duration of the study suggesting that most of the changes
observed in the HF-fed mice were probably attributable to change in diet.
However, some temporal variations in the microbiota were apparent in
the ob/ob mice over this period including a decrease over time in
Bacteroidetes and Deferribacteria, at the phylum level, and Lactococcus
at the genus level. While there has been an increasing appreciation of the
impact of age on the gut microbial composition for example the
Firmicutes/Bacteroidetes ratio of the human gut microbiota changes with
age, changing from 0.4 to 10.9 to 0.6 as one moves from infants to adults
and onto elderly individuals, respectively (Mariat et al., 2009), we did not
address age-associated alterations. However, our findings suggest that a
comprehensive assessment of the role of gut microbiota in obesity should
take account of temporal variation and adaptation.
Although Proteobacteria decreased in response to a high-fat diet,
these bacteria were only present in low proportions in the murine gut
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microbiota. Interestingly, increases in the associated classes (Gamma-
Proteobacteria) and family (Enterobacteriaceae) have been associated
with weight loss in adolescents (Santacruz et al., 2009) and gastric
bypass in obese individuals (Zhang et al., 2009), respectively.
Our data demonstrate that changes in the microbiota were
dissociated from markers of energy harvest, suggesting that mechanisms
other than energy harvesting may contribute to microbiota-induced
alterations in obesity and metabolic diseases. In this regard, other work
has suggested that the gut microbiota and its products (eg, LPS and
SCFA) regulate host gene expression and, thereby, affect host energy
expenditure and storage acting through mechanisms involving fasting-
adipose adipose factor (FIAF) (Backhed et al., 2004), adenosine
monophoshate (AMP)-activated protein kinase (AMPK) (Backhed et al.,
2007), G-protein-coupled receptor (GPR)41 (Samuel et al., 2008) and
CD14/Toll-like-receptor (TLR)4 (Cani et al., 2007a). Indeed, germ-free
mice are protected from the development of diet-induced obesity
(Backhed et al., 2007). Moreover, a recent study in the TLR5-deficient
mice suggests that malfunction of the innate immune system may
promote the development of metabolic syndrome through a mechanism
involving the gut microbiota (Vijay-Kumar et al., 2010).
In conclusion, while compositional changes in the faecal
microbiota were confirmed, this was primarily a feature of high fat feeding
rather than genetically determined obesity. In addition, changes in the
proportions of the major phyla of the gut microbiota were unrelated to
markers of energy harvest which changed over time. These findings
suggest that microbial adaptation to diet over time, and perhaps with age,
is an important variable in the complex relationship between the
composition of the microbiota, energy harvesting capacity and obesity
and should be considered in future studies.
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Table 1 Obesity and diet alter the composition of the gut microbiota in high-fat (HF)-fed and ob/ob mice over time.
Lean HF-fed ob/ob
Weeks of age 7 11 15 11 15 7 11 15
Phylum*:
Firmicutes 56.2±3.5 45.4±2.4 56.6±5.3 65.2±3.4 † 70.5±4.3 ¶ 56.2±2.0 57.6±2.4 † 63.5±4.0
Bacteroidetes 24.4±4.7 19.0±5.6 16.9±3.9 19.3±3.3 15.2±3.4 25.1±3.7 11.2±1.3 ‡ 12.2±1.4 ¶
Actinobacteria 15.5±5.1 32.8±6.6 24.5±8.0 14.6±2.5 13.1±3.7 15.9±3.2 29.7±3.0 ‡ 22.9±4.3
Proteobacteria 3.0±0.4 2.2±0.8 1.3±0.2 0.6±0.4 †‡ 0.2±0.2 †¶ 0.8±0.2 0.6±0.1 † 0.6±0.2 †
Deferribacteria 1.0±0.3 0.7±0.3 0.6±0.2 0.3±0.1 1.0±0.6 1.6±0.3 0.4±0.1 ‡ 0.3±0.1 ¶
Genus:
Bacteroides 2.7±0.5 2.3±0.6 1.4±0.3 2.9±0.5 1.7±0.6 2.7±0.6 1.7±0.3 1.9±0.3
Clostridium 23.2±5.1 25.1±2.9 27.7±4.5 35.2±5.1 29.5±6.7 19.6±3.2 31.8±2.6 32.7±5.7
Lactococcus 2.5±0.5 2.1±0.4 3.4±1.0 2.8±0.6 4.6±0.9 3.5±0.5 1.6±0.2 ‡ 1.5±0.2 ¶
Lactobacillus 6.0±2.0 1.6±0.6 3.2±2.0 1.8±0.5 1.9±0.4 7.1±2.1 3.7±1.3 3.0±1.1
Bifidobacterium 14.2±5.3 32.5±6.5 24.1±8.0 12.0±2.9 † 12.8±3.8 15.4±3.2 29.5±3.0 ‡ 22.8±4.9
*Values are mean percentage read number ±SEM, n=8. † Indicated significant differences (p<0.05, two-tailed Student t test) in bacterial populations relative
to the corresponding lean control time-point (age 7 weeks in lean controls are used as baseline before introduction of high-fat feeding). ‡, ¶ indicates
significant differences (p<0.05, one-way ANOVA using the Tukey post-hoc t-test) in the composition of the gut microbiota between ages 7, 11 and 15 weeks
within lean and ob/ob groups separately and in response to high-fat feeding (‡ between 7 and 11 weeks, § between ages 11 and 15 weeks and ¶ between
ages 7 and 15 weeks).
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Table 2 Energy harvesting capacity of the gut microbiota is altered in lean, high-fat (HF)-fed and ob/ob mice over time.
Lean HF-fed ob/ob
Weeks of age 7 11 15 7 11 15 7 11 15
Faecal *:
Energy (kJ/g) 13.5±0.4 13.6±0.3 13.5±0.3 13.6±0.3 14.6±0.8 †‡ 14.3±0.6 § 13.1±0.4 † 13.5±0.4 13.5±0.2
Acetate (μmol/g) 13.9±9.6 15.0±6.3 10.6±6.3 11.8±3.1 9.7±4.4 † 4.1±2.7 §¶ 36.9±20.6 † 29.9±10.4 † 14.4±3.8 §¶
Caecal (μmol/g):
Acetate 51.6±2.2 67.1±17.8 37.3±2.0 § 49.8±6.8 54.5±11.6 37.8±1.9 68.1±5.4 † 48.8±5.35 40.8±13.0 ¶
Propionate 5.7±1.2 8.7±3.4 ND § ¶ 6.6±1.6 1.9±3.3 †‡ ND ¶ 9.2±1.6 † 6.7±1.6 1.0±2.0 ¶
Butyrate 1.9±1.7 4.25±1.5 2.1±1.9 1.7±1.3 1.6±1.8 2.6±2.6 3.7±3.1 3.9±3.2 1.2±1.9
*Values are mean ±SEM, n=8. For caecal analysis, samples were pooled; n=3-4 per group. Propionate and butyrate were not detected (ND) in faeces. †
Indicated significant differences (p<0.05, two-tailed Student t test) in energy harvesting markers relative to the corresponding lean control time-point. ‡, §, ¶
indicates significant differences (p<0.05, one-way ANOVA using the Tukey post-hoc t-test) in energy harvesting markers between ages 7, 11 and 15 weeks
within lean and ob/ob groups separately and in response to high-fat feeding (‡ between 7 and 11 weeks, § between ages 11 and 15 weeks and ¶ between
ages 7 and 15 weeks).
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Table 3 The proportion of Firmicutes, Bacteroidetes and Actinobacteria do not correlate with energy harvesting markers.
Lean High-fat-fed ob/ob
Comparisons*: r p-value r p-value r p-value
Firmicutes versus faecal energy -0.33 0.11 -0.38 0.14 -0.16 0.46
Firmicutes versus faecal acetate -0.56 0.005 -0.16 0.55 -0.01 0.98
Bacteroidetes versus faecal energy -0.26 0.22 0.06 0.82 0.23 0.27
Bacteroidetes versus faecal acetate -0.25 0.24 -0.29 0.28 -0.35 0.09
Actinobacteria versus faecal energy 0.33 0.12 0.28 0.29 0.17 0.43
Actinobacteria versus faecal acetate 0.61 0.002 0.33 0.21 0.09 0.66
*Values refer to Pearson’s r correlation and corresponding p-value.
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Figure 1 Phenotype of mouse models of obesity. Body weight (A) and
appearance (B) over the 8 week study period. Body composition (g) for
lean controls, high-fat (HF) fed and ob/ob mice at age 15 weeks (C) and
cumulative energy intake per mouse (kj/mouse) (D). Data presented as
mean ±SEM, (n= 8 per group). ***p<0.001.
313
Figure 2 The gut microbiota composition is altered in ob/ob mice (C) at
age 7, 11 and 15 weeks and in response to high-fat (HF) feeding (4 and 8
weeks) (B) but not lean mice (A) as determined by pyrosequencing of
16S rRNA tags (V4 region). Data outside the pie charts represent the
mean percentage read number for the corresponding colour coded
phylum (n=8 per group). Note: Microbial composition of faeces at age 7
weeks in lean mice is used as the baseline prior to introduction of HF-
feeding. Thus, the pie charts for the gut microbiota composition of lean
and HF-fed mice at age 7 weeks are the same only at this time-point.
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Figure 3 Markers of energy harvest are altered in mouse models of
obesity. Faecal energy (A) and acetate (B) levels in lean and ob/ob mice
at age 7, 11 and 15 weeks and in response to high-fat (HF) feeding (0, 4
and 8 weeks). Correlation of faecal energy content and faecal acetate
levels in lean, HF-fed and ob/ob mice (C). Values refer to Pearson’s r
correlation and corresponding p value.
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SUPPLEMENTARY INFORMATION
Supplementary Table 1. Diversity estimates for lean, DIO and ob/ob mice at age 7, 11 and 15 weeks.
Lean DIO ob/ob
Weeks of age 7 11 15 11 15 7 11 15
Similarity (%) 97 98 97 98 97 98 97 98 97 98 97 98 97 98 97 98
Chao1 richness
estimation 13987 19323 10376 13899 26874 40796 9678 13870 25655 39014 11622 15784 24958 37679 12089 17108
Shannon’s index for
Diversity 7.0 7.6 6.7 7.2 7.4 8.0 6.7 7.3 7.3 7.9 7.2 7.8 7.4 7.9 6.9 7.4
Good’s coverage
(%) 83.6 77.6 83.3 77.7 89.4 84.9 84.9 79.1 89.5 84.9 86.7 81.9 88.4 83.6 85.3 79.6
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Supplementary Figure 1. Freezing (1 month at -80 oC) does not
significantly alter the composition of the gut microbiota at the phylum
level in murine fecal samples as determined by pyrosequencing of
16S rRNA tags (V4 region). Data outside the pie charts represent the
mean percentage read number ±SEM of corresponding color-coded
phylum.
Fresh Frozen
Bacteriodetes 13.8 ± 3.2 17.0 ± 2.4
Firmicutes 55.5 ± 7.0 60.3 ± 4.9
Proteobacteria 2.2 ± 0.6 2.9 ± 0.9
Actinobacteria 27.3 ± 9.0 19.0 ± 6.5
Deferribacteres 0.5 ± 0.3
Tenericutes 0.7 ± 0.4
(% ± SEM)
0.4 ± 0.2
0.4 ± 0.3
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Supplementary Figure 2. Rarefaction curves for each group at 97%
similarity levels indicated that the total bacterial diversity present was well
represented. Number of operational taxonomic units (OTUs) identified as
a function of the number of sequence tags sampled.
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8.1 ABSTRACT
Obesity is associated with a number of serious health consequences,
including type 2 diabetes, cardiovascular disease and a variety of cancers
among others and has been repeatedly shown to be associated with a higher
risk of mortality. The relatively recent discovery that the composition and
metabolic activity of the gut microbiota may affect the risk of developing
obesity and related disorders has led to an explosion of interest in this
distinct research field. A corollary of these findings would suggest that
modulation of gut microbial populations can have beneficial effects with
respect to controlling obesity. In this addendum, we summarize our recent
data, showing that therapeutic manipulation of the microbiota using different
antimicrobial strategies may be a useful approach for the management of
obesity and metabolic conditions. In addition, we will explore some of the
mechanisms that may contribute to microbiota-induced susceptibility to
obesity and metabolic diseases.
8.2 INTRODUCTION
Obesity, the great pandemic of our time, is a major threat to public health
and challenge to healthcare resources. This complex syndrome is influenced
by host susceptibility and by environmental or lifestyle factors, such as diet
and physical activity. Obesity is associated with a number of serious health
consequences, including type 2 diabetes (T2DM), cardiovascular disease
and a variety of cancers amongst others (Hensrud and Klein, 2006) and has
been repeatedly shown to be associated with a higher risk of mortality
(Ogden et al., 2007). The relatively recent discovery that the composition and
metabolic activity of the gut microbiota may affect the risk of developing
obesity and related disorders has led to an explosion of interest in this
distinct research field (for review see refs. (Clarke et al., 2012, Ley, 2010)). A
corollary of these findings would suggest that modulation of gut microbial
populations can have beneficial effects with respect to controlling obesity. A
number of strategies including specific functional foods, probiotics, prebiotics
and/or antimicrobials antibiotics have the potential to favourably influence
host metabolism by targeting the gut microbiota. In this addendum, we
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summarize our recent data, showing that therapeutic manipulation of the
microbiota using different antimicrobial strategies may be a useful approach
for the management of obesity and metabolic conditions. In addition, we will
explore some of the mechanisms that may contribute to microbiota-induced
susceptibility to obesity and metabolic diseases.
8.3 OBESITY AND THE GUT MICROBIOTA
Both animal and human studies have shown that the composition of the gut
microbiota is significantly altered in obesity and diabetes and characterized
by reduced diversity (Larsen et al., 2010, Ley et al., 2005, Ley et al., 2006,
Turnbaugh et al., 2008, Turnbaugh and Gordon, 2009, Turnbaugh et al.,
2006). We and others have demonstrated the primacy of diet in influencing
the microbiota in obesity (Murphy et al., 2010, Wu et al., 2011). Further
mouse studies have highlighted the role of the gut microbiota in the
regulation of energy homeostasis (Backhed et al., 2004a, Backhed et al.,
2007), in the pathogenesis of insulin resistance (Cani et al., 2007a, Cani et
al., 2008a, Cani et al., 2008b, Cani et al., 2007b, Membrez et al., 2008), in
fatty liver (Dumas et al., 2006), in lipid and amino acid metabolism (Martin et
al., 2007) and as a modulator of host fatty acid composition (Wall et al.,
2009). These studies suggest that interventions which target the metabolic
activity of the gut microbiota may have efficacy in obesity and associated
disorders.
A number of mechanisms have been proposed to contribute to
microbiota-induced susceptibility to obesity and metabolic diseases.
Enhanced energy harvest from dietary intake, due to an alteration in
microbial composition, has been highlighted as a potential contributor to the
pathogenesis of obesity. Other work has suggested that the gut microbiota
and its products affect host energy regulation acting through mechanisms
involving fasting-adipose adipose factor (FIAF) (Backhed et al., 2004b),
adenosine monophoshate (AMP)-activated protein kinase (AMPK) (Backhed
et al., 2007), and G-protein-coupled receptor (GPR)41 (Samuel et al., 2008,
Cani et al., 2007a). Reciprocal signalling between the immune system and
the microbiota, partially via the interaction between LPS and CD14/Toll-
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receptor (TLR)4, appears to also play a pivotal role in linking alterations in
gut microbiota and chronic low-grade inflammation with risk of metabolic
disease in the host (Cani et al., 2008a). Indeed, germ-free mice are
protected from the development of diet-induced obesity (Backhed et al.,
2007). However, whether the gut microbiota represents a realistic target is
unclear.
8.4 A MICROBIAL INTERVENTION
The gut microbiota contains a large, and relatively uncharted, repository of
molecules and metabolites that can be deployed in a variety of settings. One
common feature among gut microbes is the ability to produce bacteriocins.
Bacteriocins are bacterially produced, ribosomally synthesized, small, heat-
stable antimicrobial peptides that can have broad or narrow spectrum activity
against other bacteria and to which the producer has a specific immunity
mechanism (Cotter et al., 2005). Although bacteriocin production by
probiotics has been regarded as a beneficial trait for some time (Dunne et
al., 1999), the full extent of the benefits of bacteriocin production in the gut is
only beginning to be appreciated. The ability of some bacteriocins to
modulate specific undesirable components of the gut microbiota, without
causing major collateral damage to the remainder of the population, is a very
attractive trait (Rea et al., 2011, Cotter, 2011). While the majority of studies
to date have focussed on the ability of bacteriocin-producing probiotics to
target and control well established gut pathogens, it is to be expected that as
high-throughput sequencing analyses of human microbial populations
evolves, new targets will emerge. Indeed, distinct clusters or enterotypes in
the human microbiome have been described (Arumugam et al., 2011) and
provide further support for the use of targeted strategies. With respect to
obesity, specific populations that merit targeting have yet to be clearly
defined. Although increases in the Firmicutes to Bacteroidetes ratio have
been observed in the gut of obese animals (Ley et al., 2005, Turnbaugh et
al., 2006), the subject remains controversial (Clarke et al., 2012, Ley, 2010),
and it is anticipated that other, more specific, targets will emerge (Pennisi,
2011).
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In our study published in Gut earlier this year (Murphy et al., 2012) we
explored the concept of targeting the gut microbiota using antimicrobials to
impact on metabolic abnormalities in murine diet-induced obesity (DIO). Two
antimicrobial strategies were used a bacteriocin-producing probiotic
Lactobacillus and oral vancomycin. Vancomycin is a well known clinical
antibiotic that demonstrates anti-Firmicutes activity and has limited systemic
effects (Moellering, 2006, Pultz et al., 2005, Yap et al., 2008) while
Lactobacillus salivarius UCC118 is a genetically well characterized probiotic
strain (Claesson et al., 2006) that produces a broad-spectrum class II two
peptide bacteriocin, Abp118, which is active against Firmicutes (Flynn et al.,
2002). To differentiate between the influence of the bacteriocin and that of
the probiotic per se on metabolic dysregulation, a bacteriocin-negative (Bac-)
isogenic derivative of L. salivarius UCC118 was used (Corr et al., 2007). This
approach was used previously to establish the critical importance of Abp118
production with respect to the ability of L. salivarius UCC118 to control
Listeria monocytogenes infection in the murine gut.
The experimental design involved the feeding of a high fat (45%; HF)
diet to 4 groups of mice over a 12 week period following by an 8-week
intervention period where mice continued to receive a 1) HF diet, 2) HF diet
in addition to oral vancomycin, 3) HF diet in addition to L. salivarius UCC118
and 4) HF diet with the Bac- strain, respectively. A fifth control group received
a low fat (10%) diet throughout the 20 week study. A number of analyses
took place during and/or at the end of the intervention period. A high
throughput DNA sequencing based analyses of the gut microbiota of faecal
pellets collected at the end of the intervention period showed that both
vancomycin and the bacteriocin-producing probiotic significantly altered the
gut microbiota in diet-induced obese mice, but in distinct ways (Fig 1). From
a bacteriocin perspective, the latter observation is particularly notable as, to
our knowledge, it is the first occasion upon which the full extent of the impact
of a bacteriocin producing probiotic on the gut microbiota has been assessed
in vivo. Bioinformatic analysis of sequence data showed that vancomycin
dramatically impacted upon the overall composition of the gut microbiota
whereas the bacteriocin had a more subtle impact. More specifically, at the
family level, vancomycin brought about a significant decrease in the
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proportions of the Clostridiaceae, Bacteroidaceae and Porphyromonadaceae
and a significant increase in the Enterobacteriaceae (from levels below the
detection threshold to 28% of the population), Streptococcaceae,
Desulfovibrionaceae and Alcaligenaceae relative to the HF only alone
controls. Comparison of the L. salivarius UCC118 Bac+ with the non-
bacteriocin-producing strain, L. salivarius UCC118 Bac-, showed that the
production of the antimicrobial resulted in an increase in Bacteroidaceae and
a reduction in the proportions of Bifidobactereaceae in the gut microbiota of
DIO mice.
Notably, some of the populations inhibited were not previously known
to be targeted by the antimicrobials employed, highlighting the value of
culture-independent analyses. It should also be noted that in recent work
involving mice and pigs fed a standard diet, high throughput sequencing
again revealed that the production of Abp118 by UCC118 had a significant
impact on the gut microbiota (Riboulet-Bisson et al., 2012). Furthermore,
traditionally vancomycin is directed against members of the Firmicutes and is
reserved as a drug of “last resort” treatment of infections caused by Gram-
positive bacteria. However, studies using high throughput sequencing have
shown that vancomycin appears to reduce Bacteroidetes and other taxa in
vivo (Rea et al., 2011, Robinson and Young, 2010). These obeservations
highlight the advantages of using global profiling of the gut microbiota and
emphasise the risks associated with relying solely on in vitro approaches to
assess the impact of an antimicrobial (or other bioactive) on the gut
microbiota.
In the obese mouse model both vancomycin and bacteriocin derived
from L. salivarius UCC118 impacted on weight gain over the 8 week
intervention period. However, a recovery in the rate of body weight gain for
both strategies was observed, suggesting that compensatory microbial
adjustments and/or host physiologic adaptations such as changes in energy
expenditure, satiety, and food intake (Cani and Delzenne, 2009, Cani et al.,
2009, Murphy et al., 2010) (perhaps triggered by changes in the microbiota),
may be at play. Of the interventions, only vancomycin treatment resulted in
an improvement in the metabolic abnormalities. While these changes are
desirable, the negative consequences of such a dramatic alteration of the gut
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microbiota, increasing Enterobacteriaceae populations and enhancing the
risk of antibiotic resistance, ensure that a vancomycin-based weight
management programme will remain of theoretical interest and a proof of
concept. It is noteworthy that the study shows the potential utility of
bacteriocin-producing bacteria to favourably modify the gut microbiota but
further work is required to identify bacteriocin-producing probiotics that can
have a prolonged effect on energy, metabolism, and weight control.
8.5 MECHANISMS CONTRIBUTING TO MICROBIOTA-INDUCED
SUSCEPTIBILITY TO OBESITY AND METABOLIC DISEASES.
The gut microbiota has the potential to influence weight gain and fat
deposition through a variety of mechanisms. Changes in gut microbiota
composition have been shown to influence energy expenditure, satiety, and
food intake (Cani and Delzenne, 2009, Cani et al., 2009, Murphy et al.,
2010). There is increasing evidence that the gut microbiota and their
metabolic products can influence gut hormones, inflammation, and gut
motility (Cani et al., 2012, Lin et al., 2012, Quigley, 2011). Another factor is
the ability of the gut microbiota to extract energy by fermenting otherwise
indigestible components of the diet ("energy harvest"). We have performed
additional unpublished work to examine the effect of manipulating the gut
microbiota using vancomycin and the bacteriocin-producing probiotic,
Lactobacillus salivarius UCC118, on the efficiency of energy harvest, using
the levels of short chain fatty acids (SCFA), the major fermentation end-
products, and on the energy content of the feces. No difference was found in
acetate and propionate production between lean and DIO mice over the 8
week feeding period. Only vancomycin treatment resulted in a decrease in
faecal acetate (Fig 2), while neither antimicrobial strategy altered fecal
propionate levels or energy content. Although precise energy balance
studies were not performed, when combined with our previous work where
the energy content of the diet, food intake and faecal output were measured,
these data further support our observations that changes in the microbiota
are dissociated from markers of energy harvest (Murphy et al., 2010).
Indeed, our work suggested that the improvement in metabolic abnormalities
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observed with vancomycin treatment of DIO mice may be due to alterations
in the inflammatory tone. Of note, a recent study by Cho et al., 2012 showed
that subtherapeutic antibiotic therapy increased adiposity, altered bone
development and increased hormone levels related to metabolism in young
mice suggesting that exposure of the infant gut microbiota to antibiotics may
have long-term metabolic consequences. This study highlights the important
of age and lifestage may be important factors to consider in the complex
relationship between the gut microbiota and obesity.
A recent study in TLR5-deficient mice suggests that malfunction of the
innate immune system may promote the development of metabolic syndrome
through a mechanism involving the gut microbiota (Vijay-Kumar et al., 2010).
Our work showed that vancomycin treatment of DIO mice resulted in an
improvement in the inflammatory and metabolic health of the host. In
particular, plasma TNF-α levels were reduced in vancomycin-treated DIO
mice compared to DIO controls and this corresponded with a trend towards a
reduction in the gene expression of TNF-α levels in the liver and visceral
adipose tissues. The fact that vancomycin treatment was associated with a
decrease in inflammatory tone in DIO mice, despite an increase in the
relative levels of Enterobactericeae, again highlights the complexities of the
host/microbiota relationship. Furthemore, studies by others have suggested
that the gut microbiota may contribute to the onset of insulin resistance and
the low-grade inflammatory tone characterizing obesity through a mechanism
involved in high-fat induced metabolic endotoxemia and toll-like receptors but
the specific components of the gut microbiota responsible for the interaction
remain to be identified (Cani et al., 2008a, Hotamisligil and Spiegelman,
1994, Ley et al., 2005). Interestingly, Serino et al., 2011 recently identified a
gut microbial profile specific to the diabetes-sensitive and diabetes-resistant
metabolic phenotypes and found an increased Bacteroidetes to Firmicutes
ratio and a reduction in Lachnospiraceae family and Oscillibacter genus
associated with the diabetic phenotype.
In addition to SCFA production and energy extraction from the diet, a
possible link between diet, gastrointestinal bacterial metabolism, and
immune and inflammatory responses seems likely. The G protein-coupled
receptors, GPR43 and GPR41 have been identified as endogenous
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receptors for SCFAs. Maslowski et al., 2009 showed that stimulation of
GPR43 by SCFAs was necessary for the resolution of inflammatory
responses, in models of colitis, arthritis and asthma through a mechanism
involving GPR43. In addition, new research has highlighted SCFAs and their
receptors as potential targets for the treatment of obesity and diabetes. A
recent study showed that chronic treatment of butyrate and propionate to
DIO mice suppressed food intake, protected against high-fat diet-induced
weight gain and glucose intolerance, and stimulated gut hormone secretion
(Lin et al., 2012). Indeed, it has been suggested that the amount of SCFA
produced by the gut microbes, more than the composition of the microbiota
could impact on the host’s weight balance (Schwiertz et al., 2009). However,
deciphering the role of SCFA in obesity, diabetes and inflammatory
conditions will depend on identifying the components of the obese gut
microbiota actively involved in the production of SCFAs and interactions
amongst them, in addition to, an improved understanding of how diet and
age relate to SCFA levels.
8.6 CONCLUSION
There is increasing evidence to suggest that gut microbiota and their
metabolic products can influence obesity and metabolic health. Harnessing
the bacteriocin-producing capacity of the gut and identifying selective
pharmabiotics which can alter the development of obesity and associated
conditions as a consequence of changing the gut microbiota represents a
realistic therapeutic strategy for future development.
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Figure 1 Schematic overview of the effect of bacteriocin-producing probiotic
Lactobacillus salivarius UCC118 and oral vancomycin on the composition of
the gut microbiota at family level in diet-induced obese mice.
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Figure 2 Acetate and propionate production (µmol/g) over the 8 week
intervention period in (i) lean, DIO and vancomycin-treated DIO mice and (ii)
DIO mice treated with the bacteriocin-producing probiotic strain L. salivarius
UCC118 Bac+ (1x109 cfu/day) compared to DIO mice treated with a non-
bacteriocin-producing derivative L. salivarius UCC118Bac- (1x109 cfu/day).
Data represented as mean ±SEM, n=9-10. *p<0.05
*
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Obesity has become one of the greatest health concerns of the twenty
first century, with worldwide obesity numbers having nearly doubled since
1980 (WHO, 2013). This multifactorial condition is most simply described
as a prolonged imbalance between energy intake and energy expenditure
resulting in storage of excess energy as fat. While modern eating habits
and decreased physical activity are major contributory factors, research
has pointed towards a link between obesity and the composition and
functionality of the gut microbiota (Cani and Delzenne, 2011, Flint, 2011,
Greiner and Bäckhed, 2011). More specifically, the gut microbiota
composition is significantly altered in obesity and diabetes in both animal
and human studies and is characterised by reduced diversity (Larsen et
al., 2010, Ley et al., 2005, Ley et al., 2006, Turnbaugh et al., 2008,
Turnbaugh et al., 2006, Turnbaugh and Gordon, 2009). Therefore the aim
of the work reported in this thesis was to investigate the impact of a
variety of factors on the obesity-associated gut microbiota and, in turn,
how these factors could impact on weight gain.
The gut microbiota is dynamic and adaptable, and a number of
treatments including antibiotics, prebiotics and probiotics could
hypothetically influence host metabolism favourably by targeting the gut
microbiota. In the initial study reported here (Chapter 2), disruption of the
gut microbiota with the glycopeptide antibiotic vancomycin and/or the
bacteriocin-producing probiotic L. salivarius UCC118 was shown to
reduce weight gain in diet-induced obese mice (transiently in the latter
case), with vancomycin also improving the metabolic abnormalities
associated with obesity. To our knowledge, this is the first evidence that a
bacteriocin producing probiotic can significantly alter the gut microbiota in
vivo. Bacteriocin production increased the relative proportions of
Bacteroidetes and Proteobacteria and decreased Actinobacteria
compared with a bacteriocin-negative derivative. The use of the antibiotic
vancomycin was prompted by the fact that the antibiotic had been
reported to specifically target Firmicutes (Yap et al., 2008), members of
which had previously been found to be increased in the obesity
associated gut microbiota (Ley et al., 2005, Ley et al., 2006, Turnbaugh
et al., 2006). However, culture independent analysis revealed that
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vancomycin treatment had a more global impact, with a large reduction in
Firmicutes and Bacteroidetes and a dramatic increase in Proteobacteria
being observed. Our findings provide further evidence for the role of the
microbiota in metabolic dysregulation, and highlight the merits of altering
the microbiota with antimicrobial agents, such as bacteriocins, to address
such issues.
The subsequent chapter (Chapter 3), represents a further
extension of that described in Chapter 2. Here, the effects of vancomycin
and the bacteriocin-producing probiotic on the gut microbiota were further
investigated by assessing their impact in a time-dependent manner. This
investigation highlighted the resilience of the gut microbiota to change as,
after the initially considerable vancomycin-induced changes, the gut
microbiota began to revert back to a profile more comparable to that
present in controls. The temporal resilience of the gut microbiota following
exposure to antibiotics has also been highlighted in previous studies
(Cotter PD, 2012, Fouhy et al., 2012, Lozupone et al., 2012, Rea et al.,
2011, Tims et al., 2012, Zhang et al., 2012a). These findings demonstrate
that though manipulation of the gut microbiota has the potential to
favourably influence host health, challenges remain when employing
antimicrobials, prebiotics (Dewulf et al., 2012), microbial transplantation
(Vrieze et al., 2012) or other interventions in order to bring about long-
term modifications to the obesity-associated (and other) gut microbial
populations..
Conjugated bile acids (CBAs) are thought to impact on the gut
microbiota through direct antimicrobial effects and/or up-regulation of host
defences (Jones et al., 2008, Kumar et al., 2006). Indeed, it has
previously been observed that bile acids have a direct effect on the host
with increased levels protecting against obesity in leptin deficient mice
(Zhang et al., 2012b) and reduced levels of eight bile acids species noted
in humanized obese mice (Ridaura et al., 2013). Bile salt hydrolase
(BSH) enzymes are produced by gut microbiota to catalyse the
breakdown of conjugated bile salts and neutralise this activity (Kumar et
al., 2006). In Chapter 4, isogenic strains producing different bile salt
hydrolases were shown to vary in the extent to which they alter the gut
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microbiota and reduced weight gain in mice. This was established
through administration of E. coli strains containing aBSH from L.
salivarius JCM1046 (BSH1) (accession number FJ591091) or from L.
salivarius UCC118 (accession number FJ591081). These results suggest
that the application of different BSH-producing strains as a means of
modulating the gut microbiota merits further attention.
Colorectal cancer (CRC) is the third most common cancer and
second leading cancer killer in the United States (CDC, 2009). Obese
individuals are at an increased risk of developing colorectal cancer (Calle
and Kaaks, 2004). Colitis associated cancer is a form of CRC that is
preceded by the Inflammatory Bowel Diseases (IBD), ulcerative colitis
(UC) and Crohn’s disease (CD) (Grivennikov, 2013). In Chapter 5 of this
thesis the effect of diet and the microbiota on the progression of colitis
and colitis-associated colorectal cancer (CAC) progression was
investigated. In contrast to previous reports (Singh et al., 1997, Newmark
et al., 2001), high fat lard based feeding was shown to protect mice from
developing colitis and CAC on the basis of weight and cytokine profile,
tumour incidence and number, as well as colon length. High gut
microbiota diversity is considered desirable with low diversity reported to
be associated with UC and CD (Ott et al., 2004). Analysis of the murine
gut microbiota showed a reduction in gut microbial diversity in low fat
colitis and low fat CAC mice relative to their high fat fed counterparts.
Additionally, it was revealed that high fat colitis and high fat CAC mice
had significantly lower proportions of the phylum Proteobacteria relative
to low fat fed comparators. The phylum Proteobacteria has been found to
be associated with CD, UC and CRC patients (Lepage et al., 2011,
Gophna et al., 2006, Frank et al., 2011). These results provide a further
insight into the relationship between diet, inducers of colitis and colon
cancer and the gut microbiota, and suggest that the impact of high fat
diets on microbiota-host responses, inflammation and CAC are more
complex than previously anticipated.
The degree to which exercise and diet influences the gut
microbiota was examined in Chapter 6. Diet and gut microbiota
composition was assessed in professional athletes from an international
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rugby union squad while in the regulated environment of pre-season
camp. Two control groups, one matched for athlete size with a
comparable body mass index (BMI) and another reflecting the
background age- and gender-matched population, were also investigated.
Gut microbial analysis revealed that exercise and diet, and protein in
particular, impact on gut microbial diversity. Microbiota diversity may
become a new biomarker or indicator of health (Shanahan, 2010) as loss
of biodiversity within the gut has been connected to an increasing number
of disorders such as autism, gastrointestinal diseases and obesity
associated inflammatory characteristics (Claesson et al., 2012, Kang et
al., 2013, Ott et al., 2004, Le Chatelier et al., 2013, Chang et al., 2008).
Notably, athletes and low BMI controls had significantly higher
proportions of the genus Akkermansia than the high BMI control group.
Akkermansia muciniphilla abundance has been shown to inversely
correlate with obesity and associated metabolic disorders in both mice
and humans (Everard et al., 2013, Karlsson et al., 2012). Despite these
observations, prospective studies will be required in order to better
determine the specific impact of protein consumption and exercise,
respectively, on the gut microbiota.
Overall the studies in this thesis highlight that microbial diversity is
influenced by diet, exercise, antibiotics and disease state, and, in the
process, highlights a number of interventions that merit consideration with
respect to altering the microbiota with a view to improving host health.
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